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Summary 
 
The concept of genetic clonal tiding is well established in Multiple myeloma. 
Immunophenotypic analysis as a means of sub-clone distinction is less well recognised. In 
this thesis, a ST-colour panel was designed that showed examples of distinct CDUV, CDSUV, 
CXCRX, MMP-Y, IL-Z and CDXYd sub-populations in both primary MM samples and cell 
lines. The huge variation in CDUV expression amongst the samples and its positive 
correlation with Ki-Z\, CXCRX and CD]Z expression was of particular interest, 
culminating in the previously undescribed discovery of a bimodal CDUV expression in the 
well-known cell line, MM.SS. In terms of function, I showed that CDUV expression was a 
predictor of myeloma cell migration; high expression was associated with increased cell 
migration. Furthermore, I developed a novel migratory model in MM, that had been 
previously used in our research group for CLL. In this dynamic circulatory model, I showed 
that pharmacological inhibition of CXCRX and CDXYd inhibited MM migration. 
 
To further explore the functional difference in CDUV expressing sub-populations, the 
MM.SS CDUV populations were cell sorted and the distinct subsets were examined in terms 
of phenotype, function and genotype. The weakly expressing CDUV population, termed 
MM.SSdim, was shown to contain a mutation in the gene MKI$%, providing a rationale for 
the observed decrease in cell growth. Through further genetic analysis, sub-clonality 
between the U populations were proven, ultimately showing that both of the MM.SS CDUV 
sub-clones were manifest in the MM.SR cell line. The exome analysis also identified that 
the CDUV sub-clones harboured distinct genetic mutations, which conferred differential 
sensitivity to molecular targeted inhibitors such as PIUK. 
 
This, combined with my migratory work, showed the potential for developing bespoke 
treatment plans based on the identification of cell signalling pathway mutations via 
genomic sequencing and immunophenotypic analysis. By selective targeting of these 
genetic lesions it may be possible to remove multiple sub-clones thereby diminishing the 
potential for clonal tiding and the development of drug resistance. 
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CHAPTER 1: 
Introduction 
 
1.1 Multiple Myeloma 
Multiple myeloma (MM) is an incurable cancer of plasma cells that is usually fatal. Over 
],TTT new cases are reported yearly in the UK, accounting for d% of all new cancer cases 
and SU% of haematological malignancies. Its incidence is increasing, current rates are Y 
cases per STT,TTT, which represents a Ud% increase since the early SYYT’s (Altekruse et al. 
dTST; Cancer Research UK dTS]). MM is part of a spectrum of disorders termed plasma 
cell dyscrasias, that encompasses Monoclonal Gammopathy of Undetermined Significance 
(MGUS), asymptomatic MM (also known as smouldering myeloma (SMM)), single and 
multiple plasmacytomas, symptomatic MM and plasma cell leukaemia (Rajkumar dTSZ). 
 
The treatment of MM has remained challenging due to predominantly being a disease of 
the elderly and of its natural disease course, one of repeated relapses/remissions through 
numerous lines of therapy. Despite the challenges, overall survival has greatly increased 
over the last two decades. Before the introduction of ‘novel agents’ such as the 
immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor 
bortezomib in the mid dTTT’s, the ST-year overall survival for myeloma was S\.X% 
(Brenner et al. dTTV). Since their introduction, the ST-year overall survival has doubled to 
UU% (Cancer Research UK dTSX).  
 
1.1.1 Normal plasma cell development 
Plasma cells are terminally differentiated B lymphocytes that have the capacity to produce 
and secrete large amounts of antibodies. These antibodies, also known as 
immunoglobulins, target specific foreign antigens that once bound, initiate destruction of 
the antigen or antigen-expressing cell. This process forms a key component of the adaptive 
immune system. 
 
The immature B-cell arises from a haematopoietic stem cell within the bone marrow. The 
early part of B-cell formation is characterised by immunoglobulin gene loci rearrangement 
through a process known as V(D)J recombination. The V(D)J region of the 
immunoglobulin gene encodes for the region of the protein that recognises antigen. The 
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alternative splicing of different V, (D) and J segments provides a multitude of possible 
combinations of both light and heavy chain immunoglobulins that form distinct 
antibodies. B-cells that auto-react to the host are deleted by a process called negative 
selection or “clonal deletion” (Halverson et al. dTTX; Shapiro-Shelef and Calame dTT]), 
whilst those remaining are allowed to migrate out of the marrow and traffic to the 
lymphoid tissues.  
 
B-cells can also act as antigen presenting cells (APCs), thus allowing the internalisation of 
foreign antigens, whereupon the antigen is broken up into peptides and presented, in the 
context of MHC molecules, on the cell’s surface, usually within the lymphoid tissue. The 
immature B-cell can then be activated by either T-cells or a subset of B-cells termed 
marginal zone (MZ) B-cells, resulting in further maturation into plasmablasts. This phase 
of maturation into an immature plasma cells signals the cell’s ability to secrete large 
amounts of antibodies but still have the capacity to class switch antibody production 
termed class switch recombination (CSR), which is regulated by the PIU-Kinase pathway. 
In this process, the constant region of the immunoglobulin switches from IgM and IgD to 
either IgA, IgG or IgE (Lopes-Carvalho and Kearney dTTX; Stavnezer and Amemiya dTTX; 
Shapiro-Shelef and Calame dTT]; Omori et al. dTTZ). 
 
The plasmablast either becomes a short-lived antibody-secreting cell or undergoes 
additional activation and proliferation following entry into the germinal centre within 
lymphoid tissue. It is within the germinal centre that enhanced affinity of the B-cell’s 
immunoglobulin to the antigen occurs through somatic hypermutation (SHM) of the 
variable (V) region of the gene. The germinal centre reaction gives rise to both memory B-
cells, and high-affinity antibody-producing plasma cells upon exposure to the original 
antigen/pathogen (Jacob et al. SYYS; Allen et al. dTT\; Shlomchik and Weisel dTSd). 
 
The key enzyme in antibody diversification is Activation-induced Cytidine Deaminase 
(AID) and is fundamental in the regulation of SHM and CSR. AID results in Double strand 
DNA breaks (DSB) leading to variation in antibodies and a functionally active immune 
system (Morgan et al. dTSdb). However, DSBs, although repaired locally, can potentially 
join to DSBs elsewhere in the genome and in the case of a different chromosome, result in 
chromosomal translocation. This is why the IgH loci is a hotbed of chromosome 
translocations (Gonzalez et al. dTT\). Although DSB rearrangements occur normally in 
heathy immune systems, it remains a key origin of the formation of B-cell malignancies 
including MGUS and MM. 
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1.1.2 Genetic architecture of MM 
Figure S.S outlines the genetic changes that occur in the development of MM; a multi-stage 
transformational process. Initiating genetic events that characterise the disease occur 
during B-cell development and are predominately chromosome abnormalities such as 
trisomies (chromosomes U, ], \, Y, SS, S], SY and dS) and IgH rearrangement (SXqUd). IgH 
translocations result in proximal relocation of IgH enhancers such as Eµ, EαS and Eαd 
leading to the increased transcription of oncogenes such as:   
i. CCNDB (SSqSU coding for cyclin-DS protein)  
ii. CCNDC (ZpdS coding for cyclin-DU protein)  
iii. MAF (SZqdU coding for c-maf protein)  
iv. FGFRC/MMSET (XpSZ coding for fibroblast growth factor receptor U protein) 
v. MAFB (dTqSd coding for Transcription factor MafB protein) 
 
Cyclins drive cells through the GS/S phase of the cell cycle, by activating cyclin dependent 
kinases (CDK). This in turn is able to phosphorylate and inactivate the tumour suppressor 
protein retinoblastoma (Rb), which leads to cell cycle progression. Cyclin translocations, 
as well trisomy dS and Sq gain, are regarded as poor prognostic factors in MM, whereas 
other trisomies are deemed more favourable (Lundberg and Weinberg SYYV; Bergsagel and 
Kuehl dTTS; Smadja et al. dTTS; Chretien et al. dTS]).  
 
1.1.2.1 Secondary Genetic events 
Almost half of MGUS patients have an IgH translocation, however such events are 
insufficient to cause the malignant transformation to MM. Secondary genetic 
abnormalities, either from somatic ‘driver’ mutations, epigenetic changes or further 
chromosomal changes are required for disease progression (Morgan et al. dTSdb).  
 
The advent of more widely available and efficient next generation sequencing (NGS) has 
provided the tools to identify frequent and potential driver mutations, i.e. mutations 
essential for disease progression and clonal evolution. Early results in relatively small 
cohorts of patients indicated that MM was a very heterogeneous disease, with multiple 
sub-clonal structure at diagnosis, but with only a few recurrently mutated genes of likely 
pathogenetic significance (Bolli et al. dTSX). These included KRAS, NRAS, TPNC, BRAF 
and FAMO$C (Chapman et al. dTSS; Egan et al. dTSd; Walker et al. dTSX). 
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Figure 1.1. The development and genetic events of Multiple Myeloma (MM). Initiating genetic events 
occur during normal B-cell development, resulting in Monoclonal Gammopathy of Undetermined 
Significance (MGUS). In addition to 13q deletion, these mutations are believed to be the cause of cancer. 
Further mutations labelled as secondary genetic events have to occur before Smouldering Multiple 
Myeloma (SMM) occurs that leads onto the final transformation to symptomatic MM. Eventually the MM 
clone will lose its bone marrow microenvironment dependency through additional mutations to form 
either Plasma Cell Leukaemia (PCL) or Extramedullary Myeloma (EM). Adapted from (Dutta et al. 2017). 
 
TPNC gene mutations or deletion of the short arm of chromosome S\ are seen in 
approximately SS% of patients. The tumour suppressor protein p]U has multiple functions 
in preventing oncogenesis, including invoking GS/S cell cycle arrest, activating DNA repair 
and initiating apoptotic pathways. Deletion or loss of the gene confers a poor prognosis 
and is regarded as a high-risk cytogenetic abnormality in the revised ISS prognostic 
scoring system (Avet-Loiseau et al. dTT\; Palumbo et al. dTS]). 
 
The RAS family of genes (HRAS, KRAS and NRAS) are the most commonly mutated genes 
in MM, with an incidence of d]% in newly diagnosed patients, increasing to X]% at relapse 
(Chng et al. dTTV). The RAS/MAPK pathway is frequently deregulated in the disease, with 
its function primarily in the regulation of cell proliferation (Bolli et al. dTSX).  Although 
RAS mutations are regarded as one of the key driver mutations for disease 
progression/sub-clonal evolution and associated with higher tumour burden (Chng et al. 
dTTV), data from the UK Myeloma XI trial, showed it did not have a prognostic implication  
(Walker et al. dTS]). The Myc family of proto-oncogenes (including c-Myc) is frequently 
upregulated in MM, they function as transcription factors that result in many genes related 
to cell survival and proliferation being upregulated. The c-Myc locus is on chromosome V 
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and in S]% of symptomatic MM patients is translocated with the IgH locus - t(V:SX) (Avet-
Loiseau et al. dTTS).  SUq deletions or monosomy SU can occur in up to half of MM patients. 
Deletion can be regarded as both an initiating event and a driver of disease, i.e. secondary 
genetic event. Located within the SUq arm is the RB gene; loss of expression or mutation is 
correlated with a reduced overall survival (Chiecchio et al. dTTZ). 
 
Additional genetic events that are not deemed essential for disease progression but 
nevertheless result in the biological sequelae of MM include secondary translocations, 
mutations causing increased RANKL/OPG expression resulting in osteoclast activation, 
mutations that cause increased immune evasion and mutations that result in cytokine and 
growth factor changes. 
 
1.1.2.2 NGS in MM patients 
One of the first published collections of MM next generation sequencing (NGS) was in 
dTSS (Chapman et al. dTSS). UV samples were sequenced in an attempt to identify mutations 
of high frequency. Chapman concluded that there were no common recurrent mutations, 
with a median number of mutations per genome around ZT (dS-XVV). Subsequent NGS 
analysis of larger cohorts has revised the number upwards to approximately dTT (Corre et 
al. dTS]), which when compared to other cancers is roughly average, but higher than many 
other haematological cancers (Bolli et al. dTSX).  
 
Figure S.d combines the gene mutation incidence of the U largest NGS cohorts published 
to date, showing that only a few mutations are recurrent, with less than ST genes having a 
mutation incidence of ]% or more (Corre et al. dTS]). Furthermore, many of the listed 
genes in Figure S.d (notably NRAS, KRAS and BRAF) can be clone specific within the same 
patient, inferring a single driver mutation is sufficient to form a new sub-clone  (Lohr et 
al. dTSX). To add to the complexity, there is huge spatial genomic heterogeneity within 
MM, i.e. different clones existing at different sites of the body/bone marrow. Indeed, one 
study suggested that more than 75% of patients had evidence of spatial heterogeneity, 
including clones with inactivating mutations of CDKN2C, TP53 and mutations affecting 
mitogen-activated protein kinase genes (Rasche et al. 2017). 
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Figure 1.2. Most frequent somatic mutations in patients with MM. Mutation frequencies are average of 
data from three whole-exome sequencing studies, totalling 733 patients (Bolli et al. 2014; Lohr et al. 2014; 
Walker et al. 2015). MM - multiple myeloma; WES – whole exome sequencing; * - Mutations reaching 
significance. Figure modified from (Manier et al. 2017). 
 
 
1.1.3 Clinical classification of Myeloma 
1.1.3.1 MGUS/Asymptomatic myeloma: 
The International Myeloma Working Group dTSX (IMWG) definition of MGUS and 
asymptomatic myeloma, state that both conditions present in the absence of a myeloma 
defining event or amyloidosis. Myeloma defining events are regarded as either bone 
marrow plasma cell population >ST% with end-organ damage (CRAB features see Table 
S.d), or in the absence of CRAB features bone marrow plasma cells have to be >ZT% or a 
serum-free light chain (SFLC) ratio of >STT.  
 
MGUS differs from SMM in that paraprotein levels are less than UTg/L (>UTg/L for SMM) 
and bone marrow plasma cells percentage is less than ST% (between ST-ZT% for SMM) 
(Rajkumar dTSZ). MGUS is primarily a condition of the elderly, with incidence increasing 
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with age. It is estimated U% of the general population over ZT have it (Kyle et al. dTT\). 
MGUS shares a number of cytogenetic and molecular abnormalities with MM such as 
heavy chain translocations, trisomies and increased expression of cyclin DS (Palumbo and 
Anderson dTSS). This strong molecular association is suggestive that MGUS consistently 
precedes MM (Landgren et al. dTTY). 
 
As is the case with many other cancers, genome-wide association studies (GWAS) have 
identified common genetic variations associated with the development of myeloma (Law 
et al. dTS\; Went et al. dTSV). It is already accepted that inherited factors contribute to the 
development of MM or MGUS, with a X.d]-fold increase of developing it, if a first-degree 
relative has either condition (Altieri et al. dTTZ). MGUS has a S% annual rate of 
progression to MM, whereas with SMM the annual rate of progression increases to ST% 
(Kyle et al. dTTd; Kyle et al. dTT\). This relatively low rate of progression combined with 
toxic side effects of treatment options and the lack of clinical trials for these patients, is 
why the current IMWG guidelines do not advise treatment for either condition (Rajkumar 
dTSZ). Controversially, this stance currently precludes treatment of the so called ‘high-risk’ 
SMM whose risk of transforming to MM can be as high as \d% in the first ] years (Pérez-
Persona et al. dTT\).  
 
1.1.3.2 Defining high-risk SMM   
The categorisation of ‘high-risk’ patients allows for the early identification of those likely 
to progress to MM. Debate surrounds whether such patients should be treated, as 
although not technically classified as MM, studies have shown improved OS and PFS with 
early intervention (Mateos et al. dTSU). Such studies aim is to halt clonal progression of 
the more aggressive clones, that are more likely to become drug resistant. The two most 
widely used models (Table S.S), are the U-factor Mayo Clinic and the d-factor Spanish 
PETHEMA. The reliability of these models has been questionable, with large discrepancies 
(\S.X% discordance) observed between them (Cherry et al. dTSU). The newer Penn 
prognostic models (based on the Mayo clinic model) addressed these discrepancies and 
has a calculated d-year transformation rate within the high-risk group of VS% (Waxman et 
al. dTSX). 
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Model Median 
TTP 
Risk Factors 
Mayo Clinic (Dispenzieri et al. 
dTTV) 
V.X months 
(U factors) 
Bone marrow plasma cells ≥ ST% 
Paraprotein ≥ UT g/L  
SFLC ratio < T.Sd] or > V 
PETHEMA (Pérez-Persona et al. 
dTT\)  
dU months 
(U factors) 
≥ Y]% aberrant plasma cells  
Immunoparesis 
DNA aneuploidy  
Penn (Waxman et al. dTSX)  X.d months 
(U factors) 
Bone marrow plasma cells ≥ XT%  
Serum free light chain ratio ≥ ]T  
Albumin ≤ UT g/L 
Updated Mayo Clinic, incorporating 
revised dTSX IMWG diagnostic 
criteria. (Lakshman et al. dTSV) 
dY months 
(d ≥ factors) 
Bone marrow plasma cells ≥dT%  
SFLC ratio ≥dT  
Paraprotein ≥ dT g/L 
Table 1.1. The differing models for determining MGUS or SMM patients who have a high-risk of MM 
transformation. TTP – Time to progression; IMWG – International Myeloma working group; SFLC - Serum 
free light chain 
 
1.1.3.3 Symptomatic MM 
The clonal expansion of malignant plasma cells in the bone marrow, leading to an excess 
of myeloma cells, ultimately results in marrow failure and organ damage through various 
protein secretions and inhibition of bone marrow stromal cells. The end organ damage or 
CRAB features are the defining events that are required for disease diagnosis (Table S.d). 
The cause of anaemia is multifactorial and includes; reduction of normal haematopoiesis 
caused by plasma cell overexpansion in the bone marrow, inhibition of stromal cells and 
the increase in hepcidin expression (Mittelman dTTU). Renal failure occurs predominantly 
through secretion of SFLC (known as Bence Jones protein when detected in the urine), 
which aggregate in the nephrons resulting in damage. Lytic bone lesions that lead to 
hypercalcaemia and bone fractures occur through osteoclast activation and osteoblast 
inhibition by secretion of receptor activator of nuclear factor kappa-Β ligand 
(RANKL) and osteoprotegerin (Tai et al. dTT\). 
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End organ damage criteria/CRAB 
features 
Biomarkers of malignancy criteria: 
Hypercalcaemia: serum calcium >d·\] 
mmol/L  
Clonal bone marrow plasma cell 
percentage ≥ZT% 
Renal insufficiency: creatinine clearance <XT 
ml/min or serum creatinine >S\\ μmol/L 
Involved: uninvolved serum free light 
chain ratio ≥STT   
Anaemia: haemoglobin value of <STT g/L or 
>dTg/L below the lower limit of normal 
>S focal lesion on MRI studies 
 
Bone lesions: one or more osteolytic lesions 
on skeletal radiography, CT, MRI or PET-CT  
 
Table 1.2. List of the myeloma defining events required to make a diagnosis of MM from the IMWG 2014 
(Rajkumar 2016) classification of MM. Diagnosis of MM being a clonal bone marrow plasma cells ≥10% or 
biopsy-proven bony or extramedullary plasmacytoma and any one or more of the above myeloma defining 
events. Criteria divided into end organ damage or biomarker.  
 
 
1.1.4 Prognostic factors in MM 
The huge clinical heterogeneity of MM is reflected in the diverse survival outcomes 
amongst patients, ranging from a couple of months to over ST years. Certain prognostic 
factors have allowed clinicians to predict survival outcome (e.g. tumour burden and 
disease complications) and, in some circumstances, these can also help determine 
treatment strategies.  
 
1.1.4.1 Tumour burden, disease complications and cytogenetic factors 
Calculation of bone marrow infiltration of plasma cells and disease complications by 
paraprotein levels, anaemia, renal involvement and lytic lesions can offer limited 
prognostic information and formed the basis of the Durie-Salmon classifications (Durie 
and Salmon SY\]). However, this staging system has been widely replaced, first by the 
international staging system (ISS) and more recently by the revised-ISS, which aimed to 
simplify disease classification as well as incorporate advances in our understanding of the 
cytogenetics of the malignant clones. The ISS (Table S.U) uses only two disease markers 
(βd-microglobulin and serum albumin). As well as being a better predictor of survival, it 
is simpler and easier to implement in the clinic compared to the Durie-Salmon 
classification. 
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Stage Criteria 
Median overall 
survival 
I βd-microglobulin <U.]mg/dL and Serum albumin 
>U.]mg/dL 
Zd months 
II Neither stage I or stage II XX months 
III βd-microglobulin >].]mg/dL  dY months 
Table 1.3. ISS criteria and median overall survival related to the stage (Greipp et al. 2005).  
 
Although the ISS was derived from the analysis of over SS,TTT patients (Greipp et al. dTT]), 
it pre-dates the widespread use of the so called ‘novel therapies’ (proteasome inhibitors 
and/or immunomodulatory drugs), which have made a great impact on disease survival 
and therefore a revision was made in dTS] (Palumbo et al. dTS]). The R-ISS reflects the 
advances in treatment on overall survival and further stratifies prognostic groups by 
including high-risk chromosomal abnormalities (del(S\p), t(X;SX), t(SX;SZ)) as well as 
serum lactate dehydrogenase (LDH). The staging system is still divided into U subgroups, 
but survival of each group is now given as a percentage alive at ] years (stage I-Vd%, stage 
II-Zd% and stage III-XT%).  
 
1.1.4.2 Other prognostic factors 
Host factors such as performance status (ECOG <d) and age are well established. The 
response to treatment is also a key factor, with the depth of response, largely inferring 
longer progression-free survival (PFS) and overall survival (Martinez-Lopez et al. dTSX; 
Munshi et al. dTS\). The ideal method to measure response is debatable, the IMWG 
response criteria, utilising percentage of bone marrow plasma cells as well as paraprotein 
levels, is a relatively simple method that is applied to virtually all patients undergoing 
treatment.  
 
The use of minimal residual disease (MRD) either using flow cytometry or next generation 
sequencing to detect low level disease, can better predict overall survival and/or time to 
progression, but these methodologies are not widely available (Munshi et al. dTS\). 
Further, the best method for assessing MRD and what constitutes the critical level of 
response required is still debatable. Multi-parameter flow cytometry (MFC), is the most 
widely used MRD assessment tool with a sensitivity of around S in ST] cell detection 
(Rawstron et al. dTSU). Molecular deep sequencing of bone marrow is regarded as more 
reliable and accurate method than MFC, being able to detect disease down to S in STZ cells 
(Rack et al. dTSZ). Furthermore, a strong correlation between depth of response and 
overall survive, most notably in the post-transplant setting, has been shown (Martinez-
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Lopez et al. dTSX). However, the need for the design of patient-specific primers, the 
technical expertise required and the associated expense, has meant that these methods are 
not widely available. The two most commonly used molecular deep sequencing methods 
are, Allele-specific oligonucleotide-quantitative polymerase chain reaction (ASO-PCR) 
and NGS of the patient’s unique immunoglobulin region (IgH VDJ assay). In an attempt 
to reduce costs, commercially available pre-designed V(D)J multiplexed PCR amplification 
assays such as LymphoSIGHT™	are	available.	This	method	also	has	the	advantage	of	being	able	to	monitor	specific	sub-clones	throughout	the	lifetime	of	the	disease.		
Gene expression profiling (Szalat et al. dTSZ) has also been shown to identify patients with 
poorer prognosis as well as CT-PET imaging, whereby \ lesions or more corresponds to a 
worse outcome (Hillengass et al. dTSY).   
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1.2 Myeloma Therapy  
Standard of care for patients with newly diagnosed MM, who are eligible for high dose 
therapy, currently involves the combination of the so called ‘novel agents’; Proteasome 
Inhibitors (PI) such as bortezomib and carfilzomib, with one of the immunomodulatory 
drugs (IMiDs) thalidomide or lenalidomide. These drugs are usually combined with 
cyclophosphamide and/or dexamethasone. The synergistic effect of the novel agents has 
been widely documented, with response rates of around V]% for single agent treatment 
increasing to YV%, when PI and IMiD are combined (Richardson et al. dTTY; Kumar et al. 
dTSS; Morgan et al. dTSda). If fit, treatment should be consolidated with a high dose 
melphalan autologous stem cell transplant, which when combined with lenalidomide 
maintenance has been shown to increase PFS compared to no transplant (]T months vs 
UZ months), although overall survival difference is not as impressive (Attal et al. dTS\).   
 
Targeting patients with high-risk asymptomatic myeloma/SMM has remained an area of 
ongoing clinical research. In theory, by targeting high-risk patients for treatment, the aim 
is to remove clones before they accrue secondary mutations (e.g. molecular alterations of 
TPNC or oncogenic activation genes) and more aggressive sub-clones arise. Although 
current treatment is unlikely to permanently eradicate all disease, numerous studies 
involving novel therapies are being developed and trialled in the high-risk SMM group. 
For example, treatment with lenalidomide, carfilzomib and dexamethasone, followed by 
d years of lenalidomide maintenance achieved a STT% very good partial response (VGPR 
– defined as >YT% decrease in paraprotein) or better (Landgren et al. dTSU).   
 
 
1.2.1 Glucocorticoids (GC) 
Steroids have been used to treat MM since the SYZT’s (Mass SYZd) and have remained a 
key component of today’s MM treatment regimens. Short pulses of dexamethasone are the 
preferred method of glucocorticoid administration and induce cell death either through 
cell apoptosis or necrosis (Alexanian et al. SYYd).  
 
1.2.1.1 Cellular apoptosis 
Cellular apoptosis is induced through the actions of the glucocorticoid receptor (GR) and 
so its expression is crucial in determining glucocorticoid sensitivity (Reichardt et al. 
dTTT). The mechanism by which cells undergo apoptosis upon activation of the GR varies 
dependent on the cell type and the expression of key proteins such as Bim, Bcl-d and 
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Glucocorticoid-induced leucine zipper (GILZ). GR on the cell surface when activated will 
cause a number of changes that include: activation of RAFTK (normally deactivated by IL-
Z), causing apoptosis through the activity of protease enzymes and caspases; the inhibition 
of the proliferate pathways, MAPK (a key driver of IL-Z production, mediated by the 
inflammatory cytokine TNF-⍺) and PIUK/Akt, resulting in GS-phase growth arrest; and the 
block of NF-kB-mediated transcription of pro-survival/anti-apoptotic genes (Wang et al. 
dTTU; Smith and Cidlowski dTST).  
 
1.2.1.2 Cellular necrosis 
Cellular necrosis can be an indirect consequence of gene dysregulation. Internalisation 
and cytoplasmic glucocorticoids can result in a rapid turnover of gene transcription, 
resulting in cellular distress and cell death, either triggered by calcium flux, oxygen 
radicals, changes in cellular volume or pH (Fernandez et al. SYY]; Gomez-Angelats et al. 
dTTT; Matsuyama and Reed dTTT; Schmidt et al. dTTX). 
 
 
1.2.2 Proteasome Inhibitors (PI) 
1.2.2.1 The Ubiquitin Proteasome System 
The ubiquitin proteasome system regulates the destruction of misfolded or no longer 
required proteins inside cells. This occurs by the regulatory protein ubiquitin being 
attached to the protein by a process called ubiquitination. In this process, U separate 
ubiquitin-activating enzymes, ES, Ed and EU are required to add ubiquitin to the protein. 
The enzymes are highly specific to the protein to be degraded, thus allowing the cell to 
only degrade specific proteins. Once U-X ubiquitin molecules are added onto the protein, 
the proteasomes recognise the complex and can degrade it. In disease, the proteasomes 
can be either overactive, so essential cell function proteins are destroyed, or underactive, 
thereby allowing the build-up of toxic, harmful proteins (Pickart and Eddins dTTX). The 
dZS proteasome consists of a core dTS complex and one or two SYS regulatory complexes. 
Within the core complex are U sites of action (Adams dTTU);  
• β] are “chymotrypsin-like” (Chym-L)  
• βd are “trypsin-like” (Tr-L)  
• βS are “caspase-like” (Casp-L)  
The Chym-L site is seen as the most important for protein breakdown, knockout Chym-L 
mice experiments have shown retardation of growth and accumulation of proteasomes 
(Chen and Hochstrasser SYYZ; Heinemeyer et al. SYY\).  
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Proteasome inhibition has been shown to be an attractive treatment for cancer cells, 
including MM (Hideshima et al. dTTdb). The build-up of toxic proteins, in high protein 
output cells such as plasma cells that produce immunoglobulins can cause cell death as 
well as preventing degradation of pro-apoptotic proteins. Bortezomib, the first in class 
proteasome inhibitor (PI), has been shown to stop degradation of the inhibitor of NF-κB 
(IκB), through inhibition of the proteasome β] and βS subunits. A relative increase in IκB, 
results in NF-κB inhibition, a key signalling pathway involved in cancer survival and 
proliferation (Jourdan et al. dTT\; Chen et al. dTSS). The additional inhibition of βS “caspase 
like” subunit sites are thought to sensitise the cell for additional “chymotrypsin-like” 
inhibition, maximising cytotoxicity, although the newer generation of PIs are not believed 
to inhibit βS subunits (Britton et al. dTTY).  
 
1.2.2.2 Bortezomib, the first licensed PI and the emergence of the 2nd generation PI’s 
Bortezomib is currently the only PI approved for first line treatment by both the FDA and 
NICE. The irreversible, more selective PI, carfilzomib is more widely used in the relapsed 
refractory (RRMM) setting, having been approved for this use by the FDA in dTSd, with 
use as a front-line agent limited to trials such as the now closed NCRI Myeloma XI trial. 
Trials of carfilzomib as a front-line agent have tended to show superior activity when 
compared to bortezomib, resulting in a YZ% response rate with Zd% achieving a near 
complete response (CR) with an estimated PFS of Yd% at dX months (Jakubowiak et al. 
dTSd). Its use in the relapse refractory setting as monotherapy in heavily pre-treated 
patients (including bortezomib) has seen response rates up to ]d% and a medium duration 
of response of up to \.V months (O'Connor et al. dTTY; Siegel et al. dTSd; Vij et al. dTSd). 
Although carfilzomib has a similar side effect profile to bortezomib, which includes fatigue 
(]]%), myelosuppression and peripheral neuropathy (SU.Y%), the incidence of these 
features is reported to be lower, potentially making it a more attractive PI, especially in 
those not suitable for high dose therapy or those with pre-existing neuropathy (Argyriou 
et al. dTTV; Jain et al. dTSS; Siegel et al. dTSd). Although the eldest in these early trials was 
VV years old, the higher cardiotoxic signal seen with carfilzomib compared to bortezomib 
makes it less appealing in the very elderly, especially with those with pre-existing heart 
conditions.  
 
The first orally available, and third PI to be approved by the FDA is ixazomib. Results in 
phase II trials in combination with lenalidomide and dexamethasone for newly diagnosed 
patients have shown similar results to bortezomib, with a YZ% response rate, dZ% showing 
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a complete response (Kumar et al. dTSd). The tolerability of the drug, favourable side effect 
profile and ease of use make it an attractive option in the relapsed/refractory setting where 
PFS is increased by Z months when combined with lenalidomide (Moreau et al. dTSZ) and 
also as a maintenance regime (Richardson et al. dTSUa). Table S.X outlines the comparison 
between proteasome inhibitors. 
 
 
1.2.3 Immunomodulatory drugs (IMiD) 
Table S.X compares the three FDA approved immunomodulatory drugs.  Despite the 
variation in activity, they are chemically very similar. Pomalidomide and lenalidomide 
contain an extra amino group on the fourth carbon of the phthaloyl ring of thalidomide, 
with pomalidomide retaining an oxygen atom that lenalidomide losses, essentially making 
pomalidomide the combined chemical structure of thalidomide and lenalidomide (Quach 
et al. dTST). They all share similar anti-angiogenic activity, but pomalidomide has greater 
immunomodulatory effect than the other two, especially compared with thalidomide; it is 
S],TTT times more potent at inhibiting malignant B-cell proliferation and TNF-α activity 
(Corral et al. SYYY).  
 
Despite the potency and more tolerable side-effect profile of the next generation IMiDs, 
NICE currently only recommends thalidomide as front line IMiD therapy, despite being 
shown to be inferior to lenalidomide (Jackson et al. dTS\). Upon achieving a remission, 
their use as maintenance therapy has been shown to increase PFS (Hicks et al. dTTV; 
Jackson et al. dTS\). However, it remains controversial whether IMiD maintenance therapy 
can improve OS, with some experts claiming that the side effect profile, including the 
incidence of secondary malignancies associated with lenalidomide treatment, outweighs 
any gain in PFS (Attal et al. dTSd; McCarthy et al. dTSd; Palumbo et al. dTSd; Singh et al. 
dTSU).  
 
The dTSX updated BCSH Myeloma guidelines (Pratt et al. dTSX), provides the option of 
thalidomide maintenance post autograft. However, this does not necessarily correlate to 
an increase in OS (Barlogie et al. dTTZ) with therapy strongly associated with peripheral 
neuropathy and the attendant reduction in the quality of life.  These factors will likely 
mean both thalidomide and lenalidomide, will fall short of the ideal maintenance therapy, 
that of a single agent, that improves overall survival, with minimal toxicity.   
 
 16 
 
Table 1.4. Comparison between proteasome inhibitors and immunomodulatory drugs used in MM (Adapted from (Quach et al. 2010; Schmidt et al. 2011; Moreau et al. 2012; 
Guglielmelli et al. 2015; Place 2015).*against RPMI-8266 MM cell line; FDA - Food and Drug Administration; IV - intravenous; SC - subcutaneous; ‘+’ relative potency factor of 10;  Ic50 
indicated half-maximal inhibitory concentration; ADCC – antibody-dependent cell-mediated cytotoxicity; NK(T) – Natural killer (T) cells.  
 
Proteasome Inhibitors Immunomodulatory Drugs 
Bortezomib Carfilzomib Ixazomib Thalidomide Lenalidomide Pomalidomide 
Activity       
     Anti-angiogenic  - - - ++++ +++ +++ 
     Anti-inflammatory - - - + ++++ +++++ 
     T-cell co-stimulation - - - + ++++ +++++ 
     T-regs suppression - - - - + + 
     NK/NKT cell activation - - - + ++++ +++++ 
     ADCC - - - - ++++ ++++ 
     Anti-proliferative  ++++++ ++++++ ++++++ + +++ +++ 
Proteasome Features       
     Active moiety Boronate Epoxyketone Boronate - - - 
     Subunits inhibited bJ, bL bJ bJ - - - 
     Binding kinetics Reversible Irreversible Reversible - - - 
     bJ/Chymotrypsin ICJN (nM) R.T-U.V W X.T - - - 
     bR/Tryspin ICJN (nM) JVN-TRNN XWNN XJNN - - - 
     bL/Caspase ICJN (nM) RT-UT RTNN XL - - - 
MM IC;< (nM)* J.U J.N U.YJ >TNN xLNX >TNN xLNX Y xLNX 
Half-life (hours) L.Y <N.J N.X T-V X.L-T.J W.R-U.V 
Metabolism/excretion Hepatic Hepatic Hepatic Hepatic Renal Renal 
Route of administration IV/SC IV Oral/IV Oral Oral Oral 
FDA approval RNNX  RNLR  RNLJ RNNW  RNNW  RNLX  
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The 'rd generation IMiD, pomalidomide has been mainly used in the relapsed/refractory 
setting both as monotherapy or in combination. The potency of pomalidomide persists 
even in those refractory to lenalidomide and bortezomib where phase II trials have shown 
up to BC% response rates, double of that compared to single agent dexamethasone, with 
improved PFS and increased OS rates to JB.K months even in those with poor-risk 
cytogenetics, notably del JNp  (Shah et al. PCJP; Leleu et al. PCJ'; San Miguel et al. PCJ'; 
Richardson et al. PCJB). 
 
Treatment of high-risk SMM patients has been predominantly with IMiDs. Initial trials 
showed little gain in OS when treated with thalidomide or melphalan (Barlogie et al. 
PCCV). However, the seminal QuiRedex study (Mateos et al. PCJ') was the first to 
specifically look at treating high-risk SMM patients with lenalidomide and 
dexamethasone. The treatment arm showed an increase in both PFS (NN% vs 'C%) and OS 
(KB% vs VC%). This trial cemented the belief that a cure for MM lies within early treatment 
to remove the possibility of sub-clonal progression. 
 
1.2.4 Histone Deacetylase Inhibitors (HDACI) 
The mechanism of action of HDACI such as panobinostat and vorinostat involves 
preventing the inactivation of p[' and the blockade of the Unfolded Protein Response 
(UPR), a set of signalling pathways, which are essential for the survival of MM cells and 
also the site of activity for proteasome inhibitors. In the event that proteins marked for 
degradation build up in the cell, they form aggregates of misfolded/unfolded proteins that 
is termed an aggresome. The formation of aggresomes are highly organised and are a 
coping mechanism of the cell when proteasome function has reached full capacity or when 
proteasome function is inhibited (Johnston et al. JKKV). Aggresome formation is 
dependent on histone deacetylase ^ (HDAC-^) (Ouyang et al. PCJP) and has become a 
target of inhibition in cancers with possible synergy with PIs (Hideshima et al. PCJJ). 
Although improved depth of responses are seen when combined with bortezomib, it is 
unclear if this translates into improved OS and the tolerability of these agents is relatively 
poor (Kaufman et al. PCJP; Dimopoulos et al. PCJ'; Richardson et al. PCJ'b). These factors, 
combined with the emergence of targeted immunotherapy, likely infers HDACI will have 
a very limited role in the future.  
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1.2.5 Monoclonal antibodies (mAb) 
The anti-CD'V mAbs Daratumumab and Isatuximab, have both shown to be well tolerated 
with limited toxicity (Plesner et al. PCJP; Martin et al. PCJ').  Daratumumab was the first 
mAb to obtain FDA approval in PCJ[ in the relapsed setting for MM as monotherapy, on 
the back of a phase I/II trial showing increased PFS of [.^ months and a ORR of '^% 
(Lokhorst et al. PCJ[). It has been shown to have potent anti-myeloma activity both in 
vitro and vivo with multiple mechanisms of action that include complement-dependent 
cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), antibody-
dependent cellular phagocytosis (ADCP), FcgR-mediated apoptosis and CD'V ecto-
enzyme inhibition (Lee and Weber PCJ^; Lonial et al. PCJ^). The phase III trials CASTOR 
and POLLUX used daratumumab in combination with either bortezomib or lenalidomide 
in RRMM. Both trials showed promising interim data with the lenalidomide combination 
showing slightly better response rates (K'% vs V'%) (Dimopoulos et al. PCJ^; Palumbo et 
al. PCJ^).  
 
More recent trials have shown the benefit of adding Daratumumab to frontline treatment, 
for both transplant eligible (TEP) and non-transplant eligible patients (NTEP). The 
CASSIOPEA trial for TEP, combined daratumumab with bortezomib, thalidomide and 
dexamethasone, (Moreau et al. PCJK), whereas the MAIA (Facon et al. PCJK) and 
ALCYONE (Mateos et al. PCJV) NTEP trials combined daratumumab with lenalidomide 
and bortezomib respectively. Each of these trials showed impressive statistically 
significant increases in both complete remission rates and minimal residual disease 
negatively.  and ALCYONE trial, combined with bortezomib. Furthermore, the use in high-
risk smouldering myeloma shows encouraging responses in preventing MM 
transformation. The Centaurus trial used single agent Daratumumab for up to P years, 
obtaining a JP-month PFS of KV% (Hofmeister et al. PCJN).  
 
The second FDA approved mAb is elotuzumab. This antibody targets the cell marker 
SLAMN (previously known as CSJ) and is highly specific to plasma cells. Unlike 
daratumumab its mechanism of action is solely through ADCC, although inhibition of 
adhesion to bone marrow stromal cells is observed suggesting SLAMFN plays a role within 
the MM microenvironment (Lee and Weber PCJ^). The results of single agent use in 
RRMM were disappointing with no activity observed in phase I trials (Zonder et al. PCJP). 
However, when used in combination with lenalidomide and dexamethasone in the 
relapse/refactory setting, the results have been more encouraging with PB-month PFS 
increased from PN% to BJ% (Lonial et al. PCJ[).   
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1.2.6 Signal transduction pathways inhibitors 
Signal transduction pathways (notably PI'K/AKT/mTOR, MEK and NF-kB) play an 
important role in the pathogenesis of myeloma with upregulation of these pathways often 
observed and usually as a result of specific gene mutations e.g. MEK upregulation due to 
RAS mutation. Therefore, not surprisingly small molecular inhibitors of these pathways 
have been in early phase I/II development for a number of years.  
  
1.2.6.1 Phosphoinositide 3-kinase (PI3K) inhibitors 
PI'K is a lipid kinase signal transducer involved in the regulation of various cellular 
functions that include growth, proliferation, differentiation, and survival. Three classes of 
PI'K exist, with class J catalytic isoforms (pJJC) currently the main target for drug design 
(Jean and Kiger PCJB; Naymagon and Abdul-Hay PCJ^). Within myeloma, the most 
advanced of these are the oral AKT inhibitors perifosine and afuresertib. Inhibition of the 
AKT/PI'K signalling pathway has been shown to promote cell apoptosis, with additional 
cell death synergy when combined with bortezomib (Hideshima et al. PCCNa). Perifosine 
despite promising phase I/II data, saw the larger phase III trial halted early as little benefit 
was observed (Richardson et al. PCJJ; El-Amm and Tabbara PCJ'). Meanwhile, Afuresertib 
in a dose escalating phase I trial was shown to have a BJ% overall response rate when 
combined with bortezomib and dexamethasone and was reported as having a manageable 
safety prolife (Trudel PCJ^).  
 
The most established PI'K inhibitor in haematological malignancies is currently idelalisib. 
This Class I pJJCd PI'K inhibitor was approved in PCJB for the treatment of p[' mutated 
and relapsed CLL and follicular lymphoma. It has also been trialled in other B-cell 
malignancies, including MM (Jabbour et al. PCJB), where it has been shown to have a direct 
effect on MM growth and cell survival. Furthermore, it seemingly can overcome the 
protective effects of cytokines IL-^ and IGF-I within the BM milieu (Ikeda et al. PCJC). 
However to date, no PI'K inhibitor clinical trials in MM have been designed, partly due 
to the concerns over toxicity (Cheah and Fowler PCJ^). Despite this, numerous PI'K 
inhibitors have undergone preclinical investigations in MM models. The class I pan-PI'K 
inhibitors PIK-CKV and Buparlisib have shown potent preclinical effects on MM cell lines, 
with Buparlisib having a potential impact on the bone marrow microenvironment through 
downregulation of osteoclasts and upregulation of osteoblasts, thus potentially reducing 
osteolytic lesions (Martin et al. PCJ[; Zhu et al. PCJ[). Specific class I isoform PI'K 
inhibitors also exist, BAYVC-^KB^ (pJJCa) and GDC-CKBJ (pJJCa and pJJCb) have shown 
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cytotoxic, anti-proliferative and oncogene IGF-J inhibition across a number of MM cell 
lines, with synergy when combined with lenalidomide and dexamethasone in murine 
xenograft tumour models (Glauer et al. PCJ'; Munugalavadla et al. PCJB).  
 
mTOR inhibitors, such as rapamycin in theory would have benefit in preventing MM cell 
growth and proliferation by blocking the downstream effects of PI'K and Akt. (Li et al. 
PCJB). Although clinical trials of mTOR inhibition in a number of cancers have occurred, 
no significant ones involving MM have been documented.  
 
 
1.2.7 Chimeric antigen receptor T-cells (CAR-T) 
CAR-T therapy involves modifying a patient’s own T-cells, to express a chimeric protein 
that targets a specific antigen and then re-infusing the T-cells back into the patient. To 
date a number of different myeloma cell antigens have been studied, these include B-cell 
maturing antigen (BCMA), SLAMFN, CDJ'V, NKGPDA and CDJK (Kumar PCJN). The most 
promising target to date is BCMA. In a phase I study, PJ heavily pre-treated patients 
(median prior lines of therapy N), where treated in a dose-escalation study. ORR was VK%, 
with MRD achieved in all patients who had an MRD marker (Berdeja et al. PCJN). 
 
1.2.8 Other emerging therapies   
Targeted therapies such as the anti-apoptotic protein BCL-P inhibitor ABTJKK 
(venetolcax) has shown potency in both cell lines and patients with t(JJ;JB), which can be 
up to PC% of patients (Kumar et al. PCJN). However, concerns regarding venetolcax toxicity 
have been raised with the recent FDA warning. Enrolment of patients onto the venetolcax 
arm of the BELLINI trial for RRMM has been halted due to excess deaths in the venetolcax 
arm (FDA PCJK).  
 
The kinesin spindle protein inhibitor dinaciclib and the pan PIM kinase inhibitor LGH-
BBN, are other drugs which are potentially showing promising single agent activity in the 
RRMM setting (Rajan and Kumar PCJ^).
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1.2.9  Supportive care 
Recent British Society of Haematology (BSH) guidelines has put huge emphasis in the 
supportive care of myeloma patients both at diagnosis and during treatment (Snowden et 
al. PCJN). The guidance includes strategies to reduce infection, prevention of thrombosis, 
pain management and treatment of bone disease. Bisphosphonates, such as zoledronic 
acid, are routinely given to myeloma patients as treatment for bone disease. They have 
been shown to preserve bone density and reduce skeletal fractures through their 
osteoclastic inhibition as well as prolong progression-free and overall survival (Morgan et 
al. PCJ'). The mechanisms for improved OS are not clear, but likely involves modification 
of the bone marrow microenvironment as well as direct anti-myeloma activity (Aparicio 
et al. JKKV; Silbermann and Roodman PCJ').  Other treatments for bone disease include 
localised radiation, which can be effective for bone pain, treatment of unstable spinal 
disease and solitary plasmacytomas. 
 
Addition of prophylactic antibiotics, can also have a dramatic impact in preventing 
infections. Many serious infections occur within the first few months of diagnosis, due to 
the combined effects of chemotherapy, impaired normal immune function and the impact 
of spinal bone disease has on impaired breathing leading to chest infections. The PCJK 
results of the TEAMM trial, showed that both the number of infections and deaths were 
reduced if patients received JP weeks prophylactic levofloxacin upon diagnosis of MM 
(Drayson et al. PCJK). Other anti-microbial treatments include the anti-viral acyclovir, 
used with proteasome inhibitors to prevent shingles and herpes simplex infections. 
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1.3 Mechanisms of drug resistance 
MM is characterised by cycles of remission and relapse, which infers that eventually all 
forms of treatments will fail, or the disease becomes resistant to treatment. The 
mechanisms of drug resistance and how myeloma cells acquire them are complex. They 
include genetic, epigenetic or transcriptional changes usually involved in survival or 
apoptotic pathways. These changes can either be acquired or pre-existing, either way the 
selective pressures caused by drug treatment drive the emergence of drug-resistant sub-
clonal populations.  
 
1.3.1 Clonal evolution 
The concept of ‘clonal tides’ was born from the monitoring of MM sub-clones and their 
changes in relative frequency through the course of a single patient’s disease from 
diagnosis to death (Keats et al. PCJP). Through PCR analysis of the IgH VDJ region, 
multiple clones were identified at diagnosis. At each stage of disease treatment and upon 
relapse, the percentage frequency of these clones was monitored. The terminal clone most 
predominant at death (following progression to leukaemic phase of the disease) was 
shown to be present at diagnosis but represented a very small proportion of the original 
cancer bulk (<J%). This model of tumour evolution seemingly went against traditional 
paradigms of cancer evolution such as the unicellular origin linear model, where 
sequential acquisitions of NS-SNV (Non-Synonymous-Single Nucleotide Variant) 
mutations that drive disease progression.  
 
Thus, newer clonal paradigms of disease evolution that attempt to explain Keats’ findings, 
have become either an expansionist model where all mutations are present at diagnosis in 
multiple sub-clones (Walker et al. PCJB), or an intra-clonal heterogeneity model as 
outlined in Figure J.' (Egan et al. PCJP). The latter model allows distinct clones to react to 
selective pressures in a Darwinian response, selecting out clones with survival benefits, 
either through pre-existing mutations or newly acquired ones, both of which are termed 
‘driver mutations.’ The complexity of this model, makes the treatment and potential cure 
of MM extremely difficult, as all clones have the potential to further adapt independently 
through the acquisition of additional driver mutations and thereby obtain drug resistance 
(Chapman et al. PCJJ; Egan et al. PCJP; Bolli et al. PCJB; Walker et al. PCJB).  
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Figure 1.3. Intraclonal heterogeneity model of Multiple Myeloma (MM) development, adapted from 
Egan et al. 2012. Cartoon is a phylogram of the different MM clones throughout the course of disease. 
Distinct PC subclones are present at diagnosis, but the dominant subclone changing with each MM disease 
progression. All clones contain common Single nucleotide variants (SNVs) indicating a shared common 
ancestor, but also unique SNV that act as driver mutations. In Egan’s example there were 15 common SNV 
at all time points (=), 6 SNV common to the diagnostic and 2nd relapse («), while no variants where 
common to the 1st relapse and 3rd relapse/leukaemic phase. The greatest divergence is that between the 
1st and 3rd relapse/leukaemic phase, with 7 unique variants (n andÂ) detected in each sample (Egan et al. 
2012)
Normal
Cell
Common Ancestor 
Newly diagnosed
1st relapse
2nd relapse
3rd relapse
(leukaemic phase)
SNV common to all clones
SNV shared with diagnostic 
and 2nd relapse
SNV unique to diagnostic
SNV unique to 3rd relapse
SNV unique to 1st relapse
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1.3.2 Glucocorticoid Drug resistance 
There are three main mechanisms of glucocorticoid resistance (Schmidt et al. PCCB): 
i. Insufficient ligand; - intracellular GC levels may be reduced by increased levels 
of steroid binding proteins in the circulation, expression of GC metabolising 
enzymes or overexpression of cell membrane transporter proteins, thus removing 
intracellular GC e.g. P-glycoprotein (P-gp). Such resistance can be overcome by 
using P-gp inhibitors such as ciclosporin or verapamil-based drugs (Bellamy JKK^; 
Karssen et al. PCCJ). 
ii. GR mutations, splice variants or insufficient expression; - without the 
receptor, downstream signalling pathways are unable to be initiated. The lack of 
GR is thought to be the main mechanism of acquired GC resistance of the MM 
cell line MM.JR, obtained through long-term exposure to dexamethasone 
(Greenstein et al. PCC'). 
iii. Deficiency in GR-associated proteins; - these can either be cytoplasmic or 
nuclear in origin. Mutations or unresponsiveness of GC-regulated genes that are 
critical for cell death and/or genes that are able to interfere with the GC-induced 
death pathway could have overall impact on GC-induced apoptosis.   
 
Table J.[ outlines genes with the greatest microarray expression changes in the MM cell 
line MM.JS upon exposure to GC. Expression changes in these gene are not exclusive to 
MM but are seen in many other cell lines (Schmidt et al. PCCB). 
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Identifier Description Reg Other systems gene shared with  
Hs.VJ'PV NF-kBa inhibitor  
(IkB-a) 
­ PreB, SBK, WEHI, Jurkat, CEM, 
thymus-J 
Hs.N[[N FK[C^-binding protein 
[ (FKBP [J) 
­ PreB, WEHI, EoL, Jurkat, CEM 
Hs.BPC[^K GILZ ­ PreB, CEM, thymus-P 
Hs.JNK[P^ Thioredoxin interactin 
protein (TXNIP) 
­¯ PreB, CEM 
Hs.BBP^^K Glutamine synthase ­¯ PreB, thymus-P 
D[C^V' TGF-b II Receptor a ­ Jurkat, CEM 
Table 1.5. Genes regulated by GC in cells prone to GC-induced apoptosis, as identified in MM.1S cell line 
from microarray. Only genes with greater 2-fold change are shown, table adapted from (Chauhan et al. 
2002; Schmidt et al. 2004). Genes are listed according to the number of systems wherein regulation was 
observed; Identifier is either Unigene number (starting with Hs.) or GeneBank accession number (D50683); 
­  and ¯ denote two-fold or greater gene induction or repression, respectively; Cellular Human 
systems:  CEM - various sub-clones of the CCRF-CEM T-ALL cell line; PreB - PreB-697 B-ALL cells; Jurkat - T-
ALL cell lines stably transfected with either rat GRwt or rat GRLS7 Mouse: WEHI - WEHI7.2 lymphoma cell 
line; S49 - S49.A2 lymphoma cell line; thymus-1 - normal C56BL/6 thymocytes; thymus-2 - 18d foetal 
thymocytes from C57BL/6 wild-type mice or GR2KO mice.  
 
 
1.3.3 P-glycoprotein 1 (P-gp) 
P-gp is also known as multidrug resistance protein J (MDRJ) and ATP-binding cassette 
sub-family B member J (ABCBJ). Encoded by the ABCB( gene, it is a member of the ATP-
binding cassette (ABC) transporter proteins, itself a member of the MDR/TAP subfamily 
(Ueda et al. JKVN). ABC proteins are able to transport various molecules across extra- and 
intra-cellular membranes and are involved in multidrug resistance. P-gp expression has 
been shown to increase in cases of MM drug resistance and is thought to act as an efflux 
pump for xenobiotic compounds with broad substrate specificity, such as glucocorticoids 
and PI (Grogan et al. JKK'; Verbrugge et al. PCJP). This can often mediate the origin and 
subsequent clonal expansion of cancer cells, becoming resistant to anticancer therapy 
(Karssen et al. PCCJ; Breier et al. PCJ').  
 
1.3.4 Proteasome Inhibitor Resistance 
In addition to increasing P-gp expression, a number of differing mechanisms are thought 
to contribute to PI resistance. One of first reported was the gene mutation PSMB+, that 
codes for the β[ subunit bortezomib binding site (Oerlemans et al. PCCV; Ri et al. PCJC), 
thus impairing the ability of PI’s to bind to the active subunit. Other mechanisms include 
(Wallington-Beddoe et al. PCJV): 
• Aberrant expression of the ubiquitin-proteasome pathway components  
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• HDAC^ modulated activation of the aggresome autophagy pathway  
• Heat shock protein (e.g. GrpNV, HspKC) induction  
• Over-expression of NFE/L/, resulting in antioxidant response pathway induction 
• Reduced expression of the transcription factor Xbp-J, limiting PC differentiation 
required for PI sensitivity   
• Increase in survival signalling pathways such as IL-^, VEGF, c-MET, NF-kB, 
PI'K/AKT, IGF-J/IGF-JR and EGFR/JAK/STAT 
 
1.3.5 Immunomodulatory Resistance  
IMiD resistance is thought to be mainly related to cereblon pathway abnormalities, 
regarded as the main target of the IMiDs (Ito et al. PCJC). The mechanisms can either be 
due to reduced cereblon expression, therefore less available target for IMiD binding or 
pathway component mutations, reducing the ability of the IMiDs to bind to cereblon or 
their associated pathway components (Wallington-Beddoe et al. PCJV).  
 
1.3.6 Cell Adhesion Mediated-Drug Resistance (CAM-DR) 
The bone marrow (BM) microenvironment allows for MM cell proliferation, survival and 
protection against cytotoxic agents (Damiano et al. JKKK). Drug resistance can also occur 
through interaction between the adhesion receptors integrins on MM cells and their 
ligands on BM stromal cells (BMSC) and/or extracellular matrix proteins (ECM) 
(Hideshima et al. PCCNb; Noborio-Hatano et al. PCCK). This type of drug resistance has 
been termed CAM-DR, outlined in Figure J.B. Both Bortezomib and glucocorticoids have 
been shown to downregulate expression of VLA-B thus overcoming the effects of CAM-
DR (Tonko et al. PCCJ; Planey et al. PCC'; Webb et al. PCC'; Noborio-Hatano et al. PCCK). 
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1.4 Identification and immunophenotypic characterisation of 
plasma cells in MM 
1.4.1 CD138 and CD38 allows for identification of plasma cells 
CDJ'V and CD'V are highly expressed on both normal and disease bone marrow plasma 
cells. As high expression of CDJ'V is broadly unique to plasma cells, dual expression of 
these cell markers are ideal in plasma cell identification (Bataille et al. PCC^). CDJ'V, also 
known as syndecan-J, is a heparan sulfate proteoglycan that promotes cell-surface 
adhesion of plasma cells involved in their homing to the bone marrow (Katz PCJC). CD'V 
is a cell surface protein that acts both as a receptor and an ecto-enzyme. 
 
1.4.1.1 CD38 expression 
The CD'V gene is located on chromosome B (BpJ[) comprising of V exons and N introns 
spanning ^Pkb (Katz et al. JKV'). Gene transcription is regulated mainly by CpG islands in 
the promoter region but also by intron J responsive elements of retinoic acid (RA) and 
peroxisome proliferator-activated receptor γ (PPARγ) (Kishimoto et al. JKKV; Song et al. 
PCJP). It is widely expressed on cells of haematopoietic origin, both myeloid and lymphoid, 
primarily on activated cells and immature cells, with the highest expression generally seen 
on terminally differentiated plasma cells. Within the normal population and within ethnic 
groups, there is a wide variation in CD'V expression, with CD34 gene polymorphisms 
thought to be a contributing factor to this. Furthermore CD'V expression has been shown 
to correlate with anti-neoplastic drug sensitivity (Hartman et al. PCJC). CD'V expression 
on MM cells remains high and similar to that seen on normal plasma cells. Unlike CLL, it 
has not been shown to be a prognostic marker as it is expressed on virtually all MM cells 
(Hamblin et al. PCCP; Lin et al. PCCB; van de Donk et al. PCJ^). Upregulation of CD'V 
expression is observed in MM patients treated with All Trans-retinoic acid (ATRA) 
resulting in greater efficacy of the CD'V monoclonal antibody daratumumab (Nijhof et al. 
PCJ[).  
 
1.4.1.2 CD38 function 
Its function as a receptor helps regulate weak adhesion between CD'J (PECAM-J) on 
endothelial cells and migrating lymphoid cells (Dianzani et al. JKKB). CD'J (the sole ligand 
of CD'V) is also expressed on lymphoid cells, allowing for both cell-cell interaction and 
migration through the endothelial cell wall (Cesano et al. JKKV). The interaction of CD'V 
and CD'J has also been shown to cause proliferation of lymphoid cells, CXCLJP-induced 
cell migration and lymph node homing (Deaglio et al. PCJC; Vaisitti et al. PCJC).  
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CD'V also has enzymatic properties, having cyclase and hydrolase activity (van de Donk 
et al. PCJ^). Through the generation of nicotinic acid-adenine dinucleotide phosphate 
(NAADP+), CD'V is able to regulate CaP+ mobilisation from the cytoplasm, which activates 
signalling pathways such as PKC and NF-κB resulting in lymphocyte proliferation (Guse 
et al. JKKK; Moreno-Garcia et al. PCC[). 
 
 
1.4.2 Identification of malignant/clonal plasma cells  
Additional markers are required to distinguish between normal/polyclonal PC and those 
of pathological/clonal PC. Molecules involved in the maturation process of PC such as 
CDJK and CDB[ as well as the Ig superfamily molecule CD[^, are routinely used in the 
clinical setting to differentiate between normal and MM plasma cells (Manzanera et al. 
PCC[). Additional molecules such as surface or cytoplasmic immunoglobulin light chains 
(! and "), CDJ', CDPC, CDPV, CD'', CDBC, CD[P, CDV^ and CDJJN can also be used as 
clonal PC identification markers or even as MRD markers (Flores-Montero et al. PCJ^). 
Table J.^ adapted from Bataille et al., compares the immunophenotype of normal and 
malignant PCs. 
 
Cell Marker Normal (BM) MM (BM) PCL (PB) 
CDJ'V +++ +++ +++ 
CD'V +++ +++ +++ 
CD[^ - +++ - 
CDJK + - - 
CDB[ + - - 
CDPC - +/- + 
CDPV - + + 
Table 1.6. Comparison of immunophenotype of normal and malignant PC. (– infers cell marker not 
expressed, + expressed, +++ strongly expressed). MM – multiple myeloma; BM – bone marrow; PCL – 
plasma cell leukaemia; PB – peripheral blood. Adapted from (Bataille et al. 2006).     
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1.4.3 Cell markers involved in cell migration and adhesion 
1.4.3.1 CXCR4, an important cell marker for migration and survival 
CXCRB is the chemokine receptor for CXCLJP. The chemokine is highly expressed in 
various healthy tissues including lung, liver, bone marrow and is secreted by stromal cells 
as well as malignant cells. The binding of the chemokine to CXCRB initiates various 
downstream signalling pathways, resulting in gene transcription, initiating cell migration, 
proliferation and survival (Ganju et al. JKKV; Chatterjee et al. PCJ'). CXCLJP binding 
activates two major signal transduction enzymes, phospholipase C-β (PLC-β) and 
phosphoinositide '-kinase (PI'K). This ultimately induces the release of CaP+ from 
intracellular stores, activating protein kinase C (PKC), protein tyrosine kinase P (PTKP), 
paxillin and mitogen-activated protein kinase (MAPK), resulting in the induction of cell 
migration through reorganisation of the actin cytoskeleton  (Mellado et al. PCCJ).  
 
CXCRB has also been shown to activate the Ras/ERK and JAK/STAT signalling pathways, 
leading to changes in gene expression, cell cycle progression and changes in cell 
morphology required for migration (Chatterjee et al. PCJ'). Furthermore, activation of 
PI'K/AKT pathway by CXCRB has effect on the promotion of cell survival and 
proliferation. This occurs through inhibition of the pro-apoptotic protein BAD and by AKT 
stabilising the transcription factor β-catenin, which can then translocate to the nucleus 
and activate gene transcription (Clevers and Nusse PCJP; Mo et al. PCJ'). 
 
1.4.3.2 CXCR4/CXCL12 in Multiple myeloma 
Early in MM disease development, MM cells migrate to the BM through the action of 
CXCRB acting as the receptor for the chemokine CXCLJP (Alsayed et al. PCCN). Once in 
the BM microenvironment, CXCRB is able to regulate MM cell adhesion to stromal cells 
via its interaction with the integrin VLA-B (Parmo-Cabanas et al. PCCB; Chatterjee et al. 
PCJ').  
 
CXCRB expression in plasma cell dyscrasia can be very variable, but with a general trend 
of decreased expression with increasing disease activity (Moller et al. PCC'; Alsayed et al. 
PCCN). One study of PPN newly diagnosed patients showed an association between absence 
of CXCRB expression with hypercalcemia, bone destruction, occurrence of extramedullary 
disease and reduced overall survival (Bao et al. PCJ'). This clinical observation is supported 
by mouse models, which show reduced CXCRB expression is associated with bortezomib 
resistance, extramedullary disease and reduced survival (Stessman et al. PCJ').  
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However, subsequent studies have shown the relationship between CXCRB/CXCLJP 
expression and prognosis to be far more complex, especially in the role of extramedullary 
disease. Contrary of Stessman’s et al findings, increased expression of CXCRB/CXCLJP has 
been shown to play a role in the dissemination of plasma cells to extra-medullary sites, 
through Epithelial-Mesenchymal Transition (EMT) like transcriptional activation 
(Roccaro et al. PCJ[). Roccaro speculates the difference in their findings could be related 
to subclonal variation in CXCRB expression or up-regulation of CXCRB through epigenetic 
changes upon subclonal dissemination to the BM or extramedullary sites. The resulting 
increase in expression of the subclones leads to proliferation and survival of these cells in 
their new host environment (Roccaro et al. PCJ[).  
 
Subclonal CXCRB variation may explain why in certain MM cell lines and primary samples, 
CXCRB antagonists are able to inhibit MM growth and could serve as a therapeutic option 
in preventing plasma cell to disseminate (Beider et al. PCJJ). Indeed, such antagonists (e.g. 
plerixafor) are already used in the manipulation and subsequent mobilisation of 
haematopoietic stem cells, prior to stem cell collection (Steinberg and Silva PCJC). 
 
1.4.3.3 Integrins, pivotal role in plasma cell adhesion  
Integrins are transmembrane proteins found on numerous cells, that allow interactions 
with other cells and/or their extracellular matrix. Each integrin is comprised of a single 
alpha and a single beta subunit that both penetrate the cell surface membrane with small 
cytoplasmic domains. In humans, there are JV different alpha subunits and V beta 
subunits, making a large number of possible combinations. Their function is either related 
to the direct interaction with other cells/substances in the ECM or the influence they exert 
on various cytoplasmic signalling/tyrosine kinases/growth factors (Kumar JKKV; Martin et 
al. PCCP). They play a role in the following cell functions (some of which are shown in 
Figure J.B):  
• migration  (Sanz-Rodriguez et al. PCCJ; Parmo-Cabanas et al. PCCB) 
• differentiation (Kumar JKKV; Martin et al. PCCP) 
• proliferation and regulation of cell cycle (Schwartz and Assoian PCCJ) 
• cytoskeletal reorganisation and cell shape (Aplin et al. JKKK) 
• wound healing (Zeltz and Gullberg PCJ^) 
• apoptosis (Wang et al. PCJJb) 
• cancer metastasis (Hamidi and Ivaska PCJV) 
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Each integrin has a specific ligand (e.g. fibronectin, vitronectin, collagen, laminin), that 
upon binding triggers the activation of transcription within the cell. Vinculin is recruited 
to the cytoplasmic tail of integrins that are able to regulate kinases such PTKP and c-Src, 
but also results in anchoring of F-actin to the membrane forming microfilaments, which 
essentially link the cell’s cytoplasm to the ECM (Parsons et al. PCCC; Mitra and Schlaepfer 
PCC^). Uneven distribution of integrins on the cell surface can result in cell migration. 
When expressed at the front of the cell in the direction of intended travel, upon 
detachment of integrin substrates, they are absorbed back into the cell, but then reused at 
the very front of the cell with reattachment of the substrate. This continual process results 
in a moving or rolling motion of the cell along ligand-coated ECM or blood vessel walls.  
 
1.4.3.4 Specific Integrins/cell adhesion molecules found on MM plasma cells: 
• VLA-B; comprised of CDBKd (aB) and CDPK (bJ), found on many leucocytes as well 
as MM cells. Binds to fibronectin and VCAM-J (vascular adhesion molecule) on 
BMSC, modulated by CXCLJP. In MM cells, it can upregulate IL-^ secretion from 
BMSC, causing proliferation and blockade of apoptosis. MM migration (modulated 
by the chemokine CXCLJP) is a result of upregulation of VLA-B, allowing adhesion 
to endothelium and thus cell migration (Sanz-Rodriguez et al. PCCJ; Parmo-
Cabanas et al. PCCB). It also causes a decrease in osteoprotegrin, which in turn 
increases RANKL, promoting osteolysis and plays a critical role in CAM-DR of MM 
cells (Sanz-Rodriguez and Teixido PCCJ). Both Bortezomib and glucocorticoids 
have been shown to downregulate expression of VLA-B thus overcoming the 
effects of CAM-DR (Tonko et al. PCCJ; Planey et al. PCC'; Webb et al. PCC'; 
Noborio-Hatano et al. PCCK). 
• VLA-[; comprised of CDBKe (a[) CDPK (bJ), present on mature PCs. Lack of 
expression on PCs corresponds to immature and chemotherapy resistant MM PCs. 
• LFA-J; comprised of CDJJa (aL) and CDJV (bP), interacts with ICAM-J on BMSC. 
Expression increases with tumour cell growth 
• LFA-'; (CD[V) commonly positive on abnormal PC, adhesion to T-cells through 
CDP. T-cells will produce cytokines necessary for MM growth (Manzanera et al. 
PCC[). 
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Figure 1.4. Adhesion molecules and integrins within MM bone marrow microenvironment adapted from 
Morgan et al. and Katz (Katz 2010; Morgan et al. 2012b). Malignant plasma cells migrate to the bone 
marrow through the homing of the chemokine CXCL12 (localizes on the surface of stromal cells) to its 
receptor on MM cells, CXCR4. Upon cancer cells accumulating in the BM, positive cytokine and cell 
adhesion-mediated feedback loops are established between the cancer and stromal cells, establishing the 
clone and promoting cell survival, proliferation and mediates drug resistance. Integrin connection between 
the cancer cell and stromal cell include VLA-4 and LFA-1 adhering to VCAM and ICAM on the stromal cell 
respectively, with CD138 a key regulator of cell adhesion between MM cells and the ECM including stromal 
cells. CD44, RHAMM and CD38 mediate MM cells interactions with hyaluronan with expression and activity 
regulated by intracellular signal pathways and by extracellular factors such as growth factors, the enzymes 
heparanase and microenvironmental conditions such as hypoxia.  
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1.5 Aims of Project 
Sub-clonal analysis of MM through immunophenotyping is becoming more relevant in the 
age of monoclonal therapies such as the anti-CD'V therapy daratumumab. Therapy drives 
sub-clonal formation and the emergency of CD'V negative MM sub-clones post therapy 
raises new complexities in understanding drug resistance. We sought to design a complex 
(JC-colour) multi-parameter flow cytometry panel, enabling clonal and sub-clonal 
immunophenotypic analysis of both primary MM samples and known MM cell lines. 
Building upon this initial work, would allow further analysis of any sub-clones discovered 
with the aim of targeted pharmacological inhibition of MM and to develop a novel cell 
migration model using MM cell lines. The aims of this project are as follows: 
 
To immunophenotypically characterise myeloma cells related to cell adhesion and 
migration in both MM cell lines and primary MM bone marrow samples. Thus, aiming to 
identify the existence of myeloma sub-clones that can be distinguished by their 
adhesion/migration cell markers. 
 
The goal of achieving a lengthy remission or even a cure in MM, depends on fully 
understanding the many sub-clones in the disease, how they interact and the sensitivity 
to differing pharmacological agents. Building upon my initial sub-clonal analysis of MM 
cell lines, I set out to examine the phenotype, function and genotype of two related 
commercial cell lines, in order to explore the origins of glucocorticoid drug resistance. 
 
Based upon a novel migratory model used in the study of CLL migration, I aim to develop 
this model in studying MM cell migration, previously untrialled in such disease. The model 
would allow to investigate the role of SDF-J/CXCRB, BTK, PI'-k/Akt/mTOR and NF-κB 
pathways in cell MM migration/adhesion and to assess the impact of pharmacological 
inhibition of these pathways and ultimately cell survival.
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CHAPTER 2: 
2 Materials and Methods 
 
2.1 Tissue Culture 
 
2.1.1 Reagents, media and buffers 
RPMI-HIJK medium [CCml (Gibco) stored at B°C. 
DMEM high glucose medium [CCml (Gibco) stored at B°C. 
Medium HMM (MHMM), Earle’s Salts [CCml (Gibco) stored at B°C. 
Foetal calf serum (FCS) (Gibco) stored in [Cml aliquots at -PC°C.  
Penicillin ([CCCU/ml)/Streptomycin ([CCCµg/ml) (Gibco) stored in JCml aliquots at -
PC°C. 
L-glutamine PCCmM (Gibco) stored in [ml aliquots at -PC°C. 
Sodium Pyruvate JCCmM (Gibco) stored in [ml aliquots at -PC°C. 
Dulbecco's Phosphate-Buffered Saline (DPBS), no magnesium, no calcium [CCml 
(Gibco). 
Trypsin-EDTA (C.[%), no phenol red (Gibco) used at C.C[% concentration, diluted with 
PBS, stored at B°C.  
Gelatin Solution Type B, P% (Sigma-Aldrich) stored at B°C.  
Human IL-I Research grade (Miltenyi Biotec; J'C-CK[-'^[) JCµg reconstituted in JCCµl 
of deionised sterile-filtered water. Diluted with KCCµl PBS, supplemented with C.J% BSA 
to give a final concentration of JCµg/ml. JCCµl aliquots stored at -PC°C.  
Histopaque®-HKYY (Sigma-Aldrich) 
 
2.1.2 Equipment and tissue culture plastics 
Vi-cell XR cell counter (Beckman Coulter), [[Cµl single cell suspension (or dilutions of) 
added to Vi-cell sample cups. 
Greiner culture flasks, tissue culture treated w/ filtered cap (Greiner Bio-one) – sizes 
T-P[, T-N[, T-JN[  
Nunc™ Cell Culture Treated TripleFlasks™ (Thermo Scientific™) 
Corning® Cell Scraper (Sigma-Aldrich) 
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2.1.3 Cell lines 
2.1.3.1 Multiple Myeloma (MM) 
Table 2.1. List of MM cell lines used in this study and disease type. MM - multiple myeloma; PCL - plasma 
cell leukaemia; k - kappa light chain; l - lambda light chain; PE - pleural effusion; PB - peripheral blood; F 
– female; M – male; DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; ATCC – 
American Type Culture Collection; ECACC – European Collection of Cell Cultures; 
 
Cell Line IgH T Target 
gene 
Mutations Deletions  Reference 
JJN-^  t(JB;J^);  
t(V;JB)  
c-Maf  TP['  (Jackson et al. 
JKVK) 
MM.HR  t(JB;J^);  
t(V;JB) 
c-Maf KRAS (G(/A - het);  
TRAF' (K+37 - hom) 
CDKNP  (Moalli et al. 
JKKP) 
MM.HS  t(JB:J^); 
t(V;JB)  
c-Maf KRAS (G(/A - het);  
TRAF' (K+37 - hom) 
CDKNP  (Moalli et al. 
JKKP) 
NCI-
HM`M  
t(B;JB) MMSET/ 
FGFR' 
NRAS (G(3D - het);  (Gazdar et al. 
JKV^)  
OPM-`  t(B:JB) MMSET/ 
FGFR' 
FGFR' (K7+8E - het); 
TP[' (R(9+H - hom) 
CKKNP  (Katagiri et al. 
JKV[)  
RPMI-
a``I  
t(JB;J^); 
t(V;PP)  
c-Maf KRAS (G(/A - het);  
TP[' (E/4+K - hom)  
TRAF'  (Matsuoka et 
al. JK^N) 
U-`II  t(JJ;JB) CCNDJ BRAF (K78(N - het);  
RBJ (E;(<X - hom);  
         K//4R - hom);  
TP[' (A(7(T - hom);  
TRAF (K++8I - hom) 
 (Nilsson et al. 
JKNC) 
Table 2.2. MM cell line genetic characteristics. IgH – Immunoglobulin heavy chain; T – Translocation; 
MMSET - multiple myeloma SET domain; FGFR3 - fibroblast growth factor receptor-3; HD - homozygous 
deletion; het - heterozygous mutation; hom - homozygous mutation; CCND1 - cyclin D; CDKN2 - cyclin 
dependent kinase inhibitor 2; TRAF3 - tumour necrosis factor
Cell Line Disease Type Sample Sex CDJc Supplier Catalogue # 
JJN-^  MM IgAJ k PE F +/- DSMZ ACC [BJ 
MM.HR  PCL IgA l PB F - ATCC CRL-PKN[ 
MM.HS  PCL IgA l PB F - ATCC CRL-PKNB 
NCI-HM`M  MM IgA k PE F +/- ECACC K[C[CBJ[   
OPM-`  MM IgG l PB F - DSMZ ACC [C 
RPMI-a``I  MM IgG l PB M - ECACC VNCJPNCP 
U-`II  MM IgE l PB M + ECACC V[C[JCC'  
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2.1.3.2 Fibroblasts and Endothelial cells 
Cell line Cell type Description Supplier/Catalogue # 
HS-c Human 
stromal 
GFP and non GFP tagged ICR, London* 
HUVEC Human 
endothelial 
Virally transfected with hTERT by 
lentivirus containing cDNA of 
telomerase, immortalising cell 
Invitrogen, CLL group, 
Cardiff University** 
MRC-c Human 
fibroblast 
Source of SDF-J/CXCLJP secretion 
(Kang et al. PCC[)  
CLL group, Cardiff 
University** 
CDJKL 
  
Mouse 
fibroblasts 
Transfected embryonic fibroblast 
L-cells expressing CDBCL 
CLL group, Cardiff 
University** 
NTL Mouse 
fibroblasts 
Non-transfected L-cells 
(Willimott et al. PCCN) 
CLL group, Cardiff 
University** 
Table 2.3. Non-myeloma cell lines used in this study. *Kindly provided by Dr Faith Davis, Institute of 
Cancer and Genetics, London. **Kindly provided by Dr Elisabeth Walsby, CLL Group, Cardiff University 
 
2.1.4 Maintenance of cell lines 
All Myeloma cell lines are IL-^ independent and except for JJN-' were cultured in RPMI-
J^BC growth medium supplemented with JC% FCS, PmM L-glutamine and antibiotics 
(JCCU/ml Penicillin and JCCµg/ml streptomycin). JJN-' was cultured in DMEM 
supplemented with JmM pyruvate, non-essential amino acids, antibiotics (as per RPMI 
medium) and PC% FCS. The cell lines were grown in incubators containing [% COP at 
'N°C, maintaining cell densities between C.' - J.CxJC^ cells/ml, thus requiring sub-
culturing P-' times a week. MM.JR and MM.JS cells were semi-adherent to the plastic 
culture flasks and were thus removed with aid of a cell scraper. HUVEC, MRC-[ and HS-[ 
cells were maintained in MJKK media, supplemented with PC% FCS and antibiotics (as per 
myeloma cell lines). Cells were cultured in ' tier flasks, HUVEC flasks were coated with 
C.P% gelatin for 'C minutes before use. Media required replacement every ' days, with 
sub-culturing at least once a week. Cells were harvested using C.C[% trypsin due to 
adherence to flask.  
 
All cell lines were cryopreserved at low passage number, at a density of JxJCN cells/ml in 
complete growth media containing JC% DMSO. If short term storage (less than three 
months) was anticipated cells were kept at -VC°C, otherwise they were stored in liquid 
nitrogen. All cells were discarded after approximately JC-JP weeks of use. Regular 
laboratory-wide mycoplasma PCR testing was undertaken and all cells used in this study 
remained mycoplasma-free. 
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2.1.5 Cell proliferation and viability 
Cells were seeded at C.[xJC^ cells/ml in PB-well plates. At PBh intervals, cells were counted 
on a Vi-Cell XR (Beckman Coulter). 
 
2.1.6 Liquid co-culture, microscopy and camera 
Co-culture experiments involved seeding C.[xJC^ fibroblasts/endothelial cells (HUVEC, 
HS-[, MRC-[, CDBCL and NTL) into ^-well plates (HUVECs required wells to be coated 
with C.P% gelatin prior to seeding) in '.[ml MJKK medium. In every case, cells were left 
for ' hours to allow adherence to plastic before [xJC^ myeloma cells added to wells (ratio 
of JC:J).  
 
In experiments where adhesion was assessed, plates were kept at 'N°C in a [% COP 
atmosphere. Whole wells were analysed at PBh, BVh, NPh and K^h. This was done by 
removing all the media, C.[ml was analysed by the Vi-cell XR cell counter, thus counting 
non-adhered cells and validated by flow cytometry analysis on pre-determine SSC and FSC 
gates, specific to myeloma cells, using C.Jml of media. Jml of fresh MJKK media was placed 
back onto the adhered cells to allow camera screen shots (attached to a microscope) to be 
taken, using Q-Capture software. Adherent myeloma cells, were removed from wells using 
C.C[% trypsin and counted by both Vi-cell and flow cytometry methods as described 
above. Adherent myeloma cells were also phenotypically characterised by flow cytometric 
analysis having being immunostained. The percentage of adherent cells was expressed as 
a function of the total number of myeloma cells in the culture (i.e. both adherent and non-
adherent cells). 
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2.2 Flow cytometric analysis 
2.2.1 Reagents and materials 
Propidium Iodide (PI) (Sigma-Aldrich) x'C stock reconstituted in PBS, used at [Cµg/ml 
for cell cycle analysis and PCµg/ml for apoptosis analysis. Stored at B°C.  
`% Paraformaldehyde (PFA) (Sigma-Aldrich) prepared by dissolving Pg of reagent grade 
PFA in JCCml PBS at [C°C. Stored at B°C in dark to prevent depolymerisation. PCCµl added 
to fix stained samples and stored at B°C until analysed.  
Annexin V- Fluorescein Isothiocyanate (FITC) Apoptosis Detection Kit 
(eBioscience/Catalogue # BMS[CCFI/'CCCE) 
Annexin V- Allophycocyanin (APC) Apoptosis Detection Kit (BioLegend/Catalogue # 
^BCK'P) 
CellTrace™ Carboxyfluorescein Succinimidyl Ester (CFSE) cell Proliferation Kits 
(Invitrogen; C'B[NC) Stock solution JmM, stored at -PC°C. Stained cells analysed on BD 
Accuri C^, FLJ channel (BVV-nm excitation source).  
Cell Proliferation Dye eFluor® IYK (eBioscience; ^[-CVBC) Stock solution [mM, stored 
at -PC°C. Stained cells analysed on BD Accuri C^, FLB channel (^BC-nm excitation source).  
Fix & Perm® Cell Permeabilization Reagents (Invitrogen; GASCCB) 
Anti-Mouse Ig, κ/Negative Control Compensation Particles Set (BD; [[PVB') 
RNase A (sigma) stock solution JCµg/ml, aliquoted and stored at -PC°C. 
BD Phosflow™ Perm/Wash Buffer I (BD Bioscience; [[NVV[) 
BD Phosflow™ Perm Buffer III (BD Bioscience; [[VC[C) 
BD Pharmingen™ Stain Buffer (BD Bioscience; [[B^[^) 
BD Cytofix™ fixation Buffer (BD Bioscience; [[B^[[) 
Anti-human IgM (µ chain specific) antibody (Sigma-Aldrich; I CN[K) Jmg reconstituted 
in Jml PBS to give working concentration of Jmg/ml, stored at B°C. 
Sodium Pervanadate solution prepared by adding Jµl of 'C% sodium peroxide (Sigma-
Aldrich) to KKµl of JCmM sodium vanadate (sigma-Aldrich) 
 
2.2.2 Equipment and software 
BD LSRFortessa™ Cell Analyser (Becton Dickinson) – Data collected on BD Diva 
software and analysed on FlowJo® software (FlowJo, LLC). 
BD Accuri™ CI Cell Analyser (Becton Dickinson) data collected and analysed on Accuri 
C^ analysis software. 
BD FACSAria™ Cell sorter (Becton Dickinson) 
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2.2.3 Antibodies 
Target Site Fluorochrome Host Isotype / Clone Catalogue # / 
Supplier 
CDHM CS PerCP/Cy[.[ Mouse IgGJ k / HIBJK 'CPP'C / BioL 
CD`c CS PE Mouse IgGPb k / BE' JPK-CCJ-'JJ / MB 
CD^a CS PE/Dazzle™ [KB Mouse IgGJ k / HITP 'C'['V / BioL 
  FITC Mouse IgGJ k / HB-N '[^^JC / BioL 
  PerCP Mouse IgGJ k / HB-N '[^^PP / BioL 
CDJc  CS APC Mouse IgGJ k / HI'C 'CBCJP / BioL 
CDJMd  CS BV [JC™ Mouse IgGJ k / KFJC 'CB'JV / BioL 
  PerCP/Cy[.[ Mouse IgGJ k / KFJC 'CB'JP / BioL 
CDcI  CS PE Mouse IgGJ k / HCD[^ 'JV'C^ / BioL 
CDI`L CS eFluor ®B[C Mouse IgGJ k / Dreg-[^ BV-C^PK-BP/ eB 
CDMK* CS BV ^C[™ Mouse IgGJ k / [EJC 'PVJPV / BioL 
  PerCP/Cy[.[ Mouse IgGJ k / [EJC 'PVJJV / BioL 
CDH^a   CS Alexa Fluor® NCC Mouse IgGJ k / MIJ[ '[^[JP / BioL 
  PE Mouse IgGJ k / MIJ[ '[^[CB / BioL 
CDHaJ** CS PE-CyN Mouse IgGPa k / JPG[ 'C^[JB / BioL 
  APC Mouse IgGPa k / JPG[ 'C^[JC / BioL 
CD`J^# CS PE-CyN Mouse IgGPa k / UICP 'BV^JC / BioL 
IL-I IC Pacific Blue™  Rat IgGJ k / MQP-J'A[ [CJJJB / BioL 
Ki-IY IC BV ^C[™ Mouse IgGJ k / Ki-^N '[C[PP / BioL 
  FITC Mouse IgGJ k / PCRajJ JJ-[^KK-BP / eB 
MMP-M  IC FITC Mouse IgGPb k / [^JPK ICKJJJF / R&D  
MUM-H IC FITC Mouse C^CJ / Dako 
p-Syk  pY'BV PE Mouse IgGJ k / IJPC-NPP [[V[PK / BD 
p-Tyr pYKK Alexa Fluor®488 Mouse IgGPb k / PYKK SC NCPC / SC 
SyK IC FITC Mouse IgGPa k / BDJC [[PBN^ / BD 
Table 2.4. Anti-Human antibodies used in this study all stored at 4°C. PerCP - peridinin-chlorophyll-
protein; Cy – cyanine; FITC - fluorescein isothiocyanate; APC – allophycocyanin; PE – phycoerythrin; BV – 
Brilliant Violet; BioL – Biolegend Inc; R&D – R&D Systems®; SC – Santa Cruz Biotechnology, Inc; BD – BD 
Bioscience; MB – Miltenyi Biotec; CS- cell surface; IC – intracellular; *also known as thy1; **also known as 
CXCR4; #also known as Mdr-1; 
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2.2.4 Cell surface and intracellular immunostaining 
Depending on the experiment, between C.[-JxJC^ cells were harvested for cell surface 
staining. Cells were washed and re-suspended with PBS to a volume of PCCµl. [µl of 
antibody (Table B) would be used to stain JxJC^ cells. Samples were incubated in dark for 
J[ mins, and further washed in PBS before being analysed. If intracellular staining was 
required, the Invitrogen Fix & Perm® protocol was followed, which involved fixing the 
samples in JCCµl of reagent A, followed by permeabilising the samples in JCCµl of reagent 
B together with the addition of [µl of antibodies and C.^µl NP-BC. Optional final fixation 
in PCCµl of P% PFA allowed the samples to be stored at B°C prior to analysis. Unstained 
controls were always used, prepared in exactly the same manner but without the addition 
of antibodies. Multi-colour flow cytometry was then employed using a BD LSRFortessa 
instrument. The panels were set up using compensation beads (BD), such that aliquots of 
beads were labelled with a [µl aliquot of each antibody and then auto compensation was 
applied prior to analysis.  
 
2.2.5 Phosphoylation analysis and B-cell stimulation 
The ‘BD Phosflow™ protocol for Human PBMCs’ was followed.  If cell surface marker 
staining was required, BD Phosflow™ Perm/wash buffer I was used without cytofix, 
otherwise Cytofix buffer and Perm/Wash buffer III was used as per the protocol, starting 
with a single cell suspension of JxJC^ cells/ml in C.[ml of media. Cells were starved of FCS 
in FCS-free media for PBh before analysis. Where the effects of B-cell stimulation on 
phospho-protein levels were investigated, cells were stimulated with JCµg/ml anti-human 
IgM antibody for JC mins. Pre-treatment of cells with JCµl of freshly prepared sodium 
pervanadate solution for J[ mins served as a positive control of phospho-protein 
expression.  
 
2.2.6 Viability and cytotoxic assays using annexin V and propidium iodine 
(PI) 
Drug cytotoxic assays were done at BVh (unless otherwise specified), cells were seeded in 
PB-well plates, at a concentration between C.B-C.[xJC^ cells/ml in fresh media.  Samples 
were stained with [µl Annexin V (APC or FITC) and JCµl PI (PCµg/ml) as per the kit’s 
protocol and samples were analysed on BD Accuri C^ using CFlow software. Cell viability 
was calculated by first gating out debris and doublets and then acquiring [,CCC events. 
Viable cells were negative for both Annexin V and PI and were enumerated using quadrant 
gating.   
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2.2.7 Cell cycle analysis 
Cells for analyse were harvested, washed and re-suspended in a single cell suspension in 
PBS with P% FCS at C.JxJC^cells/ml. Jml ice-cold NC% ethanol was added to each cell pellet 
and the cells were resuspended and then stored for at least Jh at -PC°C. Cells were then 
washed in PBS and [Cµl of RNase A stock solution was added prior to incubation for B[ 
mins at 'N°C. C.[ml of PI staining solution was added and incubated for a further J[ mins 
at 'N°C before analysis on BD Accuri C^. Data was analysed using FlowJo cell cycle analysis 
software.  
 
2.2.8 Cell Proliferation analysis by cell tracing reagents  
The Invitrogen CellTrace experimental protocol was followed but was optimised for a final 
cell concentration of JxJC^cells/ml. The procedure was started with single cell suspension 
in Jml PBS, desired amount of CSFE or eFluor ^NC was added to form a final working 
concentration of [µM for CSFE dye and P[µM for eFluor ^NC dye. The samples were then 
incubated in the dark for PC mins at 'N°C. JCml of culture medium was then added to the 
cells and incubated for further [ mins, thus removing any free dye from the solution. Cells 
were then pelleted by centrifugation and re-suspended in fresh pre-warmed complete 
culture medium at the desired volume. [Cµl samples were analysed on a BD Accuri C^ 
flow cytometer to ensure adequate uptake of dye.  
 
2.2.9 Flow cytometer based Fluorescence-Activated Cell Sorting (FACS) 
Phenotypically distinct sub-populations of the myeloma cell line MM.JS were identified 
based on their differential CD'V expression (CD'Vdim and CD'Vbright). Approximately JC 
million cells were stained with [Cµl of CD'V-FITC Fluorochrome (BioLegend) and the 
cells were then sorted on a BD FACSAria.  Conservative gating was applied to the CD'V 
histogram, such that approximately N% of the lowest expressing cells and 'C% of highest 
expressing cells were sorted. Cells were sorted into J[ml Falcon tubes coated with FBS.  
Once collected, cell purity was checked on BD Accuri C^ flow cytometer and the 
remaining cells were washed and suspended in RPMI media containing JC% FCS. The two 
new derived cell lines were subsequently termed MM.JSdim, referring to cells sorted from 
the CD'Vdim population and MM.JSbright, referring to cells sorted from the CD'Vbright 
population. 
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2.3 Primary Multiple Myeloma samples 
Ethical approval was obtained from the South-East Wales Local Research Ethics 
Committee (approval number J'/WA/C'V').  Bone marrow samples were obtained from 
patients who were being investigated for suspected Myeloma at the University Hospital of 
Wales, Cardiff in accordance with the Declaration of Helsinki. Patient information sheets 
regarding this study were given to every patient prior to the request for consent (see 
appendix for information sheets and consent forms). A Material Transfer Agreement 
(MTA) for transfer of each sample from the clinical setting to the research laboratory was 
set up as per Cardiff University guidance. 
 
2.3.1 Cell preparation and freezing 
Bone marrow mononuclear cells (MB-MNCs) were isolated by density gradient 
centrifugation, using Histopaque®-JCNN (Sigma-Aldrich). BxJC^ cells were aliquoted for 
flow cytometry analysis. The remaining cells were cryopreserved in DMEM media 
containing PC% FBS and JC% DMSO.   
 
2.3.2 Antibody staining 
PxJC^ cells were stained with [µl of the following antibodies (see section P.P.B for 
additional procedure details) using an Invitrogen ‘fix and perm’ kit. PxJC^ cells were used 
as unstained controls and were prepared using the same method except no antibodies 
were added. Once the cell staining protocol was completed, cells were fixed in PCCµl P% 
PFA and stored at B°C, until analysed on BD LSRFortessa flow cytometer. 
 
Surface Markers - Fluorochrome  Intracellular Marker - Fluorochrome 
CDHM - PerCP/Cy[.[ IL-I - Pacific Blue™ 
CD^a - PE/Dazzle™ [KB Ki-IY - BV ^C[™ 
CDJc - APC MMP-M - FITC 
CDJMd - BV [JC™  
CDcI - PE  
CDH^a - Alexa Fluor® NCC  
CDHaJ (CXCRJ) - PE-CyN  
Table 2.5. Flow cytometry antibody panel used for primary samples all stored at 4°C. 
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2.4 Migration assays 
2.4.1 Reagents and equipment 
Recombinant Human SDF-Ha/CXCLH`a (R&D Systems; '[C-NS-CJC) was reconstituted 
in JCCµl of sterile PBS to give a working concentration of JCCµg/ml. Aliquots were then 
stored at B°C.  
Corning® Transwell® polycarbonate membrane cell culture inserts (Sigma) ^.[ mm 
Transwell with '.Cμm pore polycarbonate membrane insert. 
FiberCell® Systems Duet Pump (FiberCell Systems Inc; P'PCP) 
FiberCell® Small Polysulfone Cartridge - pore size K.Hµm (FiberCell Systems Inc; 
CPCP[) 
 
2.4.2 Transwell assays 
The upper (apical) chamber was seeded with C.P[xJC^ cells in P[Cµl of fresh media with or 
without the addition of investigational drug. The lower (basolateral) chamber contained 
[CCµl of media with the desired concentrations of CXCLJP (standard concentration 
JCCng/ml unless otherwise specified). Transwell plates were incubated at 'N°C for PBh 
unless otherwise specified. Cells were counted in both chambers of the transwells using a 
set acquisition volume (JCCµL) on a BD Accuri C^ flow cytometer. The percentage of 
migration was calculated from the number of cells counted in the basolateral chamber 
(migrated) divided by the number of cells originally seeded into the apical chamber. 
 
2.4.3 Dynamic Circulatory model 
2.4.3.1   Modifying a hollow fibre bioreactor 
Our research group had previously created a dynamic circulatory model for studying 
migration of leukaemic cells. The model is a modification of a hollow fibre bioreactor as 
outlined by Walsby et al (Walsby et al. PCJBc) and diagrammatically shown in Figure P.J. 
The bioreactor uses a peristaltic pump to create a flow of media at a defined shear force 
(dynes/cmP) through a closed system consisting of a reservoir of media, wide tubing, and 
a polysulfone cartridge containing porous (C.Pµm) hollow fibres. The lumen of each 
hollow fibre was coated with matrix proteins to allow attachment of endothelial cells. The 
fibres in the cartridge were first activated by NC% ethanol, followed by water, and then 
exposed to gelatin (C.P% solution; Sigma Aldrich) for Jh, providing a matrix for endothelial 
cells (HUVEC) to adhere to the insides of the hollow fibres. MJKK media supplemented 
with PC% FCS and antibiotics was used to gently wash unbound matrix protein from the 
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hollow fibres and to allow its removal from the system. J[xJC^ HUVECs were then 
introduced into the hollow fibres and allowed to adhere to the gelatin-coated fibres for Bh 
(the cartridges were inverted half way through to ensure even coating). Non-adhered cells 
were then removed from the system and counted. The system was filled with [C mL MJKK 
media, and circulation was initiated. Once the system was primed with no air bubbles, 
[xJC^ of the CXCLJP-secreting fibroblasts MRC-[ (Kang et al. PCC[) were introduced into 
the EVS via one of the EVS ports. Medium was circulated through the system under a shear 
force of J.[ dynes/cmP overnight before the shear force was increased to JC dynes/cmP for 
a further PBh. The shear force was increased in increments to encourage the HUVECs in 
the hollow fibres to form firm adhesion and to align along the fibres to form 
‘pseudovessels’. Approximately BVh after initial experimental set up, BCxJC^ myeloma cells 
(concentration of C.VxJC^ cells/ml) were subsequently introduced into the circulating 
system through port P of the cartridge (Figure P.J). Cells were then circulated for BVh at 
'N°C. Samples were taken from the circulating compartment and the EVS at Jh and BVh 
for analysis. Migrated cell were deemed to be those retrieved from the EVS, accessed via 
either EVS port (Figure P.J), with non-migrated those remaining in the circulation. Both 
samples were counted and analysed on a BD Accuri C^ flow cytometer.  
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Figure 2.1. Diagrammatical representation of the circulatory model, adapted from Walsby et al. 2014. 
HUVEC cells seeded into the hollow fibres of the bioreactor are exposed to physiologically relevant shear 
forces through the action of the peristatic pump. In addition, myeloma cells being pumped around the 
system, will have transient interaction with the endothelial layer. The hollow fibres in the bioreactor have 
0.1µm pores through which myeloma cells can migrate into the space outside fibres, attracted to the 
chemokine SDF-1, secreted by MRC-5; the EVS is shown in the cross-sectional image of the cartridge. 
Myeloma cells were recovered from the circulating compartment and the EVS of the system via the access 
ports. EVS: Extravascular space; HUVEC: Human umbilical vein endothelial cells.  
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2.4.3.2 Antibody labelling of myeloma cells 
After the retrieval of the myeloma cells from the circulating compartment and the EVS, 
the cells were labelled with the fluorescence-labelled antibodies listed in Table [. 
Depending on the experiment, separate samples were labelled with additional antibodies, 
(CXCRB-APC, CXCRB-PE/CyN, CDBKd-PerCP/Cy[.[, Ki-^N-FITC, CDJ'V-PE, CD'V-FITC, 
CDKC-PerCP/Cy[.[). Circulated myeloma cells, and where possible migrated cells 
retrieved from the EVS, were compared with cells maintained under static culture 
conditions. Flow cytometry was performed on an BD LSRFortessa or BD Accuri C^ and 
data were analysed using FlowJo software. 
 
2.4.3.3 Migration 
Migration of the myeloma cells was measured after BVh by cell counting JCCµl samples 
from the EVS on a BD Accuri C^ flow cytometer. As per the previously described method 
(Walsby et al PCJB), the percentage of the circulating population that migrated was 
calculated according to the formula:  
% Migration = 100	 × [NP'/(NPP + NP')] 
 
Where NPP is the number of live cells in the circulation compartment and NP' is the 
number of live cells in the EVS. The total cell number in the entire model was then scaled-
up e.g. JCCµl of circulation compartment volume analysed, represents J/[CC of the total 
([Cml) retrieved volume, so the cell count from a volume of JCCµl was multiplied by [CC 
to obtain the total number of cells in the compartment.  
 
2.4.3.4 Inhibiting SyK, CD49d and CXCR4 functionality 
In some experiments, the myeloma cells (BCxJC^) were pre-treated with one or a 
combination of pharmaceutical agents, listed in Table P.^, prior to being introduced into 
the circulating model. In such cases, untreated myeloma cells from the same cell line were 
introduced into a parallel cartridge as a control.  
 
Drug Action Dose Supplier/Cat. #  
Natalizumab (Tysabri) Anti-CDBKd antibody JµM Elan Pharma. Ltd 
ONO-NJ^J CXCRB antagonist JµM Ono Pharma. Ltd 
GS-KKN' (Entospletinib) Selective SyK inhibitor [µM-[CµM Selleckchem/SN[P' 
Table 2.6. Pharmaceutical agents used in circulatory model.  
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2.5 Whole exome sequencing 
2.5.1 DNA extraction 
DNA extraction of the individual cell lines (MM.JR, MM.JSdim and MM.JSbright) was 
performed using a DNeasy Blood & Tissue Kit (Qiagen; ^K[CB) as per the manufacturer’s 
instructions. P.[xJC^ cells were used per cell line for extraction and extracted samples were 
stored at -PC°C prior to downstream processing and analysis. 
 
2.5.2 Quality Control  
2.5.2.1 Nanodrop 
Duplicate J.Cµl samples were analysed on a Nanodrop; JCCC Spectrophotometer (Thermo 
Scientific). This allowed both DNA quantification and purity assessments to be 
determined. The AP^C/APVC ratio gives an indication of protein contamination and the 
P^C/P'C ratio an assessment of RNA contamination.  
 
2.5.2.2 Gel electrophoresis 
Standard agarose gel electrophoresis (JCCml), with [µl ethidium bromide (Sigma-Aldrich) 
was run for additional DNA quantification, using Fluorescent DNA Quantitation Kit 
(BioRad) and analysed on the fluorometer QuantiFluor (Promega). 
 
2.5.3   BGI sequencing and bioinformatics 
After in-house quality assurance of DNA purity, Bµg of DNA in J.[ml microfuge tube was 
centrifuged to generate a dry pellet using a vacuum centrifuge and sent to BGI laboratories 
in Hong Kong on dry ice. Whole exome sequencing (WES) analysis was generated on an 
Illumina HiSeq BCCC system at a read depth of x'C. Bioinformatics was done using the 
GATK platform, courtesy of Dr Kevin Ashelford, with mutation analysis performed using 
Enrichr (Chen et al. PCJ'). Additional bioinformatics and clonal evolution analysis, 
including phenotypic analysis and diagrams were courtesy of Dr Tom Connor, Cardiff 
University. 
 
A copy of the VCF files of the WES can be found on the Research Group shared laboratory 
protocol folder on Dropbox™, accessed by the following web link: 
 https://www.dropbox.com/sh/kdrdeKxexNzotul/AAB'umWDQOQ-
mBYWXLpOTKMTa?dl=C 
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2.6 Protein Analysis 
2.6.1 Equipment 
BioTek Cytation ^ image reader 
Dry heating block 
Orbital Shaker (Stuart-Scientific) 
NuPAGE™ J-H`% Bis-Tris Protein Gels, H.K mm, HK-well (Invitrogen; NPC''PJbox) 
X-cell SureLock™ Mini-cell SDS-PAGE apparatus (Invitrogen) 
X-cell II™ Blot module Western Blot apparatus (Invitrogen) 
Hybond-P polyvinylidene difluroide (PVDF) membrane (Amersham) 
Chromatography paper ^MM Chr (Whatman) 
Polyethylene lay flat film `KJmm (Jencons) 
Powerpac ^KK power suppliers (Biorad) 
X-OMAT™ LS Kodak film Ha x `J cm (Amersham) 
Konica SRXHKHA film processor (Konica) 
 
2.6.2 Reagents 
Lysis Buffer (`x) containing JCCmM HEPES pHN.K, JCmM NaF, JCmM iodoacetamide and 
J[CmM NaCl. Stored at B°C  
Phenylmethosulfonylfluoride (PMSF) 
NP-JK (JC%) 
Protease Inhibitor (Sigma-Aldrich; PV'BC) 
DC Protein Assay (BIO-RAD; CN [CC-CJJ^) includes Reagents A, B and S 
Bovine Serum Albumin (BSA) Jmg/ml concentration (Sigma) 
NuPAGE™ LDS Sample Buffer (xJ) (Invitrogen; NPCCCN)  
NuPAGE™ Sample Reducing Agent (xHK) (Invitrogen; NPCCCK)  
NuPAGE™ MOPS SDS Running Buffer (x`K) (Invitrogen; NPCCCJ) was diluted with 
deionised water to give a Jx working solution and store at room temperature.  
SeeBlue™ Plus` Pre-stained Protein Standard (Invitrogen; LC[KP[) supplied as a ready 
to use molecular weight marker and stored in aliquots at B°C. 
NuPAGE™ Transfer Buffer (x`K) (Invitrogen; NPCCC^) was diluted with deionised water 
containing JC% analysis grade methanol (Fisher) to give a Jx working solution and stored 
at B°C. 
PBS-Tween containing C.P% Tween®-PC detergent in JxPBS. Prepared and stored at room 
temperature 
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Blocking Buffer was prepared by heating PBS-Tween to VC°C and then adding I-Block 
(Tropix Inc; T2015) to make a concentration of 0.2%. Once dissolved, the solution was allowed 
to cool and then sodium azide was added to make a concentration of C.B%.  
Pierce® ECL Plus Western Blotting Substrate (Thermo Fisher Scientific; 'PJ'P). The 
product protocol was followed, mixing substrate A and B at a BC:J ratio. 
 
2.6.3 Cell lysis 
P.[xJC^ cells were washed in PBS, centrifuged at B°C and all supernatant removed to leave 
a semi-dry cell pellet. The pellet was then re-suspended gently in JCCµl of freshly made 
(due to short half-life) cell lysis buffer supplemented with J% NP-BC, JmM PMSF and 
protease inhibitor. Cells were incubated for [ mins on ice and then transferred to J.[ml 
microfuge tube, spun at PCC xg for JC mins at B°C. The supernatant was then decanted 
into a fresh microfuge tube and stored at -PC°C for at least J hour before JD SDS-PAGE. 
 
2.6.4 Measurement of protein concentration  
The protein concentration was determined using the Bio-Rad DC Protein Assay kit; the 
Microplate Assay Protocol (section [.P) was followed. The protein standard used was BSA, 
at concentrations Jmg/ml, C.[mg/ml, C.P[mg/ml, C.JP[mg/ml and C.C^P[ (serially diluted 
with distilled water). [µl of samples and standards were pipetted into flat bottomed K^-
well plates, in triplicate. P[µl working reagent A (J:[C reagent S to Reagent A) was 
pipetting into each well, followed by PCCµl of reagent B. After J[ mins, the absorbance of 
each well was read at N[Cnm using a microtitre plate reader (BioTeK Cytation '). Standard 
absorbance (y axis) was then plotted against its concentration (x axis) in a Microsoft Excel 
spreadsheet. The equation of the straight-line; y = mx + c (where y = absorbance, m = 
gradient, x = the concentration and c = the y intersect), thus allowed to calculate the 
concentration of each sample.  
 
2.6.5 Sample preparation 
After protein quantification, 'µl of Sample Reducing Agent (Invitrogen) and N.[µl of LDS 
Sample Buffer (Invitrogen) was added to 'Cµg of protein extract in a fresh microfuge tube. 
The volume was made up to 'Cµl with deionised water and then placed in a dry heating 
block at VC°C for JC mins.  
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2.6.6 Protein analysis by 1-Dimensional (1D) Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Pre-cast NuPage™ gels (Invitrogen) were washed with deionised water and inserted into 
the lower buffer chamber of the Mini-Cell. The gel cassette was locked into place with a 
Gel Tension Wedge. Approximately PCCml of xJ Running Buffer was added to centre 
chamber, ensuring the wells were completely submerged. N.[µl of SeeBlue™ PlusP Pre-
Stained Protein Standard (Invitrogen) was loaded into the first well, followed by PCµl of 
prepared sample to the subsequent wells. A further 'CCml of running buffer was added to 
the external chambers and lid placed on the cell. Gel was run at PCCV (JPC mA, P[.C W) 
for approximately [[ mins, until the dye front had reached the ridge at the bottom of gel.  
 
2.6.7 Western Blotting 
The PVDF membranes were soaked in methanol for 'Cs before use, rinsed with deionised 
water and then equilibrated in transfer buffer. The polyacrylamide gel was then removed 
from cassette and placed onto the PVDF membrane, between P pieces of Whatman 'MM 
filtered paper pre-soaked in transfer buffer. This was placed onto blotting pads pre-soaked 
in transfer buffer and placed in a X-cell II™ Blot module (Invitrogen). The blotting module 
was then inserted into the X-cell SureLock™ Mini-cell unit (Invitrogen) and filled with 
transfer buffer until the gel/membrane assembly was covered. The outer buffer chamber 
was filled to approximately two thirds with deionised water and the unit was run at 'CV 
(Start JNCmA End JJCmA) for KC mins.  
 
2.6.8 Immuno-probing the blot 
The PVDF membrane was removed from the module and rinsed with PBS-Tween. The 
membrane was then placed in a [Cml conical flask and incubated in J[ml of blocking 
buffer for ^C mins at room temperature on an orbital shaker (Stuart-Scientific). The 
blocking buffer was replaced with JCml of fresh blocking buffer and then probed with the 
primary antibody, diluted to the correct concentration (see Table P.J). The blots were 
incubated overnight at B°C on an orbital roller. Post-incubation, the membrane was 
washed three times in J[ml PBS-tween for JC mins. The membrane was then incubated for 
^C mins at room temperature with the secondary antibody, diluted in JCml blocking 
buffer. The membrane was subsequently removed from the secondary antibody solution 
and washed three times in J[ml PBS-tween for JC mins. JCml of Pierce® ECL Plus Western 
Blotting Substrate (BC:J Substrate A:Substrate B) was added to membrane and incubated 
for [ mins. The membrane was then placed between polyethylene film, with any excess 
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reagent removed and was exposed to autoradiographic film (Kodak) for P, JC and 'C mins. 
Films were then developed using a Konica film processor (Konica). 
 
Target  
Protein 
Antibody 
Type 
Clone/ 
Catalogue # 
Species Working 
Conc. 
Supplier 
Beta-Actin Primary J'E[/BKNC Rabbit J:JCCC CST 
PI'K pJJCδ  Primary H-PJK/sc-NJN^ Rabbit J:JCCC Santa Cruz 
AKT Primary           /KPNP Rabbit J:JCCC CST 
Rabbit IgG(H+L) 
HRP conjugate 
Secondary            /'JB^C 
 
Goat J:JCCCC Invitrogen 
Table 2.7. Antibodies used in protein analysis. CST - Cell Signalling Technologies; Santa Cruz - Santa Cruz 
Biotechnologies; Invitrogen - Invitrogen, Thermo Fisher Scientific
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2.7 DNA quantification 
2.7.1 Reagents and equipment 
TRIzol™ Reagent (Thermo Fisher Scientific; A''P[C) 
Molecular Biology Grade Chloroform (Thermo Fisher Scientific; BPEJJB[-J) 
RNeasy Mini Kit (QIAGEN; NBJCB) 
High Capacity cDNA Reverse Transcription Kit (Applied BioSystems; B'^VVJB) stored 
at -PC°C 
Veriti DX Thermal cycler (Thermo Fisher Scientific) 
ViiAY Real-Time PCR system (Thermo Fisher Scientific) 
TaqMan® Fast Advanced Master Mix (Thermo Fisher Scientific; BBBB[[^) stored at 
 -PC°C 
TaqMan® Gene Expression Assays (Thermo Fisher Scientific) stored at -PC°C 
 GAPDH – HsCPNV^^PB_gJ 
PIK'CD – HsCCJKP'KK_mJ 
 
2.7.2 RNA extraction 
Jml TRIzol was added to a dry pellet of BxJC^ harvested cells. Sample was stored at -VC°C 
until ready for extraction. Once the sample was thawed, PCCµl of chloroform was added 
and centrifuged at PCC xg for J[ mins at B°C. The aqueous layer on top was gently removed 
and added to an equal volume of NC% ethanol. NCCµl of the sample was then added to an 
RNeasy spin column and the RNeasy Mini Kit protocol was followed. The elution step used 
[Cµl RNase-free water, which was stored at -VC°C until the next step. RNA quantification 
was assessed using a Nanodrop:JCCC Spectrophotometer. Duplicate Jµl samples were 
evaluated and the RNA concentration, AP^C/PVC ration and AP^C/AP'C ratio obtained. 
 
2.7.3 Reverse Transcription (RT) 
Following the Applied BioSystems RT kit protocol, C.[µg of RNA was added to C.[ml 
microfuge tubes containing JCµl master mix and made up to PCµl with sterile RNase-free 
water. Samples were added to thermal cycler and run as per the kit’s protocol. Once the 
run was complete, PCµl of newly converted cDNA was diluted [:J with sterile DNase and 
RNase-free water to give a total volume of JCCµl and a working concentration of P.[ng/µl. 
Samples were stored at -PC°C.  
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2.7.4 Real time PCR 
The TaqMan Fast Advanced Master Mix kit protocol was followed. Samples were run in 
triplicate, including a minus RT sample and a minus cDNA sample. Samples were run on 
a K^-well plate with a running volume JCµl per well. This was composed of P.[µl of thawed 
cDNA, C.[µl primer (GAPDH or PIK'CD), [µl TaqMan master mix and Pµl of RNA-free 
water. Samples were run on a ViiAN Real-Time PCR system using the TaqMan FAST 
programme. Results were analysed using the Thermo Fisher Cloud software using the 
Relative Quantification qPCR application.   
 
 
 
2.8 Methylation Analysis 
2.8.1 Reagents and equipment 
DNeasy® Blood & Tissue Kit (QIAGEN®; ^K[CB) stored at room temperature 
EpiTect® Bisulfite Kit (QIAGEN®; [KJCB) stored at -PC°C 
EpiTect® PCR Control DNA Set (QIAGEN®; [K^K[) stored at -PC°C 
PyroMark® PCR Kit (QIAGEN®; KNVNC') stored at -PC°C 
PyroMark® CpG assay (QIAGEN; KNVB^) containing JCx PCR primer set (reconstituted 
in [[Cµl of TE buffer) and JCx Sequencing primer (reconstituted in VVCµl of PyroMark® 
Annealing Buffer). See Table P.V for additional information. 
TE Buffer (JCmM Tris·Cl, JmM EDTA, PhV.C 
PyroMark® Gold QMI Reagents (QIAGEN®; KNPVCB) stored at B°C 
PyroMark® QMI Cartridge (QIAGEN®; KNKCCB) 
PyroMark® Annealing Buffer (QIAGEN®; KNKCCK) 
PyroMark® Binding Buffer (QIAGEN®; KNKCC^) 
Streptavidin-coated Sepharose® High Performance (GE Healthcare; JN-[JJ'-CJ) 
PyroMark® QMI ID (QIAGEN®; KCCJ[P[) including PyroMark QK^ ID software 
PyroMark® QMI Vacuum Workstation (QIAGEN®; KCCJNBC) 
Veriti DX Thermal cycler (Thermo Fisher Scientific) 
 
2.8.2 DNA extraction 
As outlined in section P.^.J 
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2.8.3 Bisulfite conversion 
Jµg of sample DNA (as quantified by Nanodrop; JCCC Spectrophotometer) and C.Pµg 
QIAGEN unmethylated human Control DNA was bisulfite converted as per EpiTect® 
Bisulfite Kit protocol, using the Veriti DX Thermal cycler. Carrier RNA solution was not 
required in view of the relatively large quantity of DNA being converted (as per the 
protocol recommendation). The final elution step used PCµl of Buffer EB to give a 
concentration of roughly [Cng/µl. Samples were then stored at -PC°C until the next step.  
 
2.8.4 PCR amplification 
The PyroMark PCR handbook (May PCCK) protocol was followed. Reaction composition 
per sample included JP.[µl PyroMark master mix, P.[µl CoralLoad, P.[µl PCR primers, 
PCng of bisulfite converted DNA and RNase-free water to make a total reaction volume of 
P[µl per well of the K^-well plate. Samples where done in triplicate in addition to EpiTect 
PCR positive control (methylated human bisulfite converted DNA JCng/µl) and negative 
control (unmethylated human bisulfite converted DNA JCng/µl). The thermal cycling 
protocol was set as per the handbook; B[ cycles with an annealing temperature of [^°C.  
 
2.8.5 Pyrosequencing 
PCµl of the P[µl PCR reaction was used for the subsequent pyrosequencing analysis. The 
PyroMark QK^ CpG Handbook (December PCJC) protocol was followed. Immobilisation 
of PCµl of PCR product was done in the same K^-well plate, using BCµl of binding buffer, 
Pµl of Streptavidin-coated Sepharose® HP (beads equivalent) and this was made up to a 
final volume VCµl with RNase-free water. Annealing of the sequence primer to the 
template was done using the QK^ Vacuum workstation followed by heating the K^-well 
plate to VC°C to obtain single stranded DNA as per the handbook protocol. The cartridge 
was loaded with appropriate volumes of Gold QK^ reagents and was inserted into the 
pyrosequencer in addition to the plate. Quantification of CpG methylation was analysed 
using PyroMark QK^ ID software. 
2.8.5.1 Sequence primers  
Qiagen produces two separate PyroMark CpG primer assays for the PIK3CD gene. Both of 
which were used in this thesis. The gene has ' promoter regions with high CpG activity. 
Each promoter region has flanking regions either side with minimal or no CpG islands. 
The middle and largest promoter region (highlighted figure P.P) is the site of Qiagen’s P 
primer assays (termed PIK'CD-J and PIK'CD-P).  The dispensation order for the different 
CpG assay primers is outlined in Table P.V.
 56 
CpG assay H Hs_PIK'CD_CJ_PM 
Catalogue # PMCCCK''JC 
Chromosome Location ChrJ:KNBKP^B-KNBK'B' 
Amplicon Length NK 
CpG sites V 
Sequence to be Analysed*  AGYGTGYGYGTYGTYGGGGTTTYGYGGT 
Dispensation Order TAGTCGTAGTCGTCGTCGATCGTCGGTTCGTCG 
  
CpG assay ` Hs_PIK'CD_CP_PM 
Catalogue # PMCCCK''JN 
Chromosome Location ChrJ:KNBKK^'-KN[CJ[[ 
Amplicon Length JKP 
CpG sites ' 
Sequence to Analysed* TTTAGGTTTTTTYGTTGTYGTTTTTGATGGGATTYGT 
Dispensation Order ATAGTTCGTCTAGATCGTTGAGTGATCG 
Table 2.8. PyroMark CpG Assay information. *Bisulfite converted sequence 
 
 
2.9 Telomere Analysis: 
Single Telomere Length Analysis (STELA) was performed using a PCR-based method for 
the determination of telomere length (Baird et al. PCC'). Profile was on the XpYp 
chromosome. All of the data shown were produced courtesy of Professor Duncan Baird’s 
laboratory. 
 
 
2.10 Statistical analysis 
All statistical analysis was performed using GraphPad Prism ^.C software unless otherwise 
specified. Continuous variables were analysed by P-tailed parametric (t-test) or non-
parametric (Wilcoxon rank sum test) tests as appropriate. Multivariable analyses were 
performed using P-way ANOVA Fisher’s LSD test, with P £ C.C[ considered to represent 
statistical significance. All error bars are standard deviation and are calculated by repeated 
independent experiments (as opposed to technical replicates) unless specified otherwise. 
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Figure 2.2. Image taken from GRCH37 ensembl showing Chromosome 1:9693258-9855191 (Yates et al. 
2016). Enlarged area is promoter region for the gene, with shaded areas showing the location for the 2 
Qiagen PyroMark CpG primer assays, identified as PIK3CD-1 (amplicon length 79bp containing 8 CpG sites) 
and PIK3CD-2 (amplicon length 192bp containing 3 CpG sites). 
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3           CHAPTER 3: 
 
Immunophenotypic Characterisation 
of Myeloma 
 
 
3.1 Introduction: 
Immunophenotyping of multiple myeloma (MM) plays an important role for both clinical 
and research purposes. It is essential for both the diagnosis of MM and the monitoring of 
minimal residual disease (MRD). In the era of B-colour flow cytometry, a primary 
diagnostic panel would include CD'V and CDJ'V for identification of plasma cells with 
CDJK, CDB[ and CD[^ distinguishing MM plasma cells from normal plasma cells (PCs). 
The percentage of aberrant PCs identified alone can define the stage of the disease (e.g. 
less than JC% for Monoclonal Gammopathy of Undetermined Significance (MGUS), JC-
^C% for Smouldering MM (SMM) and greater than ^C% for symptomatic MM), thus 
determining if treatment is necessary (Rajkumar PCJ^). IMWG guidance states that 
clonality and sub-clonal identification of bone marrow plasma cells are established by 
showing abnormal κ/λ light-chain ratio of >':J or <J:' by flow cytometry 
immunofluorescence (Rawstron PCC^; Peceliunas et al. PCJJ). 
 
MRD monitoring by flow cytometry can be obtained in virtually all MM patients, by using 
the PC diagnostic panel and a combination of aberrant cell markers that include CDVJ, 
CDPN, CDJJN, CDPV and CDPC (Rawstron et al. PCCV; Rawstron et al. PCJ'; Rajkumar et 
al. PCJB; Flores-Montero et al. PCJ^). Munshi et al. meta-analysis showed multi-parameter 
flow cytometry (MFC) MRD negativity resulted in longer OS (hazard ratio C.^C). Although 
there is a lack of standardisation in the MFC technique between laboratories and a lower 
sensitivity (up to J × JC−[) compared to other MRD methods (ASO-qPCR, NGS), it remains 
the most widely used form of MRD monitoring owing to its relatively low cost, wide 
availability and short turnaround time (Mailankody et al. PCJ[; Munshi et al. PCJN).  
 
Although cytogenetic analysis remains the prominent prognostic tool, influencing disease 
course and response to therapy, and forms a key component of the revised international 
staging system score (R-ISS) (Rajkumar PCJ^), immunophenotyping has been shown to 
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provide prognostic value using a  range of different cell markers, including CD[^, CDB[, 
CDPC, CDPN, CDPV and CDJJN, some of which are linked to cytogenetic abnormalities 
(Kumar et al. PCJC). The advent of polychromatic flow cytometry and CyTOF (cytometry 
by time-of-flight) technology, as well as the availability of a vast array of monoclonal 
antibodies, has provided the opportunity to design ever more sophisticated analysis 
panels, which have wide-ranging research applications. However, to date few complex 
multi-coloured flow panels have been routinely used on either primary MM samples or 
MM cell lines. The aims of this chapter were to design a multi-colour flow cytometry panel 
to immunophenotypically characterise cell adhesion and migration properties in both MM 
cell lines and primary MM bone marrow samples. I also set out to potentially identify the 
existence of phenotypically distinct myeloma sub-populations based on differential 
expression of adhesion/migration markers.  
 
 
3.2 Designing a MM multi-colour flow cytometry panel 
Table '.J details the ten cell markers selected for the flow cytometry panel. The panel was 
broadly divided into two - half of the cell markers were used for PC identification and/or 
aberrant markers associated with MM - the other half were used to characterise markers 
associated with adhesion, migration and proliferation 
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3.3 MM gating strategy 
Figures '.J and '.P show the gating strategies applied to MM cells lines (Figure '.J) and 
primary bone marrow cells (Figure '.P). Samples were analysed on a BD Fortessa flow 
cytometer. Primary samples, prior to analysis, were red cell lysed and centrifuged on a 
layer of Ficoll. Plasma cells were identified by CDJ'V and CD'V positive single gated cells.  
All samples, were analysed using FlowJo software, calculating MFI (median fluorescence 
intensity), percentage positive expression compared to unstained control and the presence 
of distinct sub-populations. Subsets (potentially indicative of sub-populations/sub-clones) 
were identified by bivariate pseudocolour dot plots. As a minimum, the following dot plots 
were composed: 
i. CD'V vs. CDJ'V 
ii. CDJK vs. CDB[ 
iii. CDB[ vs. CD[^ 
iv. CDJK vs. CD[^ 
v. CDBKd vs. CXCRB 
vi. CDBKd vs. Ki-^N 
vii. CXCRB vs. Ki-^N 
viii. IL-^ vs. MMP-K 
 
In the event that sub-populations were identified, overlaid histograms were used to 
illustrate differences in antigen expression and the MFI values for each sub-population 
were used for quantitative comparison.
 62 
 
Table 3.1. Explanation of the ten cell marker fluorochrome panel used in this chapter, brief function of 
each cell marker as well as intended purpose are included; PC, plasma cells; PAX-5, paired box-5; NCAM, 
neural cell adhesion molecule; VCAM, vascular cell adhesion molecule; BMSC, bone marrow stromal cell; 
IL-6, interleukin-6; STAT-3, signal transducer and activator of transcription 3; RANKL, Receptor activator 
of nuclear factor kappa-B ligand; MMP-9, Matrix metallopeptidase 9; 
 
Antigen Function Purpose 
CDJ'V  
(syndecan-J) 
Heparan sulfate proteoglycan – promotes cell-surface 
adhesion. High expression broadly unique to plasma 
cells  
Plasma cell 
gating 
CD'V Transmembrane glycoprotein with enzymatic activity, 
variable expression in B-cells, high in PC 
Plasma cell 
gating 
CDB[  
(Leucocyte 
common antigen) 
Protein tyrosine phosphate – activation of 
lymphocytes and development. Generally low 
expression in MM, but increasing expression 
correlates with higher proliferation and immaturity 
Myeloma cell 
gating/aberrant 
phenotype 
CDJK Pan B-cell marker – regulatory role in expansion of B-
cells. Loss in myeloma PCs correlates with altered 
PAX-[ expression 
Myeloma cell 
gating/aberrant 
phenotype 
CD[^  
(NCAM) 
Glycoprotein of Ig superfamily 
Weakly expressed on normal PC, strongly positive in 
^C% myeloma cells, expression loss in PC leukaemia 
Myeloma cell 
gating/aberrant 
phenotype 
CDBKd  
(αB) 
Integrin subunit forming VLA-B (αB/βJ), ligates to 
VCAM on BMSC. Upregulates IL-^ secretions from 
BMSC 
Adhesion 
marker 
IL-^ Induces proliferation (Ras pathway), blocks apoptosis 
(STAT-'), protects against dexamethasone cytotoxicity 
(PI'K pathway)         
Decreases: osteoprotegerin secretion,  
Increases: expression of RANKL (promoting 
osteolysis) and antiapoptotic molecules (bcl-P, bcl-xL, 
Mcl-J) 
Survival marker 
CXCRB Chemokine receptor for CXCLJP (SDF-J) 
Induces chemotaxis of PC towards BM 
Modulates adhesion activity of VLA-B 
Migration 
marker 
MMP-K  
 
Secreted as inactive proproteins, cleaved by 
extracellular proteinases. Role in breakdown of 
extracellular matrix, IL-V induced mobilisation of 
blood cells from bone marrow, cleavage of 
chemokines and possible role in cancer-associated 
tissue remodelling and angiogenesis 
Bone marrow 
micro-
environment 
remodelling 
Ki-^N Nuclear marker, necessary for cellular proliferation Proliferative 
marker 
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Figure 3.1. Gating strategy applied for each MM cell line flow cytometry Immunophenotyping analysis. 
In this example 30,000 events of the cell line MM.1S were recorded (both stained and unstained samples). 
(A) Alive cells for either sample were gated on side scatter area (SSC-A) and forward scatter area (FSC-A) 
dot plot, thus removing debris. (B) Of the Alive cells gated events, doublets were removed by single cells 
gate from FSC-height and FSC-area dot plot. (C) Stained single cells where then analysed by individual cell 
marker histograms. This allowed for either median fluorescence intensity (MFI) or comparison of 
percentage positivity staining to unstained sample. In this example 97.7% of the MM.1S cells showed 
positive expression for CD38. (D) Subset analysis of different cell markers undertaken to identify 
phenotypically distinct sub-populations, e.g. the bimodal expression of CD38.
(B) (A) 
(C) (D) 
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Figure 3.2. Immunophenotyping gating strategy applied for each primary bone marrow sample. In this example, 
100,000 events were analysed from a Ficoll centrifuged bone marrow sample, from a newly diagnosed MM patient 
and stained with fluorescence-labelled antibodies. (A) Live cells were gated on side scatter area (SSC-A) and forward 
scatter area (FSC-A) dot plot, thus removing debris. (B) Of the live-cell gated events, doublets were removed by single 
cell gating using a FSC-height vs FSC-area dot plot. (C) Lymphocytes were gated by CD45 SSC-A dot plots (provided 
sufficient cell numbers, an additional subset analysis was performed using CD19 to identify B-cells). (D) Plasma cells 
were identified through gating CD138/CD38 double positive single cells, with MFI and percentage positivity referenced 
to unstained sample undertaken for each sample (not shown for this example). (E) and (F) Overlaid dot plot 
immunophenotypic comparison of gated PC from (D) (coloured red) with gated lymphocytes from (C) (coloured blue). 
(E)  Analysis of PC aberrant cell markers CD56 and CD45 to determine if PC are phenotypically abnormal (in this 
example PC are predominantly CD45-, CD56+, in keeping with the phenotype of myeloma PC, but with a small (3% of 
PC) CD45+ subset also identified. (F) Additional analysis undertaken looking at other cell markers expression outlined 
in Table 3.1, in this example PC (red) CXCR4 and CD49d expression was positive and when compared to lymphocytes 
(blue), had increased CXCR4 expression, but more variable CD49d expression. 
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3.4 Characterisation of MM cell lines 
Table '.P details the six IL-^ independent MM cell lines used in this thesis. The cell lines 
encompassed the main Immunoglobulin (Ig) heavy chain MM subtypes and the most 
frequent genetic and chromosomal abnormalities (Table '.P). UP^^, RPMI-VP^^ and JJN' 
were already in use by the research group, chosen for their differing genetic mutations 
affecting the NF-kB signalling pathway. MM.JS and MM.JR cell lines are derived from the 
cell line MM.J, by the same research centre who created the MM.J cell line in JKV^. In JKKC, 
Steve Rosen’s Laboratory subjected the MM.J cell line to low dose dexamethasone, forming 
a dexamethasone resistant cell line, which they termed MM.JR. The original 
dexamethasone sensitive cell line, was subsequently re-labelled MM.JS and both forms are 
now commercially available from ATCC. Using both these cell lines, provided an 
opportunity to explore sub-population expansion and cell adhesion mediated drug 
resistance (CAM-DR) between functionally different cells that originated from the same 
patient.  
  
Cell 
Line 
Disease CDJc IgH translocation 
/target oncogene 
Mutations Deletions  
JJN-^  IgAk MM +/- t(JB;J^) MAF (c-
Maf); t(V;JB)  
 TP+3  
MM.HR  IgAl PCL - t(JB;J^) MAF (c-
Maf); t(V;JB)  
KRAS (GJPA - het)  
TRAF3 (K['^ - hom) 
CDKN/  
MM.HS  IgAl PCL - t(JB;J^) MAF (c-
Maf); t(V;JB)  
KRAS (GJPA - het)  
TRAF3 (K['^ - hom) 
CDKN/  
OPM-`  IgGl MM - t(B:JB)  
MMSET/FGFR3; 
FGFR3 (K^[CE - het) 
TP+3 (RJN[H - hom) 
CKKN/  
RPMI-
a``I  
IgGl MM - t(JB;J^) MAF (c-
Maf); t(V;PP)  
 
KRAS (GJPA - het)  
TP+3 (EPV[K - hom)  
TRAF3  
U-`II  IgEl MM + t(JJ;JB) CCND( BRAF (K^CJN - het)  
RB( (EBJKX - hom)  
         KPPVR - hom) 
TP+3 (AJ^JT - hom) 
TRAF (K[[CI - hom) 
 
Table 3.2. List of MM cell lines used in this study, their disease type and genetic characteristics. IgH 
translocations are present in each cell line, target oncogene is the affected gene that is upregulated 
through the translocation of the IgH enhancer. MM - multiple myeloma; PCL - plasma cell leukaemia; k - 
kappa light chain; l - lambda light chain; IgH – Immunoglobulin heavy chain; t – Translocation; MMSET - 
multiple myeloma SET domain; FGFR3 - fibroblast growth factor receptor-3; HD - homozygous deletion; 
het - heterozygous mutation; hom - homozygous mutation; CCND1 - cyclin D; CDKN2 - cyclin dependent 
kinase inhibitor 2; TRAF3 - tumour necrosis factor. 
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3.4.1 MFI Immunophenotypic analysis 
Figure '.' shows the different cell markers Median Fluorescence Intensity (MFI) on a 
logarithmic scale for the six cell lines. Figure '.'a shows cell markers predominantly used 
for plasma cell identification (CDJ'V and CD'V) as well as the aberrant cell markers CDB[, 
CD[^ and CDJK. Between the six cell lines, expression was uniformly high for CDJ'V (V,JC^ 
SD±',^BV) and low for CDJK (J[V SD±^^), whereas a greater variation MFI was observed 
for CD'V (JC,BJ' SD±J^,NCV) and CD[^ (K,JV^ SD±JK,[N'). In contrast, Figure '.'b shows 
that there was little variation in the expression of CXCRB, IL-^, Ki-^N and MMP-K but a 
more marked variation in the expression of CDBKd (JP,C[K SD±K,^'N) between the six cell 
lines. 
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Figure 3.3. Flow cytometric comparison of antigen expression in six commonly used myeloma cell lines. 
1 x 106 cells from each of the cell lines were stained with fluorescence-labelled antibodies and data was 
acquired on a BD Fortessa flow cytometer. (A) Shows the comparison of CD138, CD38, CD45, CD56 and 
CD19 in the cell lines. (B) Shows the comparison of CD49d, CXCR4, IL-6, Ki-67 and MMP-9. The results are 
expressed as median fluorescence intensity values and are the product of n = 3 separate experiments. 
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3.4.2 Percentage positivity Immunophenotypic analysis corresponds with 
their MFI except for cell markers IL-6 and MMP-9 
Analysis of percentage positivity roughly correlated with MFI (data not shown). UP^^ 
percentage positivity for CD'V was K.K% (MFI PV), whereas all other cell lines were above 
KC%. CDB[ positivity was less than PC% for all cells except UP^^ (NB.[% positivity, MFI 
KJ^). CDBKd and CXCRB expression was broadly positive and above KC% in all cell lines 
except RPMI-VPP^ (CDBKd - J[.B%) and JJN' (CXCRB - N[.K%). The only markers where a 
discrepancy between MFI and percentage positivity was seen were IL-^ and MMP-K, 
notably in the cell lines JJN' and OPM-P, which showed high percentage positivity for 
both MMP-K and IL-^. Both of these markers showed low uniform MFI expression (Figure 
'.'B), but expression was more variable when analysed by percentage positivity (Figure 
'.BA) and was shown to have a strong positive correlation (r=C.K['K; Figure '.'B), which 
was statistically significant (p=C.CC'J). 
 
 
Figure 3.4. Comparison of IL-6 and MMP-9 percentage positivity between the six MM cell lines. Flow 
cytometric comparison of IL-6 and MMP-9 expression in six commonly used myeloma cell lines. 1 x 106 
cells from each of the cell lines were stained with fluorescence-labelled antibodies and data was acquired 
on a BD Fortessa flow cytometer. (A) Shows the comparison of IL-6 and MMP-9 percentage positivity in 
each of the cell lines. (B) Shows the correlation between MMP-9 and IL-6 positivity between the six cell 
lines, Pearson’s correlation co-efficient was r=0.9539, with a two-tailed statistical positive correlation of 
p=0.0031. The results are expressed as percentage positivity relative to unstained control samples of the 
same cell line and are the product of n = 3 separate experiments.  
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3.4.3 Ki-67 expression shows strong correlation with other cell markers.  
By individually plotting antigen expression of each cell line with (as done in Figure '.BB), 
specific cell marker correlations were able to be identified (Figure '.[). The proliferative 
marker Ki-^N expression showed the greatest number of correlations with the other cell 
markers (Figure '.[B). There was almost a perfect positive correlation with CDBKd 
expression (r=C.KK; p=C.CCCP). Other cell markers with positive correlation, although not 
statistically significant, were IL-^ expression (r=C.^C, p=C.PJ) and MMP-K expression 
(r=C.^V; p=C.J'V). A negative correlation, although again not statistically significant, was 
observed with CXCRB expression (r=-C.^V; p=C.J'). Previously, CD'V expression has been 
shown positively correlate with CDBKd and Ki-^N in other B-cell malignancies such as CLL 
(Pittner et al. PCC[). However, in this study no significant correlation between CD'V and 
the other cell markers was observed (Figure '.[A). 
 
3.4.3.1 Wide variation in CD38 expression but with uniform CD138 expression amongst 
the cell lines could represent sub-populations/subclones  
In an attempt to further characterise the cell lines and identify possible reasons for the 
lack of correlation of CD'V expression with other cell markers, such as the presence of 
different sub-sets/sub-populations within each cell line, dot plot comparison of cell 
markers for each cell line were undertaken as outlined in section '.'. 
 
As previously outlined in section '.B.J. CDJ'V expression was broadly uniformly positive 
and bright – with roughly C.[ log difference between the minimum (JJN-') and maximum 
(MM.JR) cell line fluorescence intensity (Figure '.^B). No CDJ'V expression subsets were 
identified between any of the six cell lines. CD'V expression in contrast, showed a wide 
variation (average MFI cell lines JC,[N^±SD J[,P[V). Of the six cell lines analysed, UP^^ 
cells showed the lowest MFI for CD'V expression, Whilst RPMI-VPP^ showed the highest 
MFI for CD'V (MFI BB,P[J). Furthermore, variation of CD'V expression was also observed 
within the individual cell lines. This was most prominent for MM.JS cells, with CD'V 
expression showing a bimodal distribution (Figures '.^A and '.^C), which highlighted two 
distinct CD'V expressing sub-populations within the cell line.
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Figure 3.5. Flow cytometric correlation of antigen expression for the six MM cell lines. 1 x 106 cells from 
each of the cell lines were stained with fluorescence-labelled antibodies and data was acquired on a BD 
Fortessa flow cytometer. (A) Shows the correlation of CD38 expression with the other 9 antigen expression. 
(B) Shows the correlation of Ki-67 expression with CD49d, IL-6, CXCR4 and MMP-9. The results are 
expressed as median fluorescence intensity values and are the product of n = 3 separate experiments, from 
the same data set as Figures 3.3 and 3.4. Where relevant Pearson’s r value is provided and two-tailed p 
value. 
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Figure 3.6. Flow cytometric comparison of CD138 and CD38 expression in myeloma cell lines. 1 x 106 cells 
from each of the cell lines were stained with fluorescence-labelled antibodies and data was acquired on a 
BD Fortessa flow cytometer. (A) Shows a pseudocolour dot plot of CD138 and CD38 expression in the cell 
line MM.1S. (B) Overlaid histogram of the highest (MM.1R red) and lowest (JJN3 blue) CD138 expression 
of the six MM cell lines used. (C) overlay dot plot comparing CD138 and CD38 expression between the 
lowest CD38 expressing cell line (U266 red), the bimodal population (MM.1S blue) and the highest CD38 
expressing cell line (RPMI-8226 orange).  
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3.4.3.2 Analysis of CD56/CD45/CD19 expression of the cell lines, reveals distinct 
immunophenotypic populations, indicative of sub-clonal co-existence  
Analysis of CD[^, CDB[ and CDJK expression not only allows for distinction between 
normal PC (CDB[+/CDJK+/CD[^-) and clonal myeloma PC (CDB[-/CDJK-/CD[^+), but 
also for detection of additional myeloma sub-populations that do not conform to either 
immunophenotype. Thereby providing support to the concept of numerous 
immunophenotypic sub-clones co-existing within an individual cell line, as postulated in 
section '.B.'.J. With the exception of OPM-P cells, all of the cell lines showed evidence of 
intra-cell line sub-populations (Figure '.N). In four of the six cell lines (OPM-P, MM.JS, 
MM.JR and RPMI-VPP^) the largest immunophenotypic population was that typically seen 
in myeloma plasma cells (CDB[-/CDJK-/CD[^+). The exceptions, UP^^ and JJN-', were 
CD[^-; a phenotype characteristic of plasma cell leukaemia (Harada et al. JKK'), although 
both contained small sub-populations (<JC%) that were CD[^+ (Figures '.NA and B). The 
most notable example of distinct sub-populations was found in UP^^ cells, which 
demonstrated distinct expression patterns of CDJK. In addition, four distinct CDB[/CD[^ 
expressing sub-populations were also evident (Figure '.NA). This polytypic profile is 
suggestive of clonal evolution although the necessary genetic profiling of the distinct sub-
populations was not performed. The MM.JS cell line, in which distinct bimodal CD'V 
expression existed, was shown to have variable CD[^ expression. This was particularly 
apparent when compared to cell lines OPM-P and UP^^ (Figure '.NB). Although this 
variation in CD[^ expression did not correlate with the bimodal CD'V expression (data 
not shown), it again emphasises the heterogeneity of immunophenotypic expression 
within an individual cell line.   
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Figure 3.7. Flow cytometric dot plots of CD56, CD19 and CD45 expression of MM cell lines. 1 x 106 cells 
from each of the cell lines were stained with fluorescence-labelled antibodies and data was acquired on a 
BD Fortessa flow cytometer.  (A) U266 cell line CD56 and CD45 pseudocolour dot plot. Shows 4 separate 
populations, split into quadrants with % populations provided. (B) JJN-3 cell line CD56 and CD45 
pseudocolour dot plot. The largest population was CD45-/CD56-, but a distinct CD45-/CD56+ population 
was also observed, representing 8.9% of the cell line. (C) Overlaid dot plot comparing CD19 and CD56 
expression between 3 separate cell lines, all cell lines were uniformly negative for CD19, CD56 was much 
more variable - U266 (orange) lacked CD56 expression, MM.1S (blue) had variable expression and OPM-2 
(red) strongly expressed CD56. CD56 MFI is provided in table below figure. (D) RPMI-8226 cell line CD56 
and CD45 pseudocolour dot plot. The largest population was CD45-/CD56+, but a distinct CD45+/CD56+ 
population was also evident, representing 3.2% of the cell line. 
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3.4.3.3 Identification of MM cell line sub-clones through immunophenotypic markers 
of adhesion, migration and microenvironment remodelling 
Having shown distinct immunophenotypic populations within most of the cell lines for 
the commonly used plasma cell markers (CD[^, CDB[ and CDJK), additional analysis 
looked for similar distinct populations in the other cell markers used. Although a wide 
variation in CDBKd expression was observed between the six cell lines tested (Figure '.'a), 
CDBKd expression within each individual cell line was fairly uniform (Figure '.V), except 
for RPMI-VPP^ cells, which contained a brighter CDBKd expressing sub-population, which 
accounted for ~JC% of the cell line. CXCRB expression for each cell line was much more 
variable, especially within the cell lines JJN-' and OPM-P (Figure '.V). Subtle 
immunophenotypic differences were observed between MM.JS and MMJ.R cell lines in 
terms of CDBKd and CXCRB expression. In contrast, no obvious MMP-K or IL-^ sub-
populations were identified. 
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Figure 3.8. Flow cytometry pseudocolour dot plots comparison of CXCR4 and CD49d expression of six 
MM cell lines. 1 x 106 cells from each of the cell lines were stained with fluorescence-labelled antibodies 
for the cell markers CXCR4 and CD49d. Data was acquired on a BD Fortessa flow cytometer. The cell line 
is stated in the top left corner of each figure. Where a distinct sub-population was identified (OPM-2, RPMI-
8226 and JJN-3), it was gated with the percentage of each population stated.  
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3.4.4 CXCR4 expression a marker of migratory potential 
The chemokine CXCLJP and its receptor CXCRB are known to play a key role in MM cell 
migration and regulation of CDBKd (Sanz-Rodriguez et al. PCCJ; Moller et al. PCC'). The 
variability in CXCRB expression both between the cell lines but also individually, could 
imply different migratory capacities of the cell lines, but also of the existence of sub-clones 
with differing migratory potential.   
 
To identify whether baseline CXCRB expression or indeed any of the other cell marker 
expression (outlined in Table '.J) correlated with MM cell line migration, PBh Transwell 
('µm membrane pore size) migration assays, against a CXCLJP concentration gradient 
were undertaken. Transwell migration assays (Costar; Corning, Acton, MA) are a 
recognised method of assessing CXCLJP induced MM migration (Tai et al. PCC'; Alsayed 
et al. PCCN). The static chambers are separated by a membranous film with numerous 
micropores that allow migration of cells in theory in the direction of a homing stimulus 
such as CXCLJP. Cells are usually suspended in the upper chamber, with the migratory 
stimuli in the lower chamber, with the migrated cells recovered from the lower after a 
period of time.  
 
In my experiments, minimal migration (C.J% of total cells) was observed for the cell lines 
UP^^ and RPMI-VPP^ (Figure '.KA). In contrast, MM.JS cells showed the greatest cell 
migration (B.CB%±C.VP), followed by the related, steroid resistant, cell line MM.JR 
('.P^%±J.'B). The difference in migration between these two lines was not statistically 
significant (p=C.JV). Interestingly, there was a negative correlation between cell line 
percentage migration and baseline CXCRB expression (prior to migration experiment) 
(p=C.CB'^; Figure '.KB). No correlation was observed between CDBKd, CD'V and Ki-^N 
baseline expression (Figure '.Kb), all of which have been previously shown to play a role 
in migration in B-cell malignancies (Moller et al. PCC'; Vaisitti et al. PCJC).
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Figure 3.9. Comparison of MM cell line CXCL12 induced migration and correlation with CXCR4 
expression. (A) 0.25x106 cells were placed in the apical chamber of a 3µm transwell plate. Migrated cells 
where retrieved from basolateral chamber of transwell at 24h. Migration was stated as a percentage of 
the total number of cells inserted into transwell. Cell lines analysed, JJN-3 (n=5), RPMI-8226 (n=3), U266 
(n=8), MM.1S (n=8), MM.1R (n=8) and OPM-2 (n=6). (B) MM cell lines correlation between percentage 
transwell migration at 24h (at stated in figure 3.9A) and cell markers baseline CXCR4, Ki-67, CD38 and 
CD49d expression (MFI). A statistically significant negative correlation was observed for CXCR4 expression. 
(r=-0.8242; p=0.0436). Each legend also states Pearson’s correlation (r) and whether the correlation was 
statistically significant (P<0.05). Error bars are standard deviation and calculated by repeated independent 
experiments. 
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3.5 Immunophenotypic comparison of primary bone marrow 
plasma cell dyscrasia samples  
Of the findings obtained from the immunophenotypic analysis of MM cell lines (section 
'.B), I aimed to establish if the discoveries could also be applicable to primary samples of 
patients with plasma cell dyscrasia. In particular I aimed to confirm if large variation in 
CD'V expression is seen and correlation with other cell markers. Such analysis would also 
allow for the confirmation of CD'V negative or weakly expressive populations.  In addition, 
I aimed to identify the degree of immunophenotypic sub-populations within individual 
primary samples as well as showing if statistical correlation of cell marker expressions 
existed, as seen in the MM cell line analysis. My data would also allow for sub-group 
analysis between MGUS, newly diagnosis MM and Relapsed/Refractory MM (RRMM).  
 
3.5.1 Sample characteristics 
'^ samples were immunophenotypically analysed stained with JC-colour panel in Table 
'.J. PP were of newly diagnosed MM, K MGUS and [ RRMM. Table '.' shows baseline 
characteristics of primary bone marrow samples. 
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 MGUS* Newly Dx. MM RRMM 
Total number K PP [ 
Type of plasma cell dyscrasia    
      IgGk N N [ 
      IgGl J B - 
      IgAk - [ - 
      IgAl - J - 
      Plasma cell leukaemia  - ' - 
      Plasmacytoma - P - 
      Smouldering Myeloma J - - 
R-ISS stage    
      I - K - 
      II - ^ - 
      III - N  - 
No. analysed for cytogenetics  P (PP.P%) JV (VJ.V%) B (VC.C%) 
      Normal J N ' 
      p['   - - J 
      t(B:JB) - J - 
      CKSJB (+Jq) J K - 
      CDKNPC (-Jp) - ' J 
      Extra copy JJq (CCNDJ) - J - 
      Loss of IGH - ' - 
      Extra copy IGH - - J 
Table 3.3. Baseline characteristics of primary marrow samples analyses. MGUS – monoclonal 
gammopathy of unknown significance; RRMM – relapsed refractory multiple myeloma; PCL – plasma cell 
leukaemia; *Includes one low risk Smouldering myeloma. Cytogenetics analysed by Cytocell IGH 
breakapart probe, interphase score 200 analysed - other probes – p53 and CKS1B (+1q)/CDKN2C (-1p). 
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3.5.2 Immunophenotypic variation at different stages of disease 
Figure '.JC compares the JC-cell marker expression, for the different stages of plasma cell 
disease (MGUS, newly diagnosed MM and RRMM). Although only [ RRMM samples were 
obtained, statistically significant expression differences between the different stages of 
disease were seen. Consistent with the MM cell line expression data, CDJ'V was uniformly 
bright for each of the three sub-groups of plasma cell disorder, with a statistically lower 
difference in CDJ'V expression between newly diagnosed MM and RRMM (p=C.C'J). This 
could either imply CDJ'V is shed and/or sub-populations of plasma cells expressing lower 
levels of CDJ'V are selected for during treatment. 
 
Consistent with the MM cell lines data, there was a large variation in CD'V expression for 
all stages of disease (Figure '.JCa). The average MFI for all newly diagnosed MM was 
BC,'B[ (SD±PB,^'N), B',[^J (SD±PP,V^V) for MGUS and JK,[^' (SD±P^,KN^) for RRMM. 
Although, a decrease in CD'V expression was seen in RRMM compared to newly diagnosed 
MM, no statistical difference existed (p=C.CKN). Other statistical expression differences 
between the three groups included reduced CD[^ expression in RRMM compared to 
newly diagnosed MM (MFI J[,[^K vs. B[C, p=C.CB) and CDJK expression, showing a 
general trend of decrease expression as disease progressed (MGUS [,^PK vs. newly 
diagnosed MM J,[V[ (p=C.CCCN) and MGUS vs. RRMM J,JV[ (p=C.CC^B)).  Wide variation 
in CDBKd and CXCRB expression was seen for all stages of disease, especially newly 
diagnosed MM (CDBKd MFI N,NKJ±',VNK and CXCRB MFI N,J[K±B,BVK). CXCRB expression 
was lower in relapsed disease compared to newly diagnosed (p=C.CC[K).  Ki-^N expression 
was statistically lower in RRMM compared to MGUS (p=C.CBP) and newly diagnosed MM 
(p=C.CPN). MMP-K expression upon relapse was statistically higher than at diagnosis 
(p=C.CP^) and for MGUS (p=C.CPP).  
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Figure 3.10. Scatter plot flow cytometric comparison of antigen expression in plasma cell dyscrasia 
primary bone marrow samples. Bone marrow samples were separated into mononuclear cells by Ficoll 
centrifuge. 1 x 106 cells were stained with fluorescence-labelled antibodies and data was acquired on a BD 
Fortessa flow cytometer. (A) Shows the comparison of CD138, CD38, CD45, CD56 and CD19 in the primary 
samples. (B) Shows the comparison of CD49d, CXCR4, IL-6, Ki-67 and MMP-9. The results are expressed as 
median fluorescence intensity values and are the product of n = 36 separate experiments. Analysis of each 
cell marker was further divided into separate plasma cell dyscrasia sub-group (MGUS n=9, newly 
diagnosed MM n=22 and RRMM n=5). Each scatter plot has SD error bar lines, with mean.  Where a 
statistical difference between the same cell marker and different plasma cell disease stage, an ordinary 
one-way ANOVA Fishers LSD test p value is provided. 
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Table '.B shows the mean percentage positivity between the cell markers and the different 
stages of disease. A complimentary method of presenting expression data to MFI, similar 
patterns were observed to the MFI values. As seen with the MFI data, RRMM CD[^ 
percentage positivity ('B.^%) was statistical lower compared to both MGUS (KV.C%, 
p<C.CCCJ) and newly diagnosed MM (KN.J%, p<C.CCCJ). The only conflicting data 
comparison between MFI and percentage positivity was for RRMM CDBKd expression 
(MFI JJ,C^N, [^.[% positive). Here, percentage positivity was statistically lower compared 
to MGUS (V'.'%, p=C.CBV) and newly diagnosed MM (KP.[%, p=C.CC'V), a trend that was 
not observed in MFI data (MFI V,JKJ and N,NKJ respectively). The reason for the discrepancy 
is likely due to small numbers within the RRMM group, and also the inclusion of an outlier 
sample (MFI PN,'BB, KK.K% positive). 
 
Cell marker MGUS (M) New MM (``) RRMM (c) 
CDH^a JCC% (±C.C, p=C.[') KK.J% (±B.B) KN.J% (±'.K, p=C.'J) 
CD^a JCC% (±C.C, p=C.[C) KN.V% (±JC.P) JCC% (±C.C, p=C.[K) 
CDJc 'V.B% (±B^.[, p=C.^C) BN.[% (±BP.B) BV.K% (±'[.V, p=C.K[) 
CDcI KV.C% (±B.', p=C.VK) KN.J% (±K.K) 'B.^% (±BC.V, p=<C.CCCJ***) 
CDHM VC.B% (±P^.N, p=C.CJ'*) [P.[% (±PN.N) 'B.^% (±PB.', p=C.JK) 
CDJMd V'.'% (±PP.K, p=C.'') KP.[% (±JN.') [^.[% (±B'.', p=C.CC'V**) 
CXCRJ KK.K% (±C.P, p=C.NK) KV.^% (±[.P) BJ.B% (±'B.^, p=<C.CCCJ***) 
IL-I JV.'% (±PB.J, p=C.JJ) 'K.K% (±'V.J) JC.V% (±PP.B, p=C.CKC) 
Ki-IY K^.'% (±N.N, p=C.KV) K^.P% (±JB.') [P.C% (±BB.J, p=<C.CCCJ***) 
MMP-M P'.P% (±J'.B, p=C.JC) BB.[% (±'N.C) BJ.J% (±'C.J, p=C.V') 
Table 3.4. Mean percentage positivity (±SD) of cell markers at different stages of disease; (Monoclonal 
Gammopathy of underdetermined significance (MGUS), newly diagnosed Multiple Myeloma (MM) and 
Relapsed/refractory MM (RRMM)). P values are two tailed ANOVA comparison of percentage positivity 
with newly diagnosed MM and MGUS or RRMM.  
3.5.3 Primary plasma cell dyscrasia samples, show strong correlation with 
Ki-67 and CD38 expression: 
When MFI data for the three-plasma cell dyscrasia groups were combined, specific cell 
marker correlations were able to be identified by individually plotting antigen expression 
of each sample (figure '.JJ). Unlike the MM cell line MFI data, CD'V expression exhibited 
strong correlations with a number of cell markers (figure '.JJA), the strongest correlation 
being between Ki-^N (r=C.VK, p=<C.CCCJ). Statistically positive correlations were also seen 
in CD[^ (r=C.'^, p=C.CPK), CXCRB (r=C.[N, p=C.CC') and CDJK (r=C.'N, p=C.CP[). The 
strong correlation between CD'V and Ki-^N expression also inferred statistical positive 
correlation with CD[^ (r=C.[V, pC.CCCP), CXCRB (r=C.[', p=C.CCCV) and CDJK (r=C.BB, 
p=C.CCN) (figure '.JJB). The only other statistical correlation observed was between IL-^ 
and CDBKd (r=C.[J, p=C.CCJ^). 
 83 
 
Figure 3.11. Flow cytometric correlation of antigen expression for primary bone marrow samples. The 
mononuclear fractions were isolated from Bone marrow samples by density gradient centrifugation. 1 x 
106 cells were stained with fluorescence-labelled antibodies and data was acquired on a BD Fortessa flow 
cytometer.  (A) CD38 MFI correlation between MFI of CD19, CD56 and Ki-67 (B) Ki-67 MFI correlation 
between MFI of CD19, CD56 and CD38. (C) CD49d MFI correlation between IL-6 MFI. The results are 
expressed as median fluorescence intensity values and are the product of n = 36 separate experiments, 
where relevant Pearson’s r value is provided and two-tailed p value. 
 84 
3.5.4 Confirmation of existence of CD38 negative expressing plasma cell 
populations, from primary bone marrow samples that are 
immunophenotypically distinct 
The discovery of a CD'V dim sub-clone within the MM cell lines (MM.JS and UP^^) was 
of particular interest due to its role in cell migration and activation, but also in light of the 
clinical emergence of anti-CD'V therapy. Analysis of all of the primary data looked for 
CD'V expression variability. Of the '^ samples, one newly diagnosed MM patient 
(previously diagnosed with SMM), exhibited a CD'V dim and CD'V bright population 
(Figure '.JPA). The CD'V dim population represented J.N% of the total nucleated cells and 
expression was more akin to normal B-lymphocytes (MFI B,KJ' vs. B,[PN). This expression 
was much lower than CDJ'V+/CD'V+ gated plasma cells (MFI [^,P'J). Additional 
immunophenotypic analysis between the two plasma cell populations showed them to be 
very different (Figure '.JP). The CD'V dim population was CDJK-/CDB[weak/CD[^-; the 
opposite to the CD'V bright population (Figure '.JPB). In addition, the CD'V dim 
population appeared less activated, with lower Ki-^N, CXCRB and CDBKd expression than 
the CD'V bright population (Figures '.JPC and '.JPD). The CD'V bright population 
appeared to also demonstrate bimodal expression for IL-^, with the lower expressing 
subset representing '^.^% of the population; IL-^ expression that was more like that seen 
in the CD'V dim population. 
 
3.5.5 CD45 sub-population analysis of the plasma dyscrasia primary bone 
marrow samples, reveals the possibility of multiple sub-clones co-
existing 
Additional examination for sub-clones within the primary samples, showed JN of the '^ 
(BN%) samples had evidence of differing CDB[ expressing sub-sets, with only ' of them 
having the phenotype of normal PC (CDB[+/CD[^-/CDJK+). Figure '.J' shows examples 
of B separate CDB[ expressing sub-sets, that did not conform to a normal PC phenotype. 
Such sub-sets are likely to be clonal and I have shown that there are differences in 
expression of functional cell markers (IL-^, CXCRB, MMPK and CDBKd), between the 
larger and smaller CDB[ populations.   
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Figure 3.12. Immunophenotypic evaluation of a CD38 weakly expressing sub-population. Analysis was 
from a newly diagnosed MM bone marrow sample and the mononuclear cells were isolated by density 
gradient centrifugation. 1 x 106 cells were stained with fluorescence-labelled antibodies and data was 
acquired on a BD Fortessa flow cytometer. (A) Pseudocolour dot plot of stained bone marrow mononuclear 
cells, showing MFI CD138 and CD38 expression. Two distinct CD38 populations that were positive for 
CD138 were identified; the larger (7.3% of total cells) was CD38 bright. Neither clone fitted into either a 
typical MM or normal PC phenotype as shown in (B). Overlaid dot plots were used for comparison of the 
MFI expression of the CD38 dim (blue), CD38 bright (red) populations and B-lymphocytes (orange), which 
showed that they are immunophenotypically distinct for CD45 and CD19 expression, (C) IL-6 and Ki-67 
expression and (D) CD49d and CXCR4 expression. 
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Figure 3.13. Examples of CD45 expressing sub-populations in the same plasma cell dyscrasia bone 
marrow sample. The mononuclear cells were isolated by density gradient centrifugation. 1 x 106 cells were 
stained with fluorescence-labelled antibodies and data was acquired on a BD Fortessa flow cytometer. 
Each example is CD138, CD38 gated plasma cells from MM patients bone marrow. All are from separate 
patients. (A) 3 distinct IL-6 CD45 populations, largest population is CD45-/IL-6-, there are 2 separate 
smaller populations, IL-6+/CD45- and a CD45+/IL-6-. (B) CD45+ population has a higher CXCR4 expression 
that the more dominant CD45- population. (C) 3 distinct CD45 populations all with varying CD49d 
expression. (D) CD45 weak expressing sub-set, with much higher MMP-9 expression than dominant CD45- 
population.    
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3.6 Discussion 
Although immunophenotypic comparison of MM cell lines already exists, for example a 
comparison of MM.JS and MM.JR revealed CDP[ and HLA-DR were both more highly 
expressed on MM.JS cells (Greenstein et al. PCC'). To my knowledge, no systematic intra-
cell line immunophenotyping has been done. The complexity of a JC-colour flow 
cytometry panel allows for detection of distinct myeloma sub-populations co-existing 
together as well as immunophenotypic characterisation of these populations, that can 
relate to functional elements such as migration, adhesion and survival/activation within 
their microenvironment. Greater number of fluorochromes allows for better 
characterisation, but can also lead to increased fluorochrome spectral overlap, that 
requires more complex fluorescence compensation. Insufficient or incorrect 
compensation will result in inaccurate MFI expression levels recorded and misleading 
results.  
 
Measures were taken to reduce the variation in sample analysis and assure proper 
compensation. This involved using compensation controls consisting of unstained cells as 
well as singly-stained tubes with fluorescent probes and compensation beads. Due to 
limited size of the primary samples, FMO (fluorescence minus one) staining was not 
routinely employed. Ensuring that autofluorescence artefact was accounted for in each 
primary sample was very difficult as no two samples had the same proportion of 
mononuclear cells. However, the same compensation settings were used for each primary 
sample analysis. Compensation was based on CDJ'V and CD'V positive cell, so only cells 
with identical autofluorescence characteristics to plasma cells were able to be viewed 
correctly. In the event of reduced expression of these markers, compensation settings 
required post-acquisition adjustment using Flow-Jo software, but this was minimised as 
much as possible. B-Lymphocyte gating based on SSC-A-/CDB[+/CD[^-/CDJK+ made for 
a good immunophenotypic reference to malignant PC comparison. 
 
The choice of fluorochrome for the antibody is a key factor in designing a successful panel. 
Pairing cell marker expression with the correct fluorochrome brightness will ensure subtle 
differences in expression between populations are easily identified. For example, MMP-K 
and IL-^ expression used low brightness fluorochromes, as a result MFI variation was 
subtler for these markers and why percentage positivity differences, showed greater 
variation in expression that was not apparent for the MFI data. In addition choosing a high 
brightness fluorochrome for highly expressing antigens can result in difficulties in 
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maintaining a standard PMT voltage. PMT voltages were attempted to be standardised for 
both cell lines and primary samples, with the aim of both negative and positive antigen 
expressing population within the axis in every channel. However, this was not possible, 
because of the variation in cell size (cell lines tending to be larger) and expression variation 
in the higher brightness fluorochromes (most notably CF[KB fluorochrome on the anti-
CD'V antibody). This meant that generally, primary samples PMT voltages appeared too 
low and cell lines PMT voltage, most notably RPMI-VPP^, appeared too high. Therefore, 
different PMT voltages where used for cell lines and primary samples, but were 
standardised within their group. 
 
Although CD'V expression was predominantly positive for cell line and primary data, a 
wide variation in expression was observed for both, each showing evidence of CD'V 
negative/weak populations (including the cell lines UP^^ and MM.JS). The presence of 
CD'V weakly or negatively expressing clones are estimated at less than P% but are 
becoming more prevalent in the advent of anti-CD'V therapy (Minarik et al. PCJN). Thus, 
the study and understanding of CD'V negative clones are becoming more relevant in the 
attempt of developing novel myeloma treatment. Additional understanding of CD'V 
function in MM can also be obtained from expression correlation. Although no correlation 
was observed from the cell line data, statistical positive correlation between CD'V 
expression and other cell markers was observed in the primary bone marrow samples. The 
strongest correlation was with Ki-^N expression (r=C.VK, p=C.CCCJ) and although such 
relationship has been well described in other B-cell malignancies such as CLL (Pittner et 
al. PCC[), it has not been for MM. The positive correlation of Ki-^N and CD'V expression 
in MM emphasises CD'V function as a marker of activation/proliferation, highlighted in 
Figure '.JPC, showing the comparison of CD'V expressing sub-populations with Ki-^N 
expression greatly reduced in the weakly expressing CD'V sub-population. CD'V 
correlation was also seen for CXCRB, and to a lesser extent CDJK and CD[^. I am unaware 
of published data that shows these correlations, in CLL it has been shown that CD'V 
increases CXCLJP/CXCRB axis mediated migration (Vaisitti et al. PCJC) and it is possible 
that similar mechanisms occur here. A larger cohort of primary samples and sub-group 
analysis would strengthen these correlations.     
 
In contrast to CD'V expression, CDJ'V expression within each primary sample sub-group 
(MGUS, MM and RRMM) was fairly uniform, but with statistical decrease in expression in 
the relapsed/refractory group compared to newly diagnosed MM (p=C.C'J). This has been 
previously described in the literature (Kawano et al. PCJP) and attributed to increase in 
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CDJ'V negative clones, which can be up to 'C% in the relapsed/refractory setting (Bataille 
et al. PCC^; Reid et al. PCJC; Kawano et al. PCJP), although I did not identify any obvious 
negatively expressing populations in my data set.  
 
CDJ'V negative clones both at diagnosis and relapse have also been shown to contain a 
greater proliferative ability and subsequently greater clonogenic expansion (Reid et al. 
PCJC) and may partly explain why CDJ'V expression is reduced at relapse. It was therefore 
surprising that Ki-^N expression was statistically lower (p=C.CPN) in the RRMM group and 
is contradictory to what  has been previously described in the literature (Drach et al. JKKP). 
Reasons for this could be that although CDJ'V expression was lower, no true CDJ'V 
negative expression sub-populations were observed. However, this may not fully explain 
why Ki-^N expression for RRMM was reduced and the difference may be inaccurate due 
small numbers of RRMM samples (n=[), the difference in age of samples and 
methodological variation in intracellular staining. In view of CD'V expression also being 
lower in the RRMM group (although not statistical, p=C.CKN), would suggest the RRMM 
samples for whatever reason did indeed have a lower proliferative propensity and where 
not as activated as would be expected. By increasing the cohort of RRMM samples, 
potentially would change the findings. One statistical finding which is more in keeping 
with RRMM pathophysiology is the increased MMP-K expression compared to MGUS or 
newly diagnosed. Increased MMP-K expression is associated with remodelling of the bone 
marrow microenvironment and of a more aggressive disease state (Barillé et al. JKKN). 
         
Primary bone marrow samples expression of CDJK/CDB[/CD[^ remains a crude and 
simple '-colour panel for differentiating between normal PC, disease PC and possible sub-
clones. The immunophenotypic data was largely consistent with that expected for its stage 
of disease (i.e. MGUS, MM or leukaemic phase), but many samples co-existed with small 
distinct immunophenotypic sub-populations. CDB[ expression usually decreases with 
disease progression, but expression can be variable and may represent differing sub-clone 
formation at different stages of disease. In one study, BB% of MM patients were shown to 
contain a CDB[ positive sub-clone that was at least PC% of the total malignant plasma cell 
population (Kumar et al. PCC[). My data is strongly supportive of this study, with BN% of 
samples containing a CDB[ sub-population. In addition, I showed the CDB[ sub-
populations to be phenotypically distinct, highlighting the potential of 
immunophenotyping in identifying sub-clones that may have functional differentiation 
(e.g. migration and adhesion).  
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My data saw a statistical decrease in CDJK expression from MGUS group to both newly 
diagnosed MM (p=C.CCN) and RRMM (p=C.CC^B). This is an expected occurrence where 
CDJK expression decreases through B-cell maturation and a change in phenotype from 
normal to malignant plasma cell (Zandecki et al. JKK[). CD[^ expression was reduced in 
the RRMM group compared to newly diagnosed (p=C.CBC) and in keeping with the 
immunophenotype of plasma cell leukaemia or the leukaemic phase of MM (CD[^ 
negative), a disease state that the majority of cell lines including MM.JS and MM.JR arise 
from and are predominantly CD[^ weak/negative (Pellat-Deceunynck et al. JKKV).  
 
The statistical difference in lower CXCRB expression in relapsed disease compared to 
newly diagnosed, is in keeping with the published literature, where CXCRB expression is 
downregulated through disease progression (Moller et al. PCC'). In addition, a larger 
variation in CXCRB expression was observed within the newly diagnosed primary samples 
compared to other stages of the disease and the cell lines data. Although no distinct 
CXCRB expressing sub-populations were identified within my primary sample data, the 
wide expression variation observed potentially represents cells/clones at different stages 
of disease progression. Cells with lower CXCRB expression possibly signifying cells/clones 
becoming more autonomous of the bone marrow microenvironment and developing 
migration mechanisms independent of CXCRB-CXCLJP axis. Serial measurements of 
CXCRB expression for the same patient at different  stages of disease/treatment would 
provide additional information into the role of CXCRB in relapsing disease and whether 
CXCRB expression can be regulated or is clone dependent, especially in view that CXCRB 
expression has been shown to be a prognostic factor in relapsed disease, especially those 
treated with bortezomib (Alsayed et al. PCCN; Stessman et al. PCJ').  
 
Although myself and others have shown MM cell lines such as MM.JS, MM.JR and OPM-
P migrate across a CXCLJP gradient in Transwell assay conditions (Fedyk et al. JKKK), I 
have shown MM cell lines expression levels of CXCRB do not positively correlate with 
chemotactic responsiveness to SDF-J, indeed contrary to other studies I showed a negative 
correlation between transwell migration and CXCRB baseline expression. The cell lines 
UP^^ and RPMI-VPP^ I showed to have poor migratory CXCLJP potential, (figure '.KA), 
which for UP^^ is in keeping with the results of others (Moller et al. PCC'), yet RPMI-VPP^ 
has shown by some to migratory respond to SDF-J stimulation (Tai et al. PCC'). Reasons 
for these findings could be due to differing experimental conditions. Notably, my 
experiments used smaller Transwell transmembrane pores ('µm compared to Vµm) and I 
did not use fibronectin or endothelial layers on the transmembrane unlike the 
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aforementioned referenced research groups. Ideally, I would conduct the same 
experiments with additional MM cell lines and primary samples for confirmation as well 
as measure CXCRB expression post migration, to confirm if SDF-J blockage of the antigen 
occurred or even if CXCRB is upregulated. Possible explanations for this finding could be 
that reduced CXCRB expression is a marker of disease progression to leukaemic phase with 
migratory mechanism becoming independent of the CXCRB-CXCLJP migratory axis, as 
seen in extramedullary disease (Stessman et al. PCJ').  
 
The cell line migratory work implied that SDF-J induced migration is independent of 
CDBKd expression (r=C.P^, p=C.^P), indicating migration occurs through different 
mechanisms within these cell lines. However, the relative limited number of cell lines used 
and the selection bias means that migration correlation with CDBKd expression still may 
exist for other MM cell lines and/or primary samples. Provided with greater time and 
resources, other cell lines transwell migratory experiments could occur, that would 
provide greater confidence in saying whether certain markers had definite correlation with 
migration or not, such as CD'V expression (r= C.BV, p=C.P'), which has been shown to 
regulate migration for other B-cell malignancies (Vaisitti et al. PCJC).  
 
In summary, I have shown the complexity of sub-clonal populations that exist in both 
myeloma cell lines and primary myeloma samples. Although the concept of MM clones is 
not novel, I have shown that both primary samples and MM cell lines exhibit wide 
variation in CD'V expression and multiple sub-populations and that they have variable 
expression of functional markers within my flow panel (CXCRB, MMP-K, CDBKd, IL-^). 
Thus, identification of sub-clones by immunophenotyping has the advantage over other 
clonal identification methods, in that very small sub-clones can be accurately identified 
and functional differences, that can result in possible selection advantages, driving clonal 
evolution can be explored. This work confirms the heterogeneity of the disease and that 
multiple treatment strategies are required to treat and even cure the disease.  
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CHAPTER 4: 
4 A Novel Model of Investigating 
__Multiple Myeloma Cell Migration 
 
 
4.1 Introduction 
Migration of myeloma cells is a key step in the development of the disease as clonal plasma 
cell require homing to the bone marrow niche, essential for providing myeloma cells with 
signals for cell survival and proliferation (Hideshima et al. PCCJ). The presence of both 
lytic disease in bones and circulating myeloma cells in more than NC% of patients 
(Billadeau et al. JKK^), is indicative of active trafficking of myeloma cells between the bone 
marrow and peripheral blood. Binding of SDF-J (CXCLJP) to the chemokine receptor, 
CXCRB, has been shown to promote homing of circulating myeloma cells back to the bone 
marrow and use of CXCRB antagonists reduces CXCLJP-induced cell migration (Alsayed 
et al. PCCN). The rationale of inhibiting migration and disrupting the myeloma cell and 
bone marrow microenvironment has led to clinical studies involving CXCRB inhibitors. 
For example, the inhibitor AMDBC was shown to increase the number of peripheral 
circulating myeloma cells, indicating its ability to disrupt bone marrow homing and/or 
retention. In addition, AMDBC was synergistic with the proteasome inhibitor bortezomib 
(Azab et al. PCCKb). The clinical relevance of CXCRB expression was further demonstrated 
by the fact that lower expression was seen in extramedullary disease and was associated 
with poorer survival outcomes, especially in those treated with bortezomib (Stessman et 
al. PCJ'). This is consistent with the tumour becoming independent of the bone marrow 
niche. However, it implies that treatment strategies employing CXCRB antagonists may 
not be appropriate or effective for extramedullary disease.  
 
Cellular integrins, particularly CDBKd, are key regulators of cell-to-cell adhesion. They 
modulate the interaction between bone marrow stromal cells and myeloma cells and play 
a role in a mechanism of drug resistance termed CAM-DR (cell adhesion-mediated drug 
resistance) (Springer JKKB; Damiano et al. JKKK). Disruption of CDBKd in myeloma can 
prevent transendothelial migration as well as inhibit recruitment of other immune cells 
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into the tissues (Podar et al. PCJJ). Given the importance of myeloma cell migration both 
in disease development and drug resistance, several research groups have developed 
migration models with each having their advantages and disadvantages (Urashima et al. 
JKKN; Podar et al. PCCJ; Hideshima et al. PCCPa; Mitsiades et al. PCC'). In this study MM 
cell migration was assessed using conventional transwell assays and a novel, circulating 
model system containing endothelium-lined ‘pseudo-vessels’ through which the myeloma 
cells were circulated under physiological shear forces. This novel model, uses a modified 
Fibercell bioreactor, allowing cells to circulate under shear force and for migration to 
occur within the ‘CPCP[’ cartridge, packed with hollow fibres with an internal radius of 
'[Cµm. The hollow fibres contain pores of C.Jµm along their length to allow the exchange 
of medium (and potentially cells) with surrounding enclosed space termed the 
extravascular space (EVS). To migrate, cells have to adhere to a pre-layered endothelial 
lining, travel through the pseudovessels and move through a C.Jµm pore into the EVS. The 
comparative pore size of transwells range from C.Bµm-Vµm. The EVS can be set up to 
contain cells, chemokines, cytokines or whatever is desired to attract circulating cells. This 
chapter sets out to investigate the role CXCRB and CDBKd blockade on myeloma 
migration in a novel in-vitro migratory model.  
 
4.2 Developing the modified hollow fibre bioreactor as a model 
for MM migration  
Walsby et al. successfully established a circulatory transendothelial migration model, to 
investigate the effects of shear force and transient endothelial cell interactions on CLL cell 
migration. In this model CPCP[ cartridges were endothelialised, with the aim of forming 
‘pseudo-vessels’, providing the matrix for migration (Walsby et al. PCJBc). This was done 
by coating the lumen of each hollow fibre with gelatin to allow attachment of 
approximately J[xJC^ endothelial cells (HUVEC). To ensure that the majority of 
endothelial cells had adhered to the lumen of the hollow fibres, non-adhered HUVEC were 
removed from the system by gentle PBS washing (see section P.B.' and figure P.J for greater 
detail) and counted using a Vi-cell XR instrument (Beckman Coulter). If more than JC% 
of the total input endothelial cells were recovered, the endothelisation process was 
repeated. The system was then incubated for BVh in cell culture media under a shear force 
that encourage the HUVECs in the hollow fibres to spread and form ‘pseudovessels’. At 
which point, migratory experiments could occur between the circulating system and the 
EVS. Shear force was set to a higher value (minimum [ dynes/cm') than described by 
Walsby et al. due to the unexpected issue of cells pooling in the reservoir of the system. 
This was likely as a result of MM cells being larger than CLL cells, however the shear forces 
 95 
were still within the expected physiological conditions found in trabecular bone and 
capillaries (Metzger et al. PCJ[). Note, no HUVECs were inserted into the EVS and none 
were found to migrate, thus ensuring any cells obtained from the EVS, would be either 
migrated cancer cells (e.g. CLL or MM) or any pre-inserted cells/fibroblasts (e.g. CXCLJP 
secreted MRC-[ cells). 
 
For this study and the investigation of MM migration, the bioreactor model aimed to 
represent the migration of MM cells from the peripheral blood to the bone marrow. For 
this, the endothelial lining (HUVEC) aimed to represent the barrier between peripheral 
circulation and the bone marrow microenvironment. And in an attempt to replicate the 
bone marrow microenvironment, MRC-[ cells (a fibroblast cell line known to secrete 
CXCLJP (Kang et al. PCC[)) were introduced into the EVS. Walsby et al. previously showed 
(figure B.J) that a sufficient concentration gradient of CXCLJP was created by [xJC^ MRC-
[ cells (Walsby et al. PCJBb). 
 
 
Figure 4.1. CXCL12 expression in dynamic migratory model. CXCL12 concentration as measured by ELISA, 
at 1h and 48h, comparing EVS to circulation, after 5x106 MRC-5 cells were seeded into EVS. No statistical 
difference existed between CXCL12 levels at 1h and 48h, inferring continual steady state secretion of 
CXCL12. Mean CXCL12 concentration was higher in the EVS than circulation at both time points, inferring 
continual concentration gradient persisted. Figure courtesy of Dr Elisabeth Walsby, manuscript awaiting 
publication. Error bars show standard deviation and are calculated by repeated independent experiments. 
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4.2.1 The addition of CXCL12-secreting cells to the EVS significantly 
enhances myeloma cell migration 
In the knowledge that a CXCLJP concentration gradient could be replicated between the 
EVS and circulation, I set out to prove that the CXCLJP-secreting fibroblasts were 
necessary for MM migration. The hollow fibre bioreactor was prepared as for CLL 
migration experiments outlined by Walsby et al. (PCJB) and described in greater detail in 
chapter P. Briefly, the cartridge was lined with gelatin before J[xJC^ HUVEC were seeded 
into the circulating compartment of the system, with an optional [xJC^ MRC-[ seeded into 
EVS. Gradual increase in shear force was applied to the model over BVh, before BCxJC^ 
MM cells were added to the circulating compartment, making a concentration of around 
C.VxJC^/ml. After BVh of circulation, media within the EVS was harvested and migrated 
cell were counted using an Accuri flow cytometer as outlined by Walsby et al. (PCJB). 
Preliminary migrated data (results including within section '.P) suggested the MM cell 
line OPM-P (CXCRB expression KK.K% positivity, section '.B) had one of the greatest 
CXCLJP migration potential, making it an ideal cell line to measure the effects of MRC-[ 
induced migration. I previously showed (section '.B.B) that the cell line was responsive to 
CXCLJP-induced transwell migration. Figure B.P shows the difference in migration 
between experiments with and without the addition of MRC-[. Mean migration for MRC-
[ containing group was P.VP% (n=JC), compared to without MRC-[ C.C'% (n=[), p value 
was C.CCCN, inferring that the difference was statistically significant.  
 
4.2.2 Addition of IL-6 to independent cell lines does not affect migration 
In an attempt to identify whether migration in this model could be optimised, IL-^, a key 
component of myeloma cell regulation and migration, was added at a concentration of 
Jng/ml. At this concentration, the effects of IL-^ are thought to be maximised and are 
roughly the recorded levels seen in the most aggressive forms and leukaemic phases of the 
disease (Bataille et al. JKVK; Podar et al. PCCJ; French et al. PCCP). 
 
The cell lines MM.JS and MM.JR were chosen as the had comparatively the lowest 
expression of IL-^ of all the cell lines used in this thesis (see chapter '). No significant 
difference in migration was observed between the cell lines with the addition of IL-^ 
(p>C.KK for both cell lines). Mean migration for MM.JR was C.^[% and C.[V% for IL-^ 
addition. This compared to MM.JS mean migration of C.'C% and C.'K% with addition of 
IL-^. Although mean migration was over P-fold higher in MM.JR, this was not statistically 
significant (p=C.P[).  
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Figure 4.2. The effect of MRC-5 cells on MM cell migration. Myeloma cell line OPM-2 percentage 
migration at 48h with addition of MRC-5 in EVS (n=10) and without MRC-5 (n=5). Migration was measured 
by flow cytometry cell counting, within a strict alive cell gate, of 100µl of EVS and circulation media. The 
cell count was then multiplied to give estimated count of total retrieved from the EVS as a percentage of 
the total number of cells seeded into the circulating compartment. Error bars indicate mean ± SD. Mann-
Whitney U-test compared the 2 groups, showing a statistical difference in migration, p=0.0007. ***<0.005 
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Figure 4.3. The effect of IL-6 of MM cell line migration. Paired 48h migration experiments of MM.1R and 
MM.1S (n=4), comparing the effect 1ng/ml of IL-6 has on migration. Migration was measured by flow 
cytometry cell counting, within a strict alive cell gate, of 100µl of EVS and circulation media. Cell count 
was then multiplied to give estimated count of total retrieved EVS and circulation volumes. Error bars 
indicate mean with SD and are calculated by repeated independent experiments. Mann-Whitney T-test 
compared the 2 groups
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4.2.3 Ensuring correct identification of migrated Myeloma cells 
The addition of approximately [xJC^ CXCLJP-secreting MRC-[ cells into the EVS raises the 
difficulty of identifying migrated myeloma cells from “resident” MRC-[ cells. Although 
MRC-[ cells are naturally adherent to plastic, a certain degree of non-adherent MRC-[ 
could be expected especially when the cells become confluent. Thus, the retrieval of cells 
from the EVS at BV hours to determine myeloma cell migration could potentially include 
the fibroblasts. The collection process involved gentle flushing with PBS (as opposed to 
trypsin) through the P EVS ports with the aim to collect all migrated cells in suspension, 
plus cells loosely attached to MRC-[ fibroblasts. The process of flushing, instead of the use 
of the proteolytic trypsin for cell removal, aimed to reduce disruption of MRC-[ adhesion, 
thereby limiting ‘contamination’ as much as possible. Concern also existed that myeloma 
cells could adhere loosely to MRC-[ due to their chemokine attraction (see appendix, co-
culture experiments showing myeloma cells adhere to MRC-[), thus simply aspiration of 
the EVS suspension may not be sufficient for retrieving all migrated MM cells.   
 
The Vi-cell XR cell counter provided a quick and easy method of calculating migration 
through a cell count (trypan blue staining) and subsequent concentration of cells from the 
media retrieved from the circulation and EVS. A significant disadvantage of this method 
was that the instrument could not reliably differentiate between different cell types found 
in the sample. Thus, cells retrieved from the EVS could not be guaranteed to be migrated 
MM if MRC-[ cells were added into the EVS. Walsby et al. (PCJB) addressed the potential 
‘contamination’ of fibroblasts in their CLL migratory experiments, by applying a tight 
‘lymphocyte’ gating strategy during flow cytometric analysis. CLL cells are smaller than 
MRC-[ cells (typically V-JCµm compared to J[-JNµm respectively) and can therefore be 
easily discriminated between each other through forward scatter (FSC-A) and side scatter 
(SSC-A) flow cytometry plots.  
 
Immunophenotyping cells offer another method of positively or negatively identifying 
cell. However, concerns are raised to the integrity of cell markers following active 
migration of myeloma cells through a C.Jµm pore, whereby possible physical stress to the 
cell membrane could occur. CDJ'V (syndecan-J) is a well-documented antigen that is 
highly expressed on normal and malignant plasma cells. This makes it a useful antigen for 
myeloma identification (Paiva et al. PCJC). However, it is regarded as a very fragile antigen, 
easily shed either due to cell ageing or physical stress (Jourdan et al. JKKV; Yang et al. PCCN; 
Sanderson and Yang PCCV). The extracellular bone marrow environment of patients with 
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myeloma tend to stain very heavily for CDJ'V, which is thought to be caused by the 
shedding of the antigen from malignant plasma cells (Bayer-Garner et al. PCCJ). 
Alternatively, CDKC is a cell surface protein expressed on T-cells, mesenchymal cells and 
fibroblasts, with no documented expression on MM cell (Kisselbach et al. PCCK). 
 
The following section and experiments aimed to identify if this method was robust enough 
for MM cell identification from MRC-[ cells in media collected from the EVS or if further 
methods were required. For standardisation purposes, the cell line MM.JR was used as a 
model for quantifying the migration of myeloma cells. 
 
4.2.3.1 Cell size is a good discriminator of cells used in model, with EVS cells smaller 
than MRC-5 cells and also their circulatory counterparts  
Although MM cells are larger than CLL, I showed that they are still statistically smaller 
than MRC-[ cells (figure B.BB). The mean cell size of MM.JR and MRC-[ cells in static co-
culture were measured using a Vi-cell XR instrument (JP.J^µm and J[.PPµm respectively, 
p<C.CCCJ). Although mean cell size of MM.JR was slightly higher within the circulation 
model than static culture (JP.NCµm vs JP.J^µm), the difference was not statistically 
significant (p=C.J'). However, when compared to the cell size of cells retrieved from the 
EVS, a statistical difference was observed (EVS JC.BNµm v Circulation JP.NCµm p<C.CCCJ). 
An additional observation was a positive correlation between Vi-cell XR recorded viability 
(measured by trypan blue staining) and cell size (figure B.BA). The greatest correlation 
was observed in MM.JR, followed by HUVEC then MRC-[ (Pearson r value C.KC, C.VB and 
C.[' respectively).  
 
Having proven the difference in cell size between MM cells and MRC-[, figure B.[ shows 
that applying a tight gating strategy for forward and side scatter on the flow cytometry 
analysis could remove the majority of MRC-[ cells (up to K[%). Thereby ensuring a very 
minimal ‘contamination’ of MRC-[ cells in the MM cell counts.  
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Figure 4.4. Comparison of cell size of the various cell types used in the dynamic circulatory migratory 
model. (A) shows the correlation between cell viability and size. Linear regression best fit line shows the 
relationship between cell size and cell viability for the cell lines. (B) Scatter plots of each cell size 
measurements shown as the mean ± standard deviation (SD) and are calculated by repeated independent 
experiments. Cell size and viability were measured using a Beckman Coulter Vi-cell XR. Each point is a 
separate Vi-cell sample measurement; HUVEC (n=56), MRC-5 (n=61), MM.1R (n=70) and paired MM.1R 
samples derived from the circulation (n=23) and EVS (n=23). Viability was assessed by Trypan Blue 
exclusion and data points represent the mean of 50 separate analysed images.  
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Figure 4.5. Flow cytometry restricted gating of MM.1R and MRC-5 cells results in minimal overlap of 
two different cell types. Analysis on Accuri flow cytometer of static co-cultures containing MM.1R and 
MRC-5 cells.  FSC-A and SSC-A ‘Alive cell’ gating strategy of MM.1R (A) and MRC-5 cells (B); Singlet gating 
of MM.1R (C) and MRC-5 cells (D); (E) singlet ‘Alive cells’ gated FSC-A and SSC-A of MM.1R cells, of which 
93.7% are included in a ‘restricted gate’ gating strategy; (F) singlet ‘Alive cells’ gated FSC-A and SSC-A of 
MRC-5 cells, of which 0.4% are included in the same ‘restricted gate’ gating strategy as in figure (D).   
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4.2.3.2 CD138 and CD90 are cell markers differentially expressed on cells used in 
circulatory model, with CD138 expression reduced in migration   
Figure B.^ shows the expression differences between CDKC and CDJ'V in HUVEC, MRC-[ 
and MM.JR cells from static co-cultures. There was a J.[ log difference in CDKC expression 
between MRC-[ and myeloma cells. With a similar log difference in CDJ'V expression 
between myeloma cells and HUVEC/MRC-[. The contrasting expression of these two 
markers for MRC-[ and myeloma cells makes them candidates for the positive 
identification of migrated cells retrieved from the EVS. No HUVEC cells would be expected 
to be recovered from the EVS as non-adherent HUVECs were removed from the system 
prior to the introduction of shear. The addition of shear causes the flattening and 
spreading of HUVECs along the length of the lumen of the hollow fibres. 
 
Although CDJ'V was an excellent identification marker for myeloma cells recovered from 
the circulating compartment of the dynamic model, cells recovered from the EVS showed 
a reduced CDJ'V expression (figure B.N). To determine if the retrieved cells were migrated 
MM with loss of CDJ'V expression, but had the capacity to upregulate expression, cells 
obtained cells from the EVS were placed in fresh media culture for a further BVh. This 
allowed for cell replication or re-synthesis of antigen, with repeat immunophenotypic 
analysis showing a clear population of CDJ'V positive cells (figure B.ND). Therefore, the 
use of CDJ'V expression and immunophenotypic analysis as a positive identification of 
migrated MM was thus deemed unreliable.  To further guarantee that cells retrieved from 
the EVS were migrated MM cells, other confirmatory methods were employed.  
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Figure 4.6. Overlay dot plot comparison of Immunophenotypic expression of CD90 and CD138. 1 x 106 
cells from the cell lines MM.1R (orange), MRC-5 (blue) and HUVEC (red) were stained with fluorescence-
labelled antibodies and data was acquired on a BD Fortessa flow cytometer. Legend states the MFI of 
CD138 (FL2) and CD90 (FL3) of each of the cell lines.
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Figure 4.7 CD138 expression of MM cells at different stages of dynamic circulation migration model. MM.1R 
cell line used in experiment, were stained with fluorescence-labelled antibodies and data was acquired on a BD 
Accuri flow cytometer. (A) Dot plot shown is of CD138 expression and forward side scatter of gated alive singlets. 
Approximately 0.5 x 106 circulating cells at 48h were stained with CD138 fluorescence-labelled antibodies. (B) 
ungated flow cytometry analysis of 100µl EVS at 48h. (C) additional 100µl of EVS was stained with CD138 
fluorescence-labelled antibodies and gating applied on alive singlets. (D) of collected EVS cells at 48h, grown in 
fresh culture media for further 48h and CD138 fluorescence-labelled antibodies stained and gated as in (C). 
Singlet gating for (A) and (D) shown in figures (E) and (F) respectively.   
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4.2.3.3 Direct visualisation and cytogenetic analysis of EVS cells confirm the presence of 
migrated MM cells  
Figure B.KB shows the presence of myeloma cells taken from the EVS as indicated by red 
arrow. The addition of the fibroblasts MRC-[ were also shown (blue arrow) as well as 
myeloma cells loosely adhering to the fibroblasts (black arrow). As a reference, figure B.KA 
shows the MRC-[ and MM.JR cells in static co-culture and the tendency of the cells to 
clump or adhere to the fibroblasts.  
 
MM.JR cells retrieved from the EVS and circulation at BVh were tested for the presence of 
the IGH/MAF rearrangement (t(JB:J^) q'PqP'), a translocation known to be present in the 
cell line (Greenstein et al. PCC'). FISH analysis showed that all myeloma cells in 
circulation contained this translocation (JCC out of JCC cells). Of the retrieved EVS cells, 
JK out of JCC cells contained the translocation (figure B.V). 
 
 
 
Figure 4.8 FISH analysis of MM.1R cells (courtesy of Medical Genetics Service of Wales) of MM.1R EVS at 
48h using the Cytocell Aquarius IGH/MAF dual fusion translocation probe. The image shows IGH/MAF 
rearrangement t(14:16) q32q23) in all three cells shown. 
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Figure 4.9. 40x high power magnification of myeloma cells MM.1 and Fibroblasts MRC-5. (A) static liquid 
co-culture of confluent MRC-5, with adhered MM.1R cells. (B) of total retrieved EVS liquid from MM.1R 
migrated experiment, equally divided into 6 well plates and grown as static co-cultures. Red arrows 
indicate myeloma cells, blue arrows indicate adherent MRC-5 cells and black arrow indicate non-adhered 
MRC-5, with myeloma cells surrounding it. 
 
 
 
 
(A) 
(B) 
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4.3 Cell migration varies amongst myeloma cell lines 
Having successfully validated the methodology of the modified hollow fibre bioreactor as 
a model for MM migration, I felt the most accessible and easiest method to use for 
quantification of myeloma cells remains flow cytometry, which was applied for the rest of 
chapter. 
 
I next set about comparing the migratory potential of various MM cell lines. Figure B.JC 
shows the variation in CXCLJP induced migration of N different myeloma cell lines. OPM-
P cell line has the greatest propensity to migrate across a CXCLJP concentration gradient; 
mean migration was '.KB% (SD±'.[^, n=JP) of cells seeded into the circulating 
compartment migrated into the EVS over BVh. The cell line with the lowest propensity to 
migration was JJN-', where only C.N[% (SD±C.N[, n=N) of total cells migrated. Two cell 
lines which I had previously not shown to be responsive to CXCLJP-induced transwell 
migration (UP^^ and RPMI-VPP^) did show some cell migration, UP^^ J.^^% (SD±J.'', 
n=[) and RPMI-VPP^ J.BJ% (SD±J.BJ, n='), comparable to the CXCLJP responsive transwell 
migration cell line MM.JS, J.^P% (SD±C.[J, n=JN).  
 
4.3.1 Potential sub-clones within the same cell line can have a differing 
propensity for cell migration 
An additional intriguing finding was the difference in migration for the MM.J-related cell 
lines (MM.JS, MM.JR and MM.JSdim). A statistical difference in migration (p=C.CC[^, 
unpaired P tailed t-test) was observed between MM.JS (J.^P%±C.NK, n=JN) and its 
dexamethasone resistant counterpart MM.JR ('.J^%±J.K, n=JN). When comparing MM.JS 
cell sorted sub-population, a CD'V expressing negative sub-populations (termed MM.JSdim 
and further explored in chapters [ and ^) was statistically not as migratory as its parent 
cell line (C.V^%±C.[J, n=[, p=C.CPN).   
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Figure 4.10. MM cell line migration at measured by modified hollow fibre bioreactor model. Migration 
measured at 48h and calculated by the number of cells retrieved in the EVS as a percentage of cells 
retrieved from the circulation. Roughly 40x106 MM cells were inserted to the circulating compartment and 
5x106 MRC-5 cells into the EVS. Migration at 48h was measured by both Vi-cell XR and flow cytometry 
methods but this figure only shows the percentage migration for each cell line as measured by Vi-cell XR. 
The data are presented as mean ± SD with the number of replicate independent experiments shown in 
brackets. 
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4.4 The role of the CXCL12 receptor CXCR4 and the integrin CD49d 
in myeloma cell migration  
Having confirmed that the dynamic circulatory migratory model was able to demonstrate 
MM migration, my next aim was to investigate the expression changes of CXCRB and 
CDBKd within the model. In addition, the effects on migration of inhibiting these 
molecules was also investigated in order to determine whether they represent useful 
targets for myeloma treatment. Although these cell markers are known to be key in MM 
migration (Katz and Tavor PCCK), relatively little research has been undertaken into their 
potential as therapeutic targets. To explore the importance of CXCRB and CDBKd in MM 
migration, the cell lines MM.JS and its dexamethasone resistant clone MM.JR were to be 
used. These cell lines were chosen for several different reasons: 
i. Both cell lines expressed (analysed by immunophenotyping) both proteins (figure 
B.JJ).  
ii. The cell lines have been shown to be responsive to CXCLJP-induced migration, and 
the effects of CXCRB inhibitors have been studied (Alsayed et al. PCCN). 
iii. Although both cell lines originating from the same patient/clone, expression 
differences are observed, more pronounced in CDBKd with MM.JS having greater 
expression for both markers (Figures B.JJ). I have already shown the different 
migratory potential of the cell lines but could also correspond to different 
sensitivity to drug inhibition within “sub-clones”.  
iv. Despite the common origin of the cell lines, observed functional and phenotypical 
differences exist. One area of interest is the PI'K/AKT pathway, a key regulator of 
CXCLJP/CXCRB induced migration (Hideshima et al. PCCNa). Differing expression 
levels of PI'K could result in varying susceptibility to PI'K inhibition and/or could 
be an indicator of different migratory potential and responsiveness to inhibition of 
CXCRB or CDBKd.  
 
Pharmacological inhibition of CXCRB would be through the small molecule inhibitor 
ONO-NJ^J, whereas CDBKd inhibition would be through the monoclonal antibody 
Natalizumab. 
   
The CXCR4 inhibitor ONO-7161 
Several commercially available CXCRB inhibitors were considered. Plerixafor (AMD'JCC-
Genzyme) is the most widely accessible as it is licensed for stem cell mobilisation for a 
number of haematological conditions (including myeloma), prior to autologous stem cell 
transplants. It has also been used in limited circumstances for the treatment of relapsed 
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multiple myeloma. Phase II trials using Plerixafor in combination with bortezomib have 
been undertaken at the Dana-Faber Institute (Ghobrial et al. PCJB). The rationale for 
combining these drugs is that CXCRB inhibition would induce de-adhesion of myeloma 
cells, removing them from their protective microenvironment and thus sensitising the 
cells to bortezomib. Whether such inhibition changes the clinical behaviour of mobilised 
plasma cells is unclear, but when the effects of CXCRB inhibition has resolved, plasma 
cells/stem cells return to their bone marrow microenvironment niche. ONO-NJ^J, like 
plerixafor, is a small molecule inhibitor of CXCRB. It was developed by ONO-
pharmaceuticals but to date it has not been developed beyond pre-clinical studies 
undertaken in CLL (Walsby et al. PCJBb), within our research laboratory. Despite the 
apparent lack of development into clinical studies, Walsby et al, showed that ONO-NJ^J is 
a more potent inhibitor of CXCRB expression than plerixafor and inhibits CXCLJP-induced 
CLL migration, both in transwell assays and in the dynamic circulatory model used in this 
thesis. Inhibition of migration was observed at a concentration of 'CnM and is non-
cytotoxic up to concentrations of JCµM. 
 
The CD49d monoclonal antibody Natalizumab 
Natalizumab is a purified, recombinant, humanised monoclonal antibody (IgGB subclass) 
that binds to the αB subunit (CDBKd) of integrin αBβJ (also known as VLA-B), thus 
blocking the binding of ligands VCAM and MadCAM to VLA-B and to the αBβN integrin 
(Leger et al. JKKN). The IgGB class of antibodies demonstrates reduced binding to Fcγ 
 receptors and lack of ability to fix complement in vitro. It is also characterised by a shorter 
hinge region in comparison to antibodies of the IgGJ subclass, leading to a reduced 
flexibility of the hinge region. Produced in non-immunoglobulin secreting murine 
myeloma cells it has a molecular weight of JBK kilodaltons (Leger et al. JKKN). Natalizumab 
was initially developed for use in inflammatory disorders, where inhibition of immune cell 
recruitment to inflamed tissues had obvious appeal and was initially granted license by 
the FDA in PCCB for use in such conditions (more information available at 
www.accessdata.fda.gov/drugsatfda_docs/label/PCCV/JP[JCBsJC^lbl.pdf). However, this 
licence was temporarily revoked after cases of progressive multifocal leukoencephalopathy 
(PML) were reported (Kappos et al. PCCN). The licence was eventually reintroduced in 
conjunction with European Medicines Agency (EMA) findings, but solely approved for 
multiple sclerosis, as the benefits, on balance outweighed the risks of PML at a dose of 
'CCmg or ' mg/kg every PB days, roughly equating to a concentration of BCCnM 
(European Medicines Agency PCCN).    
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Figure 4.11. CXCR4 and CD49d MM.1S and MM.1R expression. Overlay histograms showing (A) 
expression of CXCR4 and (B) expression of CD49d of MM.1R (red) and MM.1S (blue). Legend for each 
histogram shows the number of events analysed (count), median fluorescence intensity (MFI) and 
percentage positivity (%). 1 x 106 cells were stained with fluorescence-labelled antibodies and data was 
acquired on a BD Fortessa flow cytometer.  
 
 
(A) (B) 
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4.4.1 Migrated cells up regulate expression of CXCR4 and Ki-67 but not 
CD49d 
Table B.J and figure B.PC outlines the variation of CXCRB and CDBKd expression between 
circulating (non-migrated) and migrated MM cells after BVh in the dynamic circulatory 
model. The experiment included the seeding of MRC-[ cells into the EVS, thus creating a 
CXCLJP concentration gradient. CXCRB expression changes of the two cells lines are 
broadly similar. After BVh of cells circulating within the dynamic model, those circulating 
cells still within the circuit, CXCRB expression was lower than compared to baseline 
expression in static culture (MFI as a percentage of baseline - MM.JS V[%, MM.JR K[%, 
see table B.J). However only in MM.JS was the decrease in expression statistically 
significant (p=C.CC'K vs p=C.BN). Meanwhile, migrated cells retrieved from the EVS (at 
BVh) showed a statistically significant upregulated of CXCRB expression for both cell lines 
compared to control circulating cells (MM.JS MFI J'V% of baseline, p=C.C'K and MM.JR 
MFI J[^% of baseline, p=C.CBN). 
 
Both cell lines showed a reduction in CDBKd expression on circulating control cells at BVh 
compared to static culture; MFI percentage of baseline expression (n=V), MM.JR NK% (MFI 
B',^PN to PK,'C') and MM.JS [N% (MFI BV,^C^ to P',KCC), however, the differences were 
not significant (MM.JS p=C.PN, MM.JR p=C.JK). MM.JS (higher baseline CDBKd expression) 
CDBKd expression of migrated cells (MFI JK,PCJ n=[) were similar to expression of 
circulating cells and almost half the MFI of static culture CDBKd expression ([N.^% vs. 
[N.B% - normalised to baseline). Whereas MM.JR showed an increase in CDBKd expression 
(JK,JJN n=[) of migrated cells retrieved from EVS compared to static culture baseline, 
however the wide variation in MFI results (SD±K'%) meant no statistically significant was 
shown.  
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 MFI (%) SD No. pairs 
Paired  
t-test 
p-value Summary 
MM.HS CXCRJ       
Baseline JCC ^[.[K 
 
 
 
 
Circulation  VB.^J K.CN K Baseline  C.CC'K ** 
EVS  J'V.'C NJ.KN K Circulation C.C'K * 
MM.HS CDJMd       
Baseline JCC [^.P[ 
 
 
 
 
Circulation [N.BC JV.VP [ Baseline  C.PN ns 
EVS [N.^J 'P.CV ' Circulation C.'J ns 
MM.HR CXCRJ       
Baseline JCC ^J.^N 
 
 
 
 
Circulation  KB.^[ JC.PP N Baseline  C.BN ns 
EVS  J[J.[C ^K.JV N Circulation C.CBN * 
MM.HR CDJMd       
Baseline JCC [P.[P 
 
 
 
 
Circulation NK.'P JK.[V [ Baseline  C.JK ns 
EVS JCN.'C K'.BJ [ Circulation C.VJ ns 
Table 4.1. Median fluorescence intensity (MFI) and statistical data of MM.1S and MM.1R CXCR4 and 
CD49d expression taken at 48h post experiment from either static culture (Baseline), control circulating 
system (Circ), Control EVS (EVS) or from paired Circulating and EVS containing drug (ONO-
7161/Natalizumab or in combination). MFI values were normalised to paired static culture sample under 
same experimental conditions and calculated as a percentage. T-test are Wilcoxon paired, 2 tailed non-
parametric. Number of pairs are stated in table and MFI was measured on BD Accuri, with approximately 
0.5x106 cells stained with fluorescence-labelled antibody. In the event of EVS, 100µl of retrieved media was 
stained with antibody without washing.  
 
4.4.1.1 Migrated MM cells show increased Ki-67 expression  
As well as upregulation of CXCRB, Ki-^N (a key intracellular protein associated with active 
proliferation) was also shown to be upregulated in migrated MM after BVh derived from 
the circulatory model. Table B.P shows Ki-^N expression as a total percentage compared 
to unstained MM cells for MM.JS and MM.JR as well as the cell line OPM-P (the highest 
migratory cell line – figure B.JC) as a comparison. Comparisons were made between static 
culture, cells harvested from the circulating compartment and migrated cells retrieved 
from the EVS.  
 
A statistically significant increase in Ki-^N expression was shown for each cell line between 
circulating and migrated cells (MM.JR '.^'% p=<C.CCCJ; MM.JS P.V'% p=C.CCCV; OPM-
P B.P[% p=C.CCCP). The Ki-^N percentage positivity in the migrated MM cells correlated 
with overall migration, with OPM-P the highest cell line migrator, also showing the 
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highest mean Ki-^N percentage positivity. However, this did not correspond to the highest 
fold increase in Ki-^N expression between circulating and migrated cells with the greatest 
difference observed in MM.JR ('.V-fold increase in Ki-^N positivity). Although static 
culture Ki-^N expression was higher than circulation for each cell line, none of the 
differences were significant, with fold changes ranging from J.' (OPM-P) to J.V (MM.JS).  
  
The increase in Ki-^N expression in migrated cells compared to their non-migratory 
counterparts was consistent with data generated by Elisabeth Walsby using CLL cells 
(personal communication of unpublished data).  
 
 
 
Sidak's multiple 
comparisons test 
Mean Ki-IY % Fold-change P Value Summary 
MM.HS 
    
Circulation vs. Static culture C.KC vs. J.^' J.V C.PP ns 
Circulation vs. EVS C.KC vs. P.V' '.J C.CCCV *** 
MM.HR 
    
Circulation vs. Static culture C.K[ vs. J.BN J.[ C.BJ ns 
Circulation vs. EVS C.K[ vs. '.^' '.V < C.CCCJ **** 
OPM-` 
    
Circulation vs. Static culture J.VV vs. P.'[ J.' C.[[ ns 
Circulation vs. EVS J.VV vs. B.P[ P.' C.CCCP *** 
Table 4.2. Statistical data of Ki-67 expression with the myeloma cell lines MM.1S, MM.1R and OPM-2. 
Sidak’s multiple comparison test used to show statistical differences between Ki-67 expression. 
Approximately 0.5x106 cells for circulation and static culture were intracellularly stained with Ki-67 labelled 
fluorescence antibodies, whereas 100µl EVS sample was intracellularly stained. Samples analysed on BD 
Accuri and percentage positivity set as a percentage positivity compared to negatively stained sample, 
prepared by same method apart from addition of fluorescence antibody. Each Ki-67 percentage is the 
mean of three separate experiments 
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Figure 4.12. Proliferative marker Ki-67 expression for 3 different cell lines. Difference in expression of the 
cell lines OPM-2, MM.1R and MM.1S in static culture, cells exposed to 48h of shear force in circulation 
model and migrated cells retrieved at 48h from the EVS. Error bars show standard deviation and are 
calculated by repeated independent experiments.
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4.4.1.2 Emergence of a bimodal CXCR4 expressing migrated population as possible 
explanation for upregulated CXCR4 expression 
Of the retrieved migrated cells obtained from the EVS, CXCRB expression on several 
occasions appeared to have a bimodal population. Figure B.J' provides such an example, 
of an overlaid histogram comparing CXCRB expression of circulating cells (red outline) 
with migrated cells (blue outline). The more dominant EVS population (VP.K%) had lower 
expression of CXCRB and akin to circulating cells CXCRB expression. The higher 
expressing CXCRB EVS population for this example accounted for JN.J% of the cells, with 
almost a log difference in expression. This CXCRB upregulation was seen in the majority 
of control migration experiments, with statically significant increases in CXCRB 
expression for both MM.JS (['.^K% absolute increase, p=C.C'K) and MM.JR ([V.V[% 
absolute increase, p=C.CBN). 
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Figure 4.13. Comparison of CXCR4 expression between migrated and non-migrated MM cells. (B) 
Overlaid histogram comparing CXCR4 expression between MM.1R cells retrieved from EVS (blue line) and 
Circulation (red line). Analysed on BD Accuri, 0.5x106 circulated cells and 100µl of EVS media stained with 
immunofluorescence antibodies.   Experimental method as of section 4.1, with the EVS containing 5x106 
MRC-5 cells. The bioreactor hollow fibres were seeded with 15x106 HUVEC and 40x106 MM cells entered 
into circulation (in addition with drug) and migration measured at 48h using a BD Accuri flow cytometer 
and employing the same FSC v SSC ‘tight’ gate (as shown in figure (A), circulating cells) as described 
previously. Singlet gating (FSC-H and FSC-A) is shown in figures C (circulating cells) and figure D (EVS).   
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4.4.2 Pharmacological inhibition of CXCR4 and CD49d in transwell migration 
Having shown that CXCRB expression is upregulated in migrated MM cells, I next aimed 
to identify if pharmacological inhibition of the CXCRB receptor would affect MM 
migration. Although no statistical changes in CDBKd expression was shown in MM cell 
migration within the dynamic model, I also set out to determine if CDBKd pharmacological 
inhibition affected MM migration and if any migratory synergy existed between the 
inhibitors.  
 
I decided to conduct preliminary migratory work using static transwell plates rather than 
undertake repeated dynamic circulatory model experiments in an attempt to identify the 
optimal drug concentrations to inhibit MM migration. This strategy would have a number 
of advantages. Firstly, it would be more cost effective, and less time consuming but it 
would also allow easier reproducibility of my experiments, with the aim of finding drug 
concentrations that either inhibit migration and/or provide synergy. These results would 
better inform me in deciding ONO-NJ^J and Natalizumab drug concentrations to be used 
within the dynamic circulatory model to either confirm or identify migratory synergy.     
 
 
4.4.2.1 ONO-7161 and Natalizumab are non-cytotoxic to myeloma cell lines, but only 
ONO-7161 decreases expression of its target  
Maximum suppression of CXCRB expression was achieved at a dose of JµM ONO-NJ^J after 
Jh exposure (see figure B.J[), in an apparent dose–dependent manner for both cell lines. 
CXCRB MFI at this concentration for MM.JS was ^V' (J.P% positivity) from a baseline of 
P,PJV, whereas MM.JR MFI was NC[ (J.K% positivity) from a baseline of J,VNC (figure B.JB). 
Suppression of CXCRB expression was maintained for BVh (see figure B.J[), MM.JS MFI 
VJ' (P.J% positivity), MM.JR MFI KBK (P.J% positivity). At concentrations of [CµM and 
above, cytotoxic effects of ONO-NJ^J started to become apparent, with mean viability of 
MM.JS ^C.N[% (±JJ.C[) and MM.JR [^.NC% (±JP.[) at JCCµM.  
 
The cell lines MM.JS and MM.JR highly express CDBKd (percentage positivity of MM.JS 
KK.[% and MM.JR KJ.^%, figure B.JJ). The small difference in expression positivity between 
the cell lines is represented by a much greater difference in Median Fluorescence Intensity 
(MFI) (MM.JS = K,C'[±VB[, MM.JR = B,NVB±N[', n=P). Natalizumab was non-cytotoxic to 
both cell lines (maximum dose of [CµM for BVh, figure B.J^) and did not statistically alter 
either the MFI expression or positivity of the cells at Jh or PBh.  
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This raises either the possibility that Natalizumab does not affect CDBKd expression or 
that the antibody used for immunostaining has a different epitope target to Natalizumab. 
Data from multiple sclerosis patients receiving Natalizumab showed up to a [C% decrease 
in PBMC CDBKd expression (using the same CDBKd antibody clone – KFJC, as used in this 
study), in most but not all patients. This was maintained after a number of repeated 
infusions (Defer et al. PCJP).   
 
 
 
 
 
Figure 4.14. Effect of ONO-7161 on CXCR4 expression. Overlaid histograms showing CXCR4 expression for 
(A) MM.1R (B) MM.1S. For both histograms, red outline represents unstained control, Green outline 
represents stained control and blue outline represents 24h exposure to 1µM ONO-7161 in static culture. 
For CXCR4 staining, 1 x 106 cells were stained with fluorescence-labelled antibodies and data was acquired 
on a BD Accuri flow cytometer. 
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4.4.2.2 ONO-7161 inhibition of CXCR4 expression does not correlate with reduced 
CXCL12-induced transwell migration  
Both cell lines have been shown to possess a migratory potential across a CXCLJP transwell 
barrier (chapter '). MM.JS was shown to be the better migrator with '.KN% (±C.'K) of total 
cells migrating after PBh compared to MM.JR '.PV% (±C.V'). However, this difference was 
not statistically significant (p=C.BV). Upon exposure to ONO-NJ^J, at lower doses (JCnM 
and JCCnM), both cell lines showed a slight increase in migration compared to baseline 
(figure B.J[D), although this difference was not significant. Maximum inhibition of CXCRB 
expression occurred at JµM of drug for both cell lines, however at this dose, migration was 
not affected (MM.JS B.^B%, p=C.KN; MM.JR '.BP%, p>C.KK). MM.JR migration, unlike 
MM.JS did fall with higher concentrations of drug ([CµM and JCCµM) but again neither 
was significant (J.[P% ±C.'J p=C.'^; J.^'% ±C.[J p=C.'[ respectively, figure B.J[D). In 
addition, concerns of off target effects of drug at the higher concentration (JCCµM) were 
raised, as viability started to fall, therefore no further dose increased in the drug occurred. 
 
4.4.2.3 Natalizumab reduces, but does not completely prevent, myeloma cell transwell 
migration  
Figure B.J^D shows that a reduction in CXCLJP-induced PBh transwell migration started 
to be seen at JCµM of Natalizumab (percentage migration MM.JS '.PV%, MM.JR '.[B%), 
although at this dose reduction in migration was not statistically significant (MM.JS 
p=C.CV^ and MM.JR p= C.CN). However, a statistical difference was observed at [CµM 
when percentage migration was normalised to its baseline without Natalizumab. MM.JS 
total percentage migration was P.[J% (p=C.CP compared to baseline) and MM.JR P.[J% 
(p=C.CN compared to baseline).  
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Figure 4.15. Effect of the CXCR4 inhibitor on the cell lines MM.1S and MM.1R. (A) Cell line viability after 
48h exposure to ONO-7161 in static culture (n=2) as measured by annexin V and PI staining and analysed 
on BD Accuri flow cytometer. (B) The percentage positivity of CXCR4 expression, as determined by gating 
on unstained cells, after 1h exposure of ONO-7171 in static culture, as measured on BD Accuri flow 
cytometer (n=2). (C) Comparison of CXCR4 median fluorescence intensity (MFI) at 1h and 48h exposure to 
ONO-7161. (D) 24h percentage transwell migration (CXCL12-induced) at different concentrations of ONO-
7161 (n=4)
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Figure 4.16. Effect of the monoclonal anti-CD49d antibody Natalizumab on the cell lines MM.1S and 
MM.1R. (A) Cell line viability after 48h exposure to natalizumab in static culture (n=2) as measured by 
annexin V and PI staining analysed on BD Accuri flow cytometer. (C) Comparison of CD49d median 
fluorescence intensity (MFI) after 1h exposure to Natalizumab, approximately 0.5x106 cells stained with 
fluorescence labelled CD49d antibody and measured on BD Accuri flow cytometer. (C) 24h percentage 
transwell migration (CXCL12-induced), normalised to control at different concentrations of Natalizumab 
(n=4). Error bars show standard deviation and are calculated by repeated independent experiments. 
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4.4.2.4 Transwell migration experiments provide evidence of the synergist effect of 
CXCR4 and CD49d inhibition  
To show if a possible synergistic effect of the two agents in inhibiting migration existed, 
repeat transwell experiments were undertaken combining Natalizumab and ONO-NJ^J. 
Resources and time restraints meant that full synergistic experiments at fixed ratios were 
unable to be conducted. A dose of JµM for ONO-NJ^J was decided upon, as this was the 
lowest concentration that showed complete expression inhibition of CXCRB, with no 
cytotoxic effects. Natalizumab concentration was more problematic to decide upon as the 
drug seemingly had no effect on expression and although statistically significant migration 
inhibition was shown at [CµM, this dose was much higher than the approved clinical use 
of between BCC-VCCnM, above which concentrations concerns of PML occur. Therefore, 
a dose of JµM (C.JBmg/ml, a similar level to approved drug concentration and the same 
dose as used by Walsby et al, in their CLL experiments (Walsby et al. PCJBc)) was decided 
upon.    
 
Figure B.JN shows a number of effects ONO-NJ^J and Natalizumab have on MM cell lines 
when combination both at a fixed dose of JµM. Combination therapy had no effect on cell 
viability or the expression of the proliferative marker Ki-^N at BVh. However, when the 
drugs were combined and PBh MM cell transwell migrations experiments across a CXCLJP 
concentration gradient were undertaken, a statistically significant reduction in migration 
was observed.  Migration (normalised to control) for MM.JR fell to ^'.N^% (p=C.CCB' 
compared to control) and MM.JS migration fell to [N.'B% (p=C.CCC[ compared to 
control). No inhibition of transwell migration was identified in single agent use and was 
comparable to the previous experiment (figure B.J[ and B.J^). 
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Figure 4.17. Effects of combination ONO-7161 and Natalizumab has on MM cell lines, MM.1S and 
MM.1R (A) CXCR4 and CD49d MFI (normalised to unstained) of cell lines MM.1S and MM.1R after 48h of 
drug exposure. (B) Percentage Ki-67 positivity of the 2 cell lines after 48h of drug exposure in static culture. 
Cells were intracellularly stained with fluorescence labelled antibody and analysed on BD Accuri flow 
cytometer (C) Percentage CXCL12 induced transwell migration at 24h (normalised to control) of cell lines 
MM.1S and MM.1R, with single agent drugs and in combination (n=4). (D) box and whisker plot showing 
95% confidence intervals (Sidak) between control and drug combination. Error bars show standard 
deviation and are calculated by repeated independent experiments.
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4.4.3 Inhibition of migration investigated in the dynamic circulatory model 
Transwell migration experiments showed that single agent ONO-NJ^J and Natalizumab, 
at concentrations that would otherwise not affect CXCLJP induced MM migration, could 
potentially combine synergistically to inhibit MM cell migration. My next aim was to see 
if such drug combination could also affect migration for MM cells within the dynamic 
circulatory model. Fixed concentration of JµM for both drugs were to be used, based on 
the results of the transwell experiments (Section B.'.P.B), as it was at these doses that 
promising synergistic effect in inhibiting transwell migration were observed and also at a 
dose of Natalizumab that limited the concerns of PML. As for the transwell experiments, 
MM.JS and MM.JR cell lines were to be used to add continuity and also to possibly identify 
if any migratory difference exists between the cell lines.  
  
4.4.3.1 CXCR4 inhibitor (ONO-7161) and the CD49d inhibitor (Natalizumab) are non-
cytotoxic either as single agent or in combination. 
As observed with the transwell experiments, neither agents either as single or in 
combination (JµM) was toxic to circulating cells or to cells retrieved from the EVS (figure 
B.JV). No statistical difference was seen between the MM cell viability of circulating cells 
with or without either drug (mean cell viability NN.P'% v N^.[B% p=C.KK). Likewise, no 
statistical difference was seen in cell viability between cells retrieved from EVS in either 
control or drug (mean cell viability ^V.[K% v NC.VB% p=C.KJ). A difference was seen 
between circulation control and EVS control cell viability (p=C.CCV[), but not between 
the circulating compartment and the EVS with addition of drug (p=C.BK).  
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Figure 4.18. Viability of MM cells within the dynamic circulatory model. Collective scatter plots 
comparing cell viability between the different compartment of dynamic circulatory model and between 
drug included (either in combination or single, both drugs at a concentration of 1µM) and without. Plots 
include mean and SD of cell viability (measured by Beckman Coulter Vi-cell XR) of cells retrieved from 
circulation and EVS and are of a by-product of MM.1S and MM.1R experiments combined. Experimental 
method as of section 4.1, with EVS containing 5x106 MRC-5, bioreactor seeded with 15x106 HUVEC and 
40x106 MM cells entered into circulation (in addition with drug) and migration measured at 48h. 
 
4.4.3.2 The pharmacological agents ONO-7161 and Natalizumab in combination inhibit 
migration 
When MM.JR and MM.JS were subjected into the circulation of the dynamic migratory 
model (with CXCLJP secreting MRC-[ as a chemoattractant within the EVS), mean 
migration for the cell lines without pharmacological agents was MM.JR C.[J%±C.[J (n=P[) 
and MM.JS C.''%±C.'J (n=P'). The difference between the two cell lines was not 
statistically significant (p=C.'C, unpaired t-test n=JP, table B.' and figure B.JK). These 
results were in keeping with dynamic circulatory experiments from section B.J.P (note 
migration in figure B.JC was calculated by Vi-cell cell counter for standardisation purposes 
between all cell lines). 
 
In contrast to the Transwell migratory experiments, inhibition of migration occurred with 
the addition of the single agent pharmacological agents ONO-NJ^J (JµM) and Natalizumab 
(JµM). MM.JR mean migration with ONO-NJ^J was C.P'%±C.C^^ (n=') and Natalizumab 
C.'J%±C.JP (n='), whereas MM.JS mean migration with ONO-NJ^J was C.J'%±C.C[V (n=') 
and Natalizumab C.P[%±C.JB (n='). These results indicate ONO-NJ^J resulted in greater 
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reduction in migration than Natalizumab for both cell lines with relative reduction in 
migration being [[% vs PB% for MM.JR and ^J% vs 'K% for MM.JS. However, the 
reduction in migration caused by JµM ONO-NJ^J compared to control without drug was 
non-significant (MM.JR p=C.BB, MM.JS p=C.C[', n=').  
 
When the pharmacological agents were used in (J:J) combination (JµM ONO-NJ^J and JµM 
Natalizumab), a statistically significant reduction in migration was seen when compared 
to control, (MM.JR C.J'% p=C.C'^, MM.JS C.CN% p=C.CCP). The relative reduction in 
migration was comparable between the P cell lines (MM.JR N[% vs. MM.JS NK%). 
 
 
Figure 4.19. Percentage migration in the dynamic circulation model at 48h. Table 4.3 shows statistical 
data from these experiments. The experimental method used was as described in section 4.1: the 
bioreactor seeded with 15x106 HUVEC, the EVS containing 5x106 MRC-5 and 40x106 MM cells introduced 
into circulation (in addition with drug). Migration was measured at 48h using a BD Accuri flow cytometer 
using FSC v SSC ‘tight’ gating as previously described. The data are shown as mean ± SD of three 
independent experiments, with each experiment a pair of control (untreated) and treated samples.
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Mean 
migration 
SD SEM p-value Summary 
MM.HR           
Control (n= JP) C.[J% C.[P C.J C.'C+ ns 
Natalizumab JµM (n=') C.'J% C.P' C.JP C.^[ ns 
ONO-NJ^J JµM (n=') C.P'% C.J' C.CN C.BB ns 
Combination (n=') C.J'% C.JJ C.CB C.C'^ * 
MM.HS      
Control (n=JP) C.''% C.'J C.C^ C.'C+ ns 
Natalizumab JµM (n=') C.P[% C.PK C.JB C.'' ns 
ONO-NJ^J JµM (n=') C.J'% C.JB C.C^ C.C[' ns 
Combination (n=') C.CN% C.C^ C.CP C.CCP ** 
Table 4.3. Statistical data from experiments outlined in figure 4.17. Mean percentage migration of the 
cell lines with combination of drugs in dynamic circulation model. P-value are Mann-Whitney paired T-test 
with control of the same cell line, except for (+) which is unpaired T-test between all of MM.1S control and 
MM.1R control comparing migration of the two cell lines without pharmacological agents (i.e. the 
controls). SD – standard deviation; SEM – Standard error of the mean; Cont. – control; Nat. – Natalizumab 
1µM; ONO. – ONO-7161 1µM; Comb. – Combined (Natalizumab 1µM and ONO-7161 1µM); ns – non-
significant.  
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4.4.3.3 Combined ONO-7161 and Natalizumab inhibits CXCR4 but not CD49d expression 
in circulatory model  
CXCRB expression at BVh in the combined ONO-NJ^J (JµM) and Natalizumab (JµM) 
treated circulating cells was reduced compared to non-treated circulating cells. Relative 
percentage reduction of CXCRB expression for MM.JS was greater and statistically 
significant than for MM.JR ('[% p=C.C'J vs. P^% p=C.C^' respectively). Although CDBKd 
expression in the circulation (both with and without pharmacological agents) was reduced 
compared to static culture (see figure B.PC), there was comparably no statistical difference 
in CDBKd expression between the circulating compartment and the EVS for either MM 
cell line (MM.JS p=C.N[ n=' and MM.JR p=C.P[ n=').   
 
Of the small number of EVS retrieved cells for the pharmacologically treated experiments 
(ONO-NJ^J and Natalizumab), small increases in CXCRB expression were seen for both 
cell lines, but neither were statistically significant, MM.JS (BB.P[% absolute increase, 
p=C.BN) and MM.JR (PN.BB% absolute increase, p=C.'J). Figures B.PJC and B.PJD, give an 
example of CXCRB expression of migrated cells under conditions containing combination 
drugs ONO-NJ^J and Natalizumab. Although much reduced in number, a bimodal 
population still exists, but this time the larger population (^J.J%) is the more brightly 
expressing CXCRB, compared to CXCRB expression in migrated cells without 
pharmacological agents (figures B.PJE and B.PJF). The same cautionary conclusive remarks 
apply for CDBKd expression as well and although no statistical changes in expression of 
either cell line was observed, of the pharmacologically treated migrated cells retrieved, 
CDBKd expression decreased for both cell lines (relative reduction from static culture 
baseline, MM.JS 'K.B%, MM.JR '^.'%), with the difference approaching significance 
(p=C.C^' for both cell lines).  
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Figure 4.20. Diagrammatic representation of percentage MFI changes within pharmacologically treated 
dynamic migratory experiments. Comparison of CXCR4 and CD49d expression with each bar 
corresponding to different experiment conditions (circulation, EVS, baseline, drug containing (ONO-7161 
and Natalizumab) or not), cell lines ((A)-MM.1S, (B)-MM.1R) and cell marker (CXCR4 or CD49d). MFI has 
been normalised to static culture untreated baseline MFI and represented as a percentage. Median 
fluorescence intensity (MFI) and statistical data of CXCR4 and CD49d expression taken at 48h post 
experiment from either static culture (Baseline), control circulating system (Circ), Control EVS (EVS) or from 
paired Circulating and EVS containing drug (ONO-7161/Natalizumab or in combination). Statistical 
evaluations were performed using the two tailed Wilcoxon signed -rank test. The number of pairs are 
stated in the table and MFI was measured on BD Accuri flow cytometer, with approximately 0.5x106 cells 
stained with fluorescence labelled antibody. In the event of EVS, 100µl of retrieved media was stained with 
antibody without washing. Error bars show standard deviation and are calculated by repeated 
independent experiments.
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Figure 4.21. Flow cytometry plot comparison of CXCR4 expression of migrated MM.1R cells treated with 
ONO-7161 and natalizumab (figures A-D) and those not treated (figures E-F). Experimental conditions are 
those outlined in section 4.3.1 – EVS containing 5x106 MRC-5, bioreactor coated with 15x106 HUVEC and 
40x106 MM cells entered into circulation (with or without pharmacological agents). Samples taken at at 
48h, stained with immunofluorescence antibodies (EVS 100µl sample, circulation 0.5x106 cells. Analysed 
by BD Accuri flow cytometer using a FSC v SSC ‘tight’ gate. (A) + (B) 48h FSC-A and SSC-A flow cytometer 
using same alive MM gate strategy analysed sample of (A) ONO-7161 and natalizumab treated circulation 
sample and (B) 48h EVS sample from same experiment as (A). (C) CD138 and CXCR4 stain of EVS shown in 
(B). (D) CXCR4 histogram of same sample as (C). (E) Control MM.1R experiment without combined 
pharmacological agents, EVS-derived cells were stained with CXCR4 antibody and the bimodal histogram 
is shown in (F)
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4.5 Discussion:  
My results have shown that the dynamic circulatory model initially applied to CLL cells 
developed by Walsby et al, can be applied to MM. I have proven than MM cells with the 
addition of MRC-[, HUVEC’s and shear force are able to create a model that allows MM 
cells to migrate from one compartment to another across a CXCLJP concentration 
gradient. The model is more physiological representative than transwell assays and has 
the capacity to study the effects of migration inhibitors on MM cell lines. In an attempt to 
optimise the model specifically for MM, addition of IL-^ was proposed. Early commercially 
available MM cell lines required the addition of the cytokine to ensure cell survival and 
proliferation and although the majority of commercially available MM cell lines today 
(including MM.JS and MM.JR) have been selected and cultivated to be IL-^ independent, 
thereby assisting in cell culturing (Goldman-Leikin et al. JKVK), studies have shown the 
addition of IL-^ to MM.JS can still activate key pathways and pro-survival protein such as 
Mcl-J (Zhang et al. PCC'). Nevertheless, the addition of IL-^ did not appear to influence 
cell survival or migration and was not further used.  
 
The initial concern of the dynamic migratory model was how to ensure retrieved cells from 
the EVS were migrated Multiple Myeloma (MM) cells. The recorded cell diameter of 
retrieved cells from the EVS by a Vi-cell cell counter, revealed that the cells to be smaller 
than both static culture MRC-[’s and circulating MM cells is suggestive that these cells are 
unlikely to be the fibroblasts MRC-[. This is supported by cytogenetic proof that retrieved 
EVS cells contain the known MM cytogenetic translocation of the MM.J cell lines and were 
also visualised through high power light microscopy. MM.JR and MM.JS are known to have 
the IGH/MAF rearrangement (t(JB:J^) q'PqP') (Greenstein et al. PCC'). Analysis 
confirmed that all myeloma cells in circulation contained this translocation. Of the cells 
retrieved from the EVS, the presence of the same translocation was identified, confirming 
the presence of MM cells and the ability of MM cells to migrate into the EVS. Although 
the actual number of cells with the translocation was lower than circulation (JK out of JCC 
for MM.JR), the purpose of this experiment was simply to confirm the migratory potential 
of MM.J cells within the EVS and not an estimation of total number of migrated cells or 
migration percentage. Inevitably MRC-[ would have been included in EVS sample and 
although I did not test MRC-[’s for the t(JB:J^), ATCC cell line characteristics state it has 
a normal karyotype (Jacobs et al. JKNC), giving confidence that the translocations identified 
in the retrieved EVS cells were that of migrated MM.JR. Through these different 
methodologies, I was able to confirm the presence of migrated MM cells within the EVS 
and hence confirm the robustness of the dynamic circulatory migratory model.  On this 
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basis it shows myeloma cells can remarkably migrate through pore sizes of approximately 
C.Jµm, or around J% of the cells’ diameter. The ability of a cell to migrate through this 
narrow space is remarkable and is far smaller than documented in-vitro transwell 
migration work, where pore size of between '-Vµm is traditionally used. The static nature 
of the transwell assay, in addition to relatively large pore size makes it a less than ideal 
model for studying cell migration and in no way replicates leukocyte movement from 
blood to tissue or bone marrow to blood. In-vivo migration is a dynamic process of 
transendothelial migration through capillary beds, where cells first attach to an 
endothelial cell and move through the tight junction of a process termed diapedesis 
(Johnson-Leger et al. PCCC), a process that is much more represented in our dynamic 
model, where shear force and HUVEC, allow for circulating cells to attach to the inner 
tube lining of the cartridge and from there, trans-migrate into the EVS, attracted by 
CXCLJP (SDF-J) secreting fibroblasts. Published studies investigating CXCLJP induced 
myeloma migration using transwells (Tai et al. PCJP) have tended to see higher percentage 
migration, but using greater pore size (Vµm), not much smaller than the average myeloma 
cell (JJ-J'µm). Such transwell migratory studies should be interpreted with caution. The 
Fibercell reactor used in my studies represents a much more novel, more physiological 
accurate template for investigating migration. A pore size of C.Jµm infers cells that migrate 
must have a strong potency to do so.   
 
The disadvantage of having such a small pore size for migration to occur through could be 
that overall migration is decreased, or that physical strain caused by the act of migration 
results in altered cell surface antigen expression and/or potential cell death. And is 
potentially a reason why there is a discrepancy between percentage migration between the 
two migratory models used. Syndacan-J/CDJ'V has an important role in cell adhesion, but 
is also known to be fragile, with expression loss over time (Bayer-Garner et al. PCCJ) and 
is shed quickly during early stages of apoptosis. I have shown that the cells migrated both 
in the Fibercell dynamic model and in transwell plates, have a lower expression of CDJ'V. 
What I am unable to determine if this represents cell signalling changes related to cell 
migration, i.e. CDJ'V is required to be downregulated in order to migrate, thus forming 
CDJ'V weakly expressing sub-clones, which are known to exist in MM cell lines (Chen et 
al. PCJ^). Studies have shown that that CDJ'V (syndecan-J) is an important factor in 
mediating myeloma cell adhesion both directly and indirectly. Thus, in theory CDJ'V 
negative or weakly expressing clones would find it harder to attach to the endothelium, 
making it less likely and more difficult for the cell to transmigrate (Bayer-Garner et al. 
PCCJ). However, almost contradictory to this, the loss of its CDJ'V expression has been 
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shown to precede intravascular invasion and potentially increase the extramedullary 
spread of MM (Ridley et al. JKK'; Rawstron et al. JKKN). i.e. the loss of adhesive properties, 
releases the cell from its bone marrow microenvironment/attachment to stromal cells, 
thus allowing for cell migration into the peripheral circulation. The fact that MM.JS and 
MM.JR are derived from a plasma cell leukaemic phase of the disease (Goldman-Leikin et 
al. JKVK), suggests that these cell lines, like the aforementioned CDJ'V negative clones 
lines, have lost their dependency from stromal cells in other ways. 
 
A more likely explanation is that CDJ'V is being removed or shed from the cell surface 
either by enzymes from HUVECs lysates (such as heparinase) or simply being “ripped off” 
by the active process of migrating through a small pore. As already described in section 
B.J.'.J, Syndacan-J is routinely shed within the bone-marrow by heparinase, a known 
natural proteolytic enzyme that has been shown to be part of HUVECs lysates (Godder et 
al. JKKJ; Yang et al. PCCN). This explanation is further supported by the fact CDJ'V 
expression of migrated MM cells can return back to baseline if re-cultured in media over 
BVh. Thus, suggestive that the expression changes are reversible and rejuvenation of 
CDJ'V occurs provided the correct conditions are present and that the explanation of 
CDJ'V loss of expression is not due to CDJ'V negative clones, but due to MM cell 
interaction with HUVEC and subsequent cleavage of CDJ'V by heparanase. Cell sorting 
MM.JS or MM.JR CDJ'V negative sub-clones and circulating these cells through the 
migratory model to see if migration increases could help disprove the CDJ'V negative 
migration theory, while measurement of heparinase activity either through an ELISA 
based assay or high-throughput sequencing/cDNA measurement (Rivara et al. PCJ^) of 
EVS substrate would help prove the heparinase activity theory.  
 
The potential shedding of cell surface antigens such as CDJ'V raises the possibility of other 
cell surface antigens being shed and could make the interpretation of CXCRB or CDBKd 
expression of migrated MM cells more difficult and raise scepticism regarding any 
conclusions. This could be further confounded, as cell size is drastically altered by the act 
of migration compared to circulating cells (figure B.B), smaller cell size can have fewer cell 
markers and thus result in reduce cell marker expression. However, as neither CDBKd or 
CXCRB expression was downregulated in cells retrieved from the EVS, this would infer 
that if shedding of CDJ'V does indeed occur, it appears to be isolated to just this antigen 
of the ones used in this thesis. Supportive of this point, there does not appear to be antigen 
loss for migrated CLL cells within the dynamic migratory model (Walsby et al. PCJBc) and 
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hence strengthening the conclusion that the phenomena appear to be specific to MM 
expression of CDJ'V.  
 
The baseline or static culture difference in CDBKd expression between MM.JS and MM.JR 
is an interesting occurrence. The functional differences of MM.JR compared to MM.JS, 
such as dexamethasone resistance, increased semi-adhesive properties to plastic and 
increased migratory potential would lead to believe MM.JR to have the greater CDBKd 
expression of the MM.J cell line, but it is MM.JS that has the marginally higher CDBKd 
expression, although the difference was never proven to be statistically significant and it 
is worth noting migrated MM.JR cells retrieved from the EVS have a higher expression of 
CDBKd than the circulating cells (i.e. expression upregulated), that is not observed in 
MM.JS, where expression levels remain comparable. It is possible MM.JR increased 
migratory potential compared to MM.JS could be related to its ability to upregulate CDBKd 
expression when required. An additional means of investigating migratory differences and 
adhesive properties between the cell lines given more time and resources, would be for 
direct observation of migrating myeloma cells either by a BioFlux cellular light microscopy 
or in vivo optical imaging models (Runnels et al. PCJJ). Such models can include the use 
of fluorescence staining kits of key integrins like CDBKd, allowing to directly observe 
expression differences related to either migration or adhesion to endothelial cells and 
what effects inhibitory agents such as Natalizumab have on adhesive and migratory 
properties. 
 
Another interesting property of CDBKd not fully explored in this thesis is its role in Cell 
Adhesion Mediated-Drug Resistance (CAM-DR). Although CDBKd is unlikely to be 
implicated in MM.J clonal dexamethasone resistance, with the mechanism of resistance 
widely believed be related to altered expression levels of the Glucocorticoid Receptor 
(Greenstein et al. PCC'), it is plausible that CDBKd may be involved in other MM.J drug 
resistance/CAM-DR sub-clones, e.g. lenalidomide (Zhu et al. PCJK).   
 
Regardless of the subtle CDBKd expression differences between the MM.J cell lines, it 
remains a strongly expressed cell markers in MM cell lines and patients. Indeed around 
V[% of patients positively express the integrin, with treatment naïve patients tending to 
have higher expression and when in conjunction with negatively expressing CDB[, exhibit 
a better prognosis (Suzuki et al. PCJ'). As to why this occurs is unknown, but the high 
expression, its important role in migration as well as its role in drug resistance/CAM-DR 
(Damiano et al. JKKK), makes it a promising therapeutic target in myeloma. Despite this 
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fact, Natalizumab remains the only commercially available CDBKd antagonist and its 
involvement in myeloma is very limited. A Phase I/II clinical trial in PCCV in 
relapsed/refractory multiple myeloma (RRMM) conducted by Biogen Idec 
(Identifier: NCTCC^N[BPV) was terminated due to low enrolment and major concerns 
remain as to the potential side effects, notably PML. Because of the lack of other CDBKd 
antagonists, it remains to be seen whether PML is specific to Natalizumab or potentially 
generic to any form of CDBKd inhibition. And to add further complexities surrounding the 
actions of Natalizumab, my results have provided questions regarding the effectiveness of 
Natalizumab in inhibiting CDBKd in MM cell lines, as expression was not affected, even at 
high doses of the antibody. Although Natalizumab (IgGB subclass) and the CDBKd 
immunofluorescence labelled antibody (IgGJ subclass) are different IgG subclasses (Leger 
et al. JKKN), this should not have an impact in epitope competition on the assumption the 
antibodies were competing for the same binding site. In transwells experiments, migration 
only started to be inhibited (not significantly) at a supratherapeutic dose of JCµM (clinical 
concentration for Multiple Sclerosis roughly C.BµM). At this dose, CDBKd binding sites 
should have been fully saturated, preclinical studies showed a single dose of '[nM, αB-
integrin saturation was above KC% and decreases slowly in a dose related manner, with a 
half-life of between ^C-KCh (Leger et al. JKKN). Therefore, assuming that Natalizumab 
potency was intact, is it likely the binding epitopes of Natalizumab and the CDBKd 
immunofluorescence labelled antibody are different, therefore not in competition. 
Though it is worth noting data from multiple sclerosis patients receiving Natalizumab 
showed up to a [C% decrease in PBMC CDBKd expression (using the same CDBKd 
antibody clone – KFJC, as used in this study), in most but not all patients. This was 
maintained after a number of repeated infusions (Defer et al. PCJP).   
 
The addition of an endothelial layer (HUVEC) into the dynamic circulatory migratory 
model, appears to be fundamental in allowing MM cells to migrate, as it provides a surface 
for the cells to adhere to and subsequently actively migrate. This is possibly why a 
discrepancy between the migratory models with single agent Natalizumab was observed. 
As the transwell migration model, not including HUVEC, observed no decrease in 
migration, whereas the dynamic circulatory model which did include HUVECs, observed 
a decrease in migration (albeit non-statistical). This would help to explain why Podar et al 
has showed MM.JS adhesion to fibronectin and endothelial cells is inhibited by 
Natalizumab at doses lower than used in the transwell (Jµg/ml). Podar et al. showed 
transwell migration was also inhibited at a dose of Jµg/ml, but only with the addition of 
bortezomib and on fibronectin layer above the transwell membrane (Podar et al. PCCJ). 
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Although the study confirmed the MM.JS expression of CDBKd by flow cytometry analysis, 
no mention was made of Natalizumab reducing expression on any of the myeloma cell 
lines (including MM.JS). These results strongly confirm the requirement of a fibrin contact 
for MM.JS to adhere allowing migration and that CDBKd plays a key role as an integrin in 
allowing adhesion.  
 
Limited clinical data of Natalizumab use in myeloma patients exists, therefore it is difficult 
to predict at what concentrations effective migration inhibition will start to occur, 
especially as myeloma cells have higher expression of CDBKd than healthy lymphocytes. 
which can further increase with acquired drug resistance (Suzuki et al. PCJ'). Regardless, 
pharmacokinetics of the drug in healthy individuals are likely to be comparable to 
myeloma patients. On this presumption, concentration of JµM (as used in this chapter and 
greater than the clinical use concentration) of the antibody is sufficient to fully saturate 
CDBKd antigen for BV hours. Despite CDBKd important role in migration and also as a 
prognostic factor in a number of B-cell malignancies (Shanafelt et al. PCCV; Bulian et al. 
PCJB), it is still unclear whether inhibition in cell migration would correspond in 
prevention of clonal expansion and ultimately improved PFS/OS. Sadly, as CDBKd 
antagonist research is limited with no new drugs coming into clinical trials, in addition to 
the toxicity concerns of Natalizumab (notably PML) and the discovery of developing anti-
natalizumab antibody development (titres up to JVCC µg/ml within P-' weeks after 
administration in primate toxicology studies), the likelihood of CDBKd therapy in MM in 
the near future remains remote.  
 
I successfully showed that ONO-NJ^J inhibits expression of CXCRB at low concentrations 
(JnM), an hour after exposure, with effects still seen after BVh. Its effects appear more 
potent that plerixafor, where CXCRB expression was reduced at ^h after exposure of [CµM 
with effects worn off by PBh (Azab et al. PCCKb). Azab et al. have extensively investigated 
the effect of plerixafor at a dose of [CµM on the cell line MM.JS. Their data suggested when 
used in combination with bortezomib, it can overcome drug resistance induced by bone 
marrow stromal cells (BMSC), disrupt adhesion to fibronectin by up to [C%, and 
significantly inhibit migration in response to CXCLJP. Although I have not undertaken 
adhesion assays, the presumption as with CDBKd, is that the ONO-NJN^ effect on 
migration is maximised when an endothelial platform is applied to the model. Azab et al 
data suggests that by inhibiting CXCRB, not only are myeloma cells homing signals lost, 
but also a mechanism of cell adhesion. The lack of HUVECs within the transwell 
experiment as for Natalizumab maybe why a reduction in migration was only seen at very 
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high concentrations of ONO-NJ^J and surprisingly only for MM.JR. However, minimal 
CXCRB expression differences between the two cell lines (MM.JS marginally greater) are 
observed and another possible explanation for this could be related to the uninhibited 
receptor CXCRN, a recently discovered additional receptor to CXCLJP, that has been shown 
to be involved in the CXCLJP-CXCRB migration axis and whose inhibition has shown to 
disrupt MM cell trafficking in the MM.JS cell line (Azab et al. PCJB). Measuring CXCRN 
receptor expression differences between the two cell lines in transwell experiments would 
therefore be informative in explaining why only MM.JR migration is affected at higher 
ONO-NJ^J concentrations.  
 
Another slightly surprising observation concerning ONO-NJ^J experiments and CXCRB 
expression, was that CXCRB expression appeared to increase back to baseline at higher 
drug concentrations ([CµM and JCCµM – figure B.J[). Presuming that this is a genuine 
phenomenon and not due to auto-fluorescence or background artefact/signal, this could 
be related to off target effects, or cell self-upregulation of CXCRB expression. The cytotoxic 
effects of the drug start to be observed at [CµM, as higher doses it is possible off-target 
effects are resulting in cell death, which result in up-regulation of CXCRB expression, a 
phenomenon which has been described in AML cell lines (Sison et al. PCJ'). 
Unfortunately, no pharmaceutical data exists as to how ONO-NJ^J works. The suggestion 
of possible off target effects and cytotoxicity suggests that the drug is likely internalised as 
a small molecular inhibitor rather than inhibiting the antigen on cell surface. 
 
Alsayed et al. (Alsayed et al. PCCN) gave rise to the phrase “dynamic regulation of the 
CXCRB receptor”, whereby expression of CXCRB of myeloma cells in the peripheral blood 
is high but decreases once in the bone marrow where high levels of CXCLJP exist. This 
contributes to the retention of myeloma cells in the marrow, thus preventing further 
trafficking. Indeed, this likely explains why there is an apparent decrease in CXCRB 
expression when comparing static cell line expression to those in circulation (figure B.PC). 
The latter cells, exposed to CXCLJP, would result in the internalisation of the CXCRB 
receptor and thus decrease in expression.  However, my migratory expression results are 
seemingly in contrast to this theory, whereby migrated cells in the EVS have a higher 
expression of CXCRB. Myeloma cell CXCRB expression levels are notoriously variable, with 
other studies giving conflicting results (Hideshima et al. PCCJ; Moller et al. PCC'). My 
results suggest that migrated cells in the confines of high CXCLJP concentration, do not 
downregulate CXCRB expression, but expression is seemingly upregulated in the direction 
of migration. This is supported by the bimodal CXCRB expression identified in EVS 
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retrieved myeloma cells. Serial sampling of CXCRB expression within migrated cells and 
attempted cell sorting and cell culturing of the higher CXCRB expressing population 
would help establish the existence of CXCRB sub-clones or whether the occurrence is due 
to receptor upregulation that allows for migration. Again, it should be noted that my work 
is on two closely-related cell lines and that true representation could only be obtained by 
circulating numerous primary myeloma samples. The variability observed in CXCRB 
expression amongst primary samples could easily be down to the interaction of different 
clones, sub-clones, all having different migratory potential. This theory is supported by 
my own work, where MM.JSdim, MM.JSbright and MM.JR all have varying CXCRB expression, 
but all originate from the same patient (see chapter B). Unlike CD49d, CXCR4 
antagonists are at a much more developed stage, with numerous CXCRB inhibitors already 
available, all claiming to be more potent than Plerixafor. CXCRB inhibition in cancer is not 
exclusive to myeloma, or even other blood cancers (CLL and AML), but is being 
investigated in solids tumours such as breast cancer (Kang et al. PCC[). Inhibitors include 
other small molecular inhibitors, peptidomimetics and even mono-clonal antibodies 
(Kashyap et al. PCJ^; Peng et al. PCJ^; Abraham et al. PCJN) and remain a promising target 
of inhibition in MM patients. 
 
However, it was not until combination of CDBKd and CXCRB inhibitors within a dynamic 
migratory model involving shear force (as opposed to transwells), that a statistical 
reduction in CXCLJP-induced MM migration was observed. As with many other forms of 
MM therapies, it is unclear whether such inhibition could potentially lead to the selection 
of sub-clones that could escape such inhibition, part of the tidal clones concept (Keats et 
al. PCJP). Indeed, immunophenotypic and/or genetic analysis of the small number of 
migrated cells retrieved from the EVS where pharmacological inhibition of CXCRB and 
CDBKd occurred, could determine if such migrated cells are distinct sub-clone that had 
escaped such inhibition. However, analysis proved difficult due to small cell numbers of 
migrated cells retrieved from the EVS (on average <C.JxJC^ cells in total) in the ONO-^JNJ 
and Natalizumab treated experiments. To highlight this point, figure B.PJ shows the 
difference in cell numbers between JCCµl analysed samples of ONO-NJ^J and Natalizumab 
treated MM.JR cells in the circulatory compartment at BVh (JN,KJJ events, figure B.PJA) and 
the EVS at BVh (P[J events, figure B.PJB). 
 
In summary, I have shown a potent regimen in preventing MM migration, with the 
possibility of halting disease progression. A question still remains how migration 
inhibitors like the ones used in this chapter could be introduced into therapeutic use. A 
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plausible treatment strategy would be in combination with cytotoxic agents such as 
bortezomib. Pre-clinical studies have combined similar migratory inhibitors with 
bortezomib, resulting in additional and synergistic effects on cell cytotoxic and migration 
(Podar et al. PCCJ; Ghobrial et al. PCJB).
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CHAPTER 5: 
 
5 Phenotypic and genetic analysis 
of MM.1S sub-populations 
 
 
5.1  Introduction 
The concept of clonal tiding in the field of MM research has become topical over the last 
few years.  The theory is that at diagnosis there are multiple cancer clones either co-
existing or competing for survival. Over the course of the disease, clonal selection occurs, 
usually in response to treatment. Ultimately, this results in the dominance of more 
treatment-resistant clones that culminates in treatment failure (Keats et al. PCJP).   
 
Understanding the pathology of MM and the testing of therapeutic agents has relied 
heavily on cell lines due to the inability to sustain myeloma plasma cells in long-term in 
vitro culture. The cell lines MM.JS and MM.JR have been extensively used in the field of 
myeloma research as they provide an isogenic model for the development of 
glucocorticoid drug resistance. They originate from the same parental cell line (MM.J), 
derived from the peripheral blood of a female patient with a t(JB:J^) IgA lambda Plasma 
cell leukaemia.  This cell line carried a number of gene mutations including CDKN/, KRAS 
and TRAF3 but was originally sensitive to dexamethasone (Moalli et al. JKKP).  In the JKKC’s 
Steve Rosen’s laboratory, based at Northwestern University, Chicago, created a 
dexamethasone resistant cell line from MM.J by exposing the cells to continuous low dose 
dexamethasone in cell culture for ' months. Greenstein et al. showed when the cell line 
was exposed to dexamethasone, it started to express modified GR mRNA, a variant of 
which being the hGR-P mRNA, known to be present in a number of blood cancers 
(Greenstein et al. PCC'). After '-B months of growth in dexamethasone, the cell line was 
found to no longer express either mutant GR mRNA or its wildtype GRα (the predominant 
isoform). This cell line, termed MM.JR, then became commercially available (Sánchez-
Vega et al. PCC^) and subsequently become a much-studied model of glucocorticoid 
resistance, focusing on altered GR expression, coded by its gene NR3C( (Greenstein et al. 
PCC'; Edwards V et al. PCJP). DNA microarray comparison between the MM.JS and MM.JR 
revealed JP gene expression changes that were shared. JJ upregulated genes included; 
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FKBP+(, GILZ, growth factor receptor genes for TGF-b and IL-^, enzymes  a-P ^-
sialyltransferase and prolyl B-hydroxylase, IGSG/8 (interferon stimulated gene PC) and 
the apoptosis-related gene VDUP(. Only one gene was downregulated, BCL/L(, which 
codes for the anti-apoptotic protein bcl-xL, a member of the Bcl-P family (Boise et al. JKK'). 
Table [.J provides an overview of the genetic comparisons between the two cell lines from 
Greenstein et al and Edwards V et al.  
 
CGHH mRNAH DNA Microarray`  
Whole exome 
SequenceH 
MM.JR deletion: 
• chr2:p37.1-37.3 
• chr4:q32.3-33  
• chr5:31.3  
• ? homozygous 
deletion of NR3C1 
MM.JR amplification: 
• chr7:q36.3  
 
^' genes with 
differing expression 
• NR3C1 decreased 
in MM.1R  
• MGST1 largest 
difference, 
(increase in 
MM.1R) 
Shared expression 
changes 
• Increase 11 genes 
(see text) 
• Decrease 1 gene 
(BCL2L1) 
Increase expression 
in MM.JR; 
• BTK, HLSP-1, MIC, 
HSP28, HSP72, 
Ubiquitin 
Shared mutations; 
• 208 non-
synonymous 
mutations (not 
present in 1KGP) 
MM.JR mutations; 
• PDIA5, TCERG1, 
ERN1, RANBP9, 
MMS22L, PHF19, 
PIGT, AURKB, 
RNMTL1, GPCPD1 
Table 5.1. Summary of genetic differences between MM.1S and MM.1R from Edwards V et al and 
Greenstein et al.; CGH - Comparative genomic hybridisation (copy number differences). 1(Edwards V et al. 
2012); 2(Greenstein et al. 2003);  
 
Although cellular and genetic characterisation of MM.JS and MM.JR has been published, 
none of the previous studies interrogated these cell lines using polychromatic flow 
cytometry, next generation sequencing or explored the sub-clonal selection process, a 
concept (clonal tiding) now widely recognised as a mechanism of drug resistance amongst 
treated patients (Goldman-Leikin et al. JKVK; Greenstein et al. PCC'; Keats et al. PCJP). 
Furthermore, the introduction of molecular targeted treatments, including anti-CD'V 
monoclonal antibodies such as daratumumab (de Weers et al. PCJJ), make it more likely 
that resistance will emerge due to the selection of CD'V negative or CD'V weakly 
expressing sub-clones. Therefore, the availability of CD'V negative/weak sub-clones may 
be increasingly important in order to provide further insight into the function of the CD'V 
antigen in MM disease progression and drug resistance.  
 
In both this chapter and the next, I describe the phenotype, function and genotype of the 
MM.JS and MM.JR cell lines in order to explore the origins of the glucocorticoid drug 
resistance manifested by MM.JR cells. In addition, I explored the sub-clonal architecture 
of each cell line and in the next chapter will demonstrate how functional genomics can be 
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used to preferentially target molecular pathways that are differentially expressed in sub-
clonal populations. 
 
The main aims of this chapter were as follows: 
i. Determine whether the two distinct CD'Vbright and CD'Vdim expressing sub-
populations in the MM.JS cell line showed phenotypic and functional differences.  
ii. Use whole genome sequencing to establish whether CD'Vbright and CD'Vdim 
expressing sub-populations in the MM.JS cell line are genetically distinct sub-
clonal populations.  
iii. Explore whether comparative genomics can be used to determine the origin of the 
glucocorticoid resistance cell line MM.JR.  
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5.2 Discovery of MM.1S as a potential model of the study of CD38 
sub-clonal populations in MM  
 
5.2.1 Differential CD38 expression identifies two phenotypically distinct 
sub-populations within the MM.1S cell line  
As described in chapter ', the MM.JS cell line demonstrated a bimodal CD'V expression, 
with a J.[ log difference in CD'V expression between the two populations (Figure [.JA). In 
contrast, the MM.JR cell line was uniformly CD'V bright, with expression being a further 
C.[ log higher than MM.JSbright sub-population. The CD'V MFI of the two cell lines in the 
overlay histogram in figure [.JA was ^C,^[' for MM.JR compared to P^,BVV for MM.JS. In 
contrast, the distinct CD'V sub-populations both showed uniformly high expression of 
CDJ'V, consistent with plasma cells (Figure [.JB).  
 
Upon receiving the MM.JS cell line from the commercial cell bank ATCC, the minority 
CD'Vdim population contributed around J^% of the total cell line with the CD'Vbright 
population around NB% (Figure [.JB). Over subsequent cell passages (B-[), the proportion 
of the CD'Vdim population reduced to less than [% (Figure [.JC). The rate of CD'Vdim loss 
to less than [%, was found to be even greater (P-' passages) if only adherent cells to plastic 
were passaged (i.e. cells in suspension were discarded). Thus, implying different adhesion 
properties of the CD'V sub-populations in addition to possibly different proliferation 
capacities. 
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Figure 5.1. Flow cytometry dot plots and overlaid histograms of CD38 expression in the MM.1 cell lines. 
(A) Overlaid histograms of CD38 expression, as measured on BD Fortessa, comparing MM.1S and MM.1R 
and unstained MM.1S; legend states CD38 MFI and percentage positivity. (B) Bivariate dotplot of CD38 
and CD138 expression on MM.1S cells, highlighting the percentage contribution of the different CD38 
expression populations and the invariant expression of CD138. (C) Shows the loss of the CD38dim population 
in adherent MM.1S from same culture flask over 14 days. Bottom histogram (yellow) shows CD38 
expression of newly acquired MM.1S cells from the ATCC cell repository. Sequential CD38 expression on 
adherent cells from the same flask; blue histogram +3 days, red histogram +7 days, green histogram +14 
days.   
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5.2.2 CD38bright expression is a surrogate marker of increased 
dexamethasone resistance within the MM.1S cell line 
Figure [.P shows that when MM.JS was exposed to increasing concentrations of 
dexamethasone, MM.JS CD'Vbright cells were significantly more resistant to 
dexamethasone than the MM.JS CD'Vdim cells (LD[C values ^PnM v PKnM respectively; 
p=C.CCP).  
 
To establish whether the CD'Vbright sub-population was inherently more resistant to other 
anti-myeloma therapies, the cell lines were exposed to the proteasome inhibitor, 
Bortezomib. In contrast to dexamethasone exposure, these subsets showed no significant 
difference in drug sensitivity (p=C.B'; Figure [.'B). Similar to MM.JS subsets comparison, 
no difference in Bortezomib resistance was observed between MM.JR and MM.JS (p=C.'J; 
Figure [.'A). 
 
 
 
Figure 5.2. Dexamethasone cytotoxic assays in MM.1S cells, CD38 gated sub-populations (CD38bright and 
CD38dim) and MM.1R. Cells were exposed to increasing concentrations of dexamethasone for 48h. Cells 
were then stained with Annexin V, propidium iodide and allophycocyanin-labelled anti-CD38 antibody to 
enable apoptosis analysis in the CD38bright and CD38dim sub-populations (n=3). Analysis was performed on 
a BD Accuri flow cytometer using CFlow software. In every experiment, 30,000 events were recorded to 
ensure adequate accumulation of events in the minority MM.1S CD38dim subset. Paired Wilcoxon non-
parametric t-tests were used for comparison of individual LD50 values. Error bars indicate mean with SD 
and are calculated by repeated independent experiments. 
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Figure 5.3. Bortezomib cytotoxic assays, comparison of (A) MM.1S and MM.1R and (B) CD38 gated 
subsets of MM.1S (CD38bright and CD38dim). In all experiments, Cells were exposed to increasing 
concentrations of bortezomib for 48h. Cells were then stained with Annexin V, propidium iodide and 
allophycocyanin-labelled anti-CD38 antibody to enable apoptosis analysis in the CD38bright and CD38dim 
sub-populations (n=3). Analysis was performed on a BD Accuri flow cytometer using CFlow software. In 
every experiment, 30,000 events were recorded to ensure adequate accumulation of events in the minority 
MM.1S CD38dim subset. Paired Wilcoxon non-parametric t-tests were used for comparison of individual 
LD50 values. Error bars indicate mean with SD and are calculated by repeated independent experiments. 
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5.2.3 To further explore sub-clone characteristics, CD38 sub-populations 
were isolated by FACS 
CD'Vbright and CD'Vdim subsets were purified using fluorescence-activated cell sorting 
(FACS) to allow a more comprehensive phenotypic, functional and genetic analysis. Figure 
[.BA shows the gating strategy used for the FACS purification. Figure [.BB shows the CD'V 
expression of the two MM.JS sub-populations post purification, together with MM.JR 
CD'V expression. The brightly expressing CD'V purified population was termed 
MM.JSbright cells, with the dimly expressing CD'V population termed MM.JSdim cells. 
Statistical significance of CD'V expression between the two purified population was 
confirmed (p<C.CCCJ), with over J log difference in expression (MFI PJ,VPV vs J,P[B). As 
for comparison, MM.JR had a further C.[ log higher CD'V expression compared to 
MM.JSbright (MFI ^C,NBB, p=C.CCCP). Despite the reduced CD'V expression of MM.JSdim, 
the population still retained ^P.V% positive expression relative to unstained control (Table 
[.J). 
 
It was subsequently discovered over a period of JB days post cell sorting ([-^ passages), 
the CD'Vbright population started to re-emerge within the purified MM.JSdim culture. The 
percentage of cells within the CD'Vbright gate had risen to P'.P% by passage [ and further 
increased to [C.[% after an additional JB days in culture or [ cell passages (Figure [.BC). 
Therefore, two further cell purification techniques were performed using more stringent 
CD'V gating. This ensured purer, more distinct CD'V expressing populations that were 
maintained up to six successive passages or roughly JB days (Figure [.BD).  
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Figure 5.4. Flow cytometry overlaid histograms of CD38 expression in the MM.1 cell lines. (A) Gating 
strategy used for FACS on BD FACSAria cell sorter, 10x106 MM.1S cells were immuno-stained with CD38 
conjugated with PerCP-Cy5.5. (B) Post the first sort, overlaid histograms comparing CD38 expression of 
MM.1Sdim, MM.1Sbright and MM.1R, legend records CD38 MFI (median) as well as population frequency 
within CD38bright gate. (C) Overlaid histograms comparing MM.1Sdim CD38 expression of cells from same 
culture flask 14 days apart post first sort, population frequency within CD38bright gate increased from 23.2% 
to 50.5%, with re-emergence of CD38bright subset. (D) CD38 histograms with legend stating % frequency of 
CD38+ population. After 3 consecutive cell sorting, CD38 expression overlaid histograms of MM.1Sbright and 
MM.1Sdim, comparing CD38 expression immediately post third sort (indicated on legend as A02-MM.1Sbright 
and B06-MM.1Sdim) with 14 days later (indicated on legend as E02-MM.1Sbright and G02-MM.1Sdim). 
MM.1Sbright CD38 expression mirror each other (population frequency within CD38bright gate remained 
stable, 82.4% to 85.9%) with no evidence of re-emergence of CD38dim subsets. MM.1Sdim CD38 expression 
did not increase at the rate seen post the first sort, with no evidence of re-emergence of CD38bright subset 
over 14 days period post third sort (population frequency within CD38bright gate increased from 2.4% to 
14.4%). 
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5.3 Immunophenotypic analysis of MM.1S CD38 expressing sub-
clones reveals additional heterogeneity in antigen expression 
Having isolated the two distinct CD'V expressing MM.JS populations, extended 
immunophenotypic analysis was undertaken to identify any additional 
immunophenotypic differences. The same JC-colour flow cytometry panel as described in 
Chapter ' showed the two populations to be immunophenotypically similar (figure [.[-
[.N). The main exception to this being CD'V expression (figure [.[ and [.N) as already 
described, but also the percentage positivity of the nuclear-specific cell proliferative 
marker, Ki-^N. MM.JSbright showed a statically significant higher Ki-^N percentage positivity 
compared to MM.JSdim (J.NP% (SD±C.J') vs J.CC% (SD±C.PK), p=C.CCPJ). Conversely no 
statistical difference (p=C.N', n=[) was observed between MM.JS (J.[V% SD±C.J') and 
MM.JR (J.[B% SD±C.JJ) in Ki-^N percentage positivity. 
 
Overlay histograms (Figure [.[ and [.^) showed subtle expression differences the two 
populations, MM.JSbright had mildly increased expression compared to MM.JSdim in the 
migration marker CXCRB (p=C.VN) and reduced expression in CD[^ (p=C.[P) and the 
integrin CDBKd (p=C.PJ), although none of the differences were significant (n=').  
 
Table [.P shows the JC cell markers’ average MFI (n=') and percentage positivity (relative 
to unstained control) of the two CD'V purified populations compared to MM.JR. Although 
the majority of cell marker expression were all similar, MM.JSdim CDBKd expression 
(JJ,N^B) was higher than both MM.JSbright (JC,[NB) and MM.JR (N,J^K), the latter being 
statistically significant (p=C.C'J).  
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Antigen Fluorochrome 
MM.HR MM.HSbright MM.HSdim 
MFI % MFI % MFI % 
CDJ'V  Alexa Fluor NCC ^,C[P KK.V P,['K KK.N ',C^J KK.' 
CD'V PE-CF[KB J^,JKP JCC ^,VN' KK.^ VCJ ^P.V 
CDJK PerCP-Cy[.[ ^J^ VN.C ''' [C.C P[[ JJ.' 
CDB[  APC JJV C.V N' C.N JCB C.P 
CD[^  PE P,BKJ VK.V J,^J' V'.^ P,J^B V^.J 
CDBKd  BV[JC N,J^K KV.B JC,[NB KK.[ JJ,N^B KK.J 
IL-^ VB[C VPK JV.J VNC 'C.V VBB N.K 
CXCRB PE-CyN J,KBN JCC J,KC' JCC J,NPP KK.N 
MMP-K FITC ^^K PN.' [VC P^.V NJJ V.V 
Ki-^N BV^C[ P,VBN J.N ',BC[ J.N ',B[' J.C 
Table 5.2. Mean Fluorescence intensity (MFI) and percentage positivity (referenced to negatively stained 
sample) of 10 separate cell markers within same flow cytometry panel). Analysis of 10,000 events on BD 
Fortessa of freshly passaged cell lines. Results are average of 3 separate analysis, n=3. 
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Figure 5.5. Overlaid histograms comparing the expression of 5 different MM cell markers between 
MM.1Sdim and MM.1Sbright. Analysis done on BD Fortessa, MM.1Sdim 13,920 events counted and MM.1Sbright 
13,198 events counted. Histograms were normalised to the mode to make expression of the cell lines 
comparative with individual legend stating Mean and Median Fluorescence Intensity and percentage 
positivity relative to negatively stained control indicated by black split marker.  
Sample Name Median : Comp-PE-CF594-A Mean : Comp-PE-CF594-A CD38+ :: Freq. of Parent
MM1S_bright_stained_015.fcs 21837.5 25774.3 99.6 
MM1S_dim_stained_017.fcs 1253.1 3969.4 62.8 
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
10 0 10 1 10 2 10 3 10 4 10 5
Comp-PE-CF594-A :: CD38
CD38+CD38-
CD19+CD19-
10 0 10 1 10 2 10 3 10 4 10 5
Comp-PerCP-Cy5-5-A :: CD19
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
Sample Name Median : Comp-Alexa Fluor 700-A Mean : Comp-Alexa Fluor 700-A CD138+ :: Freq. of Parent
MM1S_bright_stained_015.fcs 1931.2 2091.0 99.7 
MM1S_dim_stained_017.fcs 2326.7 2484.8 99.3 
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
10 0 10 1 10 2 10 3 10 4 10 5
Comp-Alexa Fluor 700-A :: CD138
CD138+CD138-
Sample Name Median : Comp-PerCP-Cy5-5-A Mean : Comp-PerCP-Cy5-5-A CD19+ :: Freq. of Parent
MM1S_bright_stained_015.fcs 797.0 894.2 50.0 
MM1S_dim_stained_017.fcs 448.2 500.8 11.3 
CD45+CD45-
10 0 10 1 10 2 10 3 10 4 10 5
Comp-APC-A :: CD45
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
Sample Name Median : Comp-APC-A Mean : Comp-APC-A CD45+ :: Freq. of Parent
MM1S_bright_stained_015.fcs 55.8 68.9 0.7 
MM1S_dim_stained_017.fcs 69.3 79.3 0.2 
CD56+CD56-
10 0 10 1 10 2 10 3 10 4 10 5
Comp-PE-A :: CD56
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
Sample Name Median : Comp-PE-A Mean : Comp-PE-A CD56+ :: Freq. of Parent
MM1S_bright_stained_015.fcs 1093.3 1574.6 89.7 
MM1S_dim_stained_017.fcs 1484.8 2788.3 86.1 
 155 
 
Figure 5.6. Overlay histograms comparing the expression of 5 different MM cell markers (related to 
adhesion, migration and proliferation) between MM.1Sdim and MM.1Sbright. Analysis done on BD Fortessa, 
MM.1Sdim 13,920 events counted and MM.1Sbright 13,198 events counted. Histograms were normalised to 
the mode to make expression of the cell lines comparative with individual legend stating Mean and Median 
Fluorescence Intensity and percentage positivity relative to negatively stained control indicated by black 
split marker. 
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Figure 5.7. Comparison of MM.1Sdim and MM.1Sbright MFI (mean fluorescence Intensity) of different cell 
markers. (A) logarithmic scale of 10 different cell markers MFI comparison between the cell lines 
MM.1Sdim, MM.1Sbright and MM.1R, as measured on BD Fortesa. Error bars indicate mean with SD and are 
calculated by repeated independent experiments (n=3). ****p<0.0001; ***p<0.001; *p<0.05; (B) 2-way 
ANOVA 95% confidence intervals (uncorrected Fisher’s LCD) comparison of MM.1Sdim and MM.1Sbright cell 
marker expression, with p-values included for each cell marker. 
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5.4 Proliferative differences between the sub-populations could 
explain the disappearance of sub-clone over time 
A statistically significant increase in Ki-^N expression of MM.JSbright compared to MM.JSdim, 
potentially explains why the CD'Vdim sub-population diminishes over numerous passages. 
Therefore, I aimed next to investigate the comparative proliferative properties of MM.JS, 
its two purified CD'V sub-populations and the MM.JR cell line by differing methods.  
 
5.4.1 Highly expressed Ki-67 cells associated with increased expression of 
CD38, CXCR4 and CD49d, but no difference between the sub-clones  
Dot plot quadrant gating (figure [.V) inferred a positive correlation exists between Ki-^N 
and CD'V expression for MM.JSbright and MM.JSdim cells. For both cell lines, there was over 
a P-fold increase in Ki-^N expressing cells for the higher CD'V-expressing cells (QP>QJ).  
A similar immunophenotypic pattern was observed for CXCRB and CDBKd expression 
(figure [.JJ). Both MM.JSbright and MM.JSdim highly expressing Ki-^N population also 
inferred higher CXCRB or CDBKd expression. This was more prominent for CXCRB 
expression, where highly expressed Ki-^N cells strongly expressed the migration cell 
marker (Figure [.JJA and B). Although MM.JSbright had a higher Ki-^N expression, the two 
populations had a very similar pattern of Ki-^N expression with CD'V, CXCRB and CDBKd.    
  
 
5.4.2 MM.1Sbright cells proliferate at a significantly higher rate than 
MM.1Sdim cells  
Proliferation studies were next performed to confirm whether the differential Ki-^N 
expression was associated with actual cell growth differences. Figure [.JCA shows the 
proliferative rates of MM.JSdim, MM.JSbright and MM.JR. MM.JSdim cells had the longest 
doubling time, ^C.CV hours (YC C.B[ and RP C.K[), with MM.JSbright the shortest doubling 
time of B^.^V hours (YC C.B^ and RP C.KC). Difference in doubling time (calculated over 
NPh) between MM.JSbright and MM.JSdim was statistically significant (p<C.CCCJ, Figure 
[.JPB). As for comparison, MM.JR doubling time (BV.NC hours) was also statistically 
significantly shorter than MM.JSdim (p=C.CCJ), but no difference existed between 
MM.JSbright cells (p=C.PK).  
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Figure 5.8. Bivariate dotplots of Ki-67 and CD38 expression in MM.1Sdim and MM.1Sbrightcells. 10,000 
events for each analyte were collected on a BD Fortessa flow cytometer. The dotplots show CD38-PE-CF594 
and Ki-67-BV605 in (A) MM.1Sdim (B) MM.1Sbrightcells. Both figures show arbitrary quadrant gating to 
evenly divide CD38 expression on Ki-67 negative cells (Q1 and Q4). Q2 therefore represents Ki-67 positive 
cells in the top half of CD38 expression and Q3, represents Ki-67 positive cells in the bottom half of CD38 
expression. Total Ki-67 expression of MM.1Sdim was 0.5% (0.4% within higher CD38 expression), and 
MM.1Sbright1.6% (1.1% within higher CD38 expression).  
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Figure 5.9. Flow cytometry pseudocolour dot plots comparison of Ki-67 expression against either CXCR4 
or CD49d expression of the MM.1S CD38 sub-populations. 1 x 106 cells from each of the cell lines were 
stained with fluorescence-labelled antibodies for the cell markers, Ki-67 (BV605), CXCR4 (PE-Cy7) and 
CD49d (BV510). Data of 10,000 events was acquired on a BD Fortessa flow cytometer. (A) MM.1Sdim CXCR4 
and Ki-67 expression; (B) MM.1Sbright CXCR4 and Ki-67 expression; (C) MM.1Sdim CD49d and Ki-67 
expression; (D) MM.1Sbright CD49d and Ki-67 expression; All figures show the gated Ki-67 positive 
population together with the percentage positivity. 
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Figure 5.10. Measure and comparison of cell line proliferation over a 96-hour period. Cell lines were 
seeded at a density of 0.5x106/ml, with density viability measured using a Vi-cell XR at 24h intervals (n=4). 
(A) Non-linear line of best fit for each cell line over a 96h period was used to calculate DT (doubling time), 
using exponential growth equations of the data (Prism software 6.0).  Error bars indicate mean with SD 
and are calculated by repeated independent experiments (B)  95% Confidence Intervals (Tukey) comparison 
of cell lines viability at 0 hour and 72 hours (n=4), p-value comparison between the cell lines were 
calculated by 2-way ANOVA, with Tukey’s correction for multiple comparison. 
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5.4.3 The increase in CD38 expression of the MM.1S sub-populations is 
associated with higher S-phase activity  
The S-phase of the cell cycle, represents the stage whereby cells undergoes cell synthesis. 
Although Ki-^N is not exclusively expressed in S-phase of the cell cycle (also expressed in 
GJ and GP, but not GC), its levels markedly increase in S-phase. The increase in Ki-^N 
expression for MM.JSbright compared to MM.JSdim (section [.'.J) is supported by MM.JSbright 
having higher S-phase activity ('[.^%±P.J vs. 'P.C%±J.^, p=C.C[J n='). Figure [.JJ shows 
individual cell cycle analysis for each of the MM.J cell lines and MM.JS sub-populations. 
MM.JR has the highest S-phase activity ('N.B%±P.N), although difference was not statistical 
(p=C.P[, n=') when compared to MM.JS ('P.C%±'.B). 
 
Figure 5.11. Propidium iodide (PI) cell cycle analysis. Cells were grown in RPMI-1640 cell culture medium 
with 10% FBS prior to labelling with PI to quantify DNA content and then analysing on a BD Accuri flow 
cytometer. A live cell gate was serially applied into a singlet discrimination gate prior to cell cycle analysis. 
Flow-Jo cell cycle analysis software providing RMSD (Root Mean Square Deviation), %G1, %S and %G2. (A) 
MM.1S, (B) MM.1R, (C) MM.1Sbright (D) MM.1S. 
(B) 
(D) 
(A) 
(C) 
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5.4.4 Dexamethasone causes G1 cell arrest in the MM.1S cell lines, with 
minimal differences between CD38 sub-populations   
When subjected to increasing doses of dexamethasone (PCnM to JCCµM), GJ cell arrest 
was observed for MM.JS and the two sorted populations, but not for MM.JR (Figure [.JPA). 
MM.JR cell cycle activity was confirmed to be impervious to dexamethasone, although a 
minimal increase in GP with a corresponding drop in GJ was observed at the higher doses 
of steroids. 
 
Almost complete cell cycle arrest (S-phase percentage plateau) occurred at the lowest dose 
of dexamethasone (PCnM) used for the MM.JS related cell lines and a log lower 
concentration before the cytotoxic effects of dexamethasone were observed (LD[C roughly 
at PCCnM). There appeared to be no differences in S-phase percentage with increasing 
doses of dexamethasone between MM.JSdim and MM.JSbright, thus indicating sub-clonal 
populations within MM.JS that are steroid naïve were dying upon exposure to 
dexamethasone. 
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Figure 5.12. Percentage of cell cycle phases of the MM.1 cell lines with increasing concentrations of 
dexamethasone, (A) G0/G1-phase, (B) S-phase, (C) G2-phase. Each measurement was only on alive gated 
cells, percentage cell cycle phase calculated using Flow-Jo cell cycle analysis software. Cells were grown in 
RPMI-1640 cell culture medium with 10% FBS prior to labelling with PI to quantify DNA content and then 
analysing on a BD Accuri flow cytometer. A live cell gate was serially applied into a singlet discrimination 
gate prior to cell cycle analysis.  
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5.4.5 Telomere analysis reveals differences in MM.1Sbright and MM.1Sdim 
telomere lengths suggestive of differing proliferative propensities 
Figure [.J' shows the comparative telomere lengths of the various MM.J cell lines. Mean 
telomere lengths were similar between MM.JS ('.JBKb ±J.P') and MM.JR ('.PBKb ±J.CB), 
analysed from an early passage. However, MM.JSbright when compared to MM.JSdim, of a 
similar passage and age post purification, had a shorter telomere length (P.[JKb ±C.VP vs 
'.P^Kb ±J.P'). The shorter telomere length of MM.JSbright is confounded by an increased S-
phase percentage of cell cycle analysis when compared to MM.JSdim, implying MM.JSbright 
has a more rapid proliferative history.  
 
 
 
Figure 5.13. Telomere length profiles for the cell lines MM.1S and MM.1R, MM.1Sdim and MM.1Sbright. 
Telomere length was assessed using single telomere length analysis (STELA)-based PCR technique of the 
XpYp-chromosome. Each STELA profile shows the mean 9Kb) length of telomere and the standard deviation 
(SD). All of the cell lines were assessed at similar cell passage numbers. The MM.1Sbright cells showed 
significant telomere length shortening compared to the other three cell lines. Assays courtesy of Sam 
Hyatt. 
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5.5 Differing in MM.1Sbright and MM.1Sdim adherent and migratory 
potential, emphasises functional variation and potentially of 
being distinct sub-clones  
The immunophenotypic and proliferative difference observed between the two sorted 
MM.JS CD'V sub-populations and MM.JR, led me to investigate whether further 
functional differences existed between the cell lines.  Myeloma cells (both primary and cell 
lines) are known to express the chemokine receptor CXCRB and show homing properties 
in response to the receptor’s ligand, CXCLJP (SDF-J) (Moller et al. PCC'). Determining if 
MM cells have a strong propensity to adhere to the CXCLJP secreting fibroblasts MRC-[ 
as well the confirmed minor differences in CXCRB expression between MM.JSbright and 
MM.JSdim, would be suggestive that the cell lines be susceptible to CXCLJP-induced 
migration, but also discrepancies in migratory potential between the cell lines may exist. 
 
5.5.1 Adhesion 
An early observation between the sorted MM.JS CD'V sub-populations and MM.JR was 
their differential propensity to adhere to plastic culture flasks. MM.JR was observed to be 
the most adherent, requiring thorough cell scrappage to remove the cells. This was in 
contrast to MM.JSdim cells which had a greater proportion of cells in suspension, i.e. less 
adherence. MM.JSbright was more akin to MM.JR, with cells mainly adhered to plastic.  
 
The MM cells were co-cultured with differing stromal or endothelial cells, varying degree 
of adherence between the cells were observed (see supplementary figures in appendix). 
Although no functional adherence assays were undertaken, percentage of MM cells 
adhered to either HUVEC, MRC-[ and HS-[ were calculated. The strongest affinity of 
adherence was seen with the CXCLJP-secreting fibroblast MRC-[, with a statistically 
significant difference compared to HUVEC’s (NB.N% ±V.K vs. ''.C% ±'.^, p=C.CJP). Thus, 
the MM cell lines appeared to have a greater adherence propensity to chemotaxis secreting 
cells (MRC-[) than to endothelial surfaces (HUVEC or HS-[). 
 
The integrin CDBKd, is an important adhesion marker in MM and though subtle (but not 
statistical) expression differences between the cell lines existed (section [.P), the 
difference in adherence properties (either to HUVECs or plastic) was unlikely to be 
attributed to this integrin as MM.JR had the lowest expression, and statistically lower than 
MM.JSdim (p=C.C'J). Co-culturing of the cell lines with either the chemokine CXCLJP-
secreting fibroblasts MRC-[, the human bone marrow stromal cell HS-[ or the endothelial 
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cell HUVEC, although caused a reduction in expression in CDBKd in the MM cells lines 
when co-cultured (see supplementary figures in appendix), no significant difference was 
observed between MM.JSdim and MM.JSbright. The greatest reduction in MM CDBKd 
expression with the co-cultured cells was observed for HUVECs. Although VCAM-J (the 
endothelial ligand for the integrin αBβJ for which CDBKd is a component) was not 
measured on HUVECs, MRC-[ or HS-[, the HUVECs, as causing the greatest reduction in 
CDBKd expression in MM co-culture, would imply VCAM-J is expressed at a higher degree 
on HUVEC and any of the other co-culture cells and emphasising the importance of the 
CDBKd in HUVEC-MM cell to cell interaction. 
 
5.5.2 MM.1Sbright cells show increase in migration 
Migratory potential between the sorted CD'V MM.JS sub-population was tested in two 
ways; under static conditions using 'µm pore transwell plates and in a dynamic circulatory 
migratory model (a novel migratory model as described in detail in chapter B). In the 
transwell migratory assay (Figure [.JB), MM.JSbright cells showed significantly higher 
migration (P.P'% SD±C.[C) when compared with MM.JSdim cells (J.BK%±C.'', p=C.CCJ^). 
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 Figure 5.14. Comparison of MM.1S and its CD38 sub-populations CXCL12 induced migration. Transwell 
migration ,0.25 x106 cells were placed in the apical chamber of a 3µm transwell plate. Migrated cells were 
retrieved from basolateral chamber of transwell at 24h and counted by BD Accuri flow cytometer. 
Migration was stated as a percentage of the total number of cells inserted into transwell. Error bars 
indicate mean with SD and are calculated by repeated independent experiments. Statistical difference was 
measured by paired two–tailed parametric t-test (n=5). The dynamic circulatory model, 40x106cells were 
placed in closed circuit, with migratory cells retrieved from the EVS at 48h. Statistical difference was 
measured by paired (transwell n=3) unpaired (dynamic circulatory, n=17 MM.1S and n=5 MM.1Sdim) two–
tailed parametric t-test. 
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5.5.2.1 Dynamic migratory model confirms MM.1Sdim has a reduced migratory potential 
and that migrated cells undergo additional cell division 
The dynamic circulatory model, as with the transwell assay data (figure [.JB) showed 
MM.JSdim (C.V^% SD±C.[J n=[) to have statistically lower (p=C.CPN) percentage migration 
than for the CD'V bright dominant MM.JS cell line (J.^P% SD±C.NK n=JN). Statistical 
analysis was conducted on MM.JS rather than MM.JSbight, due to resources and the number 
of MM.JS previously conducted, thus giving greater power to the statistical analysis. To 
confirm that co-existence of the two CD'V sub-populations did not affect the other’s 
migratory potential and to observe degree of cell division over BVh period, sorted MM.JSdim 
and MM.JSbright were simultaneously circulated through the same cartridge in equal 
proportions. Each cell line was pre-stained with different fluorescence cell markers, 
MM.JSdim with CFSE and MM.JSbright with eFluor ^NC. Figure [.J[ shows the overlay 
histograms of MM.JSdim and MM.JSbright fluorescence as measured on a BD Accuri flow 
cytometer, over the course of the experiment, lasting BVh. Although only a single 
experiment, of the migrated cells retrieved from the EVS at BVh, the majority were stained 
with eFluor ^NC, the marker of MM.JSbright. Of the total amount of alive cells collected from 
the EVS, BB.J% matched the fluorescence of efluor ^NC (MM.JSbright), PP.^% matched the 
fluorescence of CFSE (MM.JSdim) and the remaining cells had no fluorescence. Thus, 
implying roughly twice as many MM.JSbright cells migrated into the EVS than MM.JSdim over 
BVh period.  
 
The experiment also showed the degree of cell division over the BVh period. Every time a 
cell division occurs, the amount of cell fluorescence in theory should half. The majority of 
circulating (i.e. non-migratory) cells experienced a one log loss in fluorescence at BVh. 
Interestingly, migrated cells recovered from the EVS at BVh showed a further log reduction 
in fluorescence compared to their circulating counterparts, suggestive that migrated cells 
undergo an additional cell division compared to non-migrated cells.  
 
 169 
 
Figure 5.15. Cell marker stained single cartridge dynamic circulatory migratory model. 20x106 
MM.1Sdimand 20x106 MM.1Sbrightcells were stained with separate fluorescence cell marker (CFSE-
MM.1Sdimand eFluor 670-MM.1Sbright). At 48h, circulating and EVS cells were retrieved. Figure shows FL-1 
and FL-4 overlay dot plot of circulating cells at 0h (G05-orange), circulating cells at 48h (B01-blue) and EVS 
at 48h (B03-red), measured on BD Accuri.  EVS cells are gated as eFluor 670 positive (MM.1Sbright) and 
eFluro 670 negative, weakly CFSE positive (MM.1Sdim), with gated percentage proportion of total EVS cells.  
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5.5.2.2 Migrated MM.1Sdim cells have increased in CD38 expression, which is not 
observed for MM.1Sbright 
Having shown that migratory cells undergo further cell division compared to non-
migratory cells, is also confirmatory that they are undergoing greater cell activation. CD'V 
being a recognised marker of cell migratory activation, comparison of CD'V expression 
between migratory and non-migratory cells were analysed, using the dynamic circulatory 
model. An increase in CD'V expression of MM.JSdim migrated cells (MFI JNB,^B[ v BN,VCN, 
figure [.J^), compared to non-migrated cells was observed. MM.JSbright CD'V expression 
was not increased and comparable to their non-migratory cells.  
 
 
 
Figure 5.16. CD38 expression of MM.1Sdim migrated and non-migrated cells from dynamic circulatory 
model at 48h. (A) Overlaid dotplot of CD38 and CD138 expression of circulating MM.1Sdim cells and 
retrieved EVS cells, serially gated using a live gate and doublet discrimination gate on BD Accuri flow 
cytometer. (B) overlaid histogram of CD38 expression comparing circulating cells against EVS cells.  
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5.6 Mechanism of Sub-clonal variation in dexamethasone 
sensitivity 
The functional and phenotypic differences that I have shown between the MM.JSbright and 
MM.JSdim sub-populations raised the possibility that they are genetically distinct sub-
clones derived from a common ancestor. Although the mechanisms of dexamethasone 
resistance within the MM.JR cell line are well documented (Greenstein et al. PCC'; Sharma 
and Lichtenstein PCCV), no previous analysis of MM.JS CD'V expressing sub-populations 
has been described. I therefore set out to explain the reasons for the differential 
dexamethasone sensitivity I identified between the CD'V sub-populations. Potential 
causes of this may be related to: 
i. the glucocorticoid receptor (as for MM.JR)  
ii. efflux pumps or protective mechanisms removing or preventing internalisation of 
the drug 
iii. expression differences in molecules that causes cell adhesion mediated drug 
resistance (CAM-DR)  
iv. cytoplasmic or nuclear transcriptional changes, downstream of the GR that 
ultimately affects the cell’s dexamethasone cytotoxic susceptibility. 
 
Currently, it remains inconclusive that a direct correlation exists between the number of 
glucocorticoid receptors (GR) expressed on lymphoid cancer cells and the degree of 
glucocorticoid sensitivity (Bailey et al. PCCJ). The MM.JR cell line was derived from long-
term exposure to dexamethasone, which resulted in a complete lack of GR expression. 
Given that the parental MM.J cell line has been shown to strongly express GR (Greenstein 
et al. PCC'), it seems unlikely that MM.JSbright and MM.JSdim differential sensitivity to 
dexamethasone is mediated through altered GR expression.  
 
Alternative mechanisms as outlined above were further investigated. A simple, yet 
potentially explanatory mechanism for differences in dexamethasone sensitivity would be 
the efflux of dexamethasone by protein channel pumps. A widely recognised broad 
substrate efflux pump and a known mechanism of drug resistance is P-glycoprotein (P-gp) 
(Breier et al. PCJ'). P-gp has also been shown to play a role in glucocorticoid transport 
(Gruol and Bourgeois JKKN). 
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5.6.1 P-glycoprotein (P-gp) expression within the MM.1 cell lines in static 
culture are similar, but vary upon exposure to cytotoxic agents 
To determine if the MM.JS subset variation in dexamethasone sensitivity was due to 
altered expression of an efflux pump, P-gp was measured. In static culture, the MM.J cell 
lines uniformly express P-gp, albeit weakly. No statistical difference in MFI was found 
between MM.JS (P,CCB±P'B) and MM.JR (P,CBN±BNP) (p=C.V[), between the gated MM.JS 
CD'V populations (CD'Vdim (P,[J[ SD±KJV), CD'Vbright (P,'B' SD±NB', p=C.JP), or between 
the sorted MM.JSdim and MM.JSbright cell lines (see table [.' and overlay histograms in 
appendix supplementary figures).   
 
5.6.1.1 Difference in P-gp expression observed between MM.1 sub-populations upon 
exposure to cytotoxic agents 
Having confirmed that P-gp expression was equivalent between the two sub-population 
in static culture, P-gp expression was explored when exposed to cytotoxic agents at 
differing concentrations, to see if expression was upregulated and if so, if differences 
occurred between the sub-populations. Analysis of the sub-populations was applied to 
unsorted MM.JS and not to the separated cell lines, thus minimising experimental 
variations such as drug concentrations. Figure [.JNA shows how P-gp expression increased 
with cumulative dexamethasone concentration for MM.JR (peaking at C.PmM, MFI ^,JJB, 
J^.B% cell death), but remained fairly static for MM.JS and its CD'V sub-populations.  
 
Cells exposed to a concentration of dexamethasone closest to MM.JS IC[C (PCCnM), a 
statistical difference in P-gp expression between MM.JR (MFI ',^PN) and MM.JS (MFI 
J,KC^) existed (p=C.CBV, n='). However, no expression difference at PCCnM was observed 
between the MM.JS CD'V sub-populations (p=C.^V, n='). At concentrations higher than 
PCCnM dexamethasone, substantial (>[C%) MM.JS cell death occurred, which made it 
difficult to interpret P-gp expression accurately due to small number of live cells and 
significant cell debris.  
 
To identify whether similar P-gp expression patterns existed upon exposure to other 
cytotoxic agents, the cell lines were exposed to increasing doses of bortezomib for BV hours 
(retaining the same experimental conditions as for dexamethasone exposure). Unlike 
dexamethasone, MM.JR P-gp expression at doses lower than its IC[C (<BCnM) did not 
increase and more akin to MM.JS, with no statistical expression difference (p=C.B^, n=') 
between them at for a bortezomib concentration closest to its IC[C (BCnM). MM.JS CD'V 
sub-populations bortezomib P-gp expression pattern (up to its IC-[C, BCnM), showed a 
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similar pattern as for dexamethasone, with a fairly static, low level expression and no 
statistical expression differences between them (BCnM p=C.KV, n='). For both cell lines 
and sub-populations, there appeared to be a slight increase in P-gp expression at BCnM, 
although substantial cell death was seen (VC.'% - ^^.'%) at this concentration. Although 
such results may be artefactual (e.g. increased cell debris), the results could be consistent 
with sub-populations that have higher P-gp expression that have greater resistance to the 
cytotoxic effects of Bortezomib. The data is summarised in table [.'  
 
 
 MM.HS MM.HR 
MM.HS CD^a 
gated dim 
MM.HS CD^a 
gated bright 
Static culture 
    
% alive VV.B% VV.K% VN.[% KC.C% 
MFI (±SD) P,CCB (±P'B) P,CBN (±BNP) P,[J[' (±KJV) P,'B' (±NB') 
% positivity (±SD) ^.BN% (±[.[') K.PK% (±^.KK) ^.BP% (±'.JN) [.PN% (±'.[') 
Dex. `KKnM     
% alive BB.^% VV.C% P'.'% [B.[% 
MFI (±SD) J,KC^ (±PNP) ',^PN (±BPN) P,V[N (±'NP) P,VK[ (±P[P) 
% positivity (±SD) P.KB% (±J.CP) JV.[^% (±B.CJ) '.P'% (±P.CJ) P.K^% (±C.NV) 
Bortezomib JKnM 
    
% alive ''.N% PV.'% JK.N% 'J.^% 
MFI (±SD) ','PP (±J,[BJ) ',[[K (±J,PNV) J,VV' (±J[V) J,VVB (±JPV) 
% positivity (±SD) B.[K% (±P.'[) ^.KN% (±[.[P) [.BK% (±B.[C) '.KC% (±C.VJ) 
Table 5.3. Comparison of P-gp expression (MFI and percentage positivity) of alive gated MM.1S and 
MM.1R including MM.1S CD38 gated subsets. Comparison made between baseline (no drug) and 48-hour 
exposure of 200nM dexamethasone or 40nM of bortezomib. Standard Deviation are included in brackets 
and are calculated by repeated independent experiments, n=3. Flow cytometry analysis on BD Accuri. cell 
markers immunostained with P-gp_PE-Cy7 and CD38-APC. MFI - Mean Fluorescence Intensity; Dex. – 
dexamethasone. T-Test, parametric paired T-test, fixed ratio 2 tailed; Dex – Dexamethasone; 
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Figure 5.17. MM.1 Alive cells P-gp expression post 48h exposure of dexamethasone (A & B) and 
bortezomib (C & D). (A) P-gp expression as MFI (median) of the cell lines MM.1S, MM.1R and MM.1S CD38 
subsets, at 48h at increasing concentrations of dexamethasone (n=3). (B) Flow cytometry dot plot of 
MM.1S at 48h dexamethasone 200nM exposure, showing expression of CD38 (APC) and P-gp (PE-Cy7) as 
well as CD38 subset gating strategy. (C) P-gp expression as MFI (median) of the cell lines MM.1S, MM.1R 
and MM.1S CD38 subsets, at 48h at increasing concentrations of bortezomib (n=3). (D) Flow cytometry 
dot plot of MM.1S at 48h bortezomib 40nM exposure, showing expression of CD38 (APC) and P-gp (PE-
Cy7) as well as CD38 subset gating strategy. Flow cytometry analysis on BD Accuri. cell markers 
immunostained with P-gp_PE-Cy7 and CD38-APC. MFI - Mean Fluorescence Intensity; vel. – Velcade 
(bortezomib); Dex. – dexamethasone. 
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5.6.2 No evidence of CAM-DR as the cause of drug resistance  
MM adhesion to bone marrow stromal cells are essential for cell survival and growth 
(Mahindra et al. PCJC), making cell adhesion molecules (CAMs) a key component of these 
processes. CDBKd is known to play a role in cell adhesion mediated drug resistance (CAM-
DR) (Damiano et al. JKKK) and such differences could bring about varying sensitivities to 
cytotoxic agents. However, my previous work showed minimal differences in CDBKd 
expression between MM.JSdim and MM.JSbright, and actually a decrease in expression for the 
steroid resistance cell line MM.JR. My data also showed that co-culture did not upregulate 
CDBKd expression, with no statistical difference between the CD'V sub-populations (see 
supplementary figures in appendix).   
 
Other important molecular modulators of CAM-DR in MM include integrins such as VLAB 
(compromising CDBKd), LFA-B and selectins. Although L-selectin is known to be 
expressed in MM.JS  (Azab et al. PCJP) and expression can vary at different stages of the 
disease as well as being prognostic marker (Terpos et al. PCJ^), minimal difference in L-
selectin expression was observed between MM.JSdim (MFI P,KVB) and MM.JSbright (MFI 
',''V), with similar overlay histograms (figure [.JVB).  
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Figure 5.18. CD62L (L-Selectin) and CD38 expression of the cell lines MM.1Sdim and MM.1Sbright. Cells 
stained with Fluoro-488 anti-CD62L antibody and PerCP anti-CD38 antibody. Analysed on BD Accuri flow 
cytometer, 10,000 cells were acquired for the analysis. (A) Overlaid dotplot comparing the expression of 
CD62L and CD38 in the two cell lines. (B) overlaid histogram of CD62L expression comparing the two cell 
lines. Legend shows MFI, both median and mean as well as percentage positivity of CD62L. 
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5.7 Genetic Analysis of MM.1S CD38 expressing sub-clones and 
MM.1R  
As I was unable to explain the differences in dexamethasone sensitivity between the 
MM.JSdim and MM.JSbright sub-populations based on differential efflux pump expression, 
CAM-DR or GR expression, genetic analysis of the sorted sub-populations appeared the 
next logical step. This would potentially identify mutations affecting the glucocorticoid 
receptor pathway and CD'V expression. In addition, it could provide a means to establish 
the clonal origin of the sub-populations, with particular interest in the origins of 
glucocorticoid resistance within MM.JSbright cells. 
 
Although epigenetic changes have been assumed to be the accepted cause of absent GR 
expression within MM.JR cells, clonality is a concept in MM gathering acceptance as to 
the mechanism of disease progression (Keats et al. PCJP). Building upon Edwards V et al 
genetic data (Edwards V et al. PCJP) in identifying differences between MM.JS and MM.JR 
(Table [.J), the aim of exome sequencing was two-fold. Firstly, to identify any genetic 
variation between MM.JSdim and MM.JSbright and how such differences relate to MM.JR, 
thus examining the clonality of these cell lines. Genetic mutational analysis would enable 
the construction of an evolutionary tree of the MM.J cell line sub-clones and test the 
hypothesis that MM.JR is derived from a sub-clone from MM.JS, that is genetically similar 
to MM.JSbright. The other objective was to identify genetic mutations that are able to 
explain the functional and phenotypic differences between MM.JSdim and MM.JSbright, 
established earlier in this chapter. And whether this data could be used to form a bespoke 
treatment strategy targeting specific sub-clones based on mutations involved in key MM 
pathways.  
 
5.7.1 Whole exome sequencing and variation in calling strategies  
DNA was extracted from the cell lines MM.JR, MM.JSdim and MM.JSbright with the lowest 
passage number in order to minimise genetic drift. These samples were then sent to the 
Beijing Genomics Institute (BGI), Honk Hong, for whole exome sequence (WES) at a 
sequence coverage of 'CX reads. Following massively parallel DNA sequencing, the raw 
data requires a caller programme to decipher it into a format where it can be interpreted. 
Four separate variant callers were used, BGI’s own caller system, GATK, varscanP and 
samtools. Figure [.JK shows the variation between the different calling programmes. 
'P,JCP separate exonic mutations were called by at least one of the caller programmes, 
with JK,V[P (^J.VB%) common to all four. This highlights the huge variation in calling 
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strategies, which is a recognised problem (O'Rawe et al. PCJ') indicating that some of the 
variants identified by a single caller and not by the other callers are likely to be false 
positives. Although an option for mutational analysis would be to only include variants 
shared by all B callers, it was felt this could exclude important mutations missed by a caller 
(false negative). GATK caller analysis is the most widely used and felt to be the most 
conservative of the caller variants, thus reducing false positives and was therefore used as 
the calling programme for all my subsequent mutational analysis.     
 
Figure 5.19. Variant calls comparison among four calling strategies. Between the 4 calling variants a 
total of 32,102 individual variants were called. Of these variants, 19,852 (61.84%) were called by all four 
methods. Only variants within exonic regions were considered.   
 
Gene mutations, as called by GATK, were either ‘InDel’ (Insertion or Deletion) mutations 
comprising of both frameshift and non-frameshift mutations or single nucleotide variants 
(SNV)/point mutations. SNVs were further divided into synonymous (silent mutations 
where phenotype is not changed) or non-synonymous where phenotype is affected. Non-
synonymous mutations in some circumstances were further divided to include ‘Missense’ 
where a point mutation results in a different nucleotide and consequently a different 
amino-acid and ‘Nonsense’ resulting in premature ending of codon (variations of which 
include stop-gain, stop-loss, start-loss and splicing). Mutations can be either regarded as 
constitutional, i.e. passed on through the germline or acquired, so called somatic 
mutations. ‘Driver gene mutations’ are more commonly somatic and although my 
mutational analysis did not specifically aim to differentiate the two groups, my 
Figure 1: Variant calls comparison among four calling strategies showing that almost twenty 
thousand variants are called by all four methods. Only variants within exonic regions are 
considered.
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presumption was that the majority of mutations highlighted through this chapter and the 
next were somatic.  
 
The mutation analysis broadly took two separate approaches, a ‘top down’ or a ‘bottom-
up’. A ‘top down’ approach involves selection filters being applied to the data, reducing 
the number of mutations to a manageable amount for additional in-depth analysis. When 
assessing for functional changes, exonic, non-synonymous SNP and InDel are the minimal 
positive selection criteria to be applied. Such mutations will cause an amino acid sequence 
change invariably resulting in protein structure alteration and thus potentially affecting 
function. Filtering mutations through reference databases (e.g. Cosmic cell line database) 
can be also be applied, where common mutations or natural variants are removed. Two 
widely used reference databases are dbSNP (a reference of common SNP mutations 
(Sherry et al. PCCJ)) and JCCC Genomes project (JKGP), a public database of human 
genetic variants with a frequency of greater than J% (Birney and Soranzo PCJ[). The GATK 
calling is able to reference mutations to either of these databases. Figure [.PC provides an 
overview to the filtering strategies I used for my subsequent analysis in this chapter and 
the next, similar strategies have been used by others in the analysis of MM cell line WES 
(Leich et al. PCJ'). 
 
The other approach for mutational analysis, a ‘bottom up’ or more targeted approach, 
focuses on genes that are known to affect function and thus aim to identify if mutations 
exist for a particular gene. And in part can be used to confirm clonality if the gene in 
question is known to be fundamental to disease progression, survival or expansion. 
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Figure 5.20. Genetic mutation filtering strategy, based on Leich et al. (2013). After alignment and GATK 
mutation calling, non-exonic mutations (including introns, splice variants) were filtered. Next, SNVs that 
did not lead to an amino acid exchange (synonymous mutations) were excluded. Of the remaining, either 
divided in mutations due to an insertion or deletion of nucleotide (InDel) and non-synonymous SNV. Of the 
remaining mutations, analysis could be further filtered (as done in chapter 5) by excluding mutations that 
appear in the databases 1000 genomes or dbSNP, as these are deem to occur in healthy individuals and 
unlikely to be driver mutations resulting in cancer formation/progression.  
 
 
 
5.7.2 GATK calling reveals the 3 cell lines have high degree of mutations, the 
majority of which are common  
In total BP,[[' gene mutations (InDel and SNV) were identified, with K'.C[% of them 
common to all three cell lines. When basic inclusion criteria (mutations that were exonic, 
non-synonymous or frameshift insertion/deletion i.e. coding regions) were applied, JC,[N' 
mutations were called with JC,C[C (K[.C[%) common to all three cell lines (figure [.PJ). 
The high degree of shared mutations between the three cell lines, inferring a common 
clonal origin, but each line possessed unique genetic lesions. Of the mutations not 
common to the ' cell lines, KP (C.VN%) were identified in MM.JSdim, [' (C.[C%) in 
MM.JSbright and KJ (C.V^%) in MM.JR (see supplementary Table J and P in appendix for 
breakdown of type of mutations for each of the cell lines). 
Alignment GATK Calling 42,553
22,915
10,354
10,573
219
dbSNP +
1000Genomes 
Synonymous mutations
SNV InDel
Non-exonic mutations
19,638
12,342
36
183
261
10,093
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Figure 5.21. Venn diagram showing number of common and unique mutations between the 3 cell lines. 
(A) No filters applied. (B) Filters applied – exonic, frameshift insertion/deletion 
(A) 
(B) 
MM.1R 
MM.1Sdim MM.1Sbright 
MM.1R 
MM.1Sdim MM.1Sbright 
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5.7.3 Comparison with previous published MM.1S/MM.1R Whole Exome 
Sequencing confirms own data has many of the same mutations  
Exome sequence produces a vast array of data. Cell lines will inevitably have more 
mutations than primary samples and not all mutations are potentially related to malignant 
process. Logical methods and screening tools are required to identify key mutation 
differences.  There are a number of databases (Cosmic data base, the JCCC Genome project 
and GeneCard.org), that allow cross referencing of known cancer related mutations. As a 
reference point to key genetic mutations, (i.e. distinguishing from acquired mutations 
through repeated cell culture), it can also inform of cell line contamination through STR 
recognition. To established consistency of my WES with that of others, I compared my 
data with two separate (published) sequencing. 
 
5.7.3.1 MM.1S COSMIC database comparison  
The Cosmic database (Forbes et al. PCJN) holds a vast array of information on somatic 
mutation relating to human cancers, both on primary samples and cell lines. The cosmic 
Cell line project aims to provide a comprehensive database on multiple cancer cell lines. 
The database mutation exclusion criteria can be found at https://grch'N-
cancer.sanger.ac.uk/cell_lines/about, with the aim of identifying and excluding variants 
through comparison of over VCCC normal datasets from B separate sources (JCCC 
genomes, ESP^[CC, dbSNP and ‘In-house normal set’). Only high confidence variants are 
considered, classed as V[% or higher likelihood of being real (based on read depth of >J[ 
and mutant allele burden >J[%). MM cell lines in the database include RPMI VPP^, UP^^, 
OPM-P, HKPK, JJN-' and MM.JS, but not MM.JR.  
 
Of the ^NB COSMIC listed MM.JS mutations, JV were frameshift mutations (InDel) and 
^[^ SNVs (both synonymous and non-synonymous). BVV (NP.B%) of the ^NB mutations 
were present in my WES data in at least one cell lines (J[ frameshift and BN' SNV). 'NK of 
the BVV shared mutations were common to all three cell lines (See appendix for table of 
mutation type subset breakdown).  
 
Table [.B lists the JV MM.JS frameshift mutations from the COSMIC database. These 
mutations are traditionally thought to have a higher impact on coding changes than non-
synonymous SNV. Of the JV COSMIC mutations, J[ (V'.''%) were identified in my 
sequence data, with J' common to all three cell lines. Of the two mutations unique to a 
cell line, and therefore possibly to be considered as a driver mutation, GRID/IP was only 
unique to MM.JSdim, whilst TEMEM(9+ for MM.JR. However, neither had a tenable link to 
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cancer/MM pathogenesis, GRD/IP role in Purkinje cell signalling (Matsuda et al. PCC^) 
and TMEM(9+ coding for a protein that constitutes a major lysosomal potassium channel 
(Lee et al. PCJN).  
 
Gene 
Cell line 
with 
mutation 
Impact Gene Description 
ABCB+ All High 
ATP-Binding Cassette, Sub-Family B 
(MDR/TAP), Member [ 
BTNL<  All Moderate Butyrophilin-Like 9 
C(<orf33 All Moderate Chromosome JK Open Reading Frame '' 
CCNE/ All High Cyclin EP 
FOXM( All Moderate Forkhead Box MJ 
OR+/K/ All High Olfactory Receptor, Family [P - K, Member P 
SAMD( All Moderate Sterile Alpha Motif Domain Containing J 
SAMD< All High Sterile Alpha Motif Domain Containing K 
TLR7 All High Toll-Like Receptor ^ 
TMC3 All High Transmembrane Channel-Like ' 
TMEM79  All High Transmembrane Protein ^N 
TRAF3 All Moderate TNF Receptor-Associated Factor ' 
ZPBP/ All High Zona Pellucida Binding Protein P 
GRID/IP MM.JSdim High 
Glutamate Receptor Ionotropic dP Interacting 
Protein 
TMEM(9+ MM.JR High Transmembrane Protein JN[ 
DDX(/  None - Dead/H-Box Helicase JP, Pseudogene 
TNXB  None - Tenascin XB 
UBE3A None - Ubiquitin Protein Ligase E'a 
Table 5.4 Coding InDel mutations as documented by COSMIC cell line mutation database for cell line 
MM1.S and if mutation is present in MM1.R, MM.1Sdim and MM.1Sbright exome sequence and designated 
impact of mutation. 
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5.7.3.2 Comparison with Edwards V et al. ASH 2012 abstract 
In PCJP, Edwards V et al, published NGS comparison between MM.JS and MM.JR. Table 
[.[ lists genes that contained mutations not referenced by the JKGP, present only in 
MM.JR and not in MM.JS (Edwards V et al. PCJP). Of these JC genes, my own sequencing 
data of MM.JR called mutations in V of them, with two genes (MMS//L and AURKB) 
containing missense moderate impact mutations in all three cell lines.  
 
Gene  MM.HR MM.HSdim MM.HSbright 
PDIA[ Missense (moderate) - - 
TCERGJ Nonsense (high) - - 
RANBPK  - - - 
MMSPPL 
Nonsense (high) 
Missense (moderate) 
Missense (moderate) Missense (moderate) 
PHFJK Missense (moderate) - - 
RNMTLJ UGV-modifier - - 
AURKB 
Nonsense (high) 
Missense (moderate) 
Missense (moderate) Missense (moderate) 
ERNJ Frameshift (high) - - 
GPCPDJ Missense (moderate) - - 
PIGT - - - 
Table 5.5. List of the 10 non-synonymous or frameshift mutations as described in ASH 2012 abstract 
being present in MM.1R. Table also shows if significant impact mutations were identified in my exome 
sequence and to which cell line. Bracketed implies impact of mutation has on protein coding (low, 
moderate, high). UGV - upstream gene variant; 
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5.7.4 Confirmation of clonality between the cell lines 
As the majority of MM.JS and MM.JR genetic mutations identified from the COSMIC 
database and Edwards V et al. data were present in my exome sequence (table [.B and [.[), 
this further reassured that my cell lines were non-contaminated and had not experienced 
too significant genetic drift. However, it did not reveal key mutational discrepancies 
between MM.JSdim and MM.JSbright, that would explain sub-clonal evolution.  Thus, further 
analysis was required to confirm disease clonality and form a hierarchal picture of the 
origins of cell lines sequenced. For this purpose, four separate methods were applied. 
    
5.7.4.1 Mutation analysis in known MM driver genes reveals ROBO2 as potential sub-
clone driver 
Despite the huge genetic heterogeneity found in MM, only mutations arising in a relatively 
small number of genes are felt to drive the disease or cause new clonal populations to arise. 
Different genetic mutations arise at different stages of the disease, with each new mutation 
providing an opportunity for clonal evolution. Table [.^ outlines the JJ most common and 
likely mutations that are known to drive clonal evolution at different points of the disease 
(Bolli et al. PCJB; Manier et al. PCJN).  
 
Gene 
Mutation 
Exonic Mutations 
Mutations comparison between the ^ 
cell lines 
NRAS - - 
KRAS P (nonsynonymous and silent) Present in all ' cell lines  
BRAF J (silent) Present in all ' cell lines  
TP,- J (nonsynonymous) Present in all ' cell lines  
FAM/0C P (nonsynonymous and silent) Present in all ' cell lines 
TTN 
BB (J frameshift deletion, PN 
nonsynonymous and J^ silent) 
Present in all ' cell lines – BP/BB   
MM.JSdim + MM.JSbright – J/BB (silent) 
MM.JSbright – J/BB (frameshift deletion) 
ROBO3 J (non-synonymous) MM.JSdim + MM.JR 
PCLO 
JC (J non-frameshift deletion, [ 
nonsynonymous and B silent)  
Present in all ' cell lines 
TRAF- 
P (J non-frameshift deletion 
and J nonsynonymous) 
Present in all ' cell lines 
TET3 
[ (P nonsynonymous and ' 
silent) 
Present in all ' cell lines 
DIS- - - 
Table 5.6. Exonic genetic mutation known to cause MM disease progression/formation of subclones and 
their presence within the 3 cell lines.
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Of these JJ genes, only DIS3 and NRAS had no mutations identified. Of the genes with 
mutations, all expressed non-synonymous mutation except for BRAF (silent synonymous 
present in all ' cell lines). Majority of these mutations (N of K) were present in all three cell 
lines. However, P genes TTN and ROBO/, mutational variation between the cell lines 
occurred. TTN gene expressed the most mutations (BB), BP common to all ' cell lines. TTN 
expresses the protein Titin which comprises the highest number of exons ('^') of the 
whole genome (Bang et al. PCCJ). MM.JSbright contained a unique TTN frameshift deletion, 
not observed in the other cell lines. The other driver gene that mutational variation was 
observed was ROBO/. A non-synonymous SNV was present in MM.JSdim and MM.JR, but 
not MM.JSbright. ROBO/ is a tumour suppressor gene, a member of the ROBO family which 
codes for a protein receptor for the slit homolog P protein (SlitP) (Xu et al. PCJ[). Active 
SlitP/Robo signalling has been shown to downregulate c-myc and cyclin DJ via the 
PI'K/Akt pathway in breast cancer cells, with low SlitP expression in stromal fibroblasts 
associated with lymph node metastasis (Chang et al. PCJP). 
 
5.7.4.2 Mutations in the CD38 gene are not the driver process in MM.1S sub-clonal 
formation or expression variation of the CD38 antigen 
Previous genetic analysis of the CD34 gene from ' different non-cancer cell lines, revealed 
the gene to be prone to mutations ([' SNPs and J Indel) (Hartman et al. PCJC). An 
association with CD'V expression and presence of mutations, most notably the 'ʹ-
UTR(J'^') rsJJ'CJ^K has been shown and could in theory drive clonal formation through 
altered expression of the antigen. However, no mutations, intronic, exonic or UTR were 
observed in any of the cell lines. 
 
5.7.4.3 Inferring clonality between the cell lines is difficult by assessing high frequency 
gene mutations  
The technique of driver gene or sub-clone identification, by analysing genes with a high 
frequency of mutations has been applied to many different cancers. The theory being, such 
analysis gives an indication where the genomic stresses are occurring and the most likely 
site of phenotypically relevant mutations. This method has produced a number of high 
profile mutation discoveries with clinical implications in haematological cancers, notably 
the SF3B( gene in CLL (Quesada et al. PCJJ; Wang et al. PCJJa) and CALR in 
Myeloproliferative disease (Klampfl et al. PCJ'; Nangalia et al. PCJ'). Similar techniques 
applied to primary myeloma samples have revealed high frequency of mutations in the 
NF-κB pathway and for mutations causing activation of BRAF (Chapman et al. PCJJ). A 
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similar methodology was applied to this data in an attempt to infer the most likely 
ancestral route for clonal evolution between these three cell lines 
 
PP,KJ[ exonic mutations (non-filtered) occurred in K,N'K separate genes. PJ,V'B (K[.'%) of 
these mutations were common to all three cell lines. Of the mutations that were not 
common (J,CVP), only genes with more than P mutations were compared between the 
three cell lines (Figure [.PP). In total, VK separate genes contained more than one 
mutation. Of these genes, the chromosome containing the highest amount of separate 
gene mutations was the X chromosome. The highest number of separate mutations 
identified on a single gene was N, both CROCC and COL7A3. To discriminate the 
relationship between the cell lines further, a Venn diagram (Figure [.P'), highlighted if 
mutations were either unique to a particular cell line or at least shared between another. 
PV separate genes were identified by these means. V of these genes ('^.B%) shared exact 
mutation profile between MM.JSdim and MM.JR, a further V genes ('^.B%) shared between 
MM.JSbright and MM.JR and only P genes (K.J%) shared between MM.JSbright and MM.JSdim. 
Of these PV mutations, MM.JR had the highest number, JK (^N.K%).  
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Figure 5.22. Graphic representation of genes that had more than one exonic mutation. None of these mutations were common to all three cell lines 
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Figure 5.23. Venn diagram of genes with more than 2 mutations with the 3 cell lines. Number in bracket 
after each gene name is the total number of mutations identified within that gene.  
 
Unique mutations found in each cell line, as highlighted by the Venn diagram, could offer 
potential driver mutations for sub-clonal formation; ? mutations were unique to MM.CSdim:  
i. COL$A& contained F separate mutations not seen in the other G cell lines. This 
gene encodes for a subunit of Collagen type VI, involved in extra cellular matrix 
protein binding (Engvall et al. CNOP).  
ii. ESPNL encoded protein is involved in actin filament bundle assembly and a 
function that is unlikely to drive clonal evolutions in the presence of altered 
expression or assembly. Such genes I have termed “implausible driver gene”.  
iii. HJURP is involved in chromosome maintenance and stability and centromere 
function in early GC phase. It acts to promote mitotic cell-cycle progression 
(Dunleavy et al. GWWN) and plays a role in the immortality of cancer cells, being 
over expressed in lung cancers (Kato et al. GWWF).  
iv. SP/01L encodes for protein that binds to and regulates chromatin found on B-cells 
(Bloch et al. GWWW). 
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[ mutations unique to MM.CR:  
i. MXRA4 has been shown to have a high somatic mutation frequency in a multitude 
of cancers most notably non-small cell lung carcinoma. It encodes for a 
proteoglycan involved in cell to cell adhesion and ECM remodelling (Walker and 
Volkmuth GWWG; Rodningen et al. GWWO; Xiong et al. GWCG).   
ii. DMB encodes for the HLA class II histocompatibility antigen, DM b-chain and has 
been implicated in cell adhesion and antigen processing/presentation in MM cells 
(Zhang et al. GWCd).  
iii. NUDT/8 encodes for the protein MTH[, no mutation links have been discovered 
with MM or other haematological cancers.  
[ mutations unique to MM.CSbright:  
i. CROCC encodes for protein Ciliary Rootlet Coiled-Coil involved in the cytoplasm 
cytoskeleton structure (Nechipurenko et al. GWCP).  
ii. FUK gene encodes fucokinase, involved in glycolipid synthesis and is likely an 
“implausible driver gene”.  
iii. TRIOBP is also likely to be an “implausible driver gene”, it encodes an actin-
bundling protein that is critical for rootlet formation. Mutations are associated 
with deafness (Kitajiri et al. GWCW). 
 
5.7.4.4 Selected dbSNP filter and G1000 mutations not common to all 3 cell lines, offer 
other potential driver mutations 
Using the exclusion criteria outlined in figure d.GW, as well as mutations not shared 
between the [ cell lines, CGG separate gene mutations were identified. Of these, listed below 
are selected genes that are either involved in B-cell physiology or cancer pathogenesis and 
are suggestive as alternative clonal driver mutations. 
Mutation only in MM.CSbright:  
i. FIPCLC-PDGFRA fusion mutation is seen in a minority of patients with 
hypereosinophilic syndrome (HES), but who tend to respond extremely well when 
treated with a tyrosine kinase inhibitor such as Imatinib (Pardanani et al. GWWP). 
Although predominately observed in myeloid malignancies, cases in lymphoid 
cancer have been reported. The fusion protein activates a number of signalling 
pathways including PI[K, ERK C/G and STATd (Gotlib and Cools GWWO).  
ii. UGT/A/ codes for  enzyme UDPGT that transforms and eliminates potentially toxic 
xenobiotics and endogenous compounds such as steroids, bilirubin, hormones, 
and drugs from the cell and has been implicated in cancer drug resistance (Tukey 
and Strassburg GWWW; Holohan et al. GWC[). 
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Mutations only in MM.CSbright & MM.CR:  
i. CD=0 encodes for the cell adhesion protein of the same name. It is expressed on 
most B-cells, promoting T-cell proliferation and can prevent their terminal 
differentiation into plasma cells, with expression decreasing as B-cells mature (Li 
et al. GWW?; Fang et al. GWCW). CDG? has also been shown to regulate CXCR? 
receptor in lymphocytes and cancer cells by uncoupling CXCR? signalling, thus 
altering cell migration and tumour growth (Schabath et al. GWWP).  
ii. UNC/&D plays a role in cytotoxic granule exocytosis in lymphocytes. Mutations of 
the gene has been identified in malignant melanoma, as well as one of the defining 
mutations of familiar hemophagocytic lymphohistiocytosis. In this condition, 
lymphocytes have impaired cytotoxicity and cell apoptosis mechanisms become 
defective leading to uncontrolled proliferation of lymphocytes, invading healthy 
organs (Pachlopnik Schmid et al. GWCW; Elstak et al. GWCG). 
 
 
5.7.4.5 Phylogenetic relationship between the three cell lines reveals original clone 
Using the Human reference genome as an outgroup, phylogenetic relationship between 
the three sequenced cell lines were attempted, with the aim to infer the descent and 
relationship of the cell lines. In all cases insertion or deletion (Indel) mutations were 
excluded, as these are difficult to model phylogenetically. Two different investigation 
approaches were undertaken, both of which aimed to reduce the inferring of mutation 
order changes, in determining relationship. The approaches were either to examine sites 
that were homozygous or heterozygous in all three cell lines. 
 
For homozygous samples there were a total of ?[ sites that were variable within at least 
one lineage, relative to the others. Figure d.G? shows a phylogenetic tree from the ?[ 
homozygous sites. Amongst these, there were G non-synonymous changes within exons 
that were only found within the MM.CSdim genotype and C non-synonymous change within 
an exon that was only found within the MM.CSbright genotype.
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Chromosome  
and position 
Base 
change* 
Variant 
quality 
MM.;R 
genotype 
MM.;Sdim 
genotype 
MM.;Sbright 
genotype 
Gene id  
Chr P 
C?OOPNPGF 
G → T ?G[.dC W/W C/C W/W SASHC  
Chr C? 
FGCGOCW[ 
C → A [F[.O[ W/W C/C W/W SIPACLC  
Chr C? 
GGN[[GWP 
T → A FFG.d W/W W/W C/C 
TRDC 
(TRDVG) 
Table 5.7. Homozygous sample mutation, that form phylogenetic tree. * base change describes the 
change from reference allele to altered allele; Chr – Chromosome; SASH1 - SAM and SH3 domain 
containing 1; SIPA1L1 - Signal-induced proliferation-associated 1 like 1; TRDC – T cell receptor delta 
constant; TRDV2 – T cell receptor Delta variable 2 
 
 
 
 
Figure 5.24. Phylogenetic tree produced from a SNP alignment of 43 homozygous positions across the 
three samples, rooted on the reference genome sequence used. Tree drawn using BioNJ in Seaview 4, with 
100 bootstrap replicates. Diagram courtesy of Dr Tom Connor, Cardiff University  
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The second approach was to examine only sites that were heterozygous, i.e. sites where in 
at least one of the samples, on one chromosome there was a variant base. This resulted in 
a larger number of sites analysed, C,PON. Using an algorithm called Maximum Parsimony, 
C,Cdd of these sites were parsimony informative. The prediction showed MM.CR and 
MM.CSbright samples swap their positions compared to the homozygous phylogenetic tree 
(Figure d.Gd). When examining the dataset with a BioNJ tree, the bootstraps are also low 
on this much larger dataset (figure d.GP). 
 
 
 
 
Figure 5.25. Parsimony tree of 1,689 heterozygous sites. Diagram courtesy of Dr Tom Connor, Cardiff 
University 
. 
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Figure 5.26. Phylogenetic tree produced from a SNP alignment of 1,689 heterozygous positions across the 
three samples, rooted on the reference genome sequence used. Tree drawn using BioNJ in Seaview 4, with 
100 bootstrap replicates. Diagram courtesy of Dr Tom Connor, Cardiff University 
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5.8 Discussion 
The advent of highly sensitive deep sequencing MRD monitoring methods such as High-
Throughput Nucleotide Sequencing as outlined by Martinez-Lopez et al. has the potential 
to make MRD or clonal identification by flow cytometry redundant. Although it is widely 
accepted that flow cytometric MRD monitoring is less sensitive than NGS or PCR based 
IGH-VDJH, IGH-DJH and IGK gene assays (Martinez-Lopez et al. GWC?), I have shown that 
immunophenotypic differences between sub-populations strongly correlate with 
functional differences. Therefore, it seems possible that phenotypic differences can be 
used in conjuncture with NGS to identify clonally distinct drug resistant sub-populations. 
In my previous chapter, I showed that phenotypically distinct populations ‘that could 
represent differing clones’ exist in P of the most commonly used MM cell lines. I then 
isolated two such ‘clones’ from the MM.CS cell line and showed that they varied in 
phenotype, drug response and migration. The aim of this chapter was to explore the 
possibility that MM.CS contained G genetically distinct sub-clones distinguishable by CD[O 
expression and that MM.CR is a sub-clone derived from a CD[O highly expressing clone 
(MM.CSbright) within MM.CS. I confirmed that the variability in dexamethasone sensitivity 
was associated with CD[O expression and that MM.CSbright cells (which were more  resistant 
to dexamethasone) shared numerous phenotypic characteristics more akin to MM.CR cells 
than MM.CSdim cells, including similar CD[O expression, adherence, migration and 
proliferative properties.  
 
5.8.1 Phenotypic analysis 
The presence of MM CD[O weak/negative clones do occur but are rare (Minarik et al. 
GWCF). Such clones (unlike CDC[O negative) are not well documented, although the 
Myeloma cell line UGPP has virtually no CD[O expression (Cd.?% CD[O positivity – data 
not shown). This inevitably raised concern that the presence of CD[O weak subpopulation 
inferred cell contamination. Initial concerns were partly addressed upon MM.CS 
(containing both CD[O sub-clones) dexamethasone cytotoxicity assays, resulting in an 
ICdW consistent with the literature (W.W?dµM vs. W.WdµM respectively) (Chauhan et al. 
GWWG). This provided reassurance that pre-existing research on MM.CS by others could well 
have involved both sub-clones and I was not working with a contaminated cell line.  
However, concerns remain as to why no other researcher has described a MM.CS CD[O 
bimodal population. Few have published immunophenotypic characteristic on MM.CS or 
MM.CR since Greenstein et al. initial paper where the dexamethasone resistance cell line 
MM.CR was acquired through long term low dose dexamethasone exposure (Greenstein et 
 196 
al. GWW[). Flow cytometry analysis on the two separate cell lines by Greenstein, claimed 
them to be immunocytochemically identical, CD[O expression NP.C% positive in MM.CS 
and NF.d% positive for MM.CR. I have shown this to be misleading. Greenstein et al. 
provided no mention of CD[O expression distribution. Indeed, although my two sorted 
populations have quite clearly different levels of CD[O expression, the MM.CSdim can be 
still regarded as having a high level of CD[O expression (PG.O% positivity). Thus, 
highlighting why describing immunophenotyping expression as percentage positivity can 
be flawed and would have otherwise neglected such bimodal expressions that I have gone 
onto extensively analyse.  
 
The clinical relevance of varying CD[O expression in myeloma, is not as pronounced as for 
CLL, where it is a prognostic marker. However, it has become a very promising therapeutic 
target with the monoclonal antibody daratumumab showing encouraging clinical results 
leading to accelerated approval by the FDA in GWCF (Bhatnagar et al. GWCF). The importance 
of CD[O in MM has therefore become more apparent and the need to study CD[O negative 
clones all the more important, as already the emergence of CD[O negative clones in the 
post daratumumab era are being reported (Nijhof et al. GWCPa; Minarik et al. GWCF). As to 
the cause of the reduced CD[O expression in MM.CSdim, no mutations were detected that 
could have resulted in down regulation of gene. The study by Hartman et al. of variable 
CD[O-expressing lymphoblastic cell lines and drug sensitivity with antineoplastic agents 
(gemcitabine and cytarabine) showed a negative correlation that was caused by non-
exonic mutations (Hartman et al. GWCW). Intronic sequencing as well as CD[O promoter 
methylation analysis would aid in confirming if expression variation was due to gene 
alteration/mutation or post-transcriptional modification/signalling.    
 
FACS sorting provided a means to further analyse the CD[O sub-populations. Initial 
phenotypic analysis was done by flow cytometry. Immunophenotyping of three separate 
samples confirmed the difference in CD[O expression between the MM.CS sub-populations 
(p<W.WWWC). Although overlaid histograms showed subtle differences in expression of 
CDCN, CDdP and CXCR? between MM.CSdim and MM.CSbright, no statistically significant 
difference was observed for these or any other of the cell markers. CD?Nd expression 
difference of over C,WWW MFI between the cell lines (MM.CSdim CC,FP? vs. CW,dF?) was seen, 
but was not significant (p=W.GC) and indeed overlay histograms did not show an obvious 
difference. The low number of replicates, combined with technicality variability of a CW-
colour flow cytometry panel meant that statistical differences were hard to achieve if 
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genuine small expressions did exist. Increasing the number of repeats would confirm if 
genuine differences in expression between CDCN, CDdP, CXCR? and CD?Nd existed. 
 
To provide an explanation as to why the proportion of CD[Odim cells seemingly diminished 
through successive cell divisions, proliferative differences between the sub-populations 
were investigated extensively using four different methods: doubling time, Ki-PF 
expression, cell cycle analysis and telomere length. The reduced proliferative propensity 
of the CD[Odim sub-population provides an explanation as to why other research groups 
have never commented on a MM.CS CD[O bimodal population, as the CD[Odim sub-
population is overgrown by the CD[Obright population. Whole exome sequencing allowed 
the identification of potential mutations in genes essential for GW/GC cell cycle 
progression, such as the key proliferative protein Ki-PF, which was mutated in MM.CSdim 
but not in MM.CSbright. Although Ki-PF is a recognised nuclear cell marker for cell 
proliferation (Scholzen and Gerdes GWWW), it has also been shown to correlate with MM 
angiogenesis, cell growth as well as being a prognostic marker (Alexandrakis et al. GWW?a; 
Alexandrakis et al. GWW?b). Indeed, additional evidence to MM.CSdim being the more 
passive or susceptible of the two sub-population, is from MM.CSdim being more sensitive to 
the reversible GW/GC cell cycle arrest effect of dexamethasone (Goya et al. CNN[; Mattern et 
al. GWWF), whereby MM.CSdim had greater GW/GC cell cycle arrest than MM.CSbright upon 
exposure to sub-toxic levels of the steroid. 
 
Although the telomere lengths of all ? cell lines are roughly of similar length, the subtle 
differences between them is further proof of the differing proliferative propensities of the 
sub-populations. The measurement of telomere lengths can be regarded as a measure of 
proliferative history over a set time, on the assumption that all cell lines are derived from 
parental lines that have undergone similar numbers of passages and that they express 
approximately the same amount of telomerase activity. Every time a cell divides the 
telomeric  structure at the end of each chromosome shortens (Harley et al. CNNW). 
Although telomere lengths tend to stabilise below d.d kb, consistent with reactivation of 
telomerase (Wu et al. GWW[), cancer cells often display short (dysfunctional) telomeres 
making them susceptible to DNA repair and resulting in aberrant chromosomal fusion 
events. This is a characteristic commonly seen in MM (Walker et al. GWC?), that can 
potentially drive genomic instability and clonal evolution (Artandi et al. GWWW; Jones et al. 
GWCG; Jones et al. GWC?; Hyatt et al. GWCF).  Indeed, the relative short telomere of all the cell 
lines is confirmation of the clonal nature of them and that they have all likely been exposed 
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to genomic instability, but also the similar lengths of the telomeres confirm a common 
origin/clone shared between the cell lines. 
 
Migratory comparison between MM.CSdim and MM.CSbright by transwell and dynamic 
migration models has shown sub-clonal variation in migration, with a positive correlation 
existing between migration and CD[O expression, a similar occurrence seen in another B-
cell derived malignancy, CLL (Walsby et al. GWC?c). What is unclear (especially for 
MM.CSdim) is whether up regulation of CD[O expression occurs as a result of migration, or 
rather cells are more likely to migrate if have higher expression of CD[O. Furthermore, 
what role CD[O plays in migration or is CD[O simply a by-product/surrogate marker of 
the process of migration/cell activity. My data shows that migrated cells compared to non-
migrated cells have higher Ki-PF expression and have undergone an additional cell 
division, both factors suggestive that migrated cells are more metabolically active.  Indeed, 
my data shows the small but brightly expressing Ki-PF population for both cell lines 
(section d.G), also has increased CXCR?, CD?Nd and CD[O expression. Thus, suggestive 
even within a sub-clone, cell marker expression can be regulated, depending on how 
metabolically active the cell is. However, to date I have not been able to stimulate an 
increase in CD[O expression for MM.CSdim, either through adhesion to stromal/endothelial, 
shear force in dynamic circulation or B-cell stimulation signals such as anti-IgM 
antibodies. Successful cell stimulation using anti-IgM has been shown to be related to 
CD[O expression in CLL cells (Zupo et al. CNNP), but no such effects were observed in the 
MM.CSdim sub-clone. CD[O weakly expressing sub-clones have been identified in myeloma 
patients treated with the CD[O monoclonal antibody daratumumab (Nijhof et al. GWCPb). 
In such patients, upregulation of CD[O expression with Vitamin A derivatives such as 
ATRA has been seen (Nijhof et al. GWCd). Treatment of the MM.CSdim cell line with ATRA 
or vitamin A, would be an additional method not attempted (due to lack of time) in 
proving that expression can be altered. Regulation of CD[O expression does vary in the 
course of B-cell maturation to a plasma cell and in OW% of cases (Manzanera et al. GWWd) 
is downregulated upon transformation to a MM cell. Thus MM.CSdim, could be a sub-clone 
derived from a different stage of plasma cell maturation to that of MM.CSbright. Measuring 
key CD[O downstream non-receptor tyrosine kinases such as BTK/phospho-BTK 
(Moreno-Garcia et al. GWWd) as well as BTK regulated substrates such as Protein-Kinase-C 
(PKC),  Phosphatidylcholine-Phospholipase C (PC-PLC) and Phospholipase-D (PLD), 
would confirm if CD[O related cell-signalling cascades are affected by reduced CD[O 
expression.  
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Indeed, the concept of immunophenotypically distinct clones with differing drug 
sensitivities within MM.CS is not new (Bjorklund et al. GWCC; Bjorklund et al. GWC[). 
Bjorklund et al. separated distinct CD?? expressing sub-clones of MM.CS, through 
exposure of Lenalidomide. The Lenalidomide resistant clone had increased CD?? 
expression and mRNA, with the antigen believed to be instrumental in resistance through 
enhanced adhesion to stromal cell, resulting in activation of Wnt/b-catenin axis and 
possibly activation of Akt. ATRA was shown to blockade the Wnt/b-catenin signalling 
pathway, thus reducing the protective actions of CD?? against lenalidomide. 
Measurement of CD?? antigen as well Wnt/b-catenin signalling cascade of MM.CSdim and 
MM.CSbright would confirm whether Bjorklund’s CD??/lenalidomide resistant clones 
correspond to the CD[O clones. Whether CD[O expression has a similar direct impact on 
drug resistance remains unclear, but to my knowledge no direct link between CD[O and 
dexamethasone sensitivity exists, nor was I able to comprehensively establish one in this 
thesis. 
 
Although I was unable to causally link the difference in dexamethasone sensitivity 
between the MM.CS CD[O sub-clones, I was able to confirm that a number of known drug 
resistant mechanisms did not contribute to the altered dexamethasone sensitivity. These 
included GR gene (NR&C/) mutations, the efflux pump P-gp expression (although in 
MM.CR, expression statistically increased upon exposure to dexamethasone, not observed 
in MM.CS, thus suggestive P-gp can contribute to dexamethasone resistance in other MM 
cell lines) and variation in the CAM-DR expression of CD?Nd/L-selectin. Although I was 
unable to show any evidence of difference in CAM-DR between MM.CSdim and MM.CSbright, 
it has been shown by others that MM cell lines exhibit multiple drug resistant clones, 
predominantly attributed to CAM-DR. RPMI OGGP exhibits resistant doxorubicin and 
melphalan sub-clones, partly due to increase expression of integrins (VLA-?, CD?Nd) 
when adhered to fibronectin (Damiano et al. CNNN).   
 
Although MM.CS expresses the integrins VLA-? and LFA-C, required for adhesion to 
stromal cells (Sanz-Rodriguez and Teixido GWWC; Azab et al. GWWNa; Azab et al. GWCG), 
MM.CS does not strongly adhere to immobilised ICAM, thus inferring the reduced 
importance of LFA-C in MM.CS adhesion, whereas VLA-? and its ligand receptor does 
adhere to immobilised VCAM, thus having a potential greater role in MM.CS CAM-DR 
(Azab et al. GWWNa). Data included in the supplementary figures, showed that MM.CSbright 
has a greater adhesive propensity to HS-d than MM.CSdim (FC% vs. ??% of total co-cultured 
cells, see appendix). It is therefore plausible that CAM-DR plays a role in MM.CSbright 
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dexamethasone resistance compared to MM.CSdim. Given greater time, other adhesion 
markers such as L-selectin and P-selectin on MM cells as well as HUVEC/HS-d selectins 
could have been measured in co-culture as well as its ligand PSGL-C, as to alternative CAM-
DR mechanisms.  
 
The other possible explanation of the differing dexamethasone sensitivities, may lie within 
IL-P. Hideshima et al. has shown the dexamethasone apoptotic effect on MM.CS can be 
reversed by IL-P through the activation of the PI[-K/Akt pathway, in addition to activation 
of Ras/Raf/MEK/MAPK and JAK/STAT[ promoting MM cell survival/proliferation 
(Hideshima et al. GWWC).  Although not statistical, my data did show that MM.CSbright has a 
higher baseline cytoplasmic expression of IL-P than MM.CSdim. Given additional time, the 
impact and role of IL-P on the two CD[O populations could have been explored, including 
dexamethasone cytotoxic assays with increasing concentrations of IL-P, in addition to 
expression levels of phospho-proteins of the fore mention pathways related to IL-P 
expression. 
 
5.8.2 Genetic analysis 
The confirmation of the clonal origin of GC resistance through either key genetic 
mutations or phylogenetic analysis has been difficult. My limited bioinformatics 
knowledge, time and resources has potentially restrained the depth of genetic analysis. 
Regardless, I feel I have identified a number of key findings. Firstly, with over Nd% of 
mutations common to all [ cell lines, the common ancestor or original driving clone are 
likely to remain intact for all [ cell lines. This gives reassurances that no contamination 
with other cell lines occurred and the functional and phenotypic differences observed are 
from sub-clone mutations or alteration in their gene expression. The variation in the four 
different mutation calling strategies, raises the possibilities of false positive/negative 
called mutations, for example RANBP? mutations called by Edwards V data but not my 
own, could represent such an occurrence. The comparison of different exome sequence 
data therefore must be interpreted with caution for such reasons as well as the potential 
variation in the samples and post analytical analysis. Such variation includes different 
exclusion criteria, use of older dbSNP and CKGP databases, age of cell line, read coverage 
and acquisition of new mutations through successive passages. Duplicate exome 
sequencing at different time points with greater read depths, although expensive and time 
consuming would be able to remove uncertainties and confirm true mutations. Bolli et al. 
have shown (by serial sampling) diverse patterns of clonal evolution, including linear 
evolution, differential clonal response and branching evolution (Bolli et al. GWC?). For 
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example, the acquired driver mutations seen in my cell lines e.g. ROBOG and TTN cannot 
be fully assumed they occurred in-vivo (i.e. in the patient) and not post cell line 
immortalisation. Bolli et al, describes the diverse processes that contribute to the 
mutational repertoire, to include kataegis, somatic hypermutation and their relative 
contribution changes over time. This all contributes to the huge heterogeneity of the 
disease and difficulty in analysing it. 
 
Identifying high frequency mutations in an attempt to prove clonality has it flaws. By 
its own definition, these genes are more likely to develop further mutations amongst 
it clones, leading to gradual genetic drift/distinction. And such mutations are not 
guaranteed to result in a functional change, or selection advantage. Regardless of this 
matter, high frequency SNV are useful to follow as they will be passed on to 
subsequent generations, whereupon distinct sub-clones with functional differences 
occur. It also remains a crude filtering mechanism for mutation gene analysis.  
 
Such analysis, highlighted only G high frequency mutation genes shared between 
MM.CSdim and MM.CSbright (KCNJCG and KRRTO[), whereas MM.CR shares an equal 
number of high frequency mutations for MM.CSdim and MM.CSbright (O each including 
COLPA[ and SSPO). This would suggest that MM.CR contains sub-clones that 
represent both MM.CSdim and MM.CSbright, and not solely derived from MM.CSbright. But 
also, the greatest genetic variation and most distinct sub-clones observed, was 
between MM.CSbright and MM.CSdim. Ultimately to prove if MM.CSdim sub-clone remains 
active within MM.CR, both MM.CS CD[O sub-clones could be grown in low dose 
dexamethasone as outlined by Greenstein et al. to see whether dexamethasone 
resistance could be established (Greenstein et al. GWW[).  
 
Interrogation of gene function of the high frequency mutation analysis can provide 
mechanisms of clonal evolution. For example, COLPA[ mutation is present only in 
MM.CSdim. Although mutations in this gene have not been linked with MM or EMD to 
date, the gene codes for a protein integral to type VI collagen, important in binding 
of extracellular matrix proteins (gene GWCO). Collagen proteins have been shown to be 
of importance in binding MM cells to the extracellular matrix in bone marrow 
(Chauhan et al. CNNP; Mahindra et al. GWCW). Such mutations, could be of significance 
in migration/extramedullary disease and could warrant genetic sequencing of primary 
MM samples to establish whether a significant frequency of gene mutation occurs. 
Functional assays such as [D collagen matrix migration exists that can analyse the 
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migration of cells and examine sub-clone potential to migrate to other sites (Wolf et al. 
GWWN; Rommerswinkel et al. GWC?).  
 
Other high frequency genes of potential interest were SP/01 and SP/01L (SPC?W like), with 
G common missense mutations observed in the cell lines, but a unique mutation of SP/01L 
in MM.CSdim. Bolli et al. whole exome analysis of PF MM patients, identified ? truncated 
SP/01 mutations (G frameshift, C nonsense, C splice site) and a missense mutation. The 
proteins coded by SP/01 and SP/01L are restricted to lymphoid cells, a homologue 
of SP/11 and implicated in mature B cells antigen responses (Madani et al. GWWG). SP/01L 
is likely an evolutionarily consequence of unequal meiotic recombination 
of SP/01 and SP/11 genes, but maintains the same function as SP/01 (Madani et al. GWWG; 
Saare et al. GWCd). The authors concluded that the significant frequency of inactivating 
somatic mutations in SP/01 could implicate the gene being a novel candidate tumour 
suppressor in MM and a potential clonal driver mutation (Bolli et al. GWC?). The high 
frequency and variation of SP/01 and SP/01L within my exome sequence could thus 
provide a mechanism of sub-clonal formation.  
 
Although not applied in this chapter, pathway analysis software using high frequency 
mutations could identify signalling pathways integral to the formation of sub-clones as 
oppose to single ‘driver mutations’. For example, Enrichr (Kuleshov et al. GWCP) software 
identified that the highly mutated SSPO gene (P separate non-common mutations) affects 
the NF-kB pathway. The link with SSPO and NF-kB is an important one as this pathway 
has been linked to be a key driver in formation of sub-clones and drug resistance in 
myeloma (Chapman et al. GWCC).  
 
A much simpler method to identify mutations that could cause sub-clone formation, was 
to reference known MM driver mutations with my sequenced data. Of the GWW most 
common mutated genes (Corre et al. GWCd) in MM, I focused on the CW most recognised 
mutations of driving clonal evolution (Chapman et al. GWCC; Egan et al. GWCG; Bolli et al. 
GWC?; Manier et al. GWCF; Rasche et al. GWCF). Expanding the number over this figure would 
not only be time consuming but raised the possibility of analysing mutations that only 
have a limited impact on disease progression. The analysis concluded the cell lines are 
highly mutagenic (O of the CW driver genes mutations were observed) and for the most part 
was shared between the [ cell lines. The gene TTN, contained a large number (??) of 
different mutations, ?G of which were common to the [ cell lines. Chapman et al, questions 
the validity of TTN as being a disease driver mutation as its function does not commonly 
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correlate with disease in cancer, thus regarding it as a highly mutable gene with little 
supported by Titin the protein that coded by TTN, contains the most number of exons 
([P[) in the whole genome (Bang et al. GWWC), thus increasing the likelihood of mutations 
simply because it contains the longest base pair sequence of any other driver gene. Of the 
other CW driver gene mutations, the only other gene where mutational variation between 
the cell lines was observed was ROBO= and offers a more promising explanation as to a 
cause of sub-clonal formation than TTN. The mutation is catalogued in the COSMIC 
database (http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ROBOG) and the function 
of this protein correlates more appropriately with plasma cell function/cancer than TTN. 
ROBO= is a tumour suppressor gene, a member of ROBO family which codes for a 
transmembrane receptor for the slit homolog G protein (SlitG). Binding to SlitG regulates 
cell migration and axon guidance, with overexpression resulting in GW/GC cell cycle growth 
arrest and cell apoptosis (Xu et al. GWCd). In cancer, SlitG/Robo signalling has been shown 
to downregulate c-myc and cyclin DC expression via the PI[K/Akt pathway. In cancer 
mutations in ROBO//= has been shown to infer a poor prognosis in MDS, with low SlitG 
expression in stromal fibroblasts, associated with lymph node metastasis (Chang et al. 
GWCG; Xu et al. GWCd). The same ROBO= mutations were observed in MM.CSdim and MM.CR, 
but not MM.CSbright. Again, this reinforces the distinct clonal separation between MM.CSdim 
and MM.CSbright and that MM.CR has evidence of key driver mutations shared both with 
MM.CSdim and MM.CSbright, suggestive MM.CR contains numerous sub-clones, including 
primitive forms of both MM.CSdim and MM.CSbright. Thus, adding weight to MM.CSbright being 
the original clone, with ROBO= a potential driver mutation that parted the MM.CS CD[O 
sub-populations, eventually forming distinct sub-clones. Complicated bioinformatical 
models exist to recognise key mutational drivers in cancer (Zhao et al. GWCG). GEP, SNP 
arrays may give additional information as to the evolution of sub clones, given more time 
and resources.  
 
Phylogenetic and mutational driver analysis should complement each other as they take 
different approaches in establishing clonality. Whereas mutational driver analysis looks 
for an explanation for clonal drift by exploring gene function, phylogenetics can 
completely ignores gene function, in favour of pattern recognition of the inheritance of 
SNV that results in clonal evolution. In essence mutational driver analysis should explain 
the findings of phylogenetic analysis. However, while this is quite simple in bacteria, it is 
much less trivial in organisms that are diploid and above. In the case of cancer cell lines, 
it becomes even harder because there may be variable polyploidy within the cells. Ploidy 
is difficult to analysis phylogenetically for a number of reasons. The main one being there 
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are two possible bases for each position on a chromosome. For example, in the case of my 
three cell lines, three different genotypes may exist; 
Genotype MM.CSdim:  A \ A 
Genotype MM.CSbright:  A \ C 
Genotype MM.CR:  C \ C 
In this example, it is difficult to know whether there is one mutation, followed by a 
recombination event or two mutations. If it is two mutations, the difficulty becomes how 
to interpret that there is a mutation happening on each strand of MM.CR. Notionally the 
‘best’ approaches are ones where you do not have to infer whether there are one or two 
mutations as in the above example. I addressed this issue by two separate methods, by 
examining homozygous sites against heterozygous sites. However, the results were not 
totally consistent.  
 
The homozygous analysis, fits the narrative that MM.CR sub-clone is a manifestation of 
MM.CSbright, with MM.CSdim a separate sub-clone. Arguably, examining homozygous sites is 
more reasonable, as each variant site should potentially only require a single mutation 
event to be created. However, the bootstrap value is low and furthermore the number of 
sites (?[) is very small to make any sort of strong inference on. Thus, using heterozygous 
sites offers an alternative as the number of sites available for analysis increases 
dramatically to C,PON. This alternative approach indicates that the root for the cell lines is 
MM.CS.bright, as MM.CSdim and MM.CR show more commonality and have likely genetically 
diverged away from MM.CSbright, subsequently forming their own sub-clones. This 
approach conjectures the driver mutation analysis that showed MM.CSdim and MM.CR share 
mutations that MM.CSbright does not (ROBO= and TTN mutations). Thus re-iterating the 
mutational divergence of MM.CSbright and MM.CSdim, forming distinct phenotypes that are 
sub-clones of each other. In terms of inferring an ‘ancestral’ genotype, this remains 
problematic because the cell lines have been cultured passaged for a significant period of 
time. The phylogenetic analyses suggest that the [ cell lines are all divergent from one 
another, with MM.CR and MM.CSbright probably both being a similar distance from a shared 
common ancestor. However, without the addition of periodic sampling, inferring the 
ancestral state in a meaningful way is very difficult. Such sampling with repeated 
sequencing over a time period would be hugely time and resource consuming but would 
be the only way to answer such ancestral questioning.    
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5.8.3 Summary 
In summary, I have shown that CD[O sub-clones pre-exist within the MM.CS cell lines and 
are in fact both distinct sub-clones found in the MM.CR cell line. The three cell lines all 
have notable functional, cytotoxic and genetic difference. My hypothesis that 
dexamethasone resistance is borne out of the CD[Obright MM.CS sub-clone was not shown 
to be true, but rather MM.CSbright is a separate sub-clone to MM.CR, that diverged from the 
original ancestor at roughly the same point, potentially initiated through the acquired 
ROBO= driver mutation that is seen in MM.CSdim and MM.CR, which highlights the greater 
genetic similarities between these two sub-clones. This would seemingly suggest that 
dexamethasone resistance could be acquired through low dose dexamethasone culture of 
either MM.CSbright or MM.CSdim. The complexity of MM sub-clone and dexamethasone 
sensitivity is highlighted here, confirming the huge genetic heterogeneity of the disease 
and that many different clones and factors may be contributing towards dexamethasone 
resistance and CD[O expression. 
 
My work has also shown that CD[O expression within sub-clones correlates with increased 
migratory potential. This is of increasing relevance in the era of CD[O monoclonal 
antibody therapy, which will inevitably result in the emergence of an increasing frequency 
of CD[O negative clones as a new mechanism of drug resistance. Genetic explanation of 
the functional differences, through pathway analysis and identification of key gene 
mutations differences, that are shown to provide a survival benefit, would enhance the 
argument of sub-clonal evolution and is explored in greater detail in the next chapter.  
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6           CHAPTER 6: 
 
Genetic Analysis of Multiple 
Myeloma Sub-Clones; A Model for 
Targeted Pharmacological Treatment 
 
 
6.1 Introduction 
Increased understanding of the key pathways involved in MM survival and the mutations 
affecting them, has led to the development of targeted pathway therapies such as the 
proteasome inhibitors, bortezomib, carfilzomib  and more recently ixazomib (Allegra et 
al. GWC?), all of which inhibit the NF-κB pathway (Hideshima et al. GWWGb). Comparative 
genetic mutational analysis between sub-clones such as MM.CR, MM.CSdim and MM.CSbright 
can be used to create bespoke sub-clonal treatment strategies predominantly based on 
pathway analysis, which focuses on reversal of drug resistance, such as dexamethasone.  
 
As previously discussed in chapter d, mutational analysis can be performed either via “top-
down” approach or a “bottom-up” approach. The “bottom-up” approach, is a candidate 
approach, where a selected gene is looked at. The “top-down” approach, although a more 
time-consuming approach, it theoretically ensures all mutations are considered, with 
reduced selection bias. To reduce the number of gene mutations in the top-down 
approach, exclusion criteria can be applied to the database, aiding in further analysis. Such 
criteria can include low-frequency mutations (as previously discussed in chapter d) or 
mutations with a dbSNP reference. The dbSNP filter aims to exclude previously referenced 
SNPs. There remains a subtle difference between a SNP (single nucleotide polymorphism) 
and SNV (single nucleotide variant). A gene containing a SNP will have a single nucleotide 
variation with a frequency of higher than C% in the normal population and usually labelled 
with a dbSNP reference ID. Although it is wrong to presume that all variations with either 
a dbSNP reference or a frequency greater than C% are non-functional, in general the more 
‘common’ a variant is among the population, the less likely it will have a direct role in 
cancer pathogenesis. Indeed, not all mutations will relate to disease or process being 
studied, or even where the normal function of the gene has no correlation to the function 
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of the tissue or disease where it is derived from. Such genes can be regarded as “implausible 
genes” (Bolli et al. GWC?) and are more commonly seen in cancer cell lines, contributing to 
the large number of mutations identified. Applying dbSNP exclusion filter can remove 
many such mutations and are usually essential when applying pathway analysis tools to a 
large sequence of genetic mutations. Whilst such a method is almost essential in reducing 
the number of candidate genes to be analysed, it does risk the possibility of excluding 
dbSNP that are ever increasingly being shown (mainly from GWAS) to be associated with 
cancer (Sud et al. GWCF).    
 
Pathway analysis software tools such as Ingenuity or Enrichr provides an alternative 
method to mutational analysis than simply looking at the function of individual genes and 
is able to link many individual mutations together. The online tool Enrichr provides access 
to a variety of gene libraries, each of which have databases that links gene mutations to a 
variety of biophysiological aspects such as cell function, gene transcripts, disease and 
pathway analysis. The gene mutation library NCI-Nature GWCP links vast number of gene 
mutations to over GWW distinct pathways involved in cancer pathogenesis (Huang da et al. 
GWWN). The Enrichr software tool reports its enrichment results by either a Fisher's exact 
test p-value (provides a probability of any gene belonging to any set), a z-score (modified 
Fisher's exact test taking into account deviation from an expected rank) and a combined 
score which is a combination of the p-value and z-score (Kuleshov et al. GWCP). 
 
In this chapter I further interrogated the exome sequencing data of the MM.C cell line sub-
clonal populations, MM.CR, MM.CSdim and MM.CSbright. The clonality of these [ cell lines I 
had proven in the previous chapter and have thus referred them as sub-clones of each 
other in the Chapter. I also set out to go a step further by identifying sub-clonal genetic 
divergence that results in altered pathway inhibition or activation. In so doing, I aimed to 
test a proof of concept that targeting these lesions may preferentially affect those sub-
clones and prevent their clonal expansion following treatment with standard therapies - 
so-called clonal tiding. 
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6.2 Functional Genetic Analysis - the “Bottom-up” approach 
6.2.1 NR3C1 
The gene coding for glucocorticoid receptor, is located on chromosome d (dq[C) and is also 
known as GR or GCR. MM.CSdim and MM.CSbright both contains a heterozygous exonic 
synonymous (silent) SNV that MM.CR does not. GATK calling programme infers the 
mutation does not affect protein coding.  
 
6.2.2 Mutations in genes pertinent to this thesis: 
Table P.C lists various genes that codes for proteins specific to this thesis. They include the 
cell markers used in the flow cytometry panel from chapter [ and key B-cell signalling 
proteins (Syk and PAXd), discussed in chapter ?. Table P.G lists those genes that contain 
exonic mutations that are predicted to affect protein coding (i.e. non-synonymous and/or 
InDel.) 
 
F of the O genes listed in table P.G contained mutations that were common to all [ sub-
clones. MKI$B was the only gene that contained a mutation (heterozygous frameshift 
deletion) unique to a specific sub-clone, MM.CSdim. The GATK calling deemed this 
frameshift deletion to be of a high impact significance in protein coding and expression.   
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Gene  
Total no. 
mutations 
Intronic 
SNV 
Exonic 
synonymous 
SNV 
Exonic non- 
synonymous 
SNV 
Indel. 
SYK G C C   
MKI'( (Ki-HI) C[ G d d C 
IL'ST ? G  G  
IL' (IL-H) G C†  C  
PTPRC (CDMN) W     
ITGA0 (CDMOd) P [ G C  
NCAM2 (CDNH) d ?  C  
CD04LG [ C G   
CD04 ? ?*    
PAX6 G C  C  
CD27 W     
CD89 W     
SDC2 (CD;PQ) C   C  
CXCL2: (SDF-;a) W     
CXCR0 W     
MMP7 (MMP-O) ? G‡ C C  
Table 0.1. Selected genes and presence of mutations and type. * Includes UTR5 mutation; †Includes 
intergenic mutation; ‡includes UTR3 mutation; InDel – Insertion of deletion frameshift mutation; SNV – 
single nucleotide variant; 
 
 
Gene MM.;R MM.;Sdim MM.;Sbright 
MKI'(  
Missense SNV‡ (het) xd Missense SNV‡ (het) xd 
Frameshift del† (het) 
Missense SNV‡ (het) xd 
IL'ST Missense SNV‡ (het) xG Missense SNV‡ (het) xG Missense SNV‡ (het) xG 
IL' Missense SNV‡ (het) Missense SNV‡ (het) Missense SNV‡ (het) 
ITGA0 Missense SNV‡ (hom) Missense SNV‡ (hom) Missense SNV‡ (hom) 
NCAM2  Missense SNV‡ (hom) Missense SNV‡ (hom) Missense SNV‡ (hom) 
PAX6 Missense SNV‡ (het) Missense SNV‡ (het) Missense SNV‡ (het) 
SDC2  Missense SNV‡ (hom) Missense SNV‡ (hom) Missense SNV‡ (hom) 
MMP7 Missense SNV‡ (hom) Missense SNV‡ (hom) Missense SNV‡ (hom) 
Table 0.2 Targeted identification of specific gene mutations. Exonic gene coding effect as determined by 
BGI/GATK calling software: †High impact (Non-synonymous InDel); ‡Moderate impact (non-synonymous 
SNV); Synon. – Synonymous; SNV – single nucleotide variant; Missense – missense non-synonymous SNV; 
– Bold genes refer to exonic non-synonymous mutations, either single nucleotide variants or InDel. 
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6.3 Functional Genetic Analysis - the “Top down” approach 
Basic exclusion criteria (intronic and silent/synonymous) reduced the number of 
mutations to CW,dF[.  The majority of the remaining mutations were common to all [ sub-
clones, these were excluded, leaving only ?dG out the CW,dF[ mutations. Mutations were 
further filtered to exclude genes with only a single individual mutation, (see section P.G.C) 
or dbSNP mutations (see section P.G.G). These consolidated lists were then subjected to 
Enrichr pathway analysis, matched to the NCI-Nature GWCP database. 
 
6.3.1 Pathway analysis of genes with more than one mutation, identifies 2 
key genes affecting the NF-kB pathway 
By excluding genes that only contained a single mutation, i.e. targeting genes that have a 
higher propensity to mutate, ?O separate genes were identified for MM.CR, [F for MM.CSdim 
and GO for MM.CSbright. Of these genes, only two were cross-referenced to the NCI-Nature 
GWCP pathway analysis database; SSPO and COL$A&.  As previously discussed in chapter d, 
SSPO was a highly mutated gene (P separate mutations across all the [ sub-clones 
identified), but not all of them were identical. For example, MM.CSdim and MM.CSbright did 
not share any of the same SSPO mutations, whereas MM.CR shares [ non-synonymous with 
MM.CSdim and C non-synonymous mutation with MM.CSbright. The Enrichr pathway analysis 
highlighted the NF-kB pathway and b-catenin degradation pathways to be statistically 
affected by this mutation (table P.[) for all [ sub-clones, with the highest combined score 
seen in MM.CSbright. 
 
Mutations in COL$A&, were only observed in MM.CSdim. The Enrichr programme, indicated 
the signalling pathways potentially affected by the mutation included Syndecan-C 
(p=W.WOG), bC integrin cell surface interaction (p=W.CG) and integrin angiogenesis (p=W.C[), 
though none were deemed to be statistically significant.  
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MM.;R MM.;Sdim MM.;Sbright 
SSPO related Pathways    
Non-canonical NF-kB pathway ?.NP (p=W.WC?)* d.GP (p=W.WCC)* d.dN (p=W.WWO)* 
Canonical NF-kB pathway [.FW (p=W.Wd?) ?.WG (p=W.W?G)* ?.[P (p=W.W[G)* 
Atypical NF-kB pathway [.d? (p=W.W?W)* [.OG (p=W.W[C)* ?.C[ (p=W.WG?)* 
Degradation of b-catenin [.[d (p=W.W?W)* [.PG (p=W.W[C)* [.NC (p=W.WG?)* 
PS-C regulation of Notch/Wnt  G.O[ (p=W.CWd) [.GN (p=W.WOG) [.?O (p=W.WPG) 
PLKC signalling events [.W[ (p=W.CWd) [.GW (p=W.WOG) [.F[ (p=W.WPG) 
ATR signalling pathway G.Od (p=W.WN) [.C? (p=W.WFW) [.?P (p=W.Wd[) 
COLHAP related pathways 
 
 
 
Syndecan-C mediated signalling  
 
G.OG (p=W.WOG) 
 
Integrin related angiogenesis 
 
G.Wd (p=W.C[) 
 
bC integrin interactions 
 
G.[N (p=W.CG) 
 
Table 0.3.  NCI-Nature 2016 pathway analysis of non-synonymous exonic mutations from genes that 
express more than one mutation and not common to all 3 cell lines. Each pathway has an Enrichr Combined 
score indicating gene relevance to pathway, in addition to p value; * - indicates statistical significance; PS-
1 - Presenilin-1; NF-kB - nuclear factor kappa-light-chain-enhancer of activated B cells; 
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6.3.2 dbSNP filter and Indel offers alternative but larger mutation list for 
pathway analysis  
Of the CW,dF[ mutations, CW,[d? were non-synonymous SNV, the remaining are InDel. Of 
the SNVs, G.PN% (GFP) did not have a dbSNP reference. Table P.? shows the number of 
SNV for each cell line that did not have a dbSNP reference, in addition to the number and 
relative frequency of InDels, (see supplementary table in appendix for a list of the 
individual genes that were mutated). 
 
 
 Indel SNV TOTAL: 
MM.;Sdim ? (O.CP%) ?G (Cd.GG%) ?P (C?.Cd%) 
MM.;Sbright G (?.WO%) GP (N.?G%) GO (O.PG%) 
MM.;R P (CG.G?%) GP (N.?G%) [G (N.Od%) 
MM.;Sdim & MM.;R W (W%) C (W.[P%) C (W.[C%) 
MM.;R & MM.;Sbright W (W%) d (C.OC%) d (C.d?%) 
MM.;Sdim & MM.;Sbright W (W%) CW ([.PG%) CW ([.WO%) 
Common mutations [W (PC.GG%) CF[ (PG.PO%) GW[ (PG.?P%) 
Total ?N (CWW%) GFP (CWW%) [Gd (CWW%) 
Table 0.4. Number of exonic mutations (Indel. and non-synonymous without a dbSNP reference) that was 
used for Enrichr analysis for each cell line.   
 
 
Using this consolidated list of mutations, table P.d lists the ‘likely affected’ pathways as 
predicted by Enrichr mutational analysis (using NCI-Nature GWCP database) for each cell 
line. Figure P.C showing a clustergram of the pathways and the mutated genes related to 
the specific pathway. 
 214 
 
Figure 0.1.  Clustergram of gene mutations from dbSNP exclusion criteria of MM.1R (A), MM.1Sdim (B) and MM.1Sbright (C). Individual cell lines clustergram shows the 30 most likely 
pathways to be affected from mutational analysis by Enrichr, NCI-Nature 2016 pathway database. 
(A) (B) (C) 
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Pathway MM.*R  MM.*Sdim MM.*Sbright Associated Genes 
a%b& and a%b* integrin 
signalling 
2.45** 
p=9.99* 
4.99* 
p=9.955 
2.*:** 
p=9.99* 
MST$†§, EGFR, LAMA$, 
LAMB0 
a%b* integrin-ligand 
interactions 
*.>2* 
p=9.9&& 
*.%** 
p=9.9&: 
*.>4* 
p=9.9&& 
LAMA$, LAMB0 
AP-& transcription 
factor network 
>.&** 
p=9.9&D 
%.44* 
p=9.9:5 
>.94* 
p=9.9&2 
NFATC$, MAF, TRIP5, 
DMP$ 
Degradation of  
b-catenin 
5.:2* 
p=9.9:4 
:.%:* 
p=9.9:D 
:.%2* 
p=9.9:4 
CUL$, SSPO 
CaN-regulated NFAT- 
transcription in LYM.  
4.94* 
p=9.9:2 
9.%> 
p=9.&%& 
9.5% 
p=9.&*> 
NFATC$, MAF, EGR9† 
Signalling events 
mediated by PTP&B 
*.2%* 
p=9.9*9 
*.5>* 
p=9.9*> 
*.>5* 
p=9.9*& 
EGFE, TXN, TYK0 
Plexin-D& Signalling 
:.*&* 
p=9.9*> 
&.%: 
p=9.945 
:.95* 
p=9.9*D 
SEMA=C, IQSEC$ 
Notch signalling 
pathway 
5.%4 
p=9.94* 
5.&4 
p=9.9%4 
5.59 
p=9.94% 
CUL$, SSPO, NCOR0 
mTOR signalling 
pathway 
5.9% 
p=9.9>2 
:.44 
p=9.925 
%.&** 
p=9.9&2 
PDPK$, ULK0, SSPO, 
SREBF$§ 
Arf% signalling events 
&.&5 
p=9.92& 
%.&2* 
p=9.9&> 
9.>* 
p=9.92* 
IQSEC$, EGFR, 
ARAP0‡  
Signalling events 
mediated by c-Met 
:.%% 
p=9.&9& 
2.:** 
p=9.99> 
4.2** 
p=9.9:> 
MUC0?†‡, PRKC$‡§, 
INPPL$, PDPK$, RIN0‡§ 
Class I PI5K signalling 
events mediated by Akt 
&.4> 
p=9.9D> 
&.&& 
p=9.92D 
&.&% 
p=9.9D2 
TBC$D9, PDPK$, 
INPPL$ 
Regulation of RhoA 
activity 
-:.&* 
p=9.*29 
*.&D* 
p=9.954 
-:.5& 
p=9.*2% 
FARP$, MY?AB‡, 
ARHGAP5‡,  
Table 0.5. NCI-Nature 2016 pathway analysis of non-synonymous (no dbSNP reference) and InDel exonic 
mutations from the 3 cell lines. Each pathway has an Enrichr Combined score indicating gene relevance to 
pathway, in addition to p value; * <0.05 statistical significance; **<0.005 statistical significance. c-Met - 
tyrosine-protein kinase Met; CaN – Calcineurin; LYM – lymphocytes; - Gene mutations unless otherwise 
specified present in all 3 cell lines; †MM.1R; ‡MM.1Sdim; §MM.1Sbright 
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A number of significant differences between the sub-clones were observed from the 
pathway analysis; 
i. a%b& and a%b* integrin signalling pathway; all 5 sub-clones pathway was 
significantly affected, but MM.&R and MM.&Sbright had an additional mutation MSTI, 
resulting in lower p value (MM.&Sdim p=9.955, MM.&Sbright and MM.&R both 
p=9.99*). Integrin’s such as a%b& (also known as VLA-%) and a%b* (also known as 
TSP&D9) are known to play a role in drug resistance, with the a% subunit being a 
laminin receptor (Damiano et al. &222; Hynes :99:). 
ii. Calcineurin-regulated NFAT-dependent transcription in lymphocytes pathway is 
affected statistically in MM.&R (p=9.9:2), but not in MM.&Sdim (p=9.&%&) or 
MM.&Sbright (p=9.&*>) due to EGR9 mutation in MM.&R. Calcineurin targeted 
therapy (HDAC inhibitor Panobinostat) has been shown in part to be effective in 
MM patients, especially those with bortezomib resistance (Imai et al. :9&%).  
iii. Arf% signalling events was affected statistically in MM.&Sdim (p=9.9&>), but not in 
the other : cell lines due to mutation in ARAP0. Arf% (ADP-ribosylation factor %) 
is a GTPase-protein involved in plasma cell membrane trafficking, predominately 
endocytosis and actin remodelling (de Beco et al. :9&:). Recent studies have 
suggested activation of Arf% signalling, are correlated with cancer invasion and 
metastasis of numerous solid tumours, although to date no discoveries linking this 
pathway in MM or other haematological malignancies have been made (Li et al. 
:9&>). 
iv. Signalling events mediated by c-Met pathway showed the greatest amount of 
variation between the 5 cell lines. MM.&R contained 5 mutations related to this 
pathway, but was not deemed significant (p=9.&9&). MM.&Sbright contained * 
mutations, : shared with MM.&R but was deemed to be significant (p=9.9:>). 
MM.&Sdim contained 4 mutations (: common to all 5 cell lines, & shared with MM.&R 
and : shared with MM.&Sbright) and was highly significant (p=9.99>). c-Met 
encoded by the proto-oncogene MET, is a receptor tyrosine kinase receptor and is 
involved in an array of cellular responses such as embryonic development, 
proliferation, wound healing, motility and invasion. It also has a role in cancers, as 
activation has been shown to correlate with tumour growth and angiogenesis (Ma 
et al. :995). c-Met once engaged activates multiple signal transduction pathways 
that include P&5K, RAS, STAT, beta-catenin and Notch (Gentile et al. :99D).  
v. Regulation of RhoA activity pathway was significantly affected in MM.&Sdim 
(p=9.954), but not in the other : cell lines (due to the additional mutations in 
MY?AB and ARHGAP5). Rho proteins promote reorganization of the actin 
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cytoskeleton and regulate cell shape, attachment, and motility. Overexpression of 
this gene is associated with tumour cell proliferation and metastasis (Etienne-
Manneville and Hall :99:; McBeath et al. :99*). It has also been shown to 
potentially play a role in MM SDF-&-induced adhesion, chemotaxis, and homing of 
MM cells to the BM (Azab et al. :992a). 
vi. mTOR signalling pathway was significantly affected in MM.&Sbright (p=9.9&2) but 
not the other : cell lines, due to an additional mutation in SREBF$. mTOR is an 
atypical protein kinase belonging to the PI5K-related kinase family (Laplante and 
Sabatini :9&:) and part of the PI5K/AKT/mTOR signalling pathway important in 
cell cycle/proliferation. This pathway becomes activated in many cancers 
including MM and is regarded as a potential target for therapy (Li et al. :9&*).  
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6.3.3 Analysis of key B-cell pathways reveals high degree of mutations 
within PI3K/Akt pathway  
Coupled with the pathway analysis in section %.&.:.: (statistical difference between the 
sub-clones for the mTOR and c-Met signalling pathways), I felt the PI5K/Akt pathway and 
its related genes, specifically deserved further analysis. 
 
Of the 5*& known genes involved in the PI5K/AKT signalling pathway (Belinky et al. :9&4), 
&92 of these genes contained either non-synonymous SNV or InDel mutations, which were 
common to all 5 sub-clones. These included PIK=CD, TPD= and PIK=R$-=. Only > PI5K/AKT 
signalling pathway-related genes, contained mutations not shared between the sub-
clones, listed in table %.%. MM.&Sdim contained the highest number of mutations (4 of the 
>). The MM.&Sdim mutations COL9A5, LAMB$ (laminin subunit b&) and FN$ (fibronectin) 
all have important roles in integrin signalling. FN& activity has been shown to be associated 
with chemotherapy drug resistance such as doxorubicin, mechanism of which is believed 
to be the activation of the Akt/mTOR pathway (Hazlehurst et al. :99&; Xiong et al. :9&:). 
 
 
MM.*Sdim mutations MM.*Sbright mutations MM.*R mutations 
THBS= PDGFRA LAMB9 
COL5A= FN$ COL9A5 
FN$ LAMB$  
LAMB$   
COL9A5   
Table 0.6. Gene mutations related to the PI3K/Akt pathway that were not common to all 3 cell lines.   
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6.4 PI3Kinase p110d expression varies between the sub-clones 
The discrepancies in sub-clonal PI5K/Akt pathway mutations could potentially result in 
altered PI5K pathway activation or even transcriptional or expression changes, between 
the sub-clones. The class I PI5K catalytic subunit has * isoforms. They are all coded by 
different genes and are expressed by different cells. The delta isoform (p&&9d) is primarily 
expressed in leukocytes and is over expressed in numerous cancers (Chantry et al. &22>) 
including primary MM samples and cell lines (Ikeda et al. :9&9). I therefore aimed to show 
whether mutational differences between the sub-clones correlated to altered p&&9d 
expression.  
 
6.4.1  Immunoblotting shows MM.1Sdim upregulates expression of PI3K and 
AKT compared to MM.1Sbright and MM.1R 
Analysis of the PI5K/p&&9δ isoform by immunoblotting showed that MM.&Sdim had higher 
p&&9d and Akt expression compared to other MM.& sub-clones. p&&9d expression, expressed 
as a percentage of Actin in MM.&Sdim was 5>.&%, &D.:% in MM.&Sbright and 2.9% in MM.&R 
(Figure %.: and table %.>). The same trend was seen for Akt expression, %%.%% in MM.&Sdim, 
*D.5% in MM.&Sbright and 55.4% in MM.&R. 
 
 
Cell line Actin  Akt  p**?δ Akt norm. p**?δ norm. 
MM.*Sdim *45%> 59&2% &%D5> %%.%% 5>.&% 
MM.*Sbright *2&:% :5>:& D2%& *D.5% &D.:% 
MM.*R *D>4: &%5*: *5>5 55.4% 2.9% 
Table 0.7. Differences in Akt and p110d expression between sub-clones. Analysis of bands using ImageJ 
software. Normalised (norm.) to Actin and expressed as a percentage (n=2).
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Figure 0.2. Differences in Akt and p110d expression between sub-clones. Total lysates from cell lines 
MM.1R, MM.1Sdim and MM.1Sbright. Lysates were analysed by SDS-PAGE and Immunoblotting using b-Actin, 
AKT and p110d specific antibodies. Exposure to autoradiographic film for 30 minutes 
p110δ 
AKT 
β-Actin 
M
M
.1
Sd
im
 
M
M
.1
Sb
rig
ht
 
M
M
.1
R
 
 221 
6.4.2 qPCR shows increase in PIK3CD gene transcription, providing rationale 
for increased PI3K/p110δ protein expression 
To confirm the quantification of PI5K/p&&9δ of the sub-clones, Real-Time PCR (qPCR) 
quantification of PIK5CD transcript was undertaken. PIK5CD is the gene that codes for 
PI5K/p&&9δ. MM.&Sdim (RQ &.4%±9.:*) showed a &.4-fold increase in transcript compared to 
MM.&Sbright (RQ &.9%±9.&9) and a :-fold increase in gene expression compared to MM.&R 
(RQ 9.D9±9.92). Thus, confirming the immunoblotting data. No statistical difference was 
observed between MM.&R and MM.&S PIK5CD transcript (p=9.:>). However statistically 
significant difference was observed between MM.&Sdim and both MM.&Sbright (p=9.95:) and 
MM.&R (p=9.99>:). No difference was observed between MM.&Sbright and MM.&S (p=9.>9). 
 
 
 
 
  
Figure 0.3. Baseline qPCR of PIK3CD transcripts of the 4 MM.1 sub-clones. Transcript expression is 
quantified by ThermoFisher Relative Quantification (RQ) calculation which normalises each cell lines 
transcript to the cell lines housekeeping control gene, GAPDH and then relative to MM.1S. RQ results; 
MM.1Sbright 1.064 (SD±0.101), MM.1Sdim 1.557 (SD±0.243), MM.1R 0.803 (SD±0.087) and MM.1S 1.000 
(SD±0.251). Significance calculated by unpaired T-test parametric 2 tailed and is of the product of n=3 
experiments. 
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6.5 Sub-clone PI3K/p110d expression variation due to methylation 
of PIK3CD promoter region 
Having shown that MM.& sub-clones have differing expression of the PI5K/p&&9d 
transcript, no unique PIK=CD gene mutation were observed between the sub-clones to 
explain expression differences. However, changes in expression or function can still occur 
without nuclear DNA sequence alteration, the study of which is described as epigenetics. 
Methylation analysis of MM.&Sdim, MM.&Sbright and MM.&R aimed to identify a reason for 
different levels of PIK5CD transcript. If epigenetic changes were the cause of transcript 
variation, then hypomethylation would be observed in MM.&Sdim compared to the other : 
sub-clones. 
 
6.5.1 Methylation analysis within the same promoter region, reveals 
contrasting methylation status.  
Two separate Qiagen PIK5CD primer assays were used in analysis. Primer-& contained D 
CpG sites while Primer-: contained 5 CpG sites. Overall methylation for the PIK5CD-& 
primer were, MM.&Sdim D.9D% (SD±4.9&), MM.&Sbright D.%&% (SD±4.9&) and MM.&R 2.4>% 
(SD±*.%*). A statistical difference existed between MM.&Sdim and MM.&R (p=9.99:%). No 
difference was seen between the : MM.&S sub-clones (p=9.**) (figure %.*A).   
 
Overall methylation for PIK5CD-: were, MM.&Sdim %:.4% (SD±5.%&), MM.&Sbright %4.&>% 
(SD±4.5D) and MM.&R %>.%:% (SD±4.2:). Again, statistically significant difference was 
seen between MM.&R and MM.&Sdim (p=9.99&, figure %.*B), but no significance between 
the : MM.&S cell sorted cell lines (p=9.9D5).   
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Figure 0.4. Methylation studies of MM.1 sub-clones PIK3CD promoter regions. Box and whisker plots 
showing 95% Confidence Intervals (Corrected Tukey's) of overall methylation of the 2 primers (A) Primer 
PIK3CD-1, n=12 (B) Primer PIK3CD-2 (n=4). Experiment followed as per Qiagen methylation protocol, using 
DNA extraction from 2x106 cells and results are the product of 2 separate experiments in duplicate.  
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6.5.2 Analysis of individual CpG sites identifies unique hypomethylation in 
MM.1Sdim   
Table %.D shows the percentage methylation of individual CpG sites within the PIK5CD 
promoter.  Statistical comparison and percentage methylation bar charts of individual 
CpG sites are shown in figure %.4 (PIK5CD-& primer) and figure %.% (PIK5CD-:).  
 
 
CpG Site 
% Methylation (SD ±) 
MM.*Sdim MM.*Sbright MM.*R 
PIKHCD-*    
* *.4&% (SD ± :.&>) 4.&%% (SD ± 5.>5) >.9D% (SD ± *.4*) 
J *.>*% (SD ± :.2D) 4.92% (SD ± :.%D) %.4*% (SD ± 5.*%) 
H *.%*% (SD ± 5.:4) >.&5% (SD ± %.&%) >.D4% (SD ± *.4&) 
K 4.5:% (SD ± :.%*) 4.99% (SD ± :.:*) >.2&% (SD ± *.2>) 
L &5.D:% (SD ± &:.9:) &*.94% (SD ± &:.92) &*.92% (SD ± 2.*2) 
M &9.>:% (SD ± 2.2:) 2.%*% (SD ± D.9*) D.%4% (SD ± *.94) 
N &%.D9% (SD ± &4.*%) &D.&:% (SD ± &D.%D) &2.9D% (SD ± &>.*D) 
O *.94% (SD ± 5.94) *.>9% (SD ± 5.*>) 4.5:% (SD ± :.D*) 
PIKHCD-J    
* %%.9D% (SD ± :.&2) %>.95% (SD ± :.:>) %>.D*% (SD ± &.%5) 
J 4D.D%% (SD ± &.D2) 42.&&% (SD ± :.&&) %&.4D% (SD ± :.&:) 
H %:.4>% (SD ± 5.2>) %2.5>% (SD ± 5.54) >5.*:% (SD ± &.2D) 
Table 0.8. Percentage of methylation (±SD), of individual CpG sites with the 2 separate assays. PIK3CD-1 
methylation (n=12 for each site). PIK3CD-2 methylation (n=4 for each site). Standard deviation and are 
calculated by repeated independent experiments.  
 
CpG site methylation comparison between the sub-clones for each revealed a statistical 
difference at two separate sites, one for each primer, both at CpG site 5. PIK5CD-: primer 
CpG site 5 (figure %.%B) methylation for MM.&Sdim was %:.4>%, lower than MM.&Sbright 
(%2.5>%, p=9.992&) and MM.&R (>5.*:%, p=9.999&). PIK5CD-& primer CpG site 5 
methylation for MM.&Sdim was *.>*%, compared to MM.&R (%.4*%, p=9.9:24. figure %B). 
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Figure 0.5 Percentage Methylation of individual CpG sites from PIK3CD-1 Primer (A) Mean % methylation 
at PiK3CD-1 primer region (8 CpG sites) (B) 95% Confidence Intervals (Corrected Tukey's) of individual 
PiK3CD-1 methylation sites (n=12). Experiment followed as per Qiagen methylation protocol, using DNA 
extraction from 2x106 cells and results are the product of 4 separate experiments in triplicate.  
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Figure 0.6. Percentage Methylation of individual CpG sites from PIK3CD-2 Primer (A) Mean % 
methylation at PiK3CD-2 primer region (3 CpG sites) (B) 95% Confidence Intervals (Corrected Tukey's) of 
individual PiK3CD-2 methylation sites (n=4). Experiment followed as per Qiagen methylation protocol, 
using DNA extraction from 2x106 cells and results are the product of 2 separate experiments in duplicate. 
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6.6 PI3K-targeted treatment of Sub-clones 
Having confirmed varying expression levels of PI5K/p&&9d within the sub-clones, my next 
aim was to see if this led to differential sensitivity to PI5K inhibition and cell cytotoxicity, 
thus representing a potentially promising treatment strategy for MM. The selective 
PI5K/p&&9δ inhibitor, idelalisib (CAL-&9&, GS-&&9&), has shown potency in malignant 
lymphoid cell lines. It has an EC49 in cell-free assays of between :.4 nM and DnM and a 
LD49 cell of around 49µM (Herman et al. :9&9; Ikeda et al. :9&9; Lannutti et al. :9&&). 
 
6.6.1 The selective PI3K inhibitor Idelalisib shows an increasing cytotoxic 
effect that correlates to increasing expression levels  
The sub-clones, MM.&Sdim, MM.&Sbright and MM.&R were exposed to increasing doses of the 
idelalisib, with both cytotoxic and anti-proliferative effect measured (figures %.> and %.D). 
MM.&Sdim (LD49=*&.%>µM) was more sensitive to the cytotoxic effects of idelalisib, 
showing greater cell death than MM.&Sbright (LD49=4D.:DµM, p=9.99>>) and MM.&R 
(LD49=D4.:DµM, p<9.999&).  
 
 
  
Figure 0.7. Dose response curves of the sub-clones exposed to idelalisib over 48h period. 0.5x106 cells 
were exposed to increasing doses of idelalisib, cell death recorded by annexin V and PI immuno-staining 
and analysed on BD Accuri flow cytometer. Results are the product of 3 separate independent experiments 
(n=3) 
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6.6.2 Anti-Proliferative effects of Idelalisib 
All 5 sub-clones experienced a dose-dependent anti-proliferative affect from idelalisib. 
Baseline doubling time (chapter *) has already been discussed as a marker of cell 
proliferation. Doubling times (DT) were compared between MM.&Sdim and MM.&Sbright at 
different doses of idelalisib. Statistically significant anti-proliferative effects were observed 
at the non-cytotoxic concentration of &9µM (p=9.99&) (table %.2 and figure %.2), indicating 
that MM.&Sdim cells was more sensitive to idelalisib anti-proliferative effects than 
MM.&Sbright cells.  
 
Idelalisib  
(µM) 
Doubling Time – hours (±SD) P value 
MM.*Sbright 
vs MM.*Sdim 
Summary 
MM.*R MM.*Sbright MM.*Sdim 
*µM 4&.> (±*.&5) *4.9 (±5.95) 49.9 (±:.*%) 9.D54 ns 
LµM *D.5 (±5.5>) 4D.% (±*.45) %9.D (±%.:9) 9.%*> ns 
*?µM %:.5(±4.:%) %&.4 (±&.:D) >%.D (±4.*:) 9.99& ** 
L?µM &&9.& (±&:.5&) 2:.* (±&>.94) &D>.* (±5&.*:) 9.9&* * 
NLµM &99.% (±%>.4:) D%.> (±&5.9D) :95.% (±4>.D2) 9.995 ** 
*??µM &&%.2 (±&4.%2) &&%.* (±:4.D9) &22.* (±%4.>D) 9.9&% * 
Table 0.9. Comparison of doubling time between the 3 sub-clones at different concentrations of idelalisib 
n=3 with standard deviation (±). P-values is a comparison of DT between MM.1Sdim and MM.1Sbright 
calculated by multiple t-test (Holm-Sidak method). S 
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Figure 0.8. Comparison of proliferation and doubling times between MM.1Sbright and MM.1Sdim at 48 
hours at different concentrations of idelalisib, normalised to 0μM DT. (B) 95% Confidence Intervals (Sidak) 
comparison between MM.1SDim and MM.1SBright normalised proliferation at 48 hours at different 
concentrations of idelalisib.  
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6.6.3 Cytotoxic differences abolished by using a pan-PI3K/mTOR inhibitor 
To establish whether the differences in sub-clonal idelalisib cytotoxic effects were due to 
different p&&9d expression and/or dependence on this isoform, the sub-clones were 
exposed to the pan P&5K/mTOR inhibitor, PKI-*9:. The results showed that PKI-*9: was 
equipotent in both MM.&Sbright and MM.&Sdim cells (t-test between the data, p=9.D2). 
MM.&Sdim LD49 &:*nM (SEM±&&.>), MM.&Sbright LD49 &:%nM (SEM±&4.*) and MM.&R LD49 
&:2nM (SEM±&9.&).  
 
 
 
Figure 0.9. Dose response curves of the sub-clones exposed to PKI-402 over 48h period. 0.5x106 cells were 
exposed to increasing doses of PKI-402, cell death recorded by annexin V and PI immuno-staining and 
analysed on a BD Accuri flow cytometer. Results are the product of 3 separate experiments (n=3). 
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6.6.4 Synergistic effect with Dexamethasone offers a therapeutic option. 
Combination therapy is common place in the treatment of MM. Given that the anti-
proliferative effects of idelalisib were apparent at sub-cytotoxic concentrations in all three 
sub-clones, I set out to combine idelalisib with dexamethasone. The aim of these 
experiments was to determine whether dexamethasone resistance could be reversed in 
both MM.&R and MM.&Sbright by co-administering idelalisib. The optimal fixed molar ratio 
for the two drugs was experimentally determined starting with &::9 
deamethazone:idelalisib and finishing with a fixed molar ratio of &::99.  
 
6.6.4.1 MM.1S sub-clones show synergistic effect that MM.1R does not 
Figure %.&9 shows the individual dose response curves, including dexamethasone 
combined with idelalisib (ratio &::99). To calculate whether the combined drugs equated 
to synergy, dose-effect-curves as well as combination-index and median-dose-plot (see 
supplementary figures in appendix) were calculated using CalcuSyn software. 
Combination-index (CI) curves were plotted the CI values at ED49, ED>4 and ED29 were 
obtained. The results of which are outlined in table %.&9 and figure %.&:B. Table %.&9 shows 
that MM.&Sdim and MM.&Sbright experienced synergistic effects with combined of idelalisib 
and dexamethasone, whereas MM.&R did not (ED49 9.22) show a synergistic effect. At 
best an additive effect was possibly seen when ED49 and ED>4 were measured. MM.&Sbright 
showed the greatest synergy, ED29 for MM.&Sbright was 9.&: compared to MM.&Sdim 9.5D 
while MM.&R showed an antagonistic effect with a CI of &.:4.   
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Figure 0.10. Cytotoxic dose response curves (n=3) comparing the effects of single agent Dexamethasone 
and Idelalisib with the added effect of the 2 drugs combined at a fixed concentration ratio of 200:1, for 
combined drug responses, 2 separate curves have been for each cell line, representing the individual drug 
concentration when combined, but are the same data. (A) MM.1Sdim individual drug curves and combined 
(B) MM.1Sbright individual drug curves and combined; (C) MM.1R individual drug curves and combined; (D) 
Cytotoxic dose response curves comparison of the 3 cell lines combined Idelalisib and dexamethasone at 
fixed ratio of 200:1, dose response curves are plotted for the dexamethasone dose. 0.5x106 cells were 
exposed to increasing doses of the drugs, cell death recorded by annexin V and PI immuno-staining and 
analysed on a BD Accuri flow cytometer. Results are the product of 3 separate experiments (n=3) 
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MM.*Sdim MM.*Sbright MM.*R 
EDL? 9.%D (SD ± 9.&9) 9.:4 (SD ± 9.&>) 9.22 (SD ± 9.9>) 
EDNL 9.49 (SD ± 9.&9) 9.&* (SD ± 9.&%) &.&& (SD ± 9.&5) 
EDT? 9.5D (SD ± 9.9D) 9.&: (SD ± 9.&&) &.:4 (SD ± 9.:9) 
 
Figure 0.11.  Synergistic effect of Idelalisib with dexamethasone in MM.1Sbright and MM.1Sdim, but not 
MM.1R. (A) Algebraic estimate of the combination index (CI) constructed by CalcuSyn computer analysis 
of the data. (B) Distribution of individual CI (n=3) among the 3 different sub-clones at 50% Effective dose 
(ED50), 75% (ED75) and 90% (ED90). Table shows the Mean and SD of sub-clone CI between the different 
sub-clones at the various ED values at shown from figure 4.22 (n=3). Figures less than 1 are deemed 
synergistic, the lower the number, the greater the synergistic effect. Figures more than 1 are deemed 
antagonistic 
(A) 
(B) 
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6.6.4.2 Idelalisib median dose effect significantly decreases with addition of 
Dexamethasone in dexamethasone sensitive MM.1 sub-clones 
Both MM.&Sdim and MM.&Sbright experienced a 5D-fold reduction in Idelalisib drug required 
if combined with dexamethasone (Table %.&& and figure %.&5). The differences in Idelalisib 
drug concentrations achieving the same degree of toxicity were both significant (MM.&Sdim 
p=9.9:> and MM.&Sbright p=9.9&>), unlike for MM.&R (p=9.>*D4).   
  
 
MM.*Sdim MM.*Sbright MM.*R 
Idelalisib %2.D: (±:5.%2) &9*.: (±*%.:%) &**.> (±>:.%5) 
Idelalisib + Dexamethasone &.D: (±9.:>) :.>4 (±9.%9) &5>.>9 (±%*.*:) 
P value  9.9:> 9.9&> 9.>*D4 
Summary * * ns 
Table 0.10. Idelalisib Median Effect Dose (Dm) of the 3 cell lines comparing single agent Idelalisib 
treatment with Idelalisib in combination with Dexamethasone at a fixed ratio dose 1:200. P value is 
comparison of cell lines Dm’s between single agent and combination.  
 
 
Figure 0.12. ‘Median Effect Dose’ (Dm) - as calculated by CalcuSyn Dose-Effect Analyzer software 
(Lombardo et al. 2012) of Idelalisib with and without Dexamethasone (fixed ratio 1:200) on the sub-clones 
MM.1Sdim+bright and MM.1R (n=3).  paired fixed ratio T test (n=3). Difference between 2 treated groups were 
significant for MM.1Sdim and MM.1Sbright
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6.7 Discussion 
The majority of this chapter’s mutational analysis focused on how specific mutations 
potentially affected cell-signalling pathways. Such analysis is able to highlight the most 
frequently mutated pathways involved in disease pathologies, leading to new targets 
for therapy. Such strategies are already in existence in MM research, with early phase 
trials of RAS inhibitors, the most commonly mutated gene/pathway in MM, having 
already occurred (Walker et al. :9&4; Ostrem and Shokat :9&%). My pathway analysis 
was done through Enrichr, the free online enrichment tool. Mutation pathway 
analysis was compared to the NCI-Nature :9&% Pathway Interaction Database (PID), a 
collaborative between the NCI and Nature Publishing Group (from :99% until :9&:). It 
contains :&: separate recognised cancer pathways, with numerous genes associated to 
each pathway. Although the database is no longer contributed to by the NCI, the running 
of the database is now undertaken by the Network database exchange Project (NDEx), 
who describes it as a “highly-structured, curated collection of information about known 
bio-molecular interactions and key cellular processes assembled into signalling pathways” 
(Pratt et al. :9&4). Although the database is not as frequently updated compared to other 
pathway analysis tools such as Ingenuity Pathway Analysis (IPA), the simplicity of user 
interface, with cancer focus pathways makes it attractive as a comparable database. 
Provided with more time and expertise, IPA could have provided more in-depth 
information regarding the effect on specific pathways such as PI5K/Akt and explanations 
as to the reasons of difference in drug sensitivity. A pathway of particular interest not fully 
explored in this thesis would have been the CD5D signal transduction pathway and 
whether mutations affecting this pathway leads to the emergence of CD5D weak/negative 
sub-clones as well as determining if CD5D expression can be altered through pathway 
related mutations. Such understanding may also offer new therapy targets of CD5D 
negative drug resistant clones, which will become more predominate in the era of 
CD5D monoclonal antibody therapy. 
 
The other functional genetic analysis method I employed was searching for isolated gene 
mutations, by far the most applicable and easiest way to analyse specific differences 
between sub-clones. Despite limited analysis resources, I felt I made a number of 
significant findings by this simplistic but systematic approach. Functional genetic analysis 
has provided some plausible explanations to some of the differences observed between the 
cell lines. The frameshift InDel mutation (of high significance) of MKI5H observed only 
within MM.&Sdim and can be assumed to be an inactivating mutation, because MM.&Sdim 
cells grow more slowly Ki-67 (the protein encoded by MKI5H) is immunophenotypically 
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reduced in the MM.&Sdim population, both in static culture, but also upon migration 
compared to MM.&Sbright and MM.&R. It also explains why MM.&Sdim has longer telomere 
lengths compared to the other sub-clones, but also has particular significance as over time, 
the CD5D higher expressing sub-clone would outgrow the weakly expressing CD5D sub-
clone in cell tissue culture and may partly explain why other research groups have not 
reported my findings. The difference in Ki-%> expression between the sub-clones could 
also have implication in aggressiveness of the sub-clones. Ki-%> is a key marker of 
proliferative activity in many cancers including MM and is also associated with bone 
marrow angiogenesis (increased microvessel density of the bone marrow), tumour burden 
and poor prognosis (Alexandrakis et al. 2004a; Alexandrakis et al. 2004b; Himani et al. 
2016). Increase expression has also been shown to have clinical importance in therapy 
choice. A 3.7-fold upregulation of MKI5H expression, was associated with early-onset 
vincristine-induced peripheral neuropathy (Broyl et al. :9&9).  
 
The decision to focus on the PI5K/Akt pathway as a model for drug therapy between sub-
clones and potential dexamethasone resistance reversal was multi-fold. For one, it is an 
attractive pathway for drug induced inhibition as involved in cell proliferation, apoptosis, 
cell cycle, autophagy and dexamethasone resistance and unsurprisingly has become a 
target for novel therapy (Ikeda et al. :9&9; Munugalavadla et al. :9&*). In addition, the 
presence of PIK5CD synonymous mutations in all 5 sub-clones as well as mutations in over 
&/5 of all PI5K/Akt pathway related genes, highlighted the high frequency of mutations in 
this key cell-signalling pathway. Although Enrichr pathway analysis showed PI5K 
regulation to be affected but not quite significantly (p=9.9D2), : other pathways with 
direct links to P&5K/Akt were statistically affected, these were mTOR (MM.&Sbright) and c-
Met (MM.&Sdim>MM.&Sbright).  
 
Indeed, Ikeda et al in :9&9 proclaimed PI5K to be an interesting therapeutic target in MM, 
showing the p&&9d isoform (& of D distinct mammalian isoforms of Class IA PI5K) is 
expressed (by immunoblotting) in both primary MM cells and MM cell lines (Ikeda et al. 
:9&9). Although PI5K inhibition has been undertaken on MM cell lines before, none have 
compared the effects between sub-clones from the same patient, cell line or pre-existing 
drug resistance (Munugalavadla et al. :9&*; Zhang et al. :9&*). The selective 
PI5K/p&&9δ inhibitor Idelalisib (CAL-&9&, GS-&&9&) has up to a 599-fold greater selectivity 
for p&&9δ than the other isoforms and has shown promising results in a number of B-cell 
malignancies such as CLL and follicular lymphoma and therefore seemed an obvious 
choice to study the effects of PI5K inhibition of MM sub-clones. Indeed, the effects of 
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Idelalisib on myeloma cell lines has also been previously investigated, the cell line U:%% 
showed >%% inhibition of proliferation at *9µmol/L (2%nM) (Ikeda et al. :9&9; Zhang et 
al. :9&*). Cytotoxic effects on the 5 sub-clones were seen at higher concentrations (5 log 
difference) than this, with LD49 *9-D9µM. 
 
My data not only confirmed p&&9d isoform expression in the sub-clones as previously 
shown by Ikeda et al., but that expression levels varied between the sub-clones and with 
my results confirmed by Real-Time PCR (PIK5CD expression). Ikeda et al. showed varying 
expression of PI5K isoforms between the MM.&S and MM.&R, both expressing P&&9g, but 
only MM.&S expressed p&&9a and p&&9d very weakly (shown by immunofluorescence slide 
fixation), while only MM.&R expresses p&&9b. My results similarly showed MM.&S expressed 
p&&9d more than MM.&R, but my work in addition showed than MM.&S p&&9d expression 
predominantly arises from the MM.&Sdim sub-clone. It is therefore highly possible that 
differences seen in the expression of the alpha and beta isoform between MM.&S and 
MM.&R also arise from sub-clones not present in one or the other sub-clones. 
  
The cause of expression variation could not be attributed to PIK=CD mutations as all cell 
lines expressed the same synonymous SNV.  An alternative explanation that I explored was 
epigenetic changes by methylation of cytosine residues. CpG sites are regions of DNA 
where a cytosine nucleotide is followed by a guanine. CpG islands are usually around 
:99bp (<499 bp) that contain a high frequency of CG (44% or more). They are usually in 
the promoter region but can also occur in enhancer regions of the gene. The methylation 
of CpG islands by DNA methylase (resulting in hypermethylation) can lead to gene 
inactivation.  This silencing of gene expression is frequently seen in cancers and offers a 
therapeutic strategy as reversal of this process may restore normal expression of 
transcriptionally silenced genes (Ehrlich :992; Qiagen :992). And it was this method that 
provided a likely explanation of expression variation of PI5K between the sub-clones. The 
methylation analysis of the PIK=CD promotor region of the 5 sub-clones, showed a 
statistically significant hypomethylation of CpG site 5 site of the PIK5CD-: primer assay.  
 
Although I have not ruled out other causes of protein expression variation such as post-
translational changes or degradation of the protein, epigenetic changes remains the most 
plausible cause and one that is well known in occur in MM cell lines (Peng et al. :99%). I 
found the methylation analysis an extremely technical procedure, with huge potential of 
methodological variation, especially within the bisulfite conversation step. This step 
traditionally requires harsh conditions of high temperatures and low pH, which can lead 
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to DNA fragmentation, reducing purification. To overcome this I used the Qiagen bisulfite 
conversation and methylation kit, the advantage of which reduced the degree of variability 
and by using a thermal cycler in the bisulfite conversion, cytosine conversion rates are 
claimed to be over 22% (Qiagen :992). 
 
Furthermore, I showed the correlation between increasing PI5K/p&&9d expression and the 
cell’s susceptibility to targeted therapy. The LD49 difference between the sub-clones were 
shown to be statistical, with MM&.Sdim having the greatest expression, but also greatest 
sensitivity. This observation proved to be specific to PI5K/p&&9d inhibition as the pan-
PI5K/mTOR inhibitor PKI-*9% removed any cytotoxic differences. Although this drug was 
extremely potent, such a combination is unlikely to be tested clinically due to 
unacceptable toxic side effects from the pan-PI5K inhibition. Though beyond the scope of 
this thesis, mTOR inhibition (without pan-PI5K inhibition) has been targeted in MM 
therapy (Li et al. :9&*), with the novel pan-PIM kinase inhibitor LGB5:& showing mTOR 
signalling inhibition (Garcia et al. :9&*). Additionally, inhibition of mTOR signalling 
pathway with rapamycin inhibits JNK signalling, which sensitises both MM primary cells 
and cell lines to glucocorticoid-induced apoptosis (Smith and Cidlowski :9&9). Thus, 
raising the possibility that mTOR inhibition is just as important in reversing the effects of 
sub-clonal dexamethasone resistance than PI5K. 
 
Combination therapy of dexamethasone and Idelalisib did not provide synergy in MM.&R, 
thus I was unable to reverse dexamethasone resistance by the addition of PI5K inhibition. 
However, impressive synergistic effect was seen with MM.&Sdim and MM.&Sbright, with a 
lower CI observed in MM.&Sbright. This suggests, that the dexamethasone resistance 
obtained in the MM.&Sbright compared to MM.&Sdim, was indeed reversed by PI5K 
inhibition. Activation of the PI5K/Akt signalling pathway has been shown to correlate 
with the expansion of glucocorticoid-resistant MM cells in the bone marrow (Hideshima 
et al. :99>a; Smith and Cidlowski :9&9), thus inhibition of this pathway in theory should 
reverse such expansion. The mechanism of PI5K/Akt pathway induced glucocorticoid 
resistance is through the inhibitory phosphorylation of important apoptotic mediators 
such as Bcl-:-associated death promoter (BAD), caspase 2, Fox95A/FKHRL and CREB. In 
addition, AKT inhibits the transcription of the pro-apoptotic Bim through inhibitory 
phosphorylation of Fox95A/FKHRL which further contributes to glucocorticoid resistance 
(Maddika et al. :99>; Smith and Cidlowski :9&9). Thus, it is possible that the increased 
dexamethasone resistance found in MM.&Sbright cells when compared to MM.&Sdim cells, is 
not due to reduced GR, but rather one of the aforementioned PI5K activation, as inhibition 
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of PI5K reversed its dexamethasone resistance. One of the most important activators of 
the PI5K/Akt pathway is MM cells is IL-% which can also activate MEK/ERK signalling 
pathway, both of which are able to trigger proliferation of MM cells and protects against 
dexamethasone induced apoptosis (Cantley :99:; Luo et al. :995; Steelman et al. :99*; 
Ikeda et al. :9&9).  
 
Finding a suitable combination ratio was difficult, with 5 other ratios attempted 
before &::99 showed the most synergy for both of the MM.&S sub-clones. However, 
this ratio was likely not optimal in either confirming or disproving MM.&R synergy, 
for this reason the antagonist effects suggested by the high CI (&.:4), should be 
interpreted with caution. Based on more accurate LD49 of single therapy toxicity for 
MM.&R, a ratio of at least &:& or lower should be attempted before certain confirmation 
of lack of synergy can be made. This is especially pertinent in view of data not shown 
(see appendix), where a possible MM.&R additive effects exists at a fixed ratio of &::9 of 
&99µM idelalisib (single agent 5D% cell death) and 4µM dexamethasone (combined %>%). 
Of note, the highest dexamethasone concentration reached (4µM) in my experiments, is 
still lower than the standard clinical dose used (:9-*9mg/ &9-:9µM daily) (Bird et al. 
:9&&). Unfortunately, time constraints meant I was unable to undertake MM.&R synergy 
experiments at the lower fixed molar ratios. It is unclear why at 4µM dexamethasone a 
sudden additive effect is seen, either the dexamethasone at such high doses results in 
pathway activation through alternative signalling than the GR or possibly the high 
doses actually causes an increase in GR expression, a phenomenon that has been 
previously described in MM cell lines (Danel-Moore et al. &22:), thus allowing for GR 
induced transcriptional changes.  The other possibility regarding the antagonistic 
effects seen at ED29 could lie with P-gp expression. I have already shown that at high 
doses of dexamethasone, MM.&R P-gp expression is increased (section 4.%.&), 
providing a potential mechanism of efflux of Idelalisib. Although Idelalisib is a known 
substrate of P-gp, it has been shown to inhibit P-gp expression and activity (Jin et al. 
:9&4), further complicating the matter.     
 
In summary, I have provided a number of possible genomic causes to the MM.&S sub-
clonal difference in dexamethasone sensitivity, such as the effects of individual 
mutations have on key signalling pathways such as PI5K/Akt/mTOR, Arf%, a& integrin 
signalling, c-Met and RhoA. Furthermore, I have shown the potential for developing 
bespoke treatment plans based on the identification of cell signalling pathway mutations 
via genomic sequencing, exemplified through PI5K/Akt pathway analysis and subsequent 
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successful inhibition. I have shown that the synergy between dexamethasone and the PI5K 
inhibitor Idelalisib requires cell surface GR expression and that the effects of 
dexamethasone when combined with Idelalisib are not “off target effects”. The MM.&Sbright 
sub-clone mechanism of decreased dexamethasone sensitivity compared to MM.&Sdim 
cannot be due to absence of GR, as the drug combination reversed any survival benefit it 
may have compared to MM.&Sdim. This would suggest the mechanisms or pathways causing 
difference in dexamethasone sensitivity between the : sub-clones MM.&Sdim and 
MM.&Sbright, are different to the mechanisms between MM.&S and MM.&R. My work only 
enhances the necessity for multi-combination drug therapy, to prevent epigenetic, 
mutational, or transcriptional changes resulting in complete drug resistance. By selective 
targeting of confirmed genetic lesions or affected pathways, it may be possible to remove 
multiple sub-clones thereby diminishing the possibility of selecting drug resistant clones 
in future treatment. In theory, this could result in longer time to relapse and ultimately 
improved overall survival.  
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7           CHAPTER 7 
Final Summary and Future 
Directions: 
 
7.1 Summary: 
This study first set out to design a complex multi-parameter flow cytometry panel, 
enabling clonal and sub-clonal immunophenotypic analysis of both primary MM samples 
and known MM cell lines. Access to quality primary samples proved more difficult than 
first anticipated. Nevertheless, my &9-colour panel revealed numerous 
immunophenotypically distinct sub-populations within both primary samples and MM 
cell lines. Although the concept of MM clones is not novel, I have shown that both primary 
samples and MM cell lines exhibit wide variation in CD5D expression and multiple, 
phenotypically distinct, sub-populations exhibiting variable expression of functional 
markers within my flow panel (CXCR*, MMP-2, CD*2d, IL-%). Thus, identification of sub-
clones by immunophenotyping has the advantage over other clonal identification 
methods, in that very small sub-clones can be accurately identified and functional 
differences, that can result in possible selection advantages, driving clonal evolution can 
be explored. One example of this is CXCR* expression. Using a novel dynamic migratory 
model, I showed that CXCR* expression was more highly expressed on migrated MM cells 
than non-migratory cells. Myeloma cell CXCR* expression levels are notoriously variable, 
with numerous studies giving conflicting results (Hideshima et al. :99&; Moller et al. 
:995). My results suggest that migrated cells, even in the presence of a high CXCL&: 
chemokine gradient, do not downregulate CXCR* expression. Indeed, expression is 
seemingly higher on cells migrating towards higher levels of CXCL&:. The pattern of 
CXCR* expression appeared bimodal, rather than uniformly upregulated when migrated 
cells retrieved from EVS were stained for CXCR* expression. The possibility of myeloma 
CXCR* sub-clones with differing migratory potential adds weight to the spatial 
heterogeneity of MM sub-clones in different parts of the bone marrow (Rasche et al. :9&>). 
Such work only confirms the heterogeneity of the disease and that multiple treatment 
strategies are required to treat and or even cure the disease.  
 
Although pathway and mutational analysis may identify targets for cytotoxic therapy and 
were therefore investigated in this thesis, inhibiting MM migration and preventing the 
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interaction of early MM clones with the BM microenvironment before secondary somatic 
mutations (such as KRAS and TPD=) occur, offers an alternative treatment strategy. Indeed 
heterogeneous somatic mutations in adhesion molecules, has been shown to allow for  
sub-clonal evolution (Leich et al. 2013). The inhibition of the CXCR*/CXCL&: axis and 
adhesion molecules have been shown to affect such events, which in turn results in 
improved efficacy of cytotoxic agents (Azab et al. :992b; Azab et al. :9&:). 
Transendothelial migration is a multi-step process, whereby cells circulating under shear 
force, initially arrest onto endothelium and then roll. Commonly, this leads to encounter 
with tight junctions (the interface between two endothelial cells), where the cells 
experience high local concentrations of cytokines resulting in migration (Johnson-Leger 
et al. :999; Salanueva et al. :99>). When these processes are lost or inhibited migration 
is significantly affected. Therefore, developing the dynamic circulatory model, as 
previously used in our research group (Walsby et al. :9&*a), for MM was essential to 
investigate the effects of shear force on MM adhesion and migration. 
 
To my knowledge I have been the first to show that dual inhibition of CD*2d and CXCR* 
within a dynamic migratory model is required to induce a statistically significant reduction 
in CXCL&:-induced MM migration. The reasons why combination therapy caused this is 
likely due to the complimentary roles the receptors have on migration. The two are 
inexorably linked; CXCR* regulates VLA-* adhesion, with migration only occurring if 
there is both an adhesion signal coupled with a homing signal prior to transendothelial 
migration (Parmo-Cabanas et al. :99*).  
 
A further question remained as to when in the plasma cell dyscrasia course would CXCR* 
and/or CD*2d inhibition be most effective? CXCR* expression is a recognised marker of 
clonal plasma cell migration potential and is highest in the pre-myelomatous phase MGUS 
and lowest in relapse  (Moller et al. :995). Although in my work I showed no statistical 
difference in CXCR* expression between MGUS and newly diagnosed MM, there was a 
statistical difference between relapsed MM and newly diagnosed (higher in the later). 
These finding lead to the conclusion that CXCR* inhibition in relapsed disease may be less 
effective due to lower expression and that targeted therapy should be aimed in the high-
risk smouldering myeloma/MGUS or newly diagnosed. However, this would need to be 
tested both in vitro and in clinical trials. 
 
The logistics of culturing primary samples, meant that further phenotypic, genetic and 
functional analysis of primary samples proved difficult. Although some primary samples 
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had distinct CXCR* and CD*2d sub-populations, the limit of my work meant that I could 
not test whether these sub-populations had different adhesion or migratory potential, i.e. 
behave in a functionally different manner. Furthermore, although immunophenotyping is 
often used in Myeloma to infer clonality, it does not prove it, which is usually achieved 
through molecular testing.  A technique that is not routine in clinical practice, where time 
and resources are finite. Therefore, the practical ease of inferring clonality by 
immunophenotyping makes it more appealing, especially if it has treatment implications. 
It was therefore of great interest that the MM.&S cell line was shown to have bimodal CD5D 
sub-populations. To my knowledge, this is the first report of this phenomenon and offers 
the potential for differential treatment responses due to the emergence of anti-CD5D 
therapies, such as the monoclonal antibody Daratumumab. Combined with the existence 
of a dexamethasone resistant related cell line MM.&R, this allowed me to explore the 
origins of glucocorticoid drug resistance in relation to CD5D expression. 
 
CD5D weak or negative expressing populations have not been described in great detail in 
the literature, they have an estimated incidence of two cases per &999 examinations 
(Minarik et al. :9&>). Even in commercial MM cell lines, I and others have shown the U:%% 
cell line to negative express CD5D (Drent et al. :9&%). Indeed, MM cell lines are known to 
have immunophenotypically distinct populations, for example CD&5D, CD4% and CD*4 
sub-populations have been described within MM cell lines (Wu et al. :9&4), as well as the 
presence drug resistant sub-clones. Keith Stewart’s group in Scotsdale, Arizona has 
described a lenalidomide resistant clone within MM.&S. Such resistance would have been 
borne out of pre-existing selection advantage to the drug, as the cell line originated prior 
to the advent of IMiD therapy (Bjorklund et al. :9&&; Zhu et al. :9&&). This implies multiple 
sub-clones pre-exist within MM.&S, each with their own unique mutations, resulting in 
differing pathway activation and specific target for clonal inhibition.  
 
In chapter 4, analysis of the two phenotypically distinct CD5D expressing subsets within 
the MM.&S cell line revealed both functional and genetic differences thereby confirming 
the sub-clonal architecture within this cell line. Intriguingly, our data point to the pre-
existence of CD5D expressing sub-clones, that have differing cytotoxic sensitivity to 
dexamethasone. The existence of the dexamethasone resistant cell line MM.&R allowed me 
to perform comparative genomics thereby identifying : possible genetic origins of 
dexamethasone resistance. In one scenario MM.&Sbright cells were selected and tracked to 
the subsequent clonal evolution (induction) in the MM.&R cells. However, a lack of obvious 
driver genes made this origin less plausible and an alternative scenario inferring 
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MM.&Sbright is a separate sub-clone to MM.&R more likely. The later scenario implied that 
MM.&Sdim and MM.&Sbright diverged from the original ancestor at roughly the same point, 
potentially initiated through the acquired ROBO0 driver mutation seen only in MM.&Sdim 
that is then passed onto MM.&R. Mutations in ROBO0 have been recently linked to spatial 
genomic heterogeneity in MM and offers the explanation of genetic drift between 
MM.&Sbright and MM.&Sdim  (Rasche et al. :9&>). 
 
The comparative exome analysis in both Chapters 4 and %, identified other significant 
mutational differences between the 5 sub-clones, such as MKI5H, mutated only in 
MM.&Sdim. This mutation is likely to cause a downregulation in Ki-%> expression, which in 
part explains the difference in reduced proliferative propensity between MM.&Sdim and the 
other sub-clones. The analysis also confirmed the glucocorticoid receptor gene, NR=C$, 
was unmutated, correlating with pre-existing cell line sequence data/COSMIC database, 
implying the absence of GR in MM.&R and subsequent steroid resistance is likely due to 
epigenetic changes or bi-allelic inactivation (Greenstein et al. :995; Sánchez-Vega et al. 
:99%).  
 
In Chapter %, pathway analysis of the exome mutation data was also used to identify 
genetic differences in the sub-clones that could be used as therapeutic target and one such 
target that was explored was the PI5K/AKT pathway. The PI5K/AKT pathway is a key 
pathway involved in MM disease progression, survival and activation of the signalling 
pathway shown to correlate with the expansion of glucocorticoid-resistant MM cells in the 
bone marrow (Hideshima et al. :99>a; Smith and Cidlowski :9&9). To date, 
comprehensive genetic sequencing of MM has shown mutations involved in the PI5K/AKT 
pathway are relatively rare (<&%), with the most frequent mutations involved in the 
RAS/MAPK and NF-κB pathways (>:4%) (Chapman et al. :9&&; Lohr et al. :9&*; Walker et 
al. :9&4). Although my sequencing data is from cell lines, it is largely supportive of this, 
with a high number of mutations (e.g. SSPO) related to the NF-κB pathway. Even when 
concentrating on one particular pathway, I identified > unique PI5K/AKT pathway 
related gene mutations. PI5K inhibition of the sub-clones showed a preferential 
cytotoxicity to the sub-clone, MM.&Sdim with greatest expression of the PIK5CD p&&9d 
isoform. This discovery, also highlighted the variability in expression of key signalling 
pathway proteins amongst sub-clones, thus illustrating the potential for using genetic 
mutations as a means of identifying differential sub-clonal responses to specific pathway 
inhibitors. To clarify the frequency of these > unique mutations in my primary sample data 
would take time and resources. Such complimentary work between primary material and 
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cell lines is essential in establishing the correlation between pathway mutations of for 
example PI5K/AKT, expression levels of PI5K/p&&9d and effects of PI5K inhibition. In time, 
individually sequencing specific genes, will be replaced by more efficient methods, e.g. 
targeted NGS or WES, with the ultimate goal to undertake WES of individual patients at 
the start of treatment and subsequent lines of treatment. Outside of clinical trials this has 
yet to happen, but seems likely to be the next step forward in achieving individualised 
treatment plans.    
 
7.2 Future Directions: 
The most pressing of future directions is the role MM.&Sdim may play in the era of anti-
CD5D therapy. Just as MM.&S and MM.&R has become a model for the study of 
glucocorticoid resistance in MM, MM.&Sdim and MM.&Sbright could become the model for 
understanding the emergence of CD5D negative clones and anti-CD5D resistance. In this 
thesis, I was unable to fully explain the cause of the reduction in CD5D expression in the 
MM.&Sdim sub-clone, but suffice it to say, it was not due to a genetic mutation in the CD=N 
gene. The advent of daratumumab treatment, the anti-CD5D monoclonal antibody, has 
inevitably resulted in the existence of CD5D negative clones, (Minarik et al. :9&>). The 
Minarik et al. case report suggests the CD5D MM cells were not distinct clones, but were 
genetically identical, with the likelihood that epigenetic changes downregulate the 
expression. These case reports will over the next few years become more apparent and 
should truly confirm whether, daratumumab resistance is brought upon by epigenetic 
changes or sub clonal selection, much like the dexamethasone resistance paradigm. The 
likelihood is of course a combination of the : factors. The clonal selection challenges 
brought upon by new treatment, will enforce epigenetic changes in the sub-clones more 
adept to form resistance. Thus, work in establishing whether MM.&Sdim shows resistance 
to daratumumab compared to the other sub-clones is of importance before fully exploring 
the origins of CD5D weak/negative MM sub-clones.  
 
The dynamic migratory model that I adapted has huge potential in not only studying other 
inhibitory migratory agents in MM, but also in studying the interaction of bone marrow 
stromal cells with MM, by using the EVS as a “make shift” bone marrow 
microenvironment. The effects of interactions between different MM sub-clones and bone 
marrow stromal cells (BMSC) is not well documented. BMSCs are known to stimulat MM 
growth and survival, in part by the CXCL&:/CXCR* signalling pathway (Feng et al. :9&9) 
and their own mechanical integrity can be affected by the interaction of MM cells to 
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varying degrees dependent on CD&5D expression (Wu et al. :9&4).  The effect can be 
somewhat reversed through CXCR* inhibition and it is another example of 
immunophenotypic analysis potentially determining treatment. A more detailed 
investigation into how sheer force affects this interaction and migration potential on 
immunophenotypic distinct sub-clones is certainly warranted. 
 
Clinical trials using CXCR* inhibitors (Ghobrial et al. :9&*), show rapid mobilisation of 
plasma cells at : hours post-inhibitor, with an equally rapid return of circulating plasma 
cells to baseline levels at * hours post-inhibitor. My experimental methodology of the 
circulatory migratory model, is of the assumption that migration is a one-way process, i.e. 
from circulation into the EVS. This is certainly not the case in vivo where myeloma cells 
are in a constant flux in and out of the bone marrow microenvironment (Alsayed et al. 
:99>) and indeed such two-way migration has already been proven in this circulatory 
model for CLL cells (Walsby et al. :9&*c). Thus, it is plausible that migrated MM cells 
could “escape” back into the circulation once the effect of Natalizumab and/or ONO->&%& 
start to wear off. Attempting to identifying peak migratory time points over *D hours and 
whether at these points, administration of additional drugs such as the proteasome 
inhibitor, Bortezomib, would aid in inhibiting migration further or lead to greater cell 
death is an interesting concept and could be investigated further. Ultimately working with 
primary MM samples would help to validate the results and conclusions I have reached 
using MM cell lines. Culturing primary MM cells has its technical difficulties (Bam et al. 
:9&4) and although groups have undertaken experiments without additional cells 
(Stühmer et al. :9&9), the widely accepted method of co-culture has relied on 
mesenchymal cells such as human stromal cells, having pre-selected CD&5D positive MM 
plasma cells via bead columns  (Pawlyn et al. :9&>). More complex models, that try to 
create the bone marrow environment with either healthy or disease BM cells and cytokines 
have also been developed, that have been able to keep MM cells alive for extended periods 
(Kirshner et al. :99D; Bam et al. :9&4). Developing such a 5D model within the dynamic 
circulatory EVS would be a unique experiment and an additional advantage of this novel 
circulatory model being its versatility to create different migratory compartments. Further 
research work could be attempted to more accurately reflect a functioning bone marrow 
environment in the EVS. This might include human stromal cells (HS-4), osteoclasts, 
MRC-4 fibroblasts in addition to myeloma cells. Drug therapy could then be added either 
to circulation or EVS (such as ONO->&%&) in an attempt to cause myeloma cell escape from 
the EVS into the circulating compartment and assess whether this would sensitise cells to 
standard cytotoxic agents such as proteasome inhibitors or immunomodulatory drugs. 
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The complexity of this model is also its potential weakness - huge numbers of variables 
mean trying to accurately replicate experiments can be difficult. The expense and time 
required in setting it up compared to transwell experiments means only highly focussed 
and limited questions can be answered in a timely manner. Nevertheless, it is a unique 
model that allows for greater understanding of myeloma cell migration and study of 
potential therapeutic treatments. 
 
The future of combining genetic analysis (be it mutational, cytogenetic or pathway 
signalling analysis), with immunophenotypic, biochemical and clinical features to 
formulate a bespoke treatment strategy is the ultimate goal in MM management. However, 
the introduction of such treatment strategies will be determined by the accessibility of 
data sharing, allowing for Artificial intelligence and machine learning to develop complex 
algorithms to not only treat a single myeloma clone, but the whole disease that includes 
all sub-clones. My pathway analysis through Enrichr, adopted a logical “top-down” 
approach and identified % separate cancer-related pathways where statistical 
regulation differences between the sub-clones, due to differences in gene mutations. 
With more time, each of the following pathways could have been further evaluated, 
offering alternative therapeutic targets and if successful is showing variation in pathway 
inhibition, again this could highlight the importance of setting up treatment regimens that 
are sub-clonally targeted. 
i. a%b& and a%b* integrin signalling pathway showed a regulatory statistical 
difference through the gene mutations for all 5 cell lines, but greater statistical 
difference in MM.&R or MM.&Sbright (p=9.99*) than MM.&Sdim (p=9.955). Alpha % is 
a potentially novel integrin in MM pathogenesis, but has shown to mediate 
leukocyte tether on laminin under physiological shear and should explain the 
different adhesive properties of the sub-clones (Kitayama et al. :999).  
ii. The CaN-regulated NFAT-transcription pathway was statistically affected in 
MM.&R, but not the other : pathways.  In view of calcineurin targeted therapies, 
such as the HDAC inhibitor Panobinostat, synergy experiments with HDAC 
inhibitors and dexamethasone could be attempted to see if resistance could be 
reversed.  
iii. The regulation of RhoA activity pathway was significantly affected in MM.&Sdim 
(p=9.954), but not in the other : cell lines. RhoA has been shown to be involved 
in MM SDF-&-induced adhesion, chemotaxis, and homing of MM cells to the BM 
(Azab et al. :992a), which to some extend could explain the differences in 
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transwell migration between the sub-clones and offers a mechanism of sub-clonal 
expansion dependent on differing migratory potential.  
iv. Mutation in SSPO and CUL$ were seen in all 5 cell lines and predicted to 
statistically (p=9.95) affect degradation of b-Catenin and alter the Wnt/b-Catenin 
signalling pathway. This pathway is involved in cell-cell adhesion, disease 
progression, osteoblast activation, lytic lesions and over expression in MM has 
been related to lenalidomide resistance (Tian et al. :995; Bjorklund et al. :9&&; 
Clevers and Nusse :9&:; Bjorklund et al. :9&5). 
 
Computer software programmes such as Ingenuity, can further compare disease 
mechanisms such as proliferation between multiple mutational sequencing data sets. 
Mutational analysis of my 5 cell lines, specifically looking at proliferation, identified non-
synonymous homozygous SNV in : of the % IGF binding proteins (IGF0R and IGFBP$), 
shared between the 5 cell lines. The myeloma growth factors, IGF/IGF-&R are known to 
promote MM growth, survival, migration and drug resistance (Bataille et al. :994; 
Sprynski et al. :992; Kuhn et al. :9&:). High peripheral blood levels are linked to poor 
prognosis, and levels are reduced by % different IGF binding proteins (Bieghs et al. :9&%). 
Though no specific proliferation associated mutation differences were identified between 
the cell lines, it provides targeted genes that could be looked at in more detail, for example 
identifying if IGF0R and IGFBP$ protein expression differs between the cell lines.     
 
Furthermore, studying of the sub-clones in xenograft models, would provide greater 
understanding of the in-vitro proliferative properties as external factors e.g. bone marrow 
microenvironment, or other sub-clonal interactions would be considered and do not form 
part of my functional proliferative assays. Mice xenograft models, using retroviral 
transduction of the cell lines (LeBlanc et al. :99:; Mitsiades et al. :99*) have been 
instrumental in showing the clinical benefits of proteasome inhibitors (LeBlanc et al. 
:99:; Richmond and Su :99D) and would be key in the studying of the effect of novel 
cytotoxic agents, especially if wanting to observe the differing effects between sub-clones.    
 
Xenograft modelling would also allow for further investigation of the sub-clone migratory 
potential or spread of extra medullary disease, which has been shown to be regulated by 
CXCR* (Roccaro et al. :9&4). Although no statistical difference in CXCR* expression was 
observed between the sub-clones, MM.&Sbright has a greater MFI expression than MM.&Sdim 
(&,295 vs. &,>:: p=9.D>9) and could explain the increase in CXCL&: induced static transwell 
migration observed for MM.&Sbright. Greater CXCR* expression can also result in increased 
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cellular invasion, metastasis and ultimately disease progression (Roccaro et al. :9&4). 
Although Roccaro et al showed that by blocking CXCR* extra-medullary disease (EMD) 
was less likely, the full migratory mechanisms are less understood but epithelial 
mesenchymal transitions is thought to play a pivotal part. The increase in MM.&Sbright 
CXCR* expression could also result in a greater propensity for EMD to form. To date, no 
existing literature exists regarding CD5D expression and extra medullary disease (Kumar 
et al. :9&9). The one immunophenotype that is recognised with EMD is the absence of 
CD4% (Dahl et al. :99:), similar to plasma cell leukaemia (Pellat-Deceunynck et al. &22D). 
I have shown than MM.&Sbright has lower CD4% expression than MM.&Sdim (&,%&5 vs. :,&%* 
p=9.4&>), although non-statistical it could infer again that MM.&Sbright has a greater 
propensity for EMD, which could be confirmed through xenograft modelling. 
 
The emergence of widely available NGS in additional to other informative genetic 
techniques such as CHIPseq (Thomas et al. :9&4), has opened up the possibility of 
identifying key mutations and affected pathways for individual patient’s disease. This may 
lead to the advent of NGS based screening tools designed to predict cytotoxic susceptibility 
and aid in treatment decision for patients with cancer. Targeted NGS at present is a more 
feasible approach than WES (Ikeda et al. :9&4), but the key issues with NGS is the difficulty 
in knowing what mutations to look for and what the clinical significance are, but could 
allow for the prediction of drug resistance and facilitate improvements in the treatment of 
MM patients. What makes this task especially difficult, is that MM in keeping with many 
other cancers, demonstrates significant sub-clonal heterogeneity. Consequently, what 
treatment may be good for the eradication of one clone, may cause rapid clonal expansion 
in another clone (Keats et al. :9&:). A perfect example of this has resulted in the early 
suspension of the BELLINI trial, the use of the BCL: inhibitor Venetoclax, where a 
decrease in overall survival in non t(&&:&*) MM was observed. This makes clinicians’ 
treatment decisions more difficult, especially in the later stages of disease where large 
difference in sub-clonal drug sensitivities are more likely. To overcome the possibility of 
treatment causing worsening disease progression and/or evolution, analyse of the 
mutation variation between the many different sub-clones must occur and will pave the 
way for the development of sophisticated models for designing bespoke therapies. By 
selective targeting of these genetic lesions it may be possible to remove multiple sub-
clones thereby diminishing the potential for clonal tiding and the development of drug 
resistance. In theory, this approach could be used to optimise the depth of remissions and 
improve overall survival by targeting sub-clonal architecture. 
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8 APPENDIX: 
 
 
8.1 MM adherence to the CXCL12 secreting fibroblasts MRC-5 
 
 
Supplementary Figure 1; Percentage of myeloma cells (cell lines MM.1S) adhered to the CXCL12 
secreting fibroblasts MRC-5, Human fibroblast stromal cells HS-5 and the endothelial cell HUVEC. 
Myeloma cells were co-cultured with the corresponding fibroblast/endothelial cell for 4 hours (n=3). Non-
adhered myeloma cells were removed by media replacement with cell numbers counted by Vi-cell. 
Percentage adherence measure by retrieved myeloma cells deducted by total myeloma cells used, divided 
by total.  
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8.2 Co-culture between MM and fibroblasts/endothelial cells 
 
Supplementary Figure 2. Light microscope 40X magnification photographs of co-culture between 
MM.1S CD38 sorted cell populations and fibroblasts/endothelial cells. Roughly 0.5x106 
Fibroblasts/endothelial cells were plated on 6-well plates and left for 24h, non-adhered cells were removed 
and 5x106 MM.1Sbright or MM.1Sdim cells added to culture. After 4 hours, non-adhered cells were removed, 
counted and photographs taken of co-cultures. Red arrows indicate group of MM cells adhered to 
fibroblast/endothelial cells. Co-cultures were as follow (A) MM.1Sbright and fibroblast MRC-5; (B) MM.1Sdim 
and fibroblast MRC-5; (C) MM.1Sbright and human stromal fibroblast HS-5, GFE tagged (appearing 
fluorescence green); (D) MM.1Sdim and human stromal fibroblast HS-5, GFE tagged (appearing 
fluorescence green); (E) MM.1Sbright and endothelial HUVEC; (F) MM.1Sdim and endothelial HUVEC.
(B)  
(D) 
(A)  
(C) 
(E)  (F) 
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8.3 Comparison of P-gp expression within different MM cell lines 
 
Supplementary Figure 3. Comparison of P-gp expression within different MM cell lines, measured on BD 
Accuri. (A) Overlay histograms of static cultic P-gp expression (stained with PE-Cy7-CD243) of MM.1S, 
MM.1R and RPMI-8226. MM.1S and MM.1R overlay histograms were comparable (MM.1S; MFI-1,736, 
28.6% positivity vs. MM.1R; MFI-1,628, 26.7% positivity). As a comparison, the cell line RMPI-8226 has 
greater P-gp expression (MFI-2,652, 36.1% positivity) (B) Flow cytometry dot plot of MM.1S comparing P-
gp expression with CD38 expression. CD38 gating shown in boxes. (C) Overlay histograms comparing P-gp 
expression of the two CD38 gated subsets as shown in figure 4B. All measurements done on BD Accuri. 
Tables state corresponding overlay histograms events counted (Count), mean and median fluorescence 
intensity (Mean and median) and P-gp percentage positivity relative to unstained sample of same cell line 
(Freq. of Parent). 
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8.4 Overlay histograms of P-gp expression 
 
Supplementary Figure 4. Overlay histograms of P-gp expression measured by BD Accuri. Cells stained 
with PE-Cy7-CD243. Comparison between the unstained MM.1S and the sorted cell lines MM.1Sbright and 
MM.1Sdim. Histograms show almost identical MFI and percentage positivity (MM.1Sbrigth MFI 1,498, 26.5% 
positivity vs. MM.1Sdim MFI 1,482 25.2% positivity). 
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8.5 Overlay histograms of CD38 expression between MM.1Sdim 
and MM.1Sbright 
 
Supplementary Figure 5. Overlay histograms of CD38 expression between MM.1Sdim and MM.1Sbright in 
fibroblast/endothelial co-culture (same experiment as figure 17). Non-adhered cells were washed away 
with media, leaving adhered cells which were removed with Trypsin 0.05% and subsequently 
immunostained for flow cytometry measured on BD Fortessa. MM cell lines were identified from 
fibroblast/endothelial by CD138/CD56 gating. (A) Comparison of CD38 expression between separate co-
culture experiments of either MM.1Sdim or MM.1Sbright adhered to MRC-5, HS-5 or HUVEC. Legend contains 
MFI value for each histogram. (B) Overlay histogram comparing CD38 expression of MM.1Sdim and 
MM.1Sbright within the different co-culture experiments (HS-5, HUVEC or MRC-5) 
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MM1S-Dim_MRC-5 stained - susp_016.fcs/Alive cells/Single Cells/CD138, CD56 subset 196.1 667.0 
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MM1S-Bright_HS-5 stained - susp_008.fcs/Alive cells/Single Cells/CD138, CD56 subset 3488.9 4151.3 
MM1S-Bright_MRC-5 stained - susp_010.fcs/Alive cells/Single Cells/CD138, CD56 subset 2996.0 3826.0 
MM1S-Bright_HUVEC stained - susp_012.fcs/Alive cells/Single Cells/CD138, CD56 subset 3467.7 4231.5 
MM1S Bright_unstained_001.fcs/Alive cells/Single Cells 8.6 12.6 
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8.6 Overlay histograms of CD56 expression between MM.1Sdim 
and MM.1Sbright 
 
Supplementary Figure 6. Overlay histograms of CD56 expression between MM.1Sdim and MM.1Sbright in 
fibroblast/endothelial co-culture (same experiment as figure 17). Non-adhered cells were washed away 
with media, leaving adhered cells which were removed with Trypsin 0.05% and subsequently 
immunostained for flow cytometry measured on BD Fortessa. MM cell lines were identified from 
fibroblast/endothelial by CD138/CD38 gating. (A) Comparison of CD56 expression between separate co-
culture experiments of either MM.1Sdim or MM.1Sbright adhered to MRC-5, HS-5 or HUVEC. Legend contains 
MFI value for each histogram. MM.1Sbright CD56 expression did not vary upon adherence to fibroblasts or 
endothelial cells. This is in contrast to MM.1Sdim, where increase in CD56 expression was observed, with 
greatest increase seen with MRC-5 adherence (MFI (mean) 2,264 vs baseline 1,402). (B) Overlay histogram 
comparing CD56 expression of MM.1Sdim and MM.1Sbright within the different co-culture experiments (HS-
5, HUVEC or MRC-5). Overlay histograms between the two CD38 sub-populations confirmed the expression 
difference between the two sub-populations, with approximately 0.5 log increase in MM.1Sdim CD56 
expression.  
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MM1S-Bright_HS-5 stained - susp_008.fcs/Alive cells/Single Cells/CD138, CD38 subset 694.3 867.3 
MM1S-Bright_MRC-5 stained - susp_010.fcs/Alive cells/Single Cells/CD138, CD38 subset 618.4 869.0 
MM1S-Bright_HUVEC stained - susp_012.fcs/Alive cells/Single Cells/CD138, CD38 subset 616.5 888.3 
MM1S Bright_unstained_001.fcs/Alive cells/Single Cells 79.9 83.8 
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MM1S-Dim_HS-5 stained - susp_014.fcs/Alive cells/Single Cells/CD138, CD38 subset 1208.7 1807.0 
MM1S-Dim_MRC-5 stained - susp_016.fcs/Alive cells/Single Cells/CD138, CD38 subset 1446.7 2263.5 
MM1S-Dim_HUVEC stained - susp_018.fcs/Alive cells/Single Cells/CD138, CD38 subset 1377.9 2104.0 
MM1S Dim_unstained_003.fcs/Alive cells/Single Cells 125.3 134.6 
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8.7 Overlay histograms of IL-6 expression between MM.1Sdim and 
MM.1Sbright 
 
Supplementary Figure 7. Overlay histograms of IL-6 expression between MM.1Sdim and MM.1Sbright in 
fibroblast/endothelial co-culture (same experiment as figure 17). Non-adhered cells were washed away 
with media, leaving adhered cells which were removed with Trypsin 0.05% and subsequently 
immunostained for flow cytometry measured on BD Fortessa. MM cell lines were identified from 
fibroblast/endothelial by CD138/CD38 gating. (A) Comparison of IL-6 expression between separate co-
culture experiments of either MM.1Sdim or MM.1Sbright adhered to MRC-5, HS-5 or HUVEC. Legend contains 
MFI value for each histogram. MM.1Sbright and MM.1Sdim adhesion to the stromal fibroblast HS-5 
upregulated expression of the intracellular markers IL-6 by roughly 0.5 log difference compared to static 
culture. (B) Overlay histogram comparing IL-6 expression of MM.1Sdim and MM.1Sbright within the different 
co-culture experiments (HS-5, HUVEC or MRC-5) No difference was observed in HS-5 adhesion related 
upregulated expression of IL-6 between the two cell lines.  
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MM1S-Bright_HS-5 stained - susp_008.fcs/Alive cells/Single Cells/CD138, CD38 subset 1147.7 1201.9 
MM1S-Bright_MRC-5 stained - susp_010.fcs/Alive cells/Single Cells/CD138, CD38 subset 877.9 887.9 
MM1S-Bright_HUVEC stained - susp_012.fcs/Alive cells/Single Cells/CD138, CD38 subset 843.8 913.1 
MM1S Bright_unstained_001.fcs/Alive cells/Single Cells 526.2 559.4 
MM1S Dim_stained_004.fcs/Alive cells/Single Cells/CD138, CD38 subset 833.6 909.8 
MM1S-Dim_HS-5 stained - susp_014.fcs/Alive cells/Single Cells/CD138, CD38 subset 1280.7 1325.0 
MM1S-Dim_MRC-5 stained - susp_016.fcs/Alive cells/Single Cells/CD138, CD38 subset 1034.8 1066.6 
MM1S-Dim_HUVEC stained - susp_018.fcs/Alive cells/Single Cells/CD138, CD38 subset 831.0 877.8 
MM1S Dim_unstained_003.fcs/Alive cells/Single Cells 454.7 486.3 
Ki-67+1.8Ki-67-98.2
0
Com -BV605-A :: Ki-67
0
Co
un
t
Subset Name with Gating Path
MM1S Dim_stained_004.fcs/Alive cells/Single Cells/CD138, CD38 subset 
MM1S Bright_stained_002.fcs/Alive cells/Single Cells/CD138, CD38 subset 
 257 
8.8 Overlay histograms of MMP-9 expression between MM.1Sdim 
and MM.1Sbright 
 
Supplementary Figure 8. Overlay histograms of MMP-9 expression between MM.1Sdim and MM.1Sbright 
in fibroblast/endothelial co-culture (same experiment as figure 17). Non-adhered cells were washed away 
with media, leaving adhered cells which were removed with Trypsin 0.05% and subsequently 
immunostained for flow cytometry measured on BD Fortessa. MM cell lines were identified from 
fibroblast/endothelial by CD138/CD38 gating. (A) Comparison of MMP-9 expression between separate co-
culture experiments of either MM.1Sdim or MM.1Sbright adhered to MRC-5, HS-5 or HUVEC. Legend contains 
MFI value for each histogram. MM.1Sbright and MM.1Sdim adhesion to the stromal fibroblast HS-5 
upregulated expression of the intracellular markers MMP-9 and IL-6 by roughly 0.5 log difference 
compared to static culture. (B) Overlay histogram comparing MMP-9 expression of MM.1Sdim and 
MM.1Sbright within the different co-culture experiments (HS-5, HUVEC or MRC-5). No difference was 
observed in HS-5 adhesion related upregulated expression of MMP-9 between the two cell lines 
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MM1S Bright_stained_002.fcs/Alive cells/Single Cells/CD138, CD38 subset 510.2 549.6 
MM1S-Bright_HS-5 stained - susp_008.fcs/Alive cells/Single Cells/CD138, CD38 subset 1856.7 2034.8 
MM1S-Bright_MRC-5 stained - susp_010.fcs/Alive cells/Single Cells/CD138, CD38 subset 802.4 815.7 
MM1S-Bright_HUVEC stained - susp_012.fcs/Alive cells/Single Cells/CD138, CD38 subset 718.0 776.2 
MM1S Bright_unstained_001.fcs/Alive cells/Single Cells 328.0 352.4 
MM1S Dim_stained_004.fcs/Alive cells/Single Cells/CD138, CD38 subset 620.3 687.8 
MM1S-Dim_HS-5 stained - susp_014.fcs/Alive cells/Single Cells/CD138, CD38 subset 1872.2 2034.6 
MM1S-Dim_MRC-5 stained - susp_016.fcs/Alive cells/Single Cells/CD138, CD38 subset 953.2 987.5 
MM1S-Dim_HUVEC stained - susp_018.fcs/Alive cells/Single Cells/CD138, CD38 subset 746.5 789.9 
MM1S Dim_unstained_003.fcs/Alive cells/Single Cells 374.1 415.2 
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8.9 Overlay histograms of CXCR4 expression between MM.1Sdim 
and MM.1Sbright 
 
Supplementary Figure 9. Overlay histograms of CXCR4 expression between MM.1Sdim and MM.1Sbright in 
fibroblast/endothelial co-culture (same experiment as figure 17). Non-adhered cells were washed away 
with media, leaving adhered cells which were removed with Trypsin 0.05% and subsequently 
immunostained for flow cytometry measured on BD Fortessa. MM cell lines were identified from 
fibroblast/endothelial by CD138/CD38 gating. (A) Comparison of CXCR4 expression between separate co-
culture experiments of either MM.1Sdim or MM.1Sbright adhered to MRC-5, HS-5 or HUVEC. Legend contains 
MFI value for each histogram. CXCR4 expression was reduced for both for cell lines, but to a greater degree 
for MM.1Sdim (MFI (mean) MM.1Sbright 1,152 (static) vs 875 (co-culture) and MM.1Sdim 1,176 (static) vs 680 
(co-culture)) (B) Overlay histogram comparing CXCR4 expression of MM.1Sdim and MM.1Sbright within the 
different co-culture experiments (HS-5, HUVEC or MRC-5). Adhesion to HS-5, CXCR4 MFI for MM.1Sbright 
was 1,355 and MM.1Sdim 1,381, with no difference in overlay histograms. Adhesion with HUVEC saw 
upregulation of CXCR4 expression, with no differences between the cell lines (MFI MM.1Sbright 1,680 and 
MM.1Sdim 1,591). 
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MM1S-Bright_HS-5 stained - susp_008.fcs/Alive cells/Single Cells/CD138, CD38 subset 883.2 1355.7 
MM1S-Bright_MRC-5 stained - susp_010.fcs/Alive cells/Single Cells/CD138, CD38 subset 569.6 875.5 
MM1S-Bright_HUVEC stained - susp_012.fcs/Alive cells/Single Cells/CD138, CD38 subset 1009.9 1680.3 
MM1S Bright_unstained_001.fcs/Alive cells/Single Cells 8.9 13.2 
MM1S Dim_stained_004.fcs/Alive cells/Single Cells/CD138, CD38 subset 872.5 1175.9 
MM1S-Dim_HS-5 stained - susp_014.fcs/Alive cells/Single Cells/CD138, CD38 subset 941.6 1381.5 
MM1S-Dim_MRC-5 stained - susp_016.fcs/Alive cells/Single Cells/CD138, CD38 subset 435.7 680.7 
MM1S-Dim_HUVEC stained - susp_018.fcs/Alive cells/Single Cells/CD138, CD38 subset 1066.8 1590.9 
MM1S Dim_unstained_003.fcs/Alive cells/Single Cells 4.3 11.7 
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8.10 Overlay histograms of CD49d expression between MM.1Sdim 
and MM.1Sbright 
 
Supplementary Figure 10. Overlay histograms of CD49d expression between MM.1Sdim and MM.1Sbright 
in fibroblast/endothelial co-culture (same experiment as figure 17). Non-adhered cells were washed away 
with media, leaving adhered cells which were removed with Trypsin 0.05% and subsequently 
immunostained for flow cytometry measured on a BD Fortessa flow cytometer. MM cell lines were 
identified from fibroblast/endothelial by CD138/CD38 gating. (A) Comparison of CD49d expression 
between separate co-culture experiments of either MM.1Sdim or MM.1Sbright adhered to MRC-5, HS-5 or 
HUVEC. Legend contains MFI value for each histogram. CD49d expression was reduced from static baseline 
(i.e. not in co-culture). The greatest reduction in CD49d expression was observed in HUVEC co-culture, 
followed by MRC-5 and then HS-5. (B) Overlay histogram comparing CD49d expression of MM.1Sdim and 
MM.1Sbright within the different co-culture experiments (HS-5, HUVEC or MRC-5). MM.1Sdim reduction in 
expression (relative to static baseline) was marginally less than for MM.1Sbright for each 
fibroblast/endothelial adhesion. The greatest difference was seen in HUVEC co-culture, where MM.1Sbright 
MFI (mean) was 1,95011 compared to MM.1Sdim MFI 2,542, with increase expression non-overlapping 
occurring for MM.1Sdim 
 
100 101 102 103 104 105
Comp-BV510-A :: CD49d
MM.1S bright
100 101 102 103 104 105
Comp-BV510-A :: CD49d
MM.1S dim
100 101 102 103 104 105
Comp-BV510-A :: CD49d
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
MRC-5
(A
100 101 102 103 104 105
Comp-BV510-A :: CD49d
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
HUVEC
100 101 102 103 104 105
Comp-BV510-A :: CD49d
0
20
40
60
80
100
No
rm
ali
ze
d 
To
 M
od
e
HS-5 
10 0
Comp-BV510-A :: CD49d
Subset Name with Gating Path Mean : Comp-BV510-A Median : Comp-BV510-A
MM1S Bright_stained_002.fcs/Alive cells/Single Cells/CD138, CD38 subset 4997.6 4645.6 
MM1S-Bright_HS-5 stained - susp_008.fcs/Alive cells/Single Cells/CD138, CD38 subset 3712.2 3322.9 
MM1S-Bright_MRC-5 stained - susp_010.fcs/Alive cells/Single Cells/CD138, CD38 subset 2857.2 2526.2 
MM1S-Bright_HUVEC stained - susp_012.fcs/Alive cells/Single Cells/CD138, CD38 subset 2307.4 1949.9 
MM1S Bright_unstained_001.fcs/Alive cells/Single Cells 955.3 885.9 
MM1S Dim_stained_004.fcs/Alive cells/Single Cells/CD138, CD38 subset 6677.6 6261.6 
MM1S-Dim_HS-5 stained - susp_014.fcs/Alive cells/Single Cells/CD138, CD38 subset 4183.0 3753.5 
MM1S-Dim_MRC-5 stained - susp_016.fcs/Alive cells/Single Cells/CD138, CD38 subset 3690.8 3193.9 
MM1S-Dim_HUVEC stained - susp_018.fcs/Alive cells/Single Cells/CD138, CD38 subset 3009.1 2541.6 
MM1S Dim_unstained_003.fcs/Alive cells/Single Cells 1425.0 1284.6 
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8.11 Number of Non-synonymous (SNP) or coding frameshift 
(InDel) Exonic Mutations 
 
Cell line mutations No. of Indel No. of SNV Total No. 
Non-filtered mutations (no exclusion criteria)  
Total Number :,>*& (&99%) 52,D&: (&99%) *:,445 (&99%) 
Common mutations :,&:: (>>.*:%) 5>,9** (25.94%) 52,&%% (2:.9*%) 
MM.*Sdim D> (5.&>%) 5*D (9.D>%) *54 (&.9:%) 
MM.*Sbright 2% (5.49%) :4& (9.%5%) 5*> (9.D:%) 
MM.*R &&> (*.:>%) 5>% (9.2*%) *25 (&.&%%) 
MM.*Sdim & MM.*R 25 (5.52%) %55 (&.42%) >:% (&.>&%) 
MM.*R & MM.*Sbright &:2 (*.>&%) %59 (&.4D%) >42 (&.>D%) 
MM.*Sdim & MM.*Sbright 2> (5.4*%) 459 (&.55%) %:> (&.*>%) 
Filtered mutations – (Inclusion criteria exonic Indel. or SNV) 
Total Number :&2 (&99%) &9,54* (&99%) &9,4>5 (&99%) 
Common mutations &2* (DD.4D%) 2,D4% (24.&2%) &9,949 (24.94%) 
MM.*Sdim * (&.D5%) DD (9.D4%) 2: (9.D>%) 
MM.*Sbright % (:.>*%) *> (9.*4%) 45 (9.49%) 
MM.*R && (4.9:%) D9 (9.>>%) 2& (9.D%%) 
MM.*Sdim & MM.*R & (9.*%%) &:% (&.::%) &:> (&.:9%) 
MM.*R & MM.*Sbright & (9.*%%) DD (9.D4%) D2 (9.D*%) 
MM.*Sdim & MM.*Sbright : (9.2&%) %2 (9.%>%) >& (9.%>%) 
Supplementary Table 1. Number of Non-synonymous (SNP) or coding frameshift (InDel) Exonic 
Mutations in the 3 cell lines as outlined in Venn diagram, figure 5.21. 
 
 
8.12 Location of VCF files of whole exome sequence 
https://www.dropbox.com/sh/kdrde2xex>zotul/AAB5umWDQOQ-
m*YWXLpOTKMTa?dl=9 
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8.13 Comparison of WES genetic mutations 
 
 Samples MM.*R MM.*S 
bright 
MM.*S 
dim 
Total Com-
mon 
Coding  Frameshift :*9 :5% ::% :42 :&& 
InDel Non-frameshift insertion &&& &9: &9% &&5 2% 
 Non-frameshift deletion &:9 &92 &&* &59 2> 
 Stoploss 4 % 4 % 4 
 Startloss * 5 5 * 5 
 Splicing *: *& *5 ** 52 
       
InDel Total InDels 5,%>& 5,%*& 5,4>2 *,&%* :,2>2 
 % of InDels in dbSNP D%.%: D>.9% D>.&D D*.94 29.5> 
 % of InDels in &999g  >:.*& >:.4% >5.9& %D.5: >D.4D 
 Novel 54% 5*: 559 4&4 &D5 
 Homozygous &,4>% &,44D &,4:5 NA &,5%* 
 Heterozygous :,924 :,9D5 :,94% NA &,%&4 
 Intron :,5%> :,5D> :,5&% :,>&> &,2&: 
 4' UTRs >& %& >: D: 44 
 5' UTRs &&* &:& &&5 &:2 &9: 
 Upstream >: >5 >9 D* 4* 
 Downstream >* >* >% D> %9 
 Intergenic &D9 &>* &%> :9: &*: 
       
Coding  Synonymous &&,%&& &&,*>D &&,4*: &&,2:5 &9,2%4 
SNP Missense &9,555 &9,&D> &9,:5& &9,%D> 2,%%& 
 Stopgain D: D& D4 24 >5 
 Stoploss 5* 5* 55 5* 55 
 Startloss :& :& :& :& :9 
 Splicing %* %D %4 >* 4D 
       
SNP Total SNPs *%,DD2 *%,4:> *%,%59 *D,>4: *5,>&& 
 % of SNPs in dbSNP 2>.D* 2>.D4 2>.>5 2>.& 2D.5> 
 % of SNPs in &999g 2*.45 2*.4% 2*.*& 25.** 24.4D 
 Novel >2* D99 D** &&>% 45> 
 Homozygous &>,425 &>,>>2 &>,%:* NA &>,922 
 Heterozygous :2,:2% :D,>*D :2,99% NA :%,%&: 
 262 
 Intron &>,D2> &>,D** &>,D*2 &D,%%5 &%,%2: 
 4' UTRs >%> >*5 >42 D:4 %%: 
 5' UTRs 29> D2> 294 2*4 D** 
 Upstream %>% %42 %%: >94 %92 
 Downstream 45: 4:2 459 442 *24 
 Intergenic &,>D> &,D*% &,D9* &,2*2 &,%95 
 Ti/Tv :.4D :.4D :.4D :.4* :.%: 
Supplementary Table 2 Comparison of genetic mutations through exome sequence between the cell lines, 
MM1.R, MM1.SBright and MM1.Sdim
 263 
8.14 Comparison between my exome sequence and the COSMIC 
cell line database 
Mutation Type COSMIC 
database 
MM.*S 
Present in 
all H cell 
lines 
Present in 
at least * 
cell line 
Not present 
in any cell 
line 
Complex deletion In frame & & - - 
Complex Frameshift 5 & : - 
Deletion Frameshift > 5 - * 
Deletion In frame * 5 - & 
Insertion Frameshift > * & : 
Substitution Coding silent ::4 &%2 :5 55 
Substitution Missense 5%5 &>& D9 &&: 
Substitution Nonsense &% 2 5 * 
Unknown 49 &% * 59 
Total %>% 5>> &&5 &D% 
Supplementary Table 3. Comparison between my exome sequence and the COSMIC cell line database 
for MM.1S mutations.
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8.15 List of exonic gene mutations detected from WES 
 
List of exonic mutations (without dbSNP reference) 
Common 
ABCA>, ABCC4, ADAM55, ADO, AGPHD&, ALCAM, ALDH&DA&, ANKEF&, ANLN, ANXA&9, 
APOL*, APPL:, ARHGAP&D, ARHGAP5:, ATRN, BC&:D9*5, BICC&, C&2orf%9, C&2orf>5, 
C*orf*>, C%orf&%5, C>orf&5, CACNB*, CAPN&&, CCDC&&9, CCDCD9, CCNE:, CD&D, CD5*, 
CES*A, CHD2, CIRH&A, COL&9A&, CUL&, CYB4%&, CYP&&A&, DGCR:, DISP&, DLX5, DMP&, 
DNAH&9, DNAH&:, DNAH&>, DNAH5, DNAJB&:, DOCK>, DPP&9, DYRK&A, EEF&D, EGFR, 
ELP%, ENTPD%, ESYT&, FAM*%C, FARP&, FEM&A, GALNTD, GPR2D, GPRIN&, GUCY&A:, 
HHIPL:, HRNR, IFT&>:, IGLL4, INPPL&, IQSEC&, ITIH&, ITPA, KANSL:, KANSL5, KCNH5, 
KCNJ:, KIAA&9:*, KIAA&&92, KIAA&>9*, KIF:%A, KIR:DS4, KIR5DS&, KRT52, KRTAP&9-&, 
KRTAP&2-%, KRTAP*-*, LAMB:, LARGE, LECT&, LMAN&L, LONRF5, LRFN5, LRRC5:, 
LRRC5>BP&, LY>4, LY>4-CD59:, LYST, MAF, MAP&B, MCFD:, METTLD, MGA, MMP:%, 
MRTO*, MYO&9, NAIF&, NAPRT&, NBPF>, NCOR:, NFATC&, NOG, NPC&, NSUN5, NUDT&&, 
OFCC&, OPLAH, OR:A&, OR4:M&, OR4T5, ORDB*, OTUD>A, PAPPA:, PAXBP&, PBX&, 
PDIA%, PDPK&, PIGR, PLEC, PLLP, PLXNB:, POLR5A, POP&, PPP&R5:, PPP&R54, PRICKLE5, 
PTCHD:, RAB&&FIP&, RALGAPA:, RAP:C, RBM5D, RIMS&, RMND4A, RNF&D9, RSBN&, 
SARM&, SASH&, SEMA5C, SGK:, SH5PXD:A, SLC&:A:, SLC&:A*, SLC&%A4, SLC&>A2, 
SLC:4A&2, SLC54G5, SLC2C&, SLCO5A&, SPOCD&, SREBF:, SSPO, SSU>:, TAS:R4, TBC&D*, 
TBX&D, TBXAS&, TCHH, TCRBV&&S&A&T, TIMELESS, TLR%, TMC5, TMEM&%2, TMEM:52, 
TMEM4:B, TNKS&BP&, TOPAZ&, TRIM*&, TRIP%, TTLL&9, TTN, TXN, TYK:, UBR>, UBXN%, 
ULK:, USP5&, USP*D, WDR2%, WHSC&, XPA, YARS:, YBX:, ZER&, ZFP:D, ZKSCAN>, 
ZNF&9>,  ZNF5D:, ZNF45%, ZNF4D&, ZNF%:&, ZPBP:, ZZEF& 
MM.*Sdim 
ABCCD, ADAMTS:9, ARAP:, ARHGAP%, ATG2B, BSN, BTN:A5P, C&orf%D, C%orf&*&, 
CASC*, CCDC:>, CCDCD*, DNAH&*, DNMBP, FHAD&, GRID:IP, GRM4, GUCA&B, HTR5E, 
IRF:BP:, KXD&, LHFPL&, LRRC&4, MAML5, MKI%>, MYBPC&, MYH&*, MYO2B, OR4:R&, 
PEA&4, POLR&E, PRDM&%, PSMD&*, RAI&*, RSRC&, RUNX&T&, SASH&, SLC&5A:, THBS5, 
TM*SF&2, TM*SF&2-TCTEX&D:, TOM&L:, USP55, VPS&%, ZNF54*C, ZPLD& 
MM.*Sbright 
ADGB, ADRB&, ATE&, DENND*B, DENND4B, DPM&, ERN&, FCGBP, FIP&L&-PDGFRA, GANC, 
GCFC:, GLIS5, INSM&, ISYNA&, KANK:, KMT:E, LRRC>, MITF,  
OR*A4, PLCH&, SLC54D:, SLC*A2, SREBF&, TRDC, UGT&A&, USP5*, VWA5B, WBP: 
MM.*R 
ANPEP, DLG5, EGR*, ERCC%, ERN&, FAM&:9C, FMO&, GALNT4, GPCPD&, GPR&:%, GSPT:, 
HOXC&5, KIAA95&2, LAMB*, LRFN&, MCTP:, NR:F%, OR&9AG&, PDCD%IP, PDIA4, 
PRICKLE&, PRKG&, PUS&, RFX%, RNF:*, SLCO&C&, ZBTB*>, ZFP&&:, ZNF>:2, ZP: 
MM.*R and MM.*Sbright 
CD:*, CHD&L, CIRBP-AS&, TMC5, UNC&5D 
MM.*Sdim and MM.*Sbright 
AFM, AGBL:, GTF:I, ICAM4, MYT&L, OR*S:, PRKCI, RIN:, ZNF5%% 
MM.*R and MM.*Sdim 
UPF5 
Supplementary Table 4. List of all exonic gene mutations, that did not have a dbSNP reference. Mutated 
gene list is divided into cell lines for which the mutation is present i
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8.16 Dose-effect curves and median-effect plots of individual cell 
lines calculated by CalcuSyn 
 
 
 
 
 
Supplementary figure 11; Dose-effect curves and median-effect plots of individual cell lines calculated 
by CalcuSyn; (A) MM.1Sdim; (B) MM.1Sbright; (C) MM.1R; 
(A) 
(B) 
(C) 
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8.17 MM.1R apoptosis exposed to 100µM of Idelalisib for 48h, 
with varying doses of dexamethasone  
 
Supplementary figure 12. MM.1R cell line exposed to 100µM of Idelalisib for 48h, with varying doses of 
dexamethasone. Statistical   difference seen between 5µM of dexamethasone and control Idelalisib with 
no addition of dexamethasone (p=0.0162 n=3). Cell death was not affected by the addition of 
dexamethasone (between 40%-50%) up to a dose of 1µM. However, with the addition of 5µM 
dexamethasone (highest dose added), cell death statistically increased (p=0.0162) from the control 
(40.63% to 66.95%). 
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8.18 Consent forms used for MM bone marrow sample collection 
 
 
Developing novel targeted agents in MM version 2 30th December 2013 
 
               
Developing novel targeted agents in Multiple Myeloma 
Patient Information Sheet for Adults  
Sponsored by Cardiff University 
Chief Investigator: Professor Chris Pepper,  Principal Investigator: Professor Chris Fegan University Hospital of Wales, Heath Park Cardiff  As you know you are undergoing a bone marrow test to ascertain if you have a condition called multiple myeloma or not. Although there are many treatments available should you have myeloma more treatments are needed and the research group at Cardiff University/Cardiff and Vale University Health Board are aiming to develop new treatments. We therefore need to be able to test our new treatments against real multiple myeloma cells from patients to see if they are able to kill the multiple myeloma cells in the laboratory before attempting to treat actual patients.   Before you decide whether to take part, it is important for you to understand why this research is being done and what it will involve. Please take time to read the following information carefully and if there is anything that is not clear or if you would like more information please feel free to ask us.  Take as much time as you need to decide whether you wish to take part.  
Why have I been chosen?         You are being invited to take part in the study simply because the doctors looking after you feel that you may have a condition called multiple myeloma based on blood, urine and possibly x rays which you have already had performed. You require a bone marrow test to see if this is the case or not.   
What is Multiple Myeloma and why are more treatments needed?  Multiple Myeloma is a form of cancer of the bone marrow. There are many treatments available for multiple myeloma but more are needed. At present treatment is aimed at controlling the disease as no present treatment is curative. From our laboratory tests we now know a lot about what keeps multiple myeloma cells alive and have developed several treatments aimed at stopping the cells from living.  
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Developing novel targeted agents in Multiple Myeloma Version 2 30th December 2013.   
  
Developing novel targeted agents in Multiple Myeloma  
CONSENT FORM 
Name of Researchers: Professor Chris Pepper and Professor Chris Fegan 
          Please initial boxes 
1. I confirm that I have read and understand the information sheet dated (Version 2, Date 30th December 2013) for the above study and have had the opportunity to ask questions.   2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected.  3. I consent to the collection of an extra 1ml (1/5 of a tea spoon) of my bone marrow                                                                  as part of the diagnostic bone marrow to determine if I have multiple myeloma. This extra sample will be taken to the Research Laboratory and anonymised for potential  use in various laboratory tests to assess new treatments for multiple myeloma.  4. I understand that should my bone marrow test show that I do not have multiple myeloma that the extra sample of bone marrow I have donated will be removed from the Research Laboratory before any tests have taken place on it and  destroyed.       Name of person taking consent      Date                               Signature         Name of Patient        Date                               Signature        5. I consent that the extra bone marrow sample that has been stored in the  Research Laboratory and anonymised will now be used for use in various  laboratory tests with the aim of  using whole multiple myeloma cells to see if  new treatments under development in Cardiff can kill the myeloma cells or not.     
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